¾¦ÉʰìÍ÷
|
Ë¡Îá | ¥Ö¥é¥ó¥É | ¥«¥¿¥í¥°ÈÖ¹æ | ¾¦ÉÊ̾ | ¥µ¥¤¥º | ²Á³Ê | Êݸ²¹ÅÙ | £Ã£Á£Ó | | | |
|
¡¡ |
BML |
BML-2800-0100 |
Bioactive lipid library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Bioactive Lipid Library contains 195 bioactive lipids in a 96 well format. Ideal for screening or identifiying recombinant orphan G protein-coupled receptors, target validation, secondary screening, validating new assays and for routine pharmacological applications. Kit/Set Contains: 195 compounds including: Agonists & Antagonists, Endocannabinoids, Farnesyl/geranylgeranyl derivates, HETEs deHETEs, hepoxilins, Polyunsaturated fatty acids, Leukotrienes, lipoxins, LPA & phosphatidic acids, Octadecanoids, PAFs, Prostaglandins & thromboxanes, Retinoids, vitamin D metabolites, Sphingolipids.
|
|
¡¡ |
BML |
BML-2800-0500 |
Bioactive lipid library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Bioactive Lipid Library contains 195 bioactive lipids in a 96 well format. Ideal for screening or identifiying recombinant orphan G protein-coupled receptors, target validation, secondary screening, validating new assays and for routine pharmacological applications. Kit/Set Contains: 195 compounds including: Agonists & Antagonists, Endocannabinoids, Farnesyl/geranylgeranyl derivates, HETEs deHETEs, hepoxilins, Polyunsaturated fatty acids, Leukotrienes, lipoxins, LPA & phosphatidic acids, Octadecanoids, PAFs, Prostaglandins & thromboxanes, Retinoids, vitamin D metabolites, Sphingolipids.
|
|
¡¡ |
BML |
BML-2801-0100 |
Endocannabinoid library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Endocannabinoid Library contains 60 compounds with defined, putative, potential or speculative activity at cannabinoid (CB) and vanilloid (VR) receptors. The library is an array of 10 different fatty acids and 6 different polar head groups. Ligands are supplied dissolved in biocompatible solvents at 1 mM and aliquoted into deep-well plates at 100ul per well. The library is a rich source of ligands for receptor de-orphaning. Includes the following classes of ligands: Amides, Ethanolamides, Lipo-amino acids, Acyl-GABAs, Acyl-dopamines.
|
|
¡¡ |
BML |
BML-2801-0500 |
Endocannabinoid library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Endocannabinoid Library contains 60 compounds with defined, putative, potential or speculative activity at cannabinoid (CB) and vanilloid (VR) receptors. The library is an array of 10 different fatty acids and 6 different polar head groups. Ligands are supplied dissolved in biocompatible solvents at 1 mM and aliquoted into deep-well plates at 100ul per well. The library is a rich source of ligands for receptor de-orphaning. Includes the following classes of ligands: Amides, Ethanolamides, Lipo-amino acids, Acyl-GABAs, Acyl-dopamines.
|
|
·àʪ |
BML |
BML-2802-0100 |
Nuclear receptor ligand library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Nuclear Receptor Ligand Library contains 76 compounds with defined, putative and potential activity at nuclear receptors. Receptor agonists and antagonists are included. The library consists of a chemically diverse group of compounds which are supplied dissolved in DMSO at 10 mM and aliquoted into deep-well, 96-well plates at 500ul or 100ul per well. The library is an ideal tool for chemical genomics, receptor de-orphaning and other routine pharmacological applications.
|
|
·àʪ |
BML |
BML-2802-0500 |
Nuclear receptor ligand library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Nuclear Receptor Ligand Library contains 76 compounds with defined, putative and potential activity at nuclear receptors. Receptor agonists and antagonists are included. The library consists of a chemically diverse group of compounds which are supplied dissolved in DMSO at 10 mM and aliquoted into deep-well, 96-well plates at 500ul or 100ul per well. The library is an ideal tool for chemical genomics, receptor de-orphaning and other routine pharmacological applications.
|
|
¡¡ |
BML |
BML-2803-0100 |
Fatty acid library(100 ul/well)(20 assays) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Fatty Acid Library contains 68 fatty acids of varying saturation and chain length. Many free fatty acids and their metabolites serve as precursors to important signaling systems (e.g. prostaglandins), act directly as receptor ligands or enzyme inhibitors, and have pro- or anti-atherosclerotic and anti-hypertensive properties through mechanisms that are still being characterized. Therefore, a diverse set of fatty acids can be a rich source of compounds for receptor de-orphaning, inhibitor screening, and high content screening.
|
|
¡¡ |
BML |
BML-2803-0500 |
Fatty acid library(500 ul/well)(20 assays) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Fatty Acid Library contains 68 fatty acids of varying saturation and chain length. Many free fatty acids and their metabolites serve as precursors to important signaling systems (e.g. prostaglandins), act directly as receptor ligands or enzyme inhibitors, and have pro- or anti-atherosclerotic and anti-hypertensive properties through mechanisms that are still being characterized. Therefore, a diverse set of fatty acids can be a rich source of compounds for receptor de-orphaning, inhibitor screening, and high content screening.
|
|
·àʪ |
BML |
BML-2805-0100 |
Ion channel ligand library(100 ul/well)(20 assays) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Ion Channel Ligand Library contains 71 ion channel blockers and openers for use in characterizing and identifying ion channels in individual cells or tissue.
|
|
·àʪ |
BML |
BML-2805-0500 |
Ion channel ligand library(500 ul/well)(20 assays) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Ion Channel Ligand Library contains 71 ion channel blockers and openers for use in characterizing and identifying ion channels in individual cells or tissue.
|
|
·àʪ |
BML |
BML-2810-0100 |
Neurotransmitter library(10 plate set)(650 compounds, 100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well neurotransmitter library contains 651 CNS receptor ligands in a 96-well format. Ideal for screening or identifying recombinant orphan G protein-coupled receptors, target validation, secondary screening, validating new assays, and for routine pharmacological applications. Includes 13 classes of receptor ligands in 10 deep-well plates.
|
|
·àʪ |
BML |
BML-2810-0500 |
Neurotransmitter library(10 plate set)(650 compounds, 500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well neurotransmitter library contains 651 CNS receptor ligands in a 96-well format. Ideal for screening or identifying recombinant orphan G protein-coupled receptors, target validation, secondary screening, validating new assays, and for routine pharmacological applications. Includes 13 classes of receptor ligands in 10 deep-well plates.
|
|
·àʪ |
BML |
BML-2811-0100 |
Adrenergic ligand library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The adrenergic ligand library contains 84 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein-coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The adrenergic ligand library is 1 plate of the larger neurotransmitter library (Prod. No. BML-2810) which contains over 650 CNS receptor ligands.
|
|
·àʪ |
BML |
BML-2811-0500 |
Adrenergic ligand library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The adrenergic ligand library contains 84 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein-coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The adrenergic ligand library is 1 plate of the larger neurotransmitter library (Prod. No. BML-2810) which contains over 650 CNS receptor ligands.
|
|
·àʪ |
BML |
BML-2812-0100 |
Dopaminergic ligand library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Dopaminergic Ligands Plate contains 81 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Dopaminergic Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands
|
|
·àʪ |
BML |
BML-2812-0500 |
Dopaminergic ligand library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Dopaminergic Ligands Plate contains 81 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Dopaminergic Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands
|
|
·àʪ |
BML |
BML-2813-0100 |
Serotonergic ligand library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Serotonergic Ligands Plate contains 83 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Serotonergic Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
·àʪ |
BML |
BML-2813-0500 |
Serotonergic ligand library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Serotonergic Ligands Plate contains 83 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Serotonergic Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
¡¡ |
BML |
BML-2814-0100 |
Opioid ligand library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Opioid and Sigma Ligands Plate contains 79 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Opioid and Sigma Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
¡¡ |
BML |
BML-2814-0500 |
Opioid ligand library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Opioid and Sigma Ligands Plate contains 79 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Opioid and Sigma Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
·àʪ |
BML |
BML-2815-0100 |
Cholinergic ligand library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Cholinergic Ligands Plate contains 74 compounds ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Cholinergic Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
·àʪ |
BML |
BML-2815-0500 |
Cholinergic ligand library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Cholinergic Ligands Plate contains 74 compounds ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Cholinergic Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
¡¡ |
BML |
BML-2816-0100 |
Histaminergic ligand library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Histaminergic and Melatonin Ligands Plate contains 42 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Histaminergic and Melatonin Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
¡¡ |
BML |
BML-2816-0500 |
Histaminergic ligand library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Histaminergic and Melatonin Ligands Plate contains 42 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Histaminergic and Melatonin Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
·àʪ |
BML |
BML-2817-0100 |
Ionotropic glutamatergic ligand library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Ionotropic Glutamatergic Ligands Plate contains 64 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Ionotropic Glutamatergic Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
·àʪ |
BML |
BML-2817-0500 |
Ionotropic glutamatergic ligand library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Ionotropic Glutamatergic Ligands Plate contains 64 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Ionotropic Glutamatergic Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
¡¡ |
BML |
BML-2818-0100 |
Metabotropic glutamatergic ligand library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Metabotropic Glutamatergic Ligands Plate contains 56 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Metabotropic Glutamatergic Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
¡¡ |
BML |
BML-2818-0500 |
Metabotropic glutamatergic ligand library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Metabotropic Glutamatergic Ligands Plate contains 56 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Metabotropic Glutamatergic Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
¡¡ |
BML |
BML-2819-0100 |
GABAergic ligand library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The GABAergic Ligands library contains 58 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein-coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The GABAergics Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 CNS receptor ligands.
|
|
¡¡ |
BML |
BML-2819-0500 |
GABAergic ligand library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The GABAergic Ligands library contains 58 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein-coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The GABAergics Ligands plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 CNS receptor ligands.
|
|
¡¡ |
BML |
BML-2820-0100 |
Purinergic ligand library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Purinergic and Adenosine Ligands Plate contains 52 CNS receptor ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Purinergic and Adenosine Ligands Plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
¡¡ |
BML |
BML-2820-0500 |
Purinergic ligand library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Purinergic and Adenosine Ligands Plate contains 52 CNS receptor ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The Purinergic and Adenosine Ligands Plate is 1 plate of the larger Neurotransmitter Library (Prod. No. BML-2810) which contains over 650 ligands.
|
|
·àʪ |
BML |
BML-2825-0500 |
Orphan ligand library(84 compounds)(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Orphan ligand library contains 84 compounds with defined, putative, potential or speculative biological activity but whose protein binding partners have not been identified. Ligands are supplied dissolved in biocompatible solvents at 10mM and aliquoted into a deep-well plate at 500ul per well. The library is a rich source of ligands for receptor de-orphaning. Includes the following classes of ligands: Trace Amines, Neurotransmitter Metabolites, Endogenous ¦Â-carbolines, Urinary Metabolites, Nicotine Congeners, D-Amino Acids.
|
|
·àʪ |
BML |
BML-2832-0100 |
Kinase inhibitor library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Kinase Inhibitor Library contains 80 known kinase inhibitors of well-defined activity. Inhibitors are supplied dissolved in DMSO at 10 mM and aliquoted into deep-well plates at either 100 or 500 microliters per well. The library is an ideal tool for chemical genomics, assay development and other pharmacological applications. Includes inhibitors of these important kinases: Insulin/IGF Receptors, PI 3-Kinase, CaM Kinase II, JAK, PKA, CDK, JNK, PKC, CKI II, MAPK, RAF, EGFR, MEK, SAPK, GSK, MLCK, Src-family, IKK, PDGFR, VEGFR and many more.
Kit/Set Contains: 80 compounds including inhibitors of these important kinases: BTK, CaM Kinase, CDK, CKI & II, EGFR, GSK, IKK, Insulin receptor, JAK, JNK, MAPK, MEK, MLCK, PI 3-Kinase, PDGFR, PKA, PKC, RAF, SAPK, Src-family, VEGFR, and more.
|
|
·àʪ |
BML |
BML-2832-0500 |
Kinase inhibitor library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Kinase Inhibitor Library contains 80 known kinase inhibitors of well-defined activity. Inhibitors are supplied dissolved in DMSO at 10 mM and aliquoted into deep-well plates at either 100 or 500 microliters per well. The library is an ideal tool for chemical genomics, assay development and other pharmacological applications. Includes inhibitors of these important kinases: Insulin/IGF Receptors, PI 3-Kinase, CaM Kinase II, JAK, PKA, CDK, JNK, PKC, CKI II, MAPK, RAF, EGFR, MEK, SAPK, GSK, MLCK, Src-family, IKK, PDGFR, VEGFR and many more.
Kit/Set Contains: 80 compounds including inhibitors of these important kinases: BTK, CaM Kinase, CDK, CKI & II, EGFR, GSK, IKK, Insulin receptor, JAK, JNK, MAPK, MEK, MLCK, PI 3-Kinase, PDGFR, PKA, PKC, RAF, SAPK, Src-family, VEGFR, and more.
|
|
·àʪ |
BML |
BML-2833-0100 |
Protease inhibitor library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-WellProtease Inhibitor Library includes 53 known protease inhibitors on a single 96-well plate. Inhibitors are supplied dissolved in DMSO at 10 mM and aliquoted into deep-well plates at either 100 or 500 microliters per well. The library includes inhibitors to a broad range of important proteases and is a convenient and cost-effective way to purchase a panel of protease inhibitors for chemical genomics, assay development, and other applications. It includes inhibitors of: Calpains, TPPII, Neutrophil Elastase, Cathepsins, DPPIV, Caspases, Granzyme B, ¦Ã-Secretase, Furin, MMPs, ACE, Kallikrein, Proteasome, Aminopeptidase B, and many more.
|
|
¡¡ |
BML |
BML-2833-0500 |
Protease inhibitor library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-WellProtease Inhibitor Library includes 53 known protease inhibitors on a single 96-well plate. Inhibitors are supplied dissolved in DMSO at 10 mM and aliquoted into deep-well plates at either 100 or 500 microliters per well. The library includes inhibitors to a broad range of important proteases and is a convenient and cost-effective way to purchase a panel of protease inhibitors for chemical genomics, assay development, and other applications. It includes inhibitors of: Calpains, TPPII, Neutrophil Elastase, Cathepsins, DPPIV, Caspases, Granzyme B, ¦Ã-Secretase, Furin, MMPs, ACE, Kallikrein, Proteasome, Aminopeptidase B, and many more.
|
|
¡¡ |
BML |
BML-2834-0100 |
Phosphatase inhibitor library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Phosphatase Inhibitor Library contains 33 known phosphatase inhibitors of well-defined activity. Inhibitors are supplied dissolved in DMSO at 10 mM and aliquoted into deep-well plates at either 100ul or 500ul per well. The library is ideal for chemical genomics, assay development, and as a reference set for secondary screening. Includes inhibitors of these important phosphatases: Calcineurin(PP2B), JSP-1, PRL-1, CD45, PP1, PRL-3, CDC25, PP2A, PTEN, and many more.
|
|
·àʪ |
BML |
BML-2834-0500 |
Phosphatase inhibitor library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Phosphatase Inhibitor Library contains 33 known phosphatase inhibitors of well-defined activity. Inhibitors are supplied dissolved in DMSO at 10 mM and aliquoted into deep-well plates at either 100ul or 500ul per well. The library is ideal for chemical genomics, assay development, and as a reference set for secondary screening. Includes inhibitors of these important phosphatases: Calcineurin(PP2B), JSP-1, PRL-1, CD45, PP1, PRL-3, CDC25, PP2A, PTEN, and many more.
|
|
·àʪ |
BML |
BML-2835-0100 |
REDOX library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well REDOX library contains 84 compounds with defined prooxidant or antioxidant activity. Compounds are dissolved in DMSO at 10mM and aliquoted into deep-well plates at 100 or 500ul per well.A variety of structurally and mechanistically different compound classes are included such as hydroperoxides, polyphenolics, metal chelators, thiols, thiol traps, radical scavengers, lazaroids and glutathione modulators as well as small molecule enzyme mimetics for SOD and glutathione peroxidase.
|
|
·àʪ |
BML |
BML-2835-0500 |
REDOX library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well REDOX library contains 84 compounds with defined prooxidant or antioxidant activity. Compounds are dissolved in DMSO at 10mM and aliquoted into deep-well plates at 100 or 500ul per well.A variety of structurally and mechanistically different compound classes are included such as hydroperoxides, polyphenolics, metal chelators, thiols, thiol traps, radical scavengers, lazaroids and glutathione modulators as well as small molecule enzyme mimetics for SOD and glutathione peroxidase.
|
|
·àʪ |
BML |
BML-2836-0100 |
Epigenetics library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Application: Useful tool for chemical genomics, assay development, or other pharmacological applications in the study of epigenetic modifications of lysine and DNA methylation.. Kit Contents: 43 compounds supplied in DMSO at a concentration of 10mM.
|
|
·àʪ |
BML |
BML-2836-0500 |
Epigenetics Library(500ul/well) |
Pack |
¾È²ñ |
|
none |
|
|
|
·àʪ |
BML |
BML-2837-0100 |
Autophagy Library(100ul/well) |
Pack |
¾È²ñ |
|
none |
|
|
|
·àʪ |
BML |
BML-2837-0500 |
Autophagy Library(500ul/well) |
Pack |
¾È²ñ |
|
none |
|
|
|
·àʪ |
BML |
BML-2838-0100 |
Wnt Pathway Library |
Pack |
¾È²ñ |
|
none |
|
|
|
·àʪ |
BML |
BML-2838-0500 |
Wnt Pathway Library |
Pack |
¾È²ñ |
|
none |
|
|
|
·àʪ |
BML |
BML-2840-0100 |
ICCB Known Bioactives Library(100 ul/well) |
Pack |
¾È²ñ |
|
none |
|
|
|
·àʪ |
BML |
BML-2841-0100 |
FDA Approved Drug Library(100 ul/well) |
Pack |
¾È²ñ |
|
none |
|
|
|
·àʪ |
BML |
BML-2841-0500 |
FDA Approved Drug Library(500 ul/well) |
Pack |
¾È²ñ |
|
none |
|
|
|
·àʪ |
BML |
BML-2842-0100 |
FDA Approved Drug Library (10mM)(100 ul/well) |
Pack |
¾È²ñ |
|
none |
|
|
|
·àʪ |
BML |
BML-2842-0500 |
FDA Approved Drug Library (10mM)(500 ul/well) |
Pack |
¾È²ñ |
|
none |
|
|
|
ÆÇʪ |
BML |
BML-2850-0100 |
Cardiotoxicity library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Cardiotoxicity Library is a focused collection of 131 compounds with defined and diverse cardiotoxicity, including ion channel blockage, mitochondrial toxicity, arrhythmia, fibrosis, and many more. A variety of structurally and mechanistically different compound classes are included, as well as nontoxic controls. The compounds are dissolved in DMSO at 10mM and aliquoted into deep-well plates. The library is an essential tool for predictive toxicology screening and assay development. Kit/Set Contains: 131 compounds with defined and diverse cardiotoxicity. A variety of structurally and mechanistically different compound classes, as well as nontoxic controls, are included.
|
|
ÆÇʪ |
BML |
BML-2850-0500 |
Cardiotoxicity library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Cardiotoxicity Library is a focused collection of 131 compounds with defined and diverse cardiotoxicity, including ion channel blockage, mitochondrial toxicity, arrhythmia, fibrosis, and many more. A variety of structurally and mechanistically different compound classes are included, as well as nontoxic controls. The compounds are dissolved in DMSO at 10mM and aliquoted into deep-well plates. The library is an essential tool for predictive toxicology screening and assay development. Kit/Set Contains: 131 compounds with defined and diverse cardiotoxicity. A variety of structurally and mechanistically different compound classes, as well as nontoxic controls, are included.
|
|
·àʪ |
BML |
BML-2851-0100 |
Hepatotoxicity library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Hepatotoxicity Library is a focused collection of 240 compounds with defined and diverse hepatotoxicity, including steatosis, mitochondrial toxicity, Mallory body formation, cholestatic effects, and many more. A variety of structurally and mechanistically different compound classes are included, as well as nontoxic controls. The compounds are dissolved in DMSO at 10mM and aliquoted into deep-well plates. The library is an essential tool for predictive toxicology screening and assay development. Kit/Set Contains: 240 compounds with defined and diverse hepatotoxicity. A variety of structurally and mechanistically different compound classes, as well as nontoxic controls, are included.
|
|
·àʪ |
BML |
BML-2851-0500 |
Hepatotoxicity library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Hepatotoxicity Library is a focused collection of 240 compounds with defined and diverse hepatotoxicity, including steatosis, mitochondrial toxicity, Mallory body formation, cholestatic effects, and many more. A variety of structurally and mechanistically different compound classes are included, as well as nontoxic controls. The compounds are dissolved in DMSO at 10mM and aliquoted into deep-well plates. The library is an essential tool for predictive toxicology screening and assay development. Kit/Set Contains: 240 compounds with defined and diverse hepatotoxicity. A variety of structurally and mechanistically different compound classes, as well as nontoxic controls, are included.
|
|
¡¡ |
BML |
BML-2852-0100 |
Hematopoietic toxicity library(100 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Hematopoietic Toxicity Library is a focused collection of 116 compounds with defined and diverse hematopoietic toxicity, including myelosuppression, neutropenia, leukopenia, anemia, and many more. A variety of structurally and mechanistically different compound classes are included, as well as nontoxic controls. The compounds are dissolved in DMSO at 10mM and aliquoted into deep-well plates. The library is an essential tool for predictive toxicology screening and assay development. Kit/Set Contains: 116 compounds with defined and diverse hematopoietic toxicity. A variety of structurally and mechanistically different compound classes, as well as nontoxic controls, are included.
|
|
¡¡ |
BML |
BML-2852-0500 |
Hematopoietic toxicity library(500 ul/well) |
Pack |
¾È²ñ |
-80¡î |
none |
|
Description: The Screen-Well Hematopoietic Toxicity Library is a focused collection of 116 compounds with defined and diverse hematopoietic toxicity, including myelosuppression, neutropenia, leukopenia, anemia, and many more. A variety of structurally and mechanistically different compound classes are included, as well as nontoxic controls. The compounds are dissolved in DMSO at 10mM and aliquoted into deep-well plates. The library is an essential tool for predictive toxicology screening and assay development. Kit/Set Contains: 116 compounds with defined and diverse hematopoietic toxicity. A variety of structurally and mechanistically different compound classes, as well as nontoxic controls, are included.
|
|
·àʪ |
BML |
BML-2865-0100 |
Natural Products Library(100ul/well) |
Pack |
¾È²ñ |
|
none |
|
|
|
·àʪ |
BML |
BML-2865-0500 |
Natural Products Library(500ul/well) |
Pack |
¾È²ñ |
|
none |
|
|
|
¡¡ |
BML |
BML-A150-0005 |
Alamethacin ¡ÚU-22324¡Û |
5mg |
¡ï14,000 |
|
27061-78-5, 59588-86-2 |
|
|
|
¡¡ |
BML |
BML-A150-0025 |
Alamethacin ¡ÚU-22324¡Û |
25mg |
¡ï58,000 |
|
27061-78-5, 59588-86-2 |
|
|
|
¡¡ |
BML |
BML-A165-0001 |
Ascomycin ¡ÚFK520¡Û(Isolated from Streptomyces sp) |
1mg |
¡ï21,000 |
|
11011-38-4 |
|
|
|
¡¡ |
BML |
BML-A190-0020 |
Clindamycin, HCl ¡ÚU-21251F¡Û |
20mg |
¡ï5,000 |
|
21462-39-5 |
|
|
|
¡¡ |
BML |
BML-A190-0100 |
Clindamycin, HCl ¡ÚU-21251F¡Û |
100mg |
¡ï22,000 |
|
21462-39-5 |
|
|
|
¡¡ |
BML |
BML-A192-0020 |
Clindamycin Phosphate ¡ÚU-28508E¡Û |
20mg |
¡ï5,000 |
|
24729-96-2 |
|
|
|
¡¡ |
BML |
BML-A192-0100 |
Clindamycin Phosphate ¡ÚU-28508E¡Û |
100mg |
¡ï21,000 |
|
24729-96-2 |
|
|
|
¡¡ |
BML |
BML-A195-0100 |
Cyclosporin A ¡ÚCsA¡Û(Isolated from Fusarium solani) |
100mg |
¡ï7,000 |
|
59865-13-3 |
|
|
|
¡¡ |
BML |
BML-A195-0500 |
Cyclosporin A ¡ÚCsA¡Û(Isolated from Fusarium solani) |
500mg |
¡ï28,000 |
|
59865-13-3 |
|
|
|
¡¡ |
BML |
BML-A201-0020 |
Daptomycin ¡ÚCubicin¡Û¡ÚLY146032¡Û |
20mg |
¡ï12,000 |
|
103060-53-3 |
|
|
|
¡¡ |
BML |
BML-A201-0100 |
Daptomycin ¡ÚCubicin¡Û¡ÚLY146032¡Û |
100mg |
¡ï46,000 |
|
103060-53-3 |
|
|
|
¡¡ |
BML |
BML-A230-0010 |
Decoyinine ¡ÚU-7984¡Û¡ÚAngustmycin A¡Û¡Ú9-(6-Deoxy-D-B-erythro-hex-5-en-2-ulofuranosyl)-adenine¡Û¡Ú9-[Tetrahydro-3,4-dihydroxy-2-(hydroxymethyl0-5-methylene-2-furyl]¡Û |
10mg |
¡ï14,000 |
|
2004-04-8 |
|
|
|
¡¡ |
BML |
BML-A230-0050 |
Decoyinine ¡ÚU-7984¡Û¡ÚAngustmycin A¡Û¡Ú9-(6-Deoxy-D-B-erythro-hex-5-en-2-ulofuranosyl)-adenine¡Û¡Ú9-[Tetrahydro-3,4-dihydroxy-2-(hydroxymethyl0-5-methylene-2-furyl]¡Û |
50mg |
¡ï56,000 |
|
2004-04-8 |
|
|
|
¡¡ |
BML |
BML-A239-0001 |
Kasugamycin(Isolated from Streptomyces kasugaensis) |
1g |
¡ï8,000 |
|
6980-18-3 |
|
|
|
¡¡ |
BML |
BML-A240-0001 |
Lincomycin ¡ÚU-10149A¡Û(Isolated from Streptomyces lincolnensis) |
1g |
¡ï8,000 |
|
154-21-2 |
|
|
|
¡¡ |
BML |
BML-A240-0005 |
Lincomycin ¡ÚU-10149A¡Û(Isolated from Streptomyces lincolnensis) |
5g |
¡ï33,000 |
|
154-21-2 |
|
|
|
¡¡ |
BML |
BML-A245-0010 |
Lomofungin ¡ÚU-24792¡Û |
10mg |
¡ï10,000 |
|
26786-84-5 |
|
|
|
¡¡ |
BML |
BML-A245-0050 |
Lomofungin ¡ÚU-24792¡Û |
50mg |
¡ï39,000 |
|
26786-84-5 |
|
|
|
¡¡ |
BML |
BML-A249-0100 |
Mycophenolic Acid(Isolated from Penicillium brevi-compactum)¡Ú6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexanoic Acid¡Û |
100mg |
¡ï8,000 |
|
24280-93-1 |
|
|
|
¡¡ |
BML |
BML-A249-0500 |
Mycophenolic Acid(Isolated from Penicillium brevi-compactum)¡Ú6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexanoic Acid¡Û |
500mg |
¡ï32,000 |
|
24280-93-1 |
|
|
|
¡¡ |
BML |
BML-A256-0001 |
Novobiocin Sodium salt ¡ÚU-6591¡Û¡ÚAlbamycin¡Û¡ÚStreptonivicin¡Û¡ÚN-[7-[[3-O-Aminocarbonyl-6-deoxy-5-C-methyl-4-O-B-L-lyxo-hexapyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3 |
1g |
¡ï7,000 |
|
1476-53-5 |
|
|
|
¡¡ |
BML |
BML-A256-0005 |
Mycophenolic Acid(Isolated from Penicillium brevi-compactum)¡Ú6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexanoic Acid¡Û |
5g |
¡ï29,000 |
|
1476-53-5 |
|
|
|
¡¡ |
BML |
BML-A260-0050 |
Puromycin Aminonucleoside ¡Ú3'-Amino-3'-deoxy-N,N-dimethyladenosine¡Û |
50mg |
¡ï25,000 |
|
58-60-6 |
|
|
|
¡¡ |
BML |
BML-A275-0005 |
Rapamycin ¡ÚSirolimus¡Û¡ÚAY-22,989¡Û¡ÚRAPA¡Û¡ÚRapamune¡Û |
5mg |
¡ï21,000 |
|
53123-88-9 |
|
|
|
¡¡ |
BML |
BML-A275-0025 |
Rapamycin ¡ÚSirolimus¡Û¡ÚAY-22,989¡Û¡ÚRAPA¡Û¡ÚRapamune¡Û |
25mg |
¡ï53,000 |
|
53123-88-9 |
|
|
|
¡¡ |
BML |
BML-A280-0010 |
Spectinomycin, 2HCl ¡ÚU-18409AE¡Û¡ÚSpectinomycin, 2HCl, 5H2O ¡Û |
10g |
¡ï14,000 |
|
22189-32-8 (21736-83-4) |
|
|
|
¡¡ |
BML |
BML-A281-0010 |
Spectinomycin, Sulfate ¡ÚU-18409E¡Û |
10g |
¡ï8,000 |
|
64058-48-6 |
|
|
|
¡¡ |
BML |
BML-A283-0100 |
2,4-Pyridinedicarboxylic Acid, H2O |
100mg |
¡ï3,000 |
|
499-80-9 |
|
|
|
¡¡ |
BML |
BML-AA1105-0025 |
Atrial Natriuretic Peptide ¡ÚANP¡Û(human, aa 1-28), rabbit pAb. |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ pig | IHC |
|
|
¡¡ |
BML |
BML-AA1105-0100 |
Atrial Natriuretic Peptide ¡ÚANP¡Û(human, aa 1-28), rabbit pAb. |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ pig | IHC |
|
|
¡¡ |
BML |
BML-AA6240-0100 |
Adrenocorticotropic Hormone ¡ÚACTH¡Û(peptide, aa 1-24)(NT)[57], mouse mAb, purified |
100ul |
¡ï22,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 57 | human¡¢ rat¡¢ monkey | IHC |
|
|
¡¡ |
BML |
BML-AA6240-0500 |
Adrenocorticotropic Hormone ¡ÚACTH¡Û(peptide, aa 1-24)(NT)[57], mouse mAb, purified |
500ul |
¡ï51,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 57 | human¡¢ rat¡¢ monkey | IHC |
|
|
¡¡ |
BML |
BML-AA6244-0100 |
Atrial Natriuretic Peptide ¡ÚANP¡Û(human, aa 1-28)(recombinant)[23/1], mouse mAb, purified |
100ul |
¡ï22,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 23/1. | human | IHC |
|
|
¡¡ |
BML |
BML-AA6244-0500 |
Atrial Natriuretic Peptide ¡ÚANP¡Û(human, aa 1-28)(recombinant)[23/1], mouse mAb, purified |
500ul |
¡ï51,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 23/1. | human | IHC |
|
|
¡¡ |
BML |
BML-AD100-0020 |
PD 116,948 ¡Ú8-Cyclopentyl-1,3-dipropylxanthine¡Û |
20mg |
¡ï8,000 |
|
102146-07-6 |
|
|
|
¡¡ |
BML |
BML-AD100-0100 |
PD 116,948 ¡Ú8-Cyclopentyl-1,3-dipropylxanthine¡Û |
100mg |
¡ï32,000 |
|
102146-07-6 |
|
|
|
¡¡ |
BML |
BML-AD101-0050 |
S-(4-Nitrobenzyl)-6-thioinosine ¡ÚNBTI¡Û¡ÚNBMPR¡Û |
50mg |
¡ï17,000 |
|
38048-32-7 |
|
|
|
¡¡ |
BML |
BML-AG6070-0100 |
a-Actinin(chicken gizzard)[CB11], mouse mAb, purified |
100ul |
¡ï24,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | CB11 | mammalian¡¢ chicken | WB¡¢ ICC |
|
|
¡¡ |
BML |
BML-AK004-0001 |
Caspase Colorimetric Quantipak |
Kit |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK005-0001 |
Caspase Fluorescent(AMC)Quantipak |
Kit |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK006-0001 |
Caspase Fluorescent(AFC)Quantipak |
Kit |
¡ï15,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK010-0001 |
MultiCasPak-4 Active Caspases |
Kit |
¡ï84,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK011-0001 |
ApoCourse-1: Time Course of Etoposide-induced Apoptosis |
Kit |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK012-0001 |
ApoCourse-2: Time Course of TRAIL-induced Apoptosis |
Kit |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK013-0001 |
Matrix Metalloproteinase ¡ÚMMP¡Û Multipack-1 |
Kit |
¡ï80,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK014-0001 |
Matrix Metalloproteinase ¡ÚMMP¡Û Multipack-2 |
Kit |
¡ï80,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK015-0001 |
MMP Inhibitor Profiling Kit ¡ÚMatrix Metalloproteinase Inhibitor Profiling Kit¡Û, Colorimetric |
Kit |
¡ï104,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK016-0001 |
MMP Inhibitor Profiling Kit ¡ÚMatrix Metalloproteinase Inhibitor Profiling Kit¡Û, Fluorimetric |
Kit |
¡ï111,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK020-0001 |
Dual Specificity Phosphatase Multipack |
1set |
¡ï109,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK021-0001 |
Tyrosine Phosphatase Multipack |
1set |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK111-0250 |
BIOMOL Green Reagent |
250ml |
¡ï15,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK111-1000 |
BIOMOL Green Reagent |
1L |
¡ï40,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK115-0001 |
Sulforhodamine MultiCaspase Activity Kit(100 tests) |
Kit |
¡ï61,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK116-0001 |
Mit-E-¦× Mitochondrial Permeability Detection Kit(100 tests) |
Kit |
¡ï50,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK117-0001 |
Carboxyfluorescein Multi-Caspase Activity Kit |
Kit |
¡ï63,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK118-0001 |
CV-Caspase 3 & 7 Detection Kit ¡ÚCresyl Violet-Caspase 3 & 7 Detection Kit¡Û |
Kit |
¡ï29,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK120-0001 |
ApoStrand ELISA Apoptosis Detection Kit |
96wells |
¡ï65,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK125-0001 |
CV-Cathepsin B Dectection Kit ¡ÚCresyl Violet-Cathepsin B Dectection Kit¡Û |
Kit |
¡ï29,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK126-0001 |
CV-Cathepsin K Detection Kit ¡ÚCresyl Violet-Cathepsin K Detection Kit¡Û |
Kit |
¡ï29,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK127-0001 |
CV-Cathepsin L Detection Kit ¡ÚCresyl Violet-Cathepsin L Detection Kit¡Û |
Kit |
¡ï29,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK170-0001 |
ALDetect Lipid Peroxidation Assay Kit(100 assays) |
Kit |
¡ï69,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK171-0001 |
ALDetect(MDA-specific)Lipid Peroxidation Assay Kit(25 assays) |
Kit |
¡ï76,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK301-0001 |
Matrix Metalloproteinase-1 ¡ÚMMP-1 Kit¡Û Fluorometric Drug Discovery Kit, RED |
Kit |
¡ï65,000 |
-80¡î |
none |
|
Application: Designed to screen MMP-1 inhibitors using a quenched fluorogenic peptide. Kit Contents: 1 vial MMP-1 enzyme, 1 vial substrate (OmniMMP RED), 1 vial 6'-TAMRA calibration standard, 1 vial control inhibitor (NNGH), 1 bottle (20 ml) assay buffer, 1 black 96-well microplate, Instructions
|
|
¡¡ |
BML |
BML-AK302-0001 |
Matrix Metalloproteinase-2 ¡ÚMMP-2 Kit¡Û Fluorometric Drug Discovery Kit, RED |
Kit |
¡ï65,000 |
-80¡î |
none |
|
Application: Designed to screen MMP-2 inhibitors using a quenched fluorogenic peptide. Kit Contents: 1 vial MMP-2 enzyme, 1 vial substrate (OmniMMP RED), 1 vial 6'-TAMRA calibration standard, 1 vial control inhibitor (NNGH), 1 bottle (20 ml) assay buffer, 1 black 96-well microplate, Instructions
|
|
¡¡ |
BML |
BML-AK303-0001 |
Matrix Metalloproteinase-3 ¡ÚMMP-3 Kit¡Û Fluorometric Drug Discovery Kit, GREEN |
Kit |
¡ï65,000 |
-80¡î |
none |
|
Application: Designed to screen MMP-3 inhibitors using a quenched fluorogenic substrate. Kit Contents: 1 vial MMP-3 enzyme, 1 vial substrate (MMP-3 fluorogenic substrate), 1 vial 5-FAM calibration standard, 1 vial control inhibitor (NNGH), 1 bottle (20 ml) assay buffer, 1 black 96-well microplate, Instructions
|
|
¡¡ |
BML |
BML-AK304-0001 |
Matrix Metalloproteinase-7 ¡ÚMMP-7 Kit¡Û Fluorometric Drug Discovery Kit, RED |
Kit |
¡ï65,000 |
-80¡î |
none |
|
Application: Designed to screen MMP-7 inhibitors using a quenched fluorogenic peptide. Kit Contents: 1 vial MMP-7 enzyme, 1 vial substrate (OmniMMP RED), 1 vial 6'-TAMRA calibration standard. 1 vial control inhibitor (NNGH), 1 bottle (20 ml) assay buffer, 1 black 96-well microplate, Instructions
|
|
¡¡ |
BML |
BML-AK305-0001 |
Matrix Metalloproteinase-8 ¡ÚMMP-8 Kit¡Û Fluorometric Drug Discovery Kit, RED |
Kit |
¡ï65,000 |
-80¡î |
none |
|
Application: Designed to screen MMP-8 inhibitors using a quenched fluorogenic peptide. Kit Contents: 1 vial MMP-8 enzyme, 1 vial Substrate (OmniMMP RED). 1 vial 6¡Ç-TAMRA calibration standard, 1 vial control inhibitor (NNGH), 1 bottle (20 ml) assay buffer, 1 black 96-well microplate, Instructions
|
|
¡¡ |
BML |
BML-AK306-0001 |
Matrix Metalloproteinase-9 ¡ÚMMP-9 Kit¡Û Fluorometric Drug Discovery Kit, RED |
Kit |
¡ï65,000 |
-80¡î |
none |
|
Kit/Set Contains: 1 vial MMP-9 enzyme, 1 vial Substrate (OmniMMP RED), 1 vial 6¡Ç-TAMRA calibration standard, 1 vial control inhibitor (NNGH), 1 bottle (20 ml) assay buffer, 1 black 96-well microplate, Instructions
|
|
¡¡ |
BML |
BML-AK307-0001 |
Matrix Metalloproteinase-19 ¡ÚMMP-19 Kit¡Û Fluorometric Drug Discovery Kit, RED |
Kit |
¡ï63,000 |
-80¡î |
none |
|
Application: Designed to screen MMP-19 inhibitors using a quenched fluorogenic peptide. Kit Contents: 1 vial MMP-19 enzyme, 1 vial Substrate (OmniMMP RED), 1 vial 6¡Ç-TAMRA calibration standard, 1 vial control inhibitor (NNGH), 1 bottle (20 ml) assay buffer, 1 black 96-well microplate, Instructions
|
|
¡¡ |
BML |
BML-AK308-0001 |
Matrix Metalloproteinase(MMP)Inhibitor Profiling Kit ¡ÚMMP inhibitor profiling kit¡Û, Fluorometric RED |
Kit |
¡ï116,000 |
-80¡î |
none |
|
Application: Designed to examine the specificity of inhibitors against a panel of ten matrix metalloproteinase enzymes, using a quenched fluorogenic peptide. Kit Contents: 10 vials (10 MMP enzymes), 1 vial Substrate (OmniMMP RED), 1 vial 6'-TAMRA calibration standard, 1 vial control inhibitor (NNGH), 2 bottles (20 ml each) assay buffer, 1 black 96-well microplate, Instructions
|
|
¡¡ |
BML |
BML-AK310-0001 |
ADAM17 Fluorometric Drug Discovery Kit |
Kit |
¡ï56,000 |
-80¡î |
none |
|
Application: Designed to screen ADAM17 (TACE) inhibitors using a quenched fluorogenic peptide. Kit Contents: 1 vial ADAM17 enzyme, 1 vial Substrate (Mca-PLAQAV-Dpa-RSSSR-NH2), 1 vial DMSO, 1 vial CALIBRATION STANDARD, 1 vial control inhibitor (GM6001), 1 bottle (20 ml) assay buffer, 1 black 96-well microplate, Instructions
|
|
¡¡ |
BML |
BML-AK311-0001 |
Matrix Metalloproteinase-3 ¡ÚMMP-3 Kit¡Û Fluorometric Drug Discovery Kit, RED |
Kit |
¡ï63,000 |
-80¡î |
none |
|
Application: Designed to screen MMP-3 inhibitors using a quenched fluorogenic peptide. Kit Contents: 1 vial MMP-3 enzyme, 1 vial substrate (OmniMMP RED), 1 vial 6'-TAMRA calibration standard, 1 vial control inhibitor (NNGH), 1 bottle (20 ml) assay buffer, 1 black 96-well microplate, Instructions
|
|
¡¡ |
BML |
BML-AK312-0001 |
Matrix Metalloproteinase-12 ¡ÚMMP-12 Kit¡Û Fluorometric Drug Discovery Kit, GREEN |
Kit |
¡ï63,000 |
-80¡î |
none |
|
Application: Designed to screen MMP-12 inhibitors using a quenched fluorogenic substrate.. Kit Contents: 1 vial MMP-12 enzyme, 1 vial substrate (MMP-3 fluorogenic substrate), 1 vial 5-FAM calibration standard, 1 vial control inhibitor (NNGH), 1 bottle (20 ml) assay buffer, 1 black 96-well microplate, Instructions
|
|
¡¡ |
BML |
BML-AK400-0001 |
Matrix Metalloproteinase-3 ¡ÚMMP-3¡Û¡ÚStromelysin-1¡Û¡ÚTransin¡Û Drug Discovery Kit(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK401-0001 |
Matrix Metalloproteinase-3 ¡ÚMMP-3¡Û¡ÚStromelysin-1¡Û¡ÚTransin¡Û Fluorescent Assay Kit for Drug Discovery(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK402-0001 |
Matrix Metalloproteinase-12 ¡ÚMMP-12¡Û Colorimetric Drug Discovery Kit(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK403-0001 |
Matrix Metalloproteinase-12 ¡ÚMMP-12¡Û Fluorescent Assay Kit for Drug Discovery(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK404-0001 |
Matrix Metalloproteinase-1 ¡ÚMMP-1¡Û Colorimetric Drug Discovery Kit(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK405-0001 |
Matrix Metalloproteinase-1 ¡ÚMMP-1¡Û Fluorescent Assay Kit for Drug Discovery(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK406-0001 |
Matrix Metalloproteinase-7 ¡ÚMMP-7¡Û Colorimetric Drug Discovery Kit(1 x 96-well plate) |
Kit |
¡ï57,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK407-0001 |
Matrix Metalloproteinase-7 ¡ÚMMP-7¡Û Fluorescent Assay Kit for Drug Discovery(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK408-0001 |
Matrix Metalloproteinase-2 ¡ÚMMP-2¡Û Colorimetric Drug Discovery Kit(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK409-0001 |
Matrix Metalloproteinase-2 ¡ÚMMP-2¡Û Fluorescent Assay Kit for Drug Discovery(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK410-0001 |
Matrix Metalloproteinase-9 ¡ÚMMP-9¡Û¡ÚGelatinase B¡Û¡Ú92 kDa Type IV Collagenase¡Û Colorimetric Drug Discovery Kit(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK411-0001 |
Matrix Metalloproteinase-9 ¡ÚMMP-9¡Û¡ÚGelatinase B¡Û¡Ú92 kDa Type IV Collagenase¡Û Fluorescent Assay Kit for Drug Discovery(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK412-0001 |
Matrix Metalloproteinase-13 ¡ÚMMP-13¡Û Colorimetric Drug Discovery Kit(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK413-0001 |
Matrix Metalloproteinase-13 ¡ÚMMP-13¡Û Fluorescent Assay Kit for Drug Discovery(1 x 96-well plate) |
Kit |
¡ï57,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK414-0001 |
Matrix Metalloproteinase-8 ¡ÚMMP-8¡Û Colorimetric Drug Discovery Kit(1 x 96-well plate) |
Kit |
¡ï57,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK415-0001 |
Matrix Metalloproteinase-8 ¡ÚMMP-8¡Û Fluorescent Assay Kit for Drug Discovery(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK416-0001 |
Matrix Metalloproteinase-14 ¡ÚMMP-14¡Û Colorimetric Drug Discovery Kit(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK417-0001 |
Matrix Metalloproteinase-14 ¡ÚMMP-14¡Û Fluorescent Assay Kit for Drug Discovery(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK418-0001 |
Matrix Metalloproteinase-10 ¡ÚMMP-10¡Û Colorimetric Drug Discovery Kit(1 x 96-well plate) |
Kit |
¡ï56,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK419-0001 |
Matrix Metalloproteinase-10 ¡ÚMMP-10¡Û Fluorescent Assay Kit for Drug Discovery(1 x 96-well plate) |
Kit |
¡ï57,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK422-0001 |
Matrix Metalloproteinase-20 ¡ÚMMP-20¡Û Colorimetric Drug Discovery Kit(1 x 96-well plate) |
Kit |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK430-0001 |
Cathepsin K Drug Discovery Kit(96 assays) |
Kit |
¡ï56,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK431-0001 |
Cathepsin S Drug Discovery Kit(96 assays) |
Kit |
¡ï56,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK497-0001 |
Neutrophil Elastase Colorimetric Drug Discovery Kit(96 assays) |
Kit |
¡ï52,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK498-0001 |
DPPIV/CD26 Assay Kit ¡ÚCD26 Assay Kit¡Û¡ÚDipeptidyl Peptidase IV Assay Kit¡Û for biological samples(96 assays) |
Kit |
¡ï51,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK499-0001 |
DPPIV Drug Discovery Kit ¡ÚCD26 Drug Discovery kit¡Û¡ÚDipeptidyl Peptidase IV Drug Discovery Kit¡Û¡ÚDPP4 Drug Discovery Kit¡Û(96 assays) |
Kit |
¡ï63,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK500-0001 |
Fluor-de-Lys HDAC Fluorometric Activity Assay Kit ¡ÚHDAC Fluorometric Activity Assay Kit¡Û¡ÚHistone Deacetylase Fluorescent Assay Kit¡Û(96 assays) |
Kit |
¡ï57,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK501-0001 |
Color-de-Lys HDAC Colorimetric Activity Assay Kit ¡ÚHDAC Colorimetric Activity Assay Kit¡Û¡ÚHistone Deacetylase Colorimetric Assay Kit¡Û(96 assays) |
Kit |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK503-0001 |
Fluor-de-Lys HDAC Fluorometric Cellular Activity Assay Kit ¡ÚHDAC Fluorometric Cellular Activity Assay¡Û¡ÚCellular Histone Deacetylase Fluorescent Assay Kit¡Û(96 assays) |
Kit |
¡ï52,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK511-0001 |
Fluor-de-Lys HDAC1 Fluorometric Drug Discovery Assay Kit ¡ÚHDAC1 Fluorometric Drug Discovery Assay Kit¡Û¡ÚHistone Deacetylase 1 Fluorescent Assay Kit¡Û(96 assays) |
Kit |
¡ï77,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK512-0001 |
Fluor-de-Lys-Green HDAC2 Fluorometric Drug Discovery Assay Kit ¡ÚGreen HDAC2 Fluorometric Drug Discovery Assay Kit¡Û¡ÚHDAC2 Fluorometric Drug Discovery Assay Kit, Green-¡Û(96-192 assays) |
Kit |
¡ï77,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK513-0001 |
Fluor-de-Lys SIRT5 Fluorometric Drug Discovery Assay Kit ¡ÚSirtuin 5 fluorescent assay kit¡Û(100 assays) |
Kit |
¡ï74,000 |
-80¡î |
none |
|
Description: The SIRT5 Fluorometric Drug Discovery Kit is a complete assay system designed to measure the lysyl desuccinylase activity of the recombinant human SIRT5 included in the kit. A black 96-well microplate is packaged with the kit, but it should be noted that reagents of the Fluor de Lys system have also been successfully employed in other formats, including cuvettes and 384-well plates. The SIRT5 Fluorometric Activity Assay is based on the unique Fluor de Lys-Succinyl Substrate/Developer combination. Kit/Set Contains: SIRT5 (Sirtuin 5) (human, rec.), Succinyl, Desuccinylase Substrate, Developer Concentrate (20x), NAD+ (Sirtuin Substrate), Nicotinamide (Sirtuin Inhibitor), Suramin sodium (Sirtuin Inhibitor), Desuccinylated Standard, Sirtuin Assay Buffer, 1/2 Volume Black NBS Microplate
|
|
¡¡ |
BML |
BML-AK514-0001 |
Fluor-de-Lys Green SIRT5 Fluorometric Green Drug Discovery Assay Kit ¡ÚGreen Sirtuin 5 fluorescent assay kit¡Û¡ÚSirtuin 5, Green-, fluorescent assay kit¡Û(100 assays) |
Kit |
¡ï74,000 |
-80¡î |
none |
|
Description: The Fluor de LysGreen SIRT5 Fluorometric Drug Discovery Kitis a complete assay system designed to measure the lysyl desuccinylase activity of the recombinant human SIRT5 included in the kit. A black 96-well microplate is packaged with the kit, but it should be noted that reagents of the Fluor de Lyssystem have also been successfully employed in other formats, including cuvettes and 384-well plates. Kit/Set Contains: SIRT5 (Sirtuin 5) (human, recombinant), Succinyl Green, Desuccinylase Substrate, Developer Concentrate (20x), NAD+ (Sirtuin Substrate), Nicotinamide (Sirtuin Inhibitor), Suramin sodium (Sirtuin Inhibitor), Green Desuccinylated Standard, Sirtuin Assay Buffer, 1/2 VOLUME BLACK NBS MICROPLATE
|
|
¡¡ |
BML |
BML-AK516-0001 |
Fluor-de-Lys HDAC6 Fluorometric Drug Discovery Kit ¡ÚHDAC6 Fluorometric Drug Discovery Kit¡Û(96 assays) |
Kit |
¡ï77,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK518-0001 |
Fluor-de-Lys HDAC8 Fluorometric Drug Discovery Kit ¡ÚHDAC8 Fluorometric Drug Discovery Kit¡Û¡ÚHistone Deacetylase 8 Fluorescent Assay Kit¡Û(96 assays) |
Kit |
¡ï77,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK530-0001 |
Fluor-de-Lys-Green HDAC Fluorometric Activity Assay Kit ¡ÚGreen HDAC Fuorometric Activity Assay Kit¡Û¡ÚHDAC Fluorometric Activity Assay Kit, Green-¡Û¡ÚHistone Deacetylase Green Fluorescent Assay Kit¡Û |
Kit |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK531-0001 |
Fluor-de-Lys HDAC3/NCOR1 Fluorometric Drug Discovery Kit ¡ÚNCOR1 Fluorometric Drug Discovery Kit¡Û¡ÚHistone deacetylase 3/Nuclear Receptor Corepressor 1 Fluorometric Drug Discovery Kit¡Û(96-192 assays |
Kit |
¡ï77,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK532-0001 |
Chemilum de LysTM HDAC/SIRT Chemiluminescent Drug Discovery Kit ¡ÚHistone deacetylase fluorescent assay kit¡Û¡ÚSIRT Chemiluminescent drug discovery kit¡Û |
Kit |
¡ï74,000 |
-80¡î |
none |
|
Description: The HDAC/SIRT Chemiluminescent Drug Discovery Kit is a complete assay system designed to measure histone deacetylase (HDAC) and sirtuin activity in cell or nuclear extracts, immunoprecipitates or purified enzymes. It comes in a convenient 96-well format, with all reagents necessary for fluorescent HDAC activity measurements and calibration of the assay. In addition, a HeLa nuclear extract, rich in HDAC activity, is included with the kit. The extract is useful as either a positive control or as the source of HDAC activity for inhibitor/drug screening. Kit/Set Contains: Nuclear Extract from HeLa Cells, Substrate, Developer Concentrate, Trichostatin A (HDAC Inhibitor) , NAD (Sirtuin Substrate), Nicotinamide (Sirtuin Inhibitor), HDAC Assay Buffer, DeveloperBuffer, Enhancer part A, Enhancer part B, 1/2 volume white microplate
|
|
¡¡ |
BML |
BML-AK544-0001 |
LSD1 Fluorimetric Drug Discovery Kit ¡ÚLysine-specific Histone Demethylase 1 Fluorimetric Drug Discovery Kit¡Û¡ÚKDM1 Fluorimetric Drug Discovery Kit¡Û¡ÚAOF2 Fluorimetric Drug Discovery Kit¡Û(96 assays |
Kit |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK555-0001 |
Fluor-de-Lys SIRT1 Fluorometric Drug Discovery Assay Kit ¡ÚSIRT1 Fluorometric Drug Discovery Assay Kit¡Û¡ÚSirtuin 1 Fluorescent Assay Kit¡Û(96 assays) |
Kit |
¡ï77,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK556-0001 |
Fluor-de-Lys SIRT2 Fluorometric Drug Discovery Assay Kit ¡ÚSIRT2 Fluorometric Drug Discovery Assay Kit¡Û¡ÚSirtuin 2 Fluorescent Assay Kit¡Û(96 assays) |
Kit |
¡ï77,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK557-0001 |
Fluor-de-Lys SIRT3 Fluorometric Drug Discovery Assay Kit ¡ÚSIRT3 Fluorometric Drug Discovery Assay Kit¡Û¡ÚSirtuin 3 Fluorescent Assay Kit¡Û(96 assays) |
Kit |
¡ï77,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK601-0001 |
Inducible Nitric Oxide Synthase(iNOS)Antisense MultiOligo Pack ¡ÚiNOS Antisense MultiOligo Pack¡Û |
Set |
¡ï27,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK700-0001 |
Caspase-3 Assay Kit for Drug Discovery(96 assays) |
Kit |
¡ï62,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK701-0001 |
Caspase-1 Assay Kit for Drug Discovery(96 assays) |
Kit |
¡ï63,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK702-0001 |
Caspase-2 Assay Kit for Drug Discovery(96 assays) |
Kit |
¡ï62,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK703-0001 |
Caspase-3 Cell Assay Kit(96 assays) |
Kit |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK711-0001 |
Granzyme B Assay Kit for Drug Discovery(96 assays) |
Kit |
¡ï63,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK715-0001 |
Caspase-8 Assay Kit for Drug Discovery(96 assays) |
Kit |
¡ï62,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK740-0001 |
Proteasome 20S Assay Kit(96 assays) |
Kit |
¡ï63,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK800-0001 |
Cyclic Nucleotide Phosphodiesterase Assay Kit(96 assays) |
Kit |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK804-0001 |
Calcineurin Phosphatase Assay Kit(96 assays) |
Kit |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK812-0001 |
CD45 Tyrosine Phosphatase Assay Kit(96 assays) |
Kit |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK815-0001 |
LAR Tyrosine Phosphatase Assay Kit for Drug Discovery ¡ÚLeukocyte Antigen Related Tyrosine Phosphatase Assay Kit¡Û(96 assays) |
Kit |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK816-0001 |
Calcineurin Cellular Activity Assay Kit(96 assays) |
Kit |
¡ï57,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AK822-0001 |
PTP1B Drug Discovery Kit ¡ÚProtein Tyrosine Phosphatase-1B Drug Discovery Kit¡Û(96 assays) |
Kit |
¡ï56,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AM100-0001 |
Cyclo(Arg-Gly-Asp-D-Phe-Val)¡ÚIntegrin avB3 Antagonist¡Û |
1mg |
¡ï11,000 |
|
137813-35-5 |
|
|
|
¡¡ |
BML |
BML-AM101-0001 |
Cyclo(Arg-Ala-Asp-D-Phe-Val)¡ÚRADfv¡Û |
1mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AP101-0020 |
4-Amino-1,8-naphthalimide ¡Ú4-ANI¡Û |
20mg |
¡ï9,000 |
|
1742-95-6 |
|
|
|
¡¡ |
BML |
BML-AP101-0100 |
4-Amino-1,8-naphthalimide ¡Ú4-ANI¡Û |
100mg |
¡ï39,000 |
|
1742-95-6 |
|
|
|
¡¡ |
BML |
BML-AP102-0020 |
1,5-Isoquinolinediol |
20mg |
¡ï7,000 |
|
5154-02-9 |
|
|
|
¡¡ |
BML |
BML-AP102-0100 |
1,5-Isoquinolinediol |
100mg |
¡ï30,000 |
|
5154-02-9 |
|
|
|
¡¡ |
BML |
BML-AP200-0005 |
Sulindac Sulfide ¡ÚZ-5-Fluoro-2-methyl-1-[p-(methylthio)benzylidene]indene-3-acetic Acid¡Û |
5mg |
¡ï8,000 |
|
32004-67-4 |
|
|
|
¡¡ |
BML |
BML-AP200-0025 |
Sulindac Sulfide ¡ÚZ-5-Fluoro-2-methyl-1-[p-(methylthio)benzylidene]indene-3-acetic Acid¡Û |
25mg |
¡ï24,000 |
|
32004-67-4 |
|
|
|
¡¡ |
BML |
BML-AP201-0005 |
Sulindac Sulfone ¡ÚZ-5-Fluoro-2-methyl-1-[p-(methylsulfonyl)benzylidene]indene-3-acetic Acid¡Û |
5mg |
¡ï8,000 |
|
59864-04-9 |
|
|
|
¡¡ |
BML |
BML-AP201-0025 |
Sulindac Sulfone ¡ÚZ-5-Fluoro-2-methyl-1-[p-(methylsulfonyl)benzylidene]indene-3-acetic Acid¡Û |
25mg |
¡ï24,000 |
|
59864-04-9 |
|
|
|
¡¡ |
BML |
BML-AP302-0010 |
Bleomycin Sulfate ¡ÚBlenoxane¡Û |
10mg |
¡ï33,000 |
|
9041-93-4 |
|
|
|
¡¡ |
BML |
BML-AP302-0050 |
Bleomycin Sulfate ¡ÚBlenoxane¡Û |
50mg |
¡ï136,000 |
|
9041-93-4 |
|
|
|
¡¡ |
BML |
BML-AP303-0010 |
Bufalin ¡Ú5B,20(22)-Bufadienolide-3B,14-diol¡Û¡Ú(3B,5B)-3,14-Dihydroxybufa-20,22-dienolide¡Û |
10mg |
¡ï12,000 |
|
465-21-4 |
|
|
|
¡¡ |
BML |
BML-AP305-0005 |
Gambogic Acid |
5mg |
¡ï10,000 |
|
2752-65-0 |
|
|
|
¡¡ |
BML |
BML-AP305-0025 |
Gambogic Acid |
25mg |
¡ï40,000 |
|
2752-65-0 |
|
|
|
¡¡ |
BML |
BML-AP306-0005 |
2,3-DCPE, HCl ¡Ú2-[[3-(2,3-Dichlorophenoxy)propyl]amino]ethanol, HCl¡Û |
5mg |
¡ï8,000 |
|
418788-90-6 |
|
|
|
¡¡ |
BML |
BML-AP306-0025 |
2,3-DCPE, HCl ¡Ú2-[[3-(2,3-Dichlorophenoxy)propyl]amino]ethanol, HCl¡Û |
25mg |
¡ï34,000 |
|
418788-90-6 |
|
|
|
¡¡ |
BML |
BML-AP308-0001 |
a-Tocopheryl Succinate |
1g |
¡ï3,000 |
|
4345-03-3 |
|
|
|
¡¡ |
BML |
BML-AP309-0020 |
Necrostatin-1 ¡ÚMethylthiohydantoin-DL-tryptophan¡Û |
20mg |
¡ï10,000 |
|
4311-88-0 |
|
|
|
¡¡ |
BML |
BML-AP309-0100 |
Necrostatin-1 ¡ÚMethylthiohydantoin-DL-tryptophan¡Û |
100mg |
¡ï41,000 |
|
4311-88-0 |
|
|
|
¡¡ |
BML |
BML-AP400-0001 |
7-Aminoactinomycin D ¡Ú7-AAD¡Û |
1mg |
¡ï12,000 |
|
7240-37-1 |
|
|
|
¡¡ |
BML |
BML-AP402-0010 |
DAPI ¡Ú4¡Ç,6-Diamidino-2-phenylindole, 2HCl¡Û |
10mg |
¡ï14,000 |
|
28718-90-3 |
|
|
|
¡¡ |
BML |
BML-AP500-0005 |
C1 ¡Ú1,3-Dibutyl-2-thiooxoimidazolidine-4,5-dione¡Û |
5mg |
¡ï7,000 |
|
143413-73-4 |
|
|
|
¡¡ |
BML |
BML-AP500-0025 |
C1 ¡Ú1,3-Dibutyl-2-thiooxoimidazolidine-4,5-dione¡Û |
25mg |
¡ï27,000 |
|
143413-73-4 |
|
|
|
¡¡ |
BML |
BML-AP501-0005 |
STF-62247 ¡ÚN-(3-Methylphenyl)-4-(4-pyridinyl)-1,3-thiazol-2-amine¡Û |
5mg |
¡ï11,000 |
|
315702-99-9 |
|
|
|
¡¡ |
BML |
BML-AP501-0025 |
STF-62247 ¡ÚN-(3-Methylphenyl)-4-(4-pyridinyl)-1,3-thiazol-2-amine¡Û |
25mg |
¡ï41,000 |
|
315702-99-9 |
|
|
|
¡¡ |
BML |
BML-AP502-0025 |
3-Methyladenine ¡Ú6-Amino-3-methylpurine¡Û |
25mg |
¡ï10,000 |
|
5142-23-4 |
|
|
|
¡¡ |
BML |
BML-AP503-0005 |
Pifithrin ¦Ì ¡Ú2-Phenylethynesulfonamide¡Û |
5mg |
¡ï6,000 |
|
64984-31-2 |
|
|
|
¡¡ |
BML |
BML-AP503-0025 |
Pifithrin ¦Ì ¡Ú2-Phenylethynesulfonamide¡Û |
25mg |
¡ï23,000 |
|
64984-31-2 |
|
|
|
¡¡ |
BML |
BML-AP504-0005 |
Timosaponin AIII |
5mg |
¡ï10,000 |
|
41059-79-4 |
|
|
|
¡¡ |
BML |
BML-AP505-0010 |
Plumbagin ¡Ú5-Hydroxy-2-methyl-naphthalene-1,4-dione¡Û |
10mg |
¡ï3,000 |
|
481-42-5 |
|
|
|
¡¡ |
BML |
BML-AP600-0005 |
16F16 ¡ÚMethyl-2-(2-chloroacetyl)-1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-1-carboxylate¡Û |
5mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AP600-0025 |
16F16 ¡ÚMethyl-2-(2-chloroacetyl)-1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-1-carboxylate¡Û |
25mg |
¡ï51,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AR100-0100 |
Bopindolol Malonate |
100mg |
¡ï8,000 |
|
62658-64-4 |
|
|
|
¡¡ |
BML |
BML-AR100-0500 |
Bopindolol Malonate |
500mg |
¡ï32,000 |
|
62658-64-4 |
|
|
|
¡¡ |
BML |
BML-AR101-0010 |
(¡Þ)-Cyanopindolol Hemifumarate |
10mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AR101-0050 |
(¡Þ)-Cyanopindolol Hemifumarate |
50mg |
¡ï39,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AR102-0100 |
Guanfacine, HCl ¡ÚN-Amidino-2-(2,6-dichlorophenyl)acetamide, HCl¡Û |
100mg |
¡ï8,000 |
|
29520-14-7 |
|
|
|
¡¡ |
BML |
BML-AR102-0500 |
Guanfacine, HCl ¡ÚN-Amidino-2-(2,6-dichlorophenyl)acetamide, HCl¡Û |
500mg |
¡ï32,000 |
|
29520-14-7 |
|
|
|
¡¡ |
BML |
BML-AR103-0100 |
Tizanidine, HCl ¡Ú5-Chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazol, HCl¡Û |
100mg |
¡ï8,000 |
|
51322-75-9 |
|
|
|
¡¡ |
BML |
BML-AR103-0500 |
Tizanidine, HCl ¡Ú5-Chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazol, HCl¡Û |
500mg |
¡ï32,000 |
|
51322-75-9 |
|
|
|
¡¡ |
BML |
BML-AR104-0010 |
ICI-118,551 ¡Ú((¡Þ)-1-[2,3-(Dihydro-7-methyl-1H-inden-4-yl)oxy-3-[(1-methylethyl)amino-2-butanol), HCl¡Û |
10mg |
¡ï29,000 |
|
72795-26-7 |
|
|
|
¡¡ |
BML |
BML-AR106-0100 |
Rauwolscine, HCl ¡Úa-Yohimbine, HCl¡Û |
100mg |
¡ï12,000 |
|
6211-32-1 |
|
|
|
¡¡ |
BML |
BML-AR107-0100 |
S(-)-Propranolol, HCl ¡ÚS(-)-1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol, HCl¡Û |
100mg |
¡ï14,000 |
|
4199-10-4 |
|
|
|
¡¡ |
BML |
BML-AR108-0005 |
BRL-37344 ¡Ú(R*R*)-(¡Þ)-4-[2-[(2-(3-Chlorophenyl)-2-hydroxyethyl)amino]propyl]phenoxyacetic Acid, HCl¡Û |
5mg |
¡ï13,000 |
|
114333-71-0 |
|
|
|
¡¡ |
BML |
BML-AR109-0100 |
Urapidil, HCl ¡Ú6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione, HCl¡Û |
100mg |
¡ï8,000 |
|
64887-14-5 |
|
|
|
¡¡ |
BML |
BML-AR111-0001 |
Maprotiline, HCI ¡Ú1-(3-Methylaminopropyl)dibenzo[b,e]bicyclo[2.2.2]octadiene, HCl¡Û |
1g |
¡ï3,000 |
|
10347-81-6 |
|
|
|
¡¡ |
BML |
BML-AR112-0100 |
Carvedilol ¡Ú1-(9H-Carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol¡Û |
100mg |
¡ï7,000 |
|
72956-09-3 |
|
|
|
¡¡ |
BML |
BML-AR119-0100 |
Desipramine, HCl ¡Ú10-11-Dihydro-N-methyl-5H-dibenz[b,f]azepine-5-propanamine, HCl¡Û |
100mg |
¡ï5,000 |
|
58-28-6 |
|
|
|
¡¡ |
BML |
BML-AR119-1000 |
Desipramine, HCl ¡Ú10-11-Dihydro-N-methyl-5H-dibenz[b,f]azepine-5-propanamine, HCl¡Û |
1g |
¡ï11,000 |
|
58-28-6 |
|
|
|
¡¡ |
BML |
BML-AW8655-0005 |
Aclacinomycin A ¡ÚAclarubicin¡Û |
5mg |
¡ï10,000 |
|
57576-44-0 |
|
|
|
¡¡ |
BML |
BML-AW9155-0100 |
Ada-(Ahx)3-(Leu)3-vinyl Sulfone ¡ÚAdaAhx3L3VS¡Û |
100ug |
¡ï16,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AW9160-0100 |
Ada-Tyr-(Ahx)3-(Leu)3-vinyl Sulfone |
100ug |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AW9165-0100 |
Ada-Lys(biotinyl)-(Ahx)3-(Leu)3-vinyl Sulfone |
100ug |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AW9485-0100 |
Ac-Ala-Pro-Nle-Asp-H |
100ug |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AW9555-0005 |
Ac-Nle-Pro-Nle-Asp-AMC ¡ÚAc-nLPnLD-AMC¡Û |
5mg* |
¡ï84,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AW9560-0005 |
Ac-Gly-Pro-Leu-Asp-AMC ¡ÚAc-GPLD-AMC¡Û |
5mg* |
¡ï84,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AW9785-0005 |
Ac-Arg-Leu-Arg-AMC ¡ÚAc-RLR-AMC¡Û |
5mg |
¡ï35,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-AZ1030-0050 |
Aromatic L-Amino Acid Decarboxylase ¡ÚAADC¡Û¡ÚDOPA decarboxylase¡Û(bovine), rabbit pAb |
50ul |
¡ï48,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse¡¢ rat¡¢ bovine | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-AZ1072-0100 |
Atrial Natriuretic Peptide ¡ÚANP¡Û(peptide), rabbit pAb |
100ul |
¡ï48,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-B100-0020 |
Flumazenil ¡ÚRo 15-1788¡Û¡ÚEthyl-8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate¡Û |
20mg |
¡ï8,000 |
|
78755-81-4 |
|
|
|
¡¡ |
BML |
BML-B100-0100 |
Flumazenil ¡ÚRo 15-1788¡Û¡ÚEthyl-8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate¡Û |
100mg |
¡ï33,000 |
|
78755-81-4 |
|
|
|
¡¡ |
BML |
BML-B102-0500 |
Ethyl B-Carboline-3-carboxylate ¡ÚB-CCE¡Û |
500mg |
¡ï17,000 |
|
74214-62-3 |
|
|
|
¡¡ |
BML |
BML-B103-0005 |
3-Hydroxymethyl-B-carboline |
5mg |
¡ï6,000 |
|
65474-79-5 |
|
|
|
¡¡ |
BML |
BML-BA1115-0025 |
Bombesin(synthetic amphibian Bombesin ¡ÚPyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2¡Û), rabbit pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ chicken | IHC |
|
|
¡¡ |
BML |
BML-BA1115-0100 |
Bombesin(synthetic amphibian Bombesin ¡ÚPyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2¡Û), rabbit pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ chicken | IHC |
|
|
¡¡ |
BML |
BML-BA1117-0025 |
Brain Natriuretic Peptide ¡ÚBNP¡Û(human, peptide), rabbit pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC |
|
|
¡¡ |
BML |
BML-BA1117-0100 |
Brain Natriuretic Peptide ¡ÚBNP¡Û(human, peptide), rabbit pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC |
|
|
¡¡ |
BML |
BML-BP9115-0500 |
Bombesin Peptide, Blocking peptide for Bombesin pAb(Prod. No. BML-BA1115) |
500ug |
¡ï5,000 |
|
31362-50-2 |
|
|
|
¡¡ |
BML |
BML-BP9117-0100 |
Brain Natriuretic Peptide ¡ÚBNP¡Û, Blocking peptide for Brain natriuretic peptide pAb(Prod. No. BML-BA1117) |
100ug |
¡ï28,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-BW8515-0005 |
Boc-Leu-Arg-Arg-AMC ¡ÚBoc-LRR-AMC¡Û(Fluorogenic Substrate) |
5mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-BW9315-0100 |
Bactenecin-5 Precursor Peptide ¡ÚBac5-GRR¡Û |
0.1mg* |
¡ï16,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-BW9375-0005 |
Bz-Val-Gly-Arg-AMC ¡ÚBz-VGR-AMC¡Û(Fluorogenic Substrate) |
5mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-C104-0050 |
4-DAMP ¡Ú4-Diphenylacetoxy-N-methylpiperidine Methiodide¡Û |
50mg |
¡ï20,000 |
|
1952-15-4 |
|
|
|
¡¡ |
BML |
BML-C106-0200 |
Hydroxytacrine, Maleate ¡Ú9-Amino-1,2,3,4-tetrahydroacridin-1-ol Maleate¡Û |
200mg |
¡ï8,000 |
|
118909-22-1 |
|
|
|
¡¡ |
BML |
BML-C106-1000 |
Hydroxytacrine, Maleate ¡Ú9-Amino-1,2,3,4-tetrahydroacridin-1-ol Maleate¡Û |
1g |
¡ï33,000 |
|
118909-22-1 |
|
|
|
¡¡ |
BML |
BML-C109-0100 |
Oxotremorine, Sesquifumarate ¡ÚOxotremorine Sesquifumarate¡Û |
100mg |
¡ï5,000 |
|
17360-35-9 |
|
|
|
¡¡ |
BML |
BML-C110-0001 |
Tacrine, HCl |
1g |
¡ï3,000 |
|
1684-40-8 |
|
|
|
¡¡ |
BML |
BML-C110-0005 |
Tacrine, HCl |
5g |
¡ï14,000 |
|
1684-40-8 |
|
|
|
¡¡ |
BML |
BML-C111-0200 |
(¡Þ)-Vesamicol, HCl ¡ÚAH-5183¡Û |
200mg |
¡ï13,000 |
|
120447-62-3 |
|
|
|
¡¡ |
BML |
BML-C114-0001 |
(¡Þ)-Epibatidine |
1mg |
¡ï8,000 |
|
140111-52-0 |
|
|
|
¡¡ |
BML |
BML-C114-0005 |
(¡Þ)-Epibatidine |
5mg |
¡ï32,000 |
|
140111-52-0 |
|
|
|
¡¡ |
BML |
BML-C118-0001 |
(¡Þ)-Anatoxin ¡Ú(¡Þ)2-Acetyl-9-azabicyclo[4.2.1]non-2-ene, Fumarate¡Û |
1mg |
¡ï27,000 |
|
64285-06-9 |
|
|
|
¡¡ |
BML |
BML-C119-0050 |
McN-A-343 ¡Ú4-(N-[3-Chlorophenyl]carbamoyloxy)-2-butynyltrimethylammonium Chloride¡Û |
50mg |
¡ï12,000 |
|
55-45-8 |
|
|
|
¡¡ |
BML |
BML-C120-0010 |
Bombesin(synthetic amphibian Bombesin ¡ÚPyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2¡Û), rabbit pAb |
10mg |
¡ï11,000 |
|
123464-89-1 |
|
|
|
¡¡ |
BML |
BML-C120-0050 |
PNU-282987 ¡ÚN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide¡Û |
50mg |
¡ï46,000 |
|
123464-89-1 |
|
|
|
¡¡ |
BML |
BML-C121-0010 |
BQCA ¡Ú1-(4-Methoxybenzyl)-4-oxo-1,4-dihydro-3-quinoline carboxylic Acid¡Û |
10mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-C121-0050 |
BQCA ¡Ú1-(4-Methoxybenzyl)-4-oxo-1,4-dihydro-3-quinoline carboxylic Acid¡Û |
50mg |
¡ï50,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA100-0010 |
Antibiotic A-23187 ¡ÚCalcimycin¡Û |
10mg |
¡ï13,000 |
|
52665-69-7 |
|
|
|
¡¡ |
BML |
BML-CA101-0001 |
Antibiotic A-23187, 4-Bromo ¡Ú4-BromoAntibiotic A-23187¡Û |
1mg |
¡ï12,000 |
|
76455-82-8 |
|
|
|
¡¡ |
BML |
BML-CA1120-0050 |
Caldesmon(human)[TD107], mouse mAb,(ascites fluid)(specificity: human) |
50ul |
¡ï23,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | TD107 | human | IHC¡¢ WB¡¢ ICC |
|
|
¡¡ |
BML |
BML-CA1123-0025 |
Cholecystokinin-39 ¡ÚCCK-39¡Û(mammalian, peptide, aa 9-20), rabbit pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ pig | IHC |
|
|
¡¡ |
BML |
BML-CA1123-0100 |
Cholecystokinin-39 ¡ÚCCK-39¡Û(mammalian, peptide, aa 9-20), rabbit pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ pig | IHC |
|
|
¡¡ |
BML |
BML-CA1124-0025 |
Cholecystokinin-39 ¡ÚCCK-39¡Û(mammalian, peptide), rabbit pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ pig | IHC |
|
|
¡¡ |
BML |
BML-CA1124-0100 |
Cholecystokinin-39 ¡ÚCCK-39¡Û(mammalian, peptide), rabbit pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ pig | IHC |
|
|
¡¡ |
BML |
BML-CA1125-0025 |
Cholecystokinin-8 ¡ÚCCK-8¡Û(mammalian, peptide, 8aa(Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-OH)), rabbit pAb. |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ pig | IHC |
|
|
¡¡ |
BML |
BML-CA1125-0100 |
Cholecystokinin-8 ¡ÚCCK-8¡Û(mammalian, peptide, 8aa(Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-OH)), rabbit pAb. |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ pig | IHC |
|
|
¡¡ |
BML |
BML-CA1128-0050 |
Chromogranin A ¡ÚCgA¡Û(human, peptide(Leu-Pro-Val-Asn-Ser-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys))(NT), sheep pAb, purified |
50ul |
¡ï26,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human¡¢ rat¡¢ bovine | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CA1128-0100 |
Chromogranin A ¡ÚCgA¡Û(human, peptide(Leu-Pro-Val-Asn-Ser-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys))(NT), sheep pAb, purified |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human¡¢ rat¡¢ bovine | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CA1134-0025 |
Calcitonin Gene Related Peptide ¡ÚCGRP¡Û(rat, peptide), rabbit pAb, purified |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse¡¢ rat | IHC |
|
|
¡¡ |
BML |
BML-CA1134-0100 |
Calcitonin Gene Related Peptide ¡ÚCGRP¡Û(rat, peptide), rabbit pAb, purified |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse¡¢ rat | IHC |
|
|
¡¡ |
BML |
BML-CA1135-0025 |
Calcitonin Gene Related Peptide ¡ÚCGRP¡Û(rat, peptide:37aa)(CT)[CD8], mouse mAb, purified |
25ul |
¡ï13,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | CD8 | human¡¢ guinea pig | IHC |
|
|
¡¡ |
BML |
BML-CA1135-0100 |
Calcitonin Gene Related Peptide ¡ÚCGRP¡Û(rat, peptide:37aa)(CT)[CD8], mouse mAb, purified |
100ul |
¡ï42,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | CD8 | human¡¢ guinea pig | IHC |
|
|
¡¡ |
BML |
BML-CA1137-0025 |
Calcitonin Gene Related Peptide ¡ÚCGRP¡Û(rat, peptide), sheep pAb, purified |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human¡¢ rat¡¢ rabbit¡¢ many mammalian | IHC |
|
|
¡¡ |
BML |
BML-CA1137-0100 |
Calcitonin Gene Related Peptide ¡ÚCGRP¡Û(rat, peptide), sheep pAb, purified |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human¡¢ rat¡¢ rabbit¡¢ many mammalian | IHC |
|
|
¡¡ |
BML |
BML-CA1138-0100 |
Cytokeratin 18(porcine kidney epithelial cells(LLC-PK))[4B11], mouse mAb, purified |
100ul |
¡ï24,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 4B11 | human¡¢ mouse¡¢ rat¡¢ pig | WB(45 kDa)¡¢ ICC |
|
|
¡¡ |
BML |
BML-CA1139-0100 |
Cytokeratin 7, 17 & 19 (porcine kidney epithelial cells(LLC-PK))[4F5], mouse mAb, purified |
100ul |
¡ï24,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 4F5 | human¡¢ mouse¡¢ rat¡¢ pig | WB(54¡¢ 46¡¢ 40 kDa)¡¢ ICC |
|
|
¡¡ |
BML |
BML-CA1141-0100 |
Cytokeratin 8, 18 & 19(porcine kidney epithelial cells(LLC-PK))[2A4], mouse mAb, Affinity-purified |
100ul |
¡ï24,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 2A4 | human¡¢ mouse¡¢ rat¡¢ pig | WB(52¡¢ 45¡¢ 40 kDa)¡¢ ICC |
|
|
¡¡ |
BML |
BML-CA202-0100 |
Amlodipine |
100mg |
¡ï8,000 |
|
88150-42-9 |
|
|
|
¡¡ |
BML |
BML-CA202-1000 |
Amlodipine |
1g |
¡ï24,000 |
|
88150-42-9 |
|
|
|
¡¡ |
BML |
BML-CA204-0005 |
2',4'-Dichlorobenzamil, HCl |
5mg |
¡ï10,000 |
|
1166-01-4 |
|
|
|
¡¡ |
BML |
BML-CA204-0025 |
2',4'-Dichlorobenzamil, HCl |
25mg |
¡ï39,000 |
|
1166-01-4 |
|
|
|
¡¡ |
BML |
BML-CA207-0005 |
L-cis-Diltiazem, HCl |
5mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA213-0010 |
Isradipine |
10mg |
¡ï10,000 |
|
75695-93-1 |
|
|
|
¡¡ |
BML |
BML-CA213-0050 |
Isradipine |
50mg |
¡ï40,000 |
|
75695-93-1 |
|
|
|
¡¡ |
BML |
BML-CA216-0010 |
Niguldipine, HCl |
10mg |
¡ï10,000 |
|
113317-61-6 |
|
|
|
¡¡ |
BML |
BML-CA216-0050 |
Niguldipine, HCl |
50mg |
¡ï40,000 |
|
113317-61-6 |
|
|
|
¡¡ |
BML |
BML-CA2218-0025 |
Chromogranin A ¡ÚCgA¡Û(human phaeochromocytoma)[LK2H10], mouse mAb, purified |
25ul |
¡ï13,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | LK2H10 | mammalian | IHC¡¢ WB(68kDa)¡¢ Electron Microscopy |
|
|
¡¡ |
BML |
BML-CA230-0005 |
SK&F 96365 ¡ÚSKF-96365, HCl¡Û¡Ú1-[B-[3-(4-Methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole, HCl¡Û |
5mg |
¡ï12,000 |
|
130495-35-1 |
|
|
|
¡¡ |
BML |
BML-CA230-0025 |
SK&F 96365 ¡ÚSKF-96365, HCl¡Û¡Ú1-[B-[3-(4-Methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole, HCl¡Û |
25mg |
¡ï50,000 |
|
130495-35-1 |
|
|
|
¡¡ |
BML |
BML-CA231-0010 |
BCTC ¡ÚN-(4-tert-Butylphenyl)-4-(3-Chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide¡Û |
10mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA231-0050 |
BCTC ¡ÚN-(4-tert-Butylphenyl)-4-(3-Chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide¡Û |
50mg |
¡ï40,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA232-0010 |
AMG-9810 ¡Ú(E)-3-(4-tert-Butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide¡Û |
10mg |
¡ï10,000 |
|
545395-94-6 |
|
|
|
¡¡ |
BML |
BML-CA232-0050 |
AMG-9810 ¡Ú(E)-3-(4-tert-Butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide¡Û |
50mg |
¡ï43,000 |
|
545395-94-6 |
|
|
|
¡¡ |
BML |
BML-CA234-0020 |
Gabapentin ¡Ú1-(Aminomethyl)cyclohexaneacetic Acid¡Û¡ÚNeurontin¡Û |
20mg |
¡ï9,000 |
|
60142-96-3 |
|
|
|
¡¡ |
BML |
BML-CA234-0100 |
Gabapentin ¡Ú1-(Aminomethyl)cyclohexaneacetic Acid¡Û¡ÚNeurontin¡Û |
100mg |
¡ï37,000 |
|
60142-96-3 |
|
|
|
¡¡ |
BML |
BML-CA236-0010 |
Felodipine ¡ÚEthyl Methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine Dicarboxylate¡Û |
10mg |
¡ï8,000 |
|
72509-76-3 |
|
|
|
¡¡ |
BML |
BML-CA236-0050 |
Felodipine ¡ÚEthyl Methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine Dicarboxylate¡Û |
50mg |
¡ï28,000 |
|
72509-76-3 |
|
|
|
¡¡ |
BML |
BML-CA237-0010 |
Cilnidipine ¡ÚFRC-8653¡Û¡Ú1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 2-Methoxyethyl(2E)-3-Phenyl-2-propenyl Ester¡Û |
10mg |
¡ï9,000 |
|
132203-70-4 |
|
|
|
¡¡ |
BML |
BML-CA237-0050 |
Cilnidipine ¡ÚFRC-8653¡Û¡Ú1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 2-Methoxyethyl(2E)-3-Phenyl-2-propenyl Ester¡Û |
50mg |
¡ï37,000 |
|
132203-70-4 |
|
|
|
¡¡ |
BML |
BML-CA239-0005 |
AP-18 ¡Ú4-(4-Chlorophenyl)-3-methylbut-3-en-2-oxime¡Û |
5mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA239-0025 |
AP-18 ¡Ú4-(4-Chlorophenyl)-3-methylbut-3-en-2-oxime¡Û |
25mg |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA241-0010 |
HC31 ¡ÚTheophylline-7-(N-4-isopropylphenyl)acetamide¡Û |
10mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA241-0050 |
HC31 ¡ÚTheophylline-7-(N-4-isopropylphenyl)acetamide¡Û |
50mg |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA242-0005 |
Polygodial |
5mg |
¡ï11,000 |
|
6754-20-7 |
|
|
|
¡¡ |
BML |
BML-CA242-0025 |
Polygodial |
25mg |
¡ï43,000 |
|
6754-20-7 |
|
|
|
¡¡ |
BML |
BML-CA260-0050 |
Tetrandrine ¡Ú6,6¡Ç,7,12-Tetramethoxy-2,2¡Ç-dimethylberbaman¡Û |
50mg |
¡ï5,000 |
|
518-34-3 |
|
|
|
¡¡ |
BML |
BML-CA260-0250 |
Tetrandrine ¡Ú6,6¡Ç,7,12-Tetramethoxy-2,2¡Ç-dimethylberbaman¡Û |
250mg |
¡ï18,000 |
|
518-34-3 |
|
|
|
¡¡ |
BML |
BML-CA300-0010 |
Calmidazolium Chloride ¡ÚR24571¡Û |
10mg |
¡ï14,000 |
|
57265-65-3 |
|
|
|
¡¡ |
BML |
BML-CA300-0050 |
Calmidazolium Chloride ¡ÚR24571¡Û |
50mg |
¡ï59,000 |
|
57265-65-3 |
|
|
|
¡¡ |
BML |
BML-CA302-0010 |
E6 Berbamine |
10mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA302-0050 |
E6 Berbamine |
50mg |
¡ï52,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA315-0020 |
W-5 ¡ÚN-(6-Aminohexyl)-1-naphthalenesulfonamide, HCl¡Û |
20mg |
¡ï17,000 |
|
61714-25-8 |
|
|
|
¡¡ |
BML |
BML-CA320-0050 |
W-7 ¡ÚN-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide, HCl¡Û |
50mg |
¡ï11,000 |
|
61714-27-0 |
|
|
|
¡¡ |
BML |
BML-CA325-0050 |
Fluphenazine-N-2-chloroethane, 2HCl |
50mg |
¡ï11,000 |
|
83016-35-7 |
|
|
|
¡¡ |
BML |
BML-CA409-0050 |
Xestospongin C(Isolated from an Okinawan marine sponge Xestospongia sp) |
50ug |
¡ï47,000 |
|
88903-69-9 |
|
|
|
¡¡ |
BML |
BML-CA410-0005 |
BAY K-8644 ¡Ú1,4-Dihydro-2,6-dimethyl-5-nitro-4-(2-[trifluoromethyl]phenyl)pyridine-3-carboxylic Acid, Methyl Ester¡Û |
5mg |
¡ï24,000 |
|
93468-89-4 |
|
|
|
¡¡ |
BML |
BML-CA411-0025 |
BAPTA-AM ¡Ú1,2-bis-(o-Aminophenoxy)ethane-N,N,-N¡Ç,N¡Ç-tetraacetic Acid Tetraacetoxy Methyl Ester¡Û |
25mg |
¡ï21,000 |
|
139890-68-9 |
|
|
|
¡¡ |
BML |
BML-CA412-0100 |
BAPTA, free Acid ¡Ú1,2-bis-(o-Aminophenoxy)ethane-N,N,-N¡Ç,N¡Ç-tetraacetic Acid¡Û |
100mg |
¡ï8,000 |
|
85233-19-8 |
|
|
|
¡¡ |
BML |
BML-CA412-0500 |
BAPTA, free Acid ¡Ú1,2-bis-(o-Aminophenoxy)ethane-N,N,-N¡Ç,N¡Ç-tetraacetic Acid¡Û |
500mg |
¡ï31,000 |
|
85233-19-8 |
|
|
|
¡¡ |
BML |
BML-CA415-0010 |
Cyclopiazonic Acid ¡ÚCPA¡Û |
10mg |
¡ï14,000 |
|
18172-33-3 |
|
|
|
¡¡ |
BML |
BML-CA415-0050 |
Cyclopiazonic Acid ¡ÚCPA¡Û |
50mg |
¡ï58,000 |
|
18172-33-3 |
|
|
|
¡¡ |
BML |
BML-CA416-0100 |
cADP-ribose ¡ÚcADPR¡Û |
100ug |
¡ï9,000 |
|
119340-53-3 |
|
|
|
¡¡ |
BML |
BML-CA416-0500 |
cADP-ribose ¡ÚcADPR¡Û |
500ug |
¡ï37,000 |
|
119340-53-3 |
|
|
|
¡¡ |
BML |
BML-CA417-0100 |
8-Bromo-cADP-ribose ¡Ú8-Br-cADPR¡Û |
100ug |
¡ï8,000 |
|
151898-26-9 |
|
|
|
¡¡ |
BML |
BML-CA417-0500 |
8-Bromo-cADP-ribose ¡Ú8-Br-cADPR¡Û |
500ug |
¡ï24,000 |
|
151898-26-9 |
|
|
|
¡¡ |
BML |
BML-CA421-0005 |
Nigericin, Na salt ¡ÚAntibiotic K 178¡Û |
5mg |
¡ï8,000 |
|
28643-80-3; 28380-24-7 |
|
|
|
¡¡ |
BML |
BML-CA422-0005 |
Gingerol ¡Ú[6]-Gingerol¡Û¡Ú(S)-5-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-decanone¡Û |
5mg |
¡ï13,000 |
|
23513-14-6 |
|
|
|
¡¡ |
BML |
BML-CA422-0020 |
Gingerol ¡Ú[6]-Gingerol¡Û¡Ú(S)-5-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-decanone¡Û |
20mg |
¡ï47,000 |
|
23513-14-6 |
|
|
|
¡¡ |
BML |
BML-CA501-0005 |
SNX-482 |
5ug |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA502 |
Calciseptine |
70ug |
¡ï57,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CA9360-0025 |
aB-Crystallin(human, aa 1-10), rabbit pAb, purified(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CA9360-0100 |
aB-Crystallin(human, aa 1-10), rabbit pAb, purified(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CB10218-0050 |
Cytokeratin 3(rabbit corneal epithelial keratin)[AE5], mouse mAb, purified |
50ug |
¡ï23,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | AE5 | human¡¢ rabbit¡¢ dog¡¢ bovine | IHC¡¢ WB¡¢ ICC |
|
|
¡¡ |
BML |
BML-CC100-0100 |
2-Aminopurine ¡Ú2-AP¡Û |
100mg |
¡ï9,000 |
|
452-06-2 |
|
|
|
¡¡ |
BML |
BML-CC100-0500 |
2-Aminopurine ¡Ú2-AP¡Û |
500mg |
¡ï38,000 |
|
452-06-2 |
|
|
|
¡¡ |
BML |
BML-CC101-0001 |
(+)-Aphidicolin |
1mg |
¡ï9,000 |
|
38966-21-1 |
|
|
|
¡¡ |
BML |
BML-CC102-0500 |
L-Mimosine ¡ÚB-[N-(3-hydroxy-4-pyridone)]-a-aminopropionic Acid¡Û |
500mg |
¡ï31,000 |
|
500-44-7 |
|
|
|
¡¡ |
BML |
BML-CC104-0010 |
Tunicamycin(Isolated from Streptomyces lysosuperficus) |
10mg |
¡ï19,000 |
|
11089-65-9 |
|
|
|
¡¡ |
BML |
BML-CC205-0002 |
(R)-Roscovitine ¡ÚRoscovitine,(R)-¡Û¡Ú6-Benzylamino-2-(R)-((1-ethyl)-2-hydroxyethylamino)-9-isopropylpurine, 2(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine¡Û |
2mg |
¡ï8,000 |
-20¡î |
186692-46-6 |
|
Purity: ¡ä95%, Formula: C19H26N6O, MW: 354.4 Solubility: soluble in DMSO.
|
|
¡¡ |
BML |
BML-CC205-0005 |
(R)-Roscovitine ¡ÚRoscovitine,(R)-¡Û¡Ú6-Benzylamino-2-(R)-[(1-ethyl)-2-hydroxyethylamino]-9-isopropylpurine¡Û¡Ú2(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine¡Û |
5mg |
¡ï20,000 |
|
186692-46-6 |
|
|
|
¡¡ |
BML |
BML-CC207-0001 |
Indirubin-3'-monoxime |
1mg |
¡ï9,000 |
|
160807-49-8 |
|
|
|
¡¡ |
BML |
BML-CC207-0005 |
Indirubin-3'-monoxime |
5mg |
¡ï40,000 |
|
160807-49-8 |
|
|
|
¡¡ |
BML |
BML-CC210-0200 |
Butyrolactone I |
200ug |
¡ï13,000 |
|
87414-49-1 |
|
|
|
¡¡ |
BML |
BML-CC210-1000 |
Butyrolactone I |
1mg |
¡ï55,000 |
|
87414-49-1 |
|
|
|
¡¡ |
BML |
BML-CG1920-0100 |
Calpain I, II small subunit p30 ¡Úm-Calpain and ¦Ì-Calpain¡Û(human placenta)[28F3], mouse mAb, purified |
100ug |
¡ï32,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 28F3 | human¡¢ bovine | WB¡¢ IP¡¢ ELISA |
|
|
¡¡ |
BML |
BML-CG1925-0500 |
Calpain I, II small subunit p30 ¡Úm-Calpain and ¦Ì-Calpain¡Û(human placenta)[28F3], mouse mAb, -agarose immobilized |
0.5mL |
¡ï38,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 28F3 | human¡¢ bovine | IP |
|
|
¡¡ |
BML |
BML-CG1928-0100 |
Calpain I ¡Ú¦Ì-calpain¡Û(human placenta)[15C10], mouse mAb, purified |
100ug |
¡ï32,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 15C10 | human¡¢ mouse¡¢ rat¡¢ bovine | WB(80kDa)¡¢ IP¡¢ ELISA |
|
|
¡¡ |
BML |
BML-CL3710-0025 |
Cysteine String Proteins ¡Úcsp1and csp2¡Û(bovine)(recombinant), rabbit pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CL3710-0100 |
Cysteine String Proteins ¡Úcsp1and csp2¡Û(bovine)(recombinant), rabbit pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CM100-0010 |
NPPB ¡Ú5-Nitro-2-(3¡Ç-phenylpropylamino)benzoic Acid¡Û |
10mg |
¡ï6,000 |
|
107254-86-4 |
|
|
|
¡¡ |
BML |
BML-CM100-0050 |
NPPB ¡Ú5-Nitro-2-(3¡Ç-phenylpropylamino)benzoic Acid¡Û |
50mg |
¡ï26,000 |
|
107254-86-4 |
|
|
|
·àʪ |
BML |
BML-CM102-0020 |
Fipronil ¡Ú5-Amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile¡Û |
20mg |
¡ï6,000 |
|
120068-37-3 |
|
|
|
·àʪ |
BML |
BML-CM102-0100 |
Fipronil ¡Ú5-Amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile¡Û |
100mg |
¡ï27,000 |
|
120068-37-3 |
|
|
|
¡¡ |
BML |
BML-CM110-0100 |
Bafilomycin A1 |
100ug |
¡ï20,000 |
|
88899-55-2 |
|
|
|
¡¡ |
BML |
BML-CM111-0005 |
Oligomycin A |
5mg |
¡ï19,000 |
|
579-13-5 |
|
|
|
¡¡ |
BML |
BML-CM111-0025 |
Oligomycin A |
25mg |
¡ï79,000 |
|
579-13-5 |
|
|
|
¡¡ |
BML |
BML-CM112-0500 |
Clopamide ¡Ú4-Chloro-N-(2,6-dimethylpiperidinyl)-3-sulfamoylbenzamide¡Û |
500mg |
¡ï4,000 |
|
636-54-4 |
|
|
|
¡¡ |
BML |
BML-CM113-0100 |
Bongkrekic Acid |
100ug |
¡ï16,000 |
|
11076-19-0 |
|
|
|
¡¡ |
BML |
BML-CM113-1000 |
Bongkrekic Acid |
1mg |
¡ï144,000 |
|
11076-19-0 |
|
|
|
¡¡ |
BML |
BML-CM115-0010 |
Decylubiquinine ¡Ú2,3-Dimethoxy-5-methyl-6-decyl-1,4-benzoquinone¡Û |
10mg |
¡ï6,000 |
|
55486-00-5 |
|
|
|
¡¡ |
BML |
BML-CM115-0050 |
Decylubiquinine ¡Ú2,3-Dimethoxy-5-methyl-6-decyl-1,4-benzoquinone¡Û |
50mg |
¡ï27,000 |
|
55486-00-5 |
|
|
|
¡¡ |
BML |
BML-CM116-0005 |
Citrinin |
5mg |
¡ï11,000 |
|
518-75-2 |
|
|
|
¡¡ |
BML |
BML-CM116-0025 |
Citrinin |
25mg |
¡ï44,000 |
|
518-75-2 |
|
|
|
¡¡ |
BML |
BML-CM118-0005 |
PK-11195 ¡Ú1-(2-Chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide¡Û |
5mg |
¡ï7,000 |
|
85532-75-8 |
|
|
|
¡¡ |
BML |
BML-CM118-0025 |
PK-11195 ¡Ú1-(2-Chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide¡Û |
25mg |
¡ï30,000 |
|
85532-75-8 |
|
|
|
¡¡ |
BML |
BML-CM119-0005 |
CGP-37157 ¡Ú7-Chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one¡Û |
5mg |
¡ï12,000 |
|
75450-34-9 |
|
|
|
¡¡ |
BML |
BML-CM119-0025 |
CGP-37157 ¡Ú7-Chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one¡Û |
25mg |
¡ï51,000 |
|
75450-34-9 |
|
|
|
·àʪ |
BML |
BML-CM120-0010 |
FCCP ¡ÚCarbonylcyanide-4-(trifluoromethoxy)phenylhydrazone¡Û |
10mg |
¡ï10,000 |
|
370-86-5 |
|
|
|
·àʪ |
BML |
BML-CM120-0050 |
FCCP ¡ÚCarbonylcyanide-4-(trifluoromethoxy)phenylhydrazone¡Û |
50mg |
¡ï39,000 |
|
370-86-5 |
|
|
|
¡¡ |
BML |
BML-CM123-0001 |
2-Methoxyantimycin A3 |
1mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CM123-0005 |
2-Methoxyantimycin A3 |
5mg |
¡ï33,000 |
|
none |
|
|
|
·àʪ |
BML |
BML-CM124-0500 |
CCCP ¡ÚCarbonylcyanide 3-Chlorophenylhydrazone¡Û |
500mg |
¡ï14,000 |
|
555-60-2 |
|
|
|
¡¡ |
BML |
BML-CM125-0010 |
Embelin ¡Ú2,5-Dihydroxy-3-undecyl-1,4-benzoquinone¡Û |
10mg |
¡ï9,000 |
|
550-24-3 |
|
|
|
¡¡ |
BML |
BML-CM125-0050 |
Embelin ¡Ú2,5-Dihydroxy-3-undecyl-1,4-benzoquinone¡Û |
50mg |
¡ï36,000 |
|
550-24-3 |
|
|
|
¡¡ |
BML |
BML-CM126-0010 |
Icilin ¡ÚAG 3-5¡Û¡Ú3,6-Dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-2(1H)-pyrimidinone¡Û |
10mg |
¡ï10,000 |
|
36945-98-9 |
|
|
|
¡¡ |
BML |
BML-CM126-0050 |
Icilin ¡ÚAG 3-5¡Û¡Ú3,6-Dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-2(1H)-pyrimidinone¡Û |
50mg |
¡ï41,000 |
|
36945-98-9 |
|
|
|
¡¡ |
BML |
BML-CM127-0010 |
Mdivi-1 ¡Ú3-(2,4-Dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone¡Û |
10mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CM127-0050 |
Mdivi-1 ¡Ú3-(2,4-Dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone¡Û |
50mg |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CM128-0050 |
4,4-Pentamethylenepiperidine, HCl ¡Ú3-Azaspiro[5.5]undecane, HCl¡Û |
50mg |
¡ï9,000 |
|
180-44-9 |
|
|
|
¡¡ |
BML |
BML-CN100-0010 |
Forskolin ¡ÚColforsin¡Û(Isolated from Coleus forskohlii) |
10mg |
¡ï14,000 |
|
66575-29-9 |
|
|
|
¡¡ |
BML |
BML-CN100-0100 |
Forskolin ¡ÚColforsin¡Û(Isolated from Coleus forskohlii) |
100mg |
¡ï85,000 |
|
66575-29-9 |
|
|
|
¡¡ |
BML |
BML-CN105-0005 |
L-858051 ¡Ú7-Deacetyl-7B-(¦Ã-N-methylpiperazino)-butyrylforskolin, 2HCl¡Û |
5mg |
¡ï28,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CN110-0005 |
2',5'-Dideoxyadenosine |
5mg |
¡ï12,000 |
|
6698-26-6 |
|
|
|
¡¡ |
BML |
BML-CN110-0025 |
2',5'-Dideoxyadenosine |
25mg |
¡ï51,000 |
|
6698-26-6 |
|
|
|
¡¡ |
BML |
BML-CN115-0010 |
8-Bromo-cAMP ¡Ú8-Bromoadenosine-3',5'-cyclic Monophosphate, Na salt¡Û |
10mg |
¡ï6,000 |
|
76939-46-3 |
|
|
|
¡¡ |
BML |
BML-CN115-0050 |
8-Bromo-cAMP ¡Ú8-Bromoadenosine-3',5'-cyclic Monophosphate, Na salt¡Û |
50mg |
¡ï20,000 |
|
76939-46-3 |
|
|
|
¡¡ |
BML |
BML-CN120-0001 |
Sp-5,6-Dichloro-cBIMPS ¡ÚSp-5,6-Dichloro-1-B-D-ribofuranosylbenzimidazole-3',5'-monophosphorothioate¡Û |
1mg |
¡ï28,000 |
|
120912-54-1 |
|
|
|
¡¡ |
BML |
BML-CN125-0030 |
Dibutyryl-cAMP |
30mg |
¡ï9,300 |
|
16980-89-5 |
|
|
|
¡¡ |
BML |
BML-CN125-0100 |
Dibutyryl-cAMP |
100mg |
¡ï14,000 |
|
16980-89-5 |
|
|
|
¡¡ |
BML |
BML-CN130-0020 |
8-CPT-cAMP ¡Ú8-(4-Chlorophenylthio)adenosine-3',5'-cyclic Monophosphate, Na salt¡Û |
20mg |
¡ï8,000 |
|
93882-12-3 |
|
|
|
¡¡ |
BML |
BML-CN130-0100 |
8-CPT-cAMP ¡Ú8-(4-Chlorophenylthio)adenosine-3',5'-cyclic Monophosphate, Na salt¡Û |
100mg |
¡ï32,000 |
|
93882-12-3 |
|
|
|
¡¡ |
BML |
BML-CN135-0001 |
Rp-cAMPS ¡ÚRp-Adenosine-3',5'-cyclic Monophosphorothioate¡Û |
1mg |
¡ï15,000 |
|
73208-40-9 |
|
|
|
¡¡ |
BML |
BML-CN136-0001 |
Sp-cAMPS ¡ÚSp-Adenosine-3',5'-cyclic Monophosphorothioate¡Û |
1mg |
¡ï7,000 |
|
71774-13-5 |
|
|
|
¡¡ |
BML |
BML-CN140-0005 |
SQ 22536 ¡Ú9-(Tetrahydro-2¡Ç-furyl)adenine¡Û |
5mg |
¡ï11,000 |
|
17318-31-9 |
|
|
|
¡¡ |
BML |
BML-CN140-0025 |
SQ 22536 ¡Ú9-(Tetrahydro-2¡Ç-furyl)adenine¡Û |
25mg |
¡ï45,000 |
|
17318-31-9 |
|
|
|
¡¡ |
BML |
BML-CN145-0005 |
MDL-12,330A ¡Úcis-N-(2-Phenylcyclopentyl)azacyclotridec-1-en-2-amine, HCl¡Û |
5mg |
¡ï7,000 |
|
40297-09-4 |
|
|
|
¡¡ |
BML |
BML-CN145-0025 |
MDL-12,330A ¡Úcis-N-(2-Phenylcyclopentyl)azacyclotridec-1-en-2-amine, HCl¡Û |
25mg |
¡ï31,000 |
|
40297-09-4 |
|
|
|
¡¡ |
BML |
BML-CN150-0050 |
Adenylate Cyclase Toxin ¡ÚAC Toxin¡Û |
50ug |
¡ï46,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CN205-0010 |
8-Bromo-cGMP ¡Ú8-Bromoguanosine-3',5'-cyclic Monophosphate, Na salt¡Û |
10mg |
¡ï8,000 |
|
51116-01-9 |
|
|
|
¡¡ |
BML |
BML-CN205-0050 |
8-Bromo-cGMP ¡Ú8-Bromoguanosine-3',5'-cyclic Monophosphate, Na salt¡Û |
50mg |
¡ï32,000 |
|
51116-01-9 |
|
|
|
¡¡ |
BML |
BML-CN206-0001 |
Rp-8-pCPT-cGMPS, Na salt ¡ÚRp-8-(4-Chlorophenylthio)guanosine-3¡Ç,5¡Ç-cyclic Monophosphorothioate, Na salt¡Û |
1mg |
¡ï30,000 |
|
153660-04-9 |
|
|
|
¡¡ |
BML |
BML-CN207-0001 |
Sp-8-pCPT-cGMPS, Na salt ¡ÚSp-8-(4-Chlorophenylthio)guanosine-3¡Ç,5¡Ç-cyclic Monophosphorothioate, Na salt¡Û |
1mg |
¡ï27,000 |
|
160385-87-5 |
|
|
|
¡¡ |
BML |
BML-CN210-0020 |
SNAP ¡ÚS-Nitroso-N-acetyl-DL-penicillamine¡Û |
20mg |
¡ï8,000 |
|
79032-48-7 |
|
|
|
¡¡ |
BML |
BML-CN210-0100 |
SNAP ¡ÚS-Nitroso-N-acetyl-DL-penicillamine¡Û |
100mg |
¡ï32,000 |
|
79032-48-7 |
|
|
|
¡¡ |
BML |
BML-CN215-0010 |
Dibutyryl-cGMP ¡ÚN2,2'-O-Dibutyrylguanosine-3',5'-cyclic Monophosphate, Na salt¡Û |
10mg |
¡ï12,000 |
|
51116-00-8 |
|
|
|
¡¡ |
BML |
BML-CN215-0050 |
Dibutyryl-cGMP ¡ÚN2,2'-O-Dibutyrylguanosine-3',5'-cyclic Monophosphate, Na salt¡Û |
50mg |
¡ï46,000 |
|
51116-00-8 |
|
|
|
¡¡ |
BML |
BML-CN216-0500 |
Rp-8-Br-cGMPS ¡ÚRp-8-Bromoguanosine-3',5'-cyclic Monophosphorothioate, Na salt¡Û |
500ug |
¡ï19,000 |
|
150418-07-8 |
|
|
|
¡¡ |
BML |
BML-CN217-0500 |
Sp-8-Br-cGMPS ¡ÚSp-8-Bromoguanosine-3',5'-cyclic Monophosphorothioate, Na salt¡Û |
500ug |
¡ï7,000 |
|
153660-03-8 |
|
|
|
¡¡ |
BML |
BML-CN240-0010 |
Diphenyleneiodonium Chloride ¡ÚDibenziodolium Chloride¡Û¡ÚDPI Chloride¡Û |
10mg |
¡ï6,000 |
|
4673-26-1 |
|
|
|
¡¡ |
BML |
BML-CN245-0020 |
3-Morpholinosydnonimine ¡ÚSIN-1¡Û |
20mg |
¡ï8,000 |
|
33876-97-0 |
|
|
|
¡¡ |
BML |
BML-CN245-0100 |
3-Morpholinosydnonimine ¡ÚSIN-1¡Û |
100mg |
¡ï32,000 |
|
33876-97-0 |
|
|
|
¡¡ |
BML |
BML-CN248-0010 |
N(5)-(1-Iminoethyl)-L-ornithine?HCl ¡ÚL-NIO¡Û |
10mg |
¡ï20,000 |
|
36889-13-1 |
|
|
|
¡¡ |
BML |
BML-CN248-0050 |
N(5)-(1-Iminoethyl)-L-ornithine?HCl ¡ÚL-NIO¡Û |
50mg |
¡ï68,000 |
|
36889-13-1 |
|
|
|
¡¡ |
BML |
BML-CN254-0010 |
N,O-Diacetyl-N-hydroxy-4-chlorobenzenesulphonamide |
10mg |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CN254-0050 |
N,O-Diacetyl-N-hydroxy-4-chlorobenzenesulphonamide |
50mg |
¡ï31,000 |
|
none |
|
|
|
·àʪ |
BML |
BML-CN255-0010 |
Furoxan ¡Ú4-Phenyl-3-furoxancarbonitrile¡Û |
10mg |
¡ï8,000 |
|
none |
|
|
|
·àʪ |
BML |
BML-CN255-0050 |
Furoxan ¡Ú4-Phenyl-3-furoxancarbonitrile¡Û |
50mg |
¡ï32,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP0111-0100 |
Cytochrome P450 1A1(rat)C-terminal Peptide, Blocking peptide for Cytochrome P450 1A1(rat)pAbs(Prod. No.(Prod. No. BML-CR3110 & BML-CR3115) |
100ug |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP0121-0100 |
Cytochrome P450 1A1(human)C-terminal Peptide, Blocking peptide for Cytochrome P450 1A1(human)pAbs(Prod. No. BML-CR3120 & BML-CR3125 ) |
100ug |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP0123-0100 |
Cytochrome P450 1A2(human)Peptide ¡ÚCYP1A2(human, aa 284-295)¡Û, Blocking peptide for Cytochrome P450 1A2(human)pAb(Prod. No. BML-CR3130) |
100ug |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP0124-0100 |
Cytochrome P450 1A2(rat)C-terminal Peptide, Blocking peptide for Cytochrome P450 1A2(rat)pAb(Prod. No. BML-CR3135) |
100ug |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP0201-0100 |
Cytochrome P450 2D1(rat)C-terminal Peptide, Blocking peptide for Cytochrome P450 2D1(rat)pAb(Prod. No. BML-CR3210) |
100ug |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP0265-0100 |
Cytochrome P450 2D6(human)C-terminal Peptide, Blocking peptide for Cytochrome P450 2D6(human)pAb(Prod. No. BML-CR3245) |
100ug |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP0270-0100 |
Cytochrome P450 2E1(rat/human/rabbit/mouse)C-terminal Peptide, Blocking peptide for Cytochrome P450 2E1 pAbs(Prod. No. BML-CR3271 & BML-CR3275) |
100ug |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP0281-0100 |
Cytochrome P450 2C8, 2C9, 2C19 and 2C12 C-terminal Peptide, Blocking peptide for Cytochrome P450(human)and CYP2C12(rat)pAbs(Prod. No. BML-CR3280 & BML-CR3285) |
100ug |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP0331-0100 |
Cytochrome P450 3A1(rat)C-terminal Peptide, Blocking peptide for Cytochrome P450 3A1(rat)pAbs(Prod. No. BML-CR3310 & BML-CR3315) |
100ug |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP0334-0100 |
Cytochrome P450 3A4/3A7(human)C-terminal Peptide, Blocking peptide for Cytochrome P450 3A4(human)pAbs(Prod. No. BML-CR3340 & BML-CR3345) |
100ug |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP0335-0100 |
Cytochrome P450 3A5(human)C-terminal Peptide, Blocking Peptide for Cytochrome P450 3A5(human)pAb(Prod. No. BML-CR3350) |
100ug |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP1428-0100 |
Chromogranin A Peptide, Blocking Peptide for Chromogranin A pAb(Prod. No. BML-CA1128) |
100ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP6420-0001 |
Catestatin(human)¡ÚG643S¡Û¡ÚP370L¡Û¡ÚChromogranin A(352-372)¡Û |
1mg* |
¡ï35,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP6425-0001 |
Catestatin(P370L)(human)¡Ú[P370L]Catestatin¡Û¡Ú[P370L]Chromogranin A(352-372)¡Û¡ÚP370L¡Û |
1mg* |
¡ï33,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP6430-0001 |
Catestatin(G364S)(human)¡Ú[G364S]Catestatin¡Û¡Ú[G364S]Chromogranin A(352-372)¡Û¡ÚG364S¡Û |
1mg* |
¡ï33,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CP6435-0001 |
Catestatin(G364S, P370L)(human)¡Ú[G364S P370L]Catestatin¡Û¡Ú[G364S, P370L]Chromogranin A(352-372)¡Û¡ÚG364S¡Û |
1mg* |
¡ï33,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CR102-0005 |
CP-55,940 ¡Ú(-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxyphenyl)cyclohexanol¡Û |
5mg |
¡ï19,000 |
|
83002-04-4 |
|
|
|
¡¡ |
BML |
BML-CR102-0025 |
CP-55,940 ¡Ú(-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxyphenyl)cyclohexanol¡Û |
25mg |
¡ï78,000 |
|
83002-04-4 |
|
|
|
¡¡ |
BML |
BML-CR104-0010 |
BML-190 ¡ÚIndomethacin Morpholinylamide¡Û |
10mg |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CR104-0050 |
BML-190 ¡ÚIndomethacin Morpholinylamide¡Û |
50mg |
¡ï30,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-CR105-0010 |
WIN-55,212-2 ¡Ú(R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone, Mesylate¡Û |
10mg |
¡ï8,000 |
|
131543-23-2 |
|
|
|
¡¡ |
BML |
BML-CR105-0050 |
WIN-55,212-2 ¡Ú(R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone, Mesylate¡Û |
50mg |
¡ï34,000 |
|
131543-23-2 |
|
|
|
¡¡ |
BML |
BML-CR106-0010 |
AM-404 ¡ÚN-(4-Hydroxyphenyl)-5Z,8Z,11Z-eicosatetraenamide¡Û¡ÚN-(4-Hydroxyphenyl)arachidonoylamide¡Û |
10mg |
¡ï7,000 |
|
198022-70-7 |
|
|
|
¡¡ |
BML |
BML-CR106-0050 |
AM-404 ¡ÚN-(4-Hydroxyphenyl)-5Z,8Z,11Z-eicosatetraenamide¡Û¡ÚN-(4-Hydroxyphenyl)arachidonoylamide¡Û |
50mg |
¡ï30,000 |
|
198022-70-7 |
|
|
|
¡¡ |
BML |
BML-CR107-0010 |
AM-630 ¡Ú6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone¡Û |
10mg |
¡ï20,000 |
|
164178-33-0 |
|
|
|
¡¡ |
BML |
BML-CR108-0010 |
AM-251 ¡ÚN-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,3-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide¡Û |
10mg |
¡ï27,000 |
|
18323-66-8 |
|
|
|
¡¡ |
BML |
BML-CR109-0005 |
JWH-015 ¡Ú(2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone¡Û |
5mg |
¡ï9,000 |
|
155471-08-2 |
|
|
|
¡¡ |
BML |
BML-CR109-0025 |
JWH-015 ¡Ú(2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone¡Û |
25mg |
¡ï39,000 |
|
155471-08-2 |
|
|
|
¡¡ |
BML |
BML-CR110-0005 |
Pravadoline ¡Ú(4-Methoxyphenyl)(2-methyl-1-(2-(4-morpholinyl)ethyl)-1H-indol-3-yl)methanone¡Û |
5mg |
¡ï8,000 |
|
92623-83-1 |
|
|
|
¡¡ |
BML |
BML-CR110-0025 |
Pravadoline ¡Ú(4-Methoxyphenyl)(2-methyl-1-(2-(4-morpholinyl)ethyl)-1H-indol-3-yl)methanone¡Û |
25mg |
¡ï32,000 |
|
92623-83-1 |
|
|
|
¡¡ |
BML |
BML-CR111-0010 |
VDM-11 ¡ÚN-Arachidonoyl-4-hydroxy-2-methylaniline¡Û¡ÚN-(4-Hydroxy-2-methylphenyl)arachidonoylamide¡Û |
10mg |
¡ï7,000 |
|
313998-81-1 |
|
|
|
¡¡ |
BML |
BML-CR111-0050 |
VDM-11 ¡ÚN-Arachidonoyl-4-hydroxy-2-methylaniline¡Û¡ÚN-(4-Hydroxy-2-methylphenyl)arachidonoylamide¡Û |
50mg |
¡ï31,000 |
|
313998-81-1 |
|
|
|
¡¡ |
BML |
BML-CR112-0010 |
GW-405833 ¡Ú1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-(2-(morpholin-4-yl)ethyl)-1H-indole¡Û¡ÚL-768242¡Û |
10mg |
¡ï13,000 |
|
180002-83-9 |
|
|
|
¡¡ |
BML |
BML-CR112-0050 |
GW-405833 ¡Ú1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-(2-(morpholin-4-yl)ethyl)-1H-indole¡Û¡ÚL-768242¡Û |
50mg |
¡ï55,000 |
|
180002-83-9 |
|
|
|
¡¡ |
BML |
BML-CR113-0010 |
LY 2183240 ¡Ú5-Biphenyl-4-ylmethyl-tetrazole-1-carboxylic Acid Dimethylamide¡Û |
10mg |
¡ï8,000 |
|
874902-19-9 |
|
|
|
¡¡ |
BML |
BML-CR113-0050 |
LY 2183240 ¡Ú5-Biphenyl-4-ylmethyl-tetrazole-1-carboxylic Acid Dimethylamide¡Û |
50mg |
¡ï36,000 |
|
874902-19-9 |
|
|
|
¡¡ |
BML |
BML-CR114-0010 |
Leelamine, HCl ¡Ú(+)-Dehydroabietylamine, HCl¡Û |
10mg |
¡ï9,000 |
|
1446-61-3 |
|
|
|
¡¡ |
BML |
BML-CR114-0050 |
Leelamine, HCl ¡Ú(+)-Dehydroabietylamine, HCl¡Û |
50mg |
¡ï39,000 |
|
1446-61-3 |
|
|
|
¡¡ |
BML |
BML-CR3110-0025 |
Cytochrome P450 1A1 ¡ÚCYP1A1¡Û(rat, peptide)(CT), rabbit pAb, purified(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3110-0100 |
Cytochrome P450 1A1 ¡ÚCYP1A1¡Û(rat, peptide)(CT), rabbit pAb, purified(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3115-0025 |
Cytochrome P450 1A1 ¡ÚCYP1A1¡Û(rat, peptide)(CT), sheep pAb(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3115-0100 |
Cytochrome P450 1A1 ¡ÚCYP1A1¡Û(rat, peptide)(CT), sheep pAb(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3120-0025 |
Cytochrome P450 1A1 ¡ÚCYP1A1¡Û(human, peptide)(CT), rabbit pAb, purified(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3120-0100 |
Cytochrome P450 1A1 ¡ÚCYP1A1¡Û(human, peptide)(CT), rabbit pAb, purified(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3125-0025 |
Cytochrome P450 1A1 ¡ÚCYP1A1¡Û(human, peptide)(CT), sheep pAb(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human (not rat) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3125-0100 |
Cytochrome P450 1A1 ¡ÚCYP1A1¡Û(human, peptide)(CT), sheep pAb(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human (not rat) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3130-0025 |
Cytochrome P450 1A2 ¡ÚCYP1A2¡Û(human, aa 284-298)(internal domain), rabbit pAb(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human (not rat) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3130-0100 |
Cytochrome P450 1A2 ¡ÚCYP1A2¡Û(human, aa 284-298)(internal domain), rabbit pAb(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human (not rat) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3135-0025 |
Cytochrome P450 1A2 ¡ÚCYP1A2¡Û(rat, peptide)(CT), sheep pAb(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | rat (not human) | IHC(FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3135-0100 |
Cytochrome P450 1A2 ¡ÚCYP1A2¡Û(rat, peptide)(CT), sheep pAb(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | rat (not human) | IHC(FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3210-0025 |
Cytochrome P450 2D1 ¡ÚCYP2D1¡Û(rat liver, peptide)(CT), rabbit pAb(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3210-0100 |
Cytochrome P450 2D1 ¡ÚCYP2D1¡Û(rat liver, peptide)(CT), rabbit pAb(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3240-0025 |
Cytochrome P450 2D4 ¡ÚCYP2D4¡Û(rat liver, peptide)(CT), rabbit pAb, purified(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3240-0100 |
Cytochrome P450 2D4 ¡ÚCYP2D4¡Û(rat liver, peptide)(CT), rabbit pAb, purified(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3245-0025 |
Cytochrome P450 2D6 ¡ÚCYP2D6¡Û(human, peptide)(CT), sheep pAb(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3245-0100 |
Cytochrome P450 2D6 ¡ÚCYP2D6¡Û(human, peptide)(CT), sheep pAb(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3260-0025 |
Cytochrome P450 2A6 ¡ÚCYP2A6¡Û(human liver, peptide)(CT), rabbit pAb(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human (not rat) | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3260-0100 |
Cytochrome P450 2A6 ¡ÚCYP2A6¡Û(human liver, peptide)(CT), rabbit pAb(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human (not rat) | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3265-0025 |
Cytochrome P450 2A6 ¡ÚCYP2A6¡Û(human liver, peptide)(CT), sheep pAb(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human (not rat) | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3265-0100 |
Cytochrome P450 2A6 ¡ÚCYP2A6¡Û(human liver, peptide)(CT), sheep pAb(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human (not rat) | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3271-0025 |
Cytochrome P450 2E1 ¡ÚCYP2E1¡Û(hepatic human/rat/rabbit/mouse, peptide)(CT), rabbit pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse¡¢ rat | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3271-0100 |
Cytochrome P450 2E1 ¡ÚCYP2E1¡Û(hepatic human/rat/rabbit/mouse, peptide)(CT), rabbit pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse¡¢ rat | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3275-0025 |
Cytochrome P450 2E1 ¡ÚCYP2E1¡Û(hepatic human/rat/rabbit/mouse, peptide)(CT), sheep pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human¡¢ mouse¡¢ rat¡¢ rabbit | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3275-0100 |
Cytochrome P450 2E1 ¡ÚCYP2E1¡Û(hepatic human/rat/rabbit/mouse, peptide)(CT), sheep pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human¡¢ mouse¡¢ rat¡¢ rabbit | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3280-0025 |
Cytochrome P450 2C8, 2C9, 2C19(human liver)and 2C12(rat)(peptide)(CT)¡ÚCYP2C8, 2C9, 2C19 and CYP2C12¡Û, rabbit pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3280-0100 |
Cytochrome P450 2C8, 2C9, 2C19(human liver)and 2C12(rat)(peptide)(CT)¡ÚCYP2C8, 2C9, 2C19 and CYP2C12¡Û, rabbit pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3285-0025 |
Cytochrome P450 2C8, 2C9, 2C19(human liver)and 2C12(rat)(peptide)(CT)¡ÚCYP2C8, 2C9, 2C19 and CYP2C12¡Û, sheep pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3285-0100 |
Cytochrome P450 2C8, 2C9, 2C19(human liver)and 2C12(rat)(peptide)(CT)¡ÚCYP2C8, 2C9, 2C19 and CYP2C12¡Û, sheep pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3290-0025 |
Cytochrome P450 2B6 ¡ÚCYP2B6¡Û(human liver, aa 265-276), rabbit pAb(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3290-0100 |
Cytochrome P450 2B6 ¡ÚCYP2B6¡Û(human liver, aa 265-276), rabbit pAb(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3295-0025 |
Cytochrome P450 2B6 ¡ÚCYP2B6¡Û(human liver, aa 265-276 ), sheep pAb(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3295-0100 |
Cytochrome P450 2B6 ¡ÚCYP2B6¡Û(human liver, aa 265-276 ), sheep pAb(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3310-0025 |
Cytochrome P450 3A1 ¡ÚCYP3A1¡Û(rat, peptide)(CT), rabbit pAb(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3310-0100 |
Cytochrome P450 3A1 ¡ÚCYP3A1¡Û(rat, peptide)(CT), rabbit pAb(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3315-0025 |
Cytochrome P450 3A1 ¡ÚCYP3A1¡Û(rat, peptide)(CT), sheep pAb(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3315-0100 |
Cytochrome P450 3A1 ¡ÚCYP3A1¡Û(rat, peptide)(CT), sheep pAb(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3320-0025 |
Cytochrome P450 3A2 ¡ÚCYP3A2¡Û(rat, peptide)(CT), rabbit pAb(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3320-0100 |
Cytochrome P450 3A2 ¡ÚCYP3A2¡Û(rat, peptide)(CT), rabbit pAb(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat (not human) | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3325-0100 |
Cytochrome P450 3A2 ¡ÚCYP3A2¡Û(rat, peptide)(CT), sheep pAb(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | rat (not human) | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3340-0025 |
Cytochrome P450 3A4 ¡ÚCYP3A4¡Û(human, peptide)(CT), rabbit pAb(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human (not rat) | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3340-0100 |
Cytochrome P450 3A4 ¡ÚCYP3A4¡Û(human, peptide)(CT), rabbit pAb(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human (not rat) | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3345-0025 |
Cytochrome P450 3A4 ¡ÚCYP3A4¡Û(human, peptide)(CT), sheep pAb(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human (not rat) | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3345-0100 |
Cytochrome P450 3A4 ¡ÚCYP3A4¡Û(human, peptide)(CT), sheep pAb(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | human (not rat) | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3350-0025 |
Cytochrome P450 3A5 ¡ÚCYP3A5¡Û(human, peptide)(CT), rabbit pAb(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human (not rat) | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3350-0100 |
Cytochrome P450 3A5 ¡ÚCYP3A5¡Û(human, peptide)(CT), rabbit pAb(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human (not rat) | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3410-0025 |
Cytochrome P450 4A1, 4A2, 4A3 ¡ÚCYP4A1, CYP4A2 and CYP4A3¡Û(rat, peptide)(CT), rabbit pAb, purified(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3410-0100 |
Cytochrome P450 4A1, 4A2, 4A3 ¡ÚCYP4A1, CYP4A2 and CYP4A3¡Û(rat, peptide)(CT), rabbit pAb, purified(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat | IHC(PS¡¢FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3415-0025 |
Cytochrome P450 4A1, 4A2, 4A3 ¡ÚCYP4A1, CYP4A2 and CYP4A3¡Û(rat, peptide)(CT), sheep pAb, purified(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3415-0100 |
Cytochrome P450 4A1, 4A2, 4A3 ¡ÚCYP4A1, CYP4A2 and CYP4A3¡Û(rat, peptide)(CT), sheep pAb, purified(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
sheep | - | rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3420-0025 |
Cytochrome P450 4A1, 4A2, 4A3 ¡ÚCYP4A1, CYP4A2 and CYP4A3¡Û(rat, peptide)(CT), rabbit pAb, purified(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat | IHC(FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CR3420-0100 |
Cytochrome P450 4A1, 4A2, 4A3 ¡ÚCYP4A1, CYP4A2 and CYP4A3¡Û(rat, peptide)(CT), rabbit pAb, purified(specificity: rat) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat | IHC(FS)¡¢ WB |
|
|
¡¡ |
BML |
BML-CT100-0001 |
Fumagillin ¡ÚFumidil B¡Û¡ÚFumadil B¡Û¡ÚTNP-470¡Û |
1mg |
¡ï11,000 |
|
23110-15-8 |
|
|
|
¡¡ |
BML |
BML-CT100-0005 |
Fumagillin ¡ÚFumidil B¡Û¡ÚFumadil B¡Û¡ÚTNP-470¡Û |
5mg |
¡ï48,000 |
|
23110-15-8 |
|
|
|
¡¡ |
BML |
BML-CT104-0010 |
Withaferin A ¡Ú5,6-Epoxy-4,27-dihydroxy-1-oxowitha-2,24-dienolide¡Û(Isolated from Withania somnifera) |
10mg |
¡ï46,000 |
|
5119-48-2 |
|
|
|
¡¡ |
BML |
BML-CT105-0050 |
Ursolic Acid |
50mg |
¡ï6,000 |
|
77-52-1 |
|
|
|
¡¡ |
BML |
BML-CT105-0250 |
Ursolic Acid |
250mg |
¡ï22,000 |
|
77-52-1 |
|
|
|
¡¡ |
BML |
BML-CT107-0001 |
Thiolutin ¡Ú6-(Acetamido)-4-methyl-1,2-dithiolo[4,3-b]pyrrol-5(4H)-one¡Û(Isolated from Streptomyces luteosporeus) |
1mg |
¡ï12,000 |
|
87-11-6 |
|
|
|
¡¡ |
BML |
BML-CT107-0005 |
Thiolutin ¡Ú6-(Acetamido)-4-methyl-1,2-dithiolo[4,3-b]pyrrol-5(4H)-one¡Û(Isolated from Streptomyces luteosporeus) |
5mg |
¡ï51,000 |
|
87-11-6 |
|
|
|
¡¡ |
BML |
BML-CT115-0010 |
Shikonin |
10mg |
¡ï7,000 |
|
517-89-5 |
|
|
|
¡¡ |
BML |
BML-CT115-0050 |
Shikonin |
50mg |
¡ï27,000 |
|
517-89-5 |
|
|
|
¡¡ |
BML |
BML-CT120-0001 |
Cytochalasin E |
1mg |
¡ï6,000 |
|
36011-19-5 |
|
|
|
¡¡ |
BML |
BML-CT120-0005 |
Cytochalasin E |
5mg |
¡ï27,000 |
|
36011-19-5 |
|
|
|
¡¡ |
BML |
BML-CX101-0010 |
ZK-756326 ¡Ú2-[2-[4-[(3-Phenoxyphenyl)methyl]-1-piperazinyl]ethoxy]ethanol, 2HCl¡Û |
10mg |
¡ï12,000 |
|
874911-96-3 |
|
|
|
¡¡ |
BML |
BML-CX101-0050 |
ZK-756326 ¡Ú2-[2-[4-[(3-Phenoxyphenyl)methyl]-1-piperazinyl]ethoxy]ethanol, 2HCl¡Û |
50mg |
¡ï52,000 |
|
874911-96-3 |
|
|
|
¡¡ |
BML |
BML-D100-0025 |
6,7-ADTN ¡Ú(¡Þ)-2-Amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, HBr¡Û |
25mg |
¡ï8,000 |
|
73304-33-3 |
|
|
|
¡¡ |
BML |
BML-D101-0010 |
AJ-76 ¡Ú(1S,2R)-cis-5-Methoxy-1-methyl-2-(n-propylamino)tetralin, HCl¡Û |
10mg |
¡ï23,000 |
|
85379-09-5 |
|
|
|
¡¡ |
BML |
BML-D102-0100 |
Bromocriptine, Mesylate ¡Ú(+)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-ergotaman-3',6',18-trione Methanesulfonate¡Û |
100mg |
¡ï9,000 |
|
22260-51-1 |
|
|
|
¡¡ |
BML |
BML-D102-0500 |
Bromocriptine, Mesylate ¡Ú(+)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-ergotaman-3',6',18-trione Methanesulfonate¡Û |
500mg |
¡ï38,000 |
|
22260-51-1 |
|
|
|
¡¡ |
BML |
BML-D103-0010 |
BTCP ¡Ú1-[1-(2-Benzo[b]thienyl)cyclohexyl)]piperidine, Maleate¡Û |
10mg |
¡ï25,000 |
|
112726-66-6 |
|
|
|
¡¡ |
BML |
BML-D104-0005 |
GBR-12909 ¡Ú1-(2-bis-(4-Fluorophenyl)methoxy)ethyl)-4-(3-phenyl-2-propyl)¡Û |
5mg |
¡ï8,000 |
|
67469-78-7 |
|
|
|
¡¡ |
BML |
BML-D104-0025 |
GBR-12909 ¡Ú1-(2-bis-(4-Fluorophenyl)methoxy)ethyl)-4-(3-phenyl-2-propyl)¡Û |
25mg |
¡ï32,000 |
|
67469-78-7 |
|
|
|
¡¡ |
BML |
BML-D105-0010 |
7-Hydroxy-DPAT, HBr ¡Ú(¡Þ)-7-Hydroxy-2-dipropylaminotetralin, HBr¡Û |
10mg |
¡ï9,000 |
|
94938-11-7 |
|
|
|
¡¡ |
BML |
BML-D105-0050 |
7-Hydroxy-DPAT, HBr ¡Ú(¡Þ)-7-Hydroxy-2-dipropylaminotetralin, HBr¡Û |
50mg |
¡ï37,000 |
|
94938-11-7 |
|
|
|
¡¡ |
BML |
BML-D106-0005 |
trans-7-Hydroxy-PIPAT, Maleate ¡Útrans-7-Hydroxy-2-[N-propyl-N(3'-iodo-2'-propenyl)amino]tetralin, Maleate¡Û |
5mg |
¡ï25,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-D107-0050 |
Clozapine ¡Ú8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e]-[1,4]diazepine¡Û |
50mg |
¡ï7,000 |
|
5786-21-0 |
|
|
|
¡¡ |
BML |
BML-D107-0500 |
Clozapine ¡Ú8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e]-[1,4]diazepine¡Û |
500mg |
¡ï45,000 |
|
5786-21-0 |
|
|
|
¡¡ |
BML |
BML-D108-0020 |
Clothiapine |
20mg |
¡ï3,000 |
|
2058-52-8 |
|
|
|
¡¡ |
BML |
BML-D108-0100 |
Clothiapine |
100mg |
¡ï17,000 |
|
2058-52-8 |
|
|
|
¡¡ |
BML |
BML-D109-0005 |
(-)-Quinpirole, HCl ¡ÚL-171,555¡Û¡Útrans-(-)-4aR-4,5,6,7,8,8a,9-Octahydro-5-propyl-1H-pyrazolo[3,4-g]quinoline¡Û |
5mg |
¡ï14,000 |
|
85760-74-3 |
|
|
|
¡¡ |
BML |
BML-D109-0025 |
(-)-Quinpirole, HCl ¡ÚL-171,555¡Û¡Útrans-(-)-4aR-4,5,6,7,8,8a,9-Octahydro-5-propyl-1H-pyrazolo[3,4-g]quinoline¡Û |
25mg |
¡ï59,000 |
|
85760-74-3 |
|
|
|
¡¡ |
BML |
BML-D110-0005 |
SCH 23390 ¡ÚR-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine, HCl¡Û |
5mg |
¡ï11,000 |
|
87134-87-0 |
|
|
|
¡¡ |
BML |
BML-D110-0025 |
SCH 23390 ¡ÚR-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine, HCl¡Û |
25mg |
¡ï49,000 |
|
87134-87-0 |
|
|
|
¡¡ |
BML |
BML-D111-0010 |
Remoxipride ¡Ú(S)-(-)-3-Bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenzamide, HCl¡Û |
10mg |
¡ï12,000 |
|
73220-03-8 |
|
|
|
¡¡ |
BML |
BML-D122-0050 |
12(S),20-Dihydroxyeicosa-5Z,8Z,10E,14Z-tetraenoic Acid ¡Ú12(S),20-DiHETE¡Û |
50ug |
¡ï30,000 |
|
89614-44-8 |
|
|
|
¡¡ |
BML |
BML-D515-0050 |
5(S),15(S)-DiHETE ¡Ú5(S),15(S)-Dihydroxyeicosa-6E,8Z,11Z,13E-tetraenoic Acid¡Û |
50ug |
¡ï19,000 |
|
82200-87-1 |
|
|
|
¡¡ |
BML |
BML-D815-0050 |
8(S),15(S)-DiHETE ¡Ú8(S),15(S)-Dihydroxyeicosa-5Z,9E,11Z,13E-tetraenoic Acid¡Û |
50ug |
¡ï19,000 |
|
80234-65-7 |
|
|
|
¡¡ |
BML |
BML-DA1140-0025 |
Dopamine, rabbit pAb, purified |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC¡¢ ELISA |
|
|
¡¡ |
BML |
BML-DA1140-0100 |
Dopamine, rabbit pAb, purified |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC¡¢ ELISA |
|
|
¡¡ |
BML |
BML-DA4170-0100 |
Dishevelled-1 ¡ÚDVL-1¡Û(human, aa 557-571), rabbit pAb, purified(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat | WB |
|
|
¡¡ |
BML |
BML-DA4270-0025 |
Dishevelled-2 ¡ÚDVL-2¡Û(human/mouse, aa 600-614), rabbit pAb, purified |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-DA4270-0100 |
Dishevelled-2 ¡ÚDVL-2¡Û(human/mouse, aa 600-614), rabbit pAb, purified |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-DA4370-0025 |
Dishevelled-3 ¡ÚDVL-3¡Û(human/mouse, aa 582-596), rabbit pAb, purified |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | WB |
|
|
¡¡ |
BML |
BML-DA4370-0100 |
Dishevelled-3 ¡ÚDVL-3¡Û(human/mouse, aa 582-596), rabbit pAb, purified |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | WB |
|
|
¡¡ |
BML |
BML-DA4470-0025 |
Dishevelled-2 ¡ÚDVL-2¡Û(human, aa 633-645), rabbit pAb, purified(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | WB |
|
|
¡¡ |
BML |
BML-DA4470-0100 |
Dishevelled-2 ¡ÚDVL-2¡Û(human, aa 633-645), rabbit pAb, purified(specificity: human) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | WB |
|
|
¡¡ |
BML |
BML-DG100-0010 |
(¡Þ)-1,2-Didecanoylglycerol(10:0) |
10mg |
¡ï8,000 |
|
82950-64-9 |
|
|
|
¡¡ |
BML |
BML-DG100-0050 |
(¡Þ)-1,2-Didecanoylglycerol(10:0) |
50mg |
¡ï27,000 |
|
82950-64-9 |
|
|
|
¡¡ |
BML |
BML-DG112-0020 |
1,2-Dioctanoyl-sn-glycerol(8:0)¡ÚDOG¡Û |
20mg |
¡ï8,000 |
|
60514-48-9 |
|
|
|
¡¡ |
BML |
BML-DG112-0100 |
1,2-Dioctanoyl-sn-glycerol(8:0)¡ÚDOG¡Û |
100mg |
¡ï27,000 |
|
60514-48-9 |
|
|
|
¡¡ |
BML |
BML-DG115-0020 |
(¡Þ)-1,2-Dioleoylglycerol(18:1) |
20mg |
¡ï8,000 |
|
3738-74-7 |
|
|
|
¡¡ |
BML |
BML-DG115-0100 |
(¡Þ)-1,2-Dioleoylglycerol(18:1) |
100mg |
¡ï27,000 |
|
3738-74-7 |
|
|
|
¡¡ |
BML |
BML-DG125-0010 |
1-Oleoyl-2-acetyl-sn-glycerol ¡ÚOAG¡Û |
10mg |
¡ï13,000 |
|
86390-77-4 |
|
|
|
¡¡ |
BML |
BML-DG125-0050 |
1-Oleoyl-2-acetyl-sn-glycerol ¡ÚOAG¡Û |
50mg |
¡ï55,000 |
|
86390-77-4 |
|
|
|
¡¡ |
BML |
BML-DG130-0010 |
1-Stearoyl-2-arachidonoyl-sn-glycerol |
10mg |
¡ï9,000 |
|
65914-84-3 |
|
|
|
¡¡ |
BML |
BML-DG135-0010 |
1-Stearoyl-2-linoleoyl-sn-glycerol |
10mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-DG135-0050 |
1-Stearoyl-2-linoleoyl-sn-glycerol |
50mg |
¡ï39,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-DG140-0005 |
1-O-Hexadecyl-2-O-arachidonoyl-sn-glycerol |
5mg |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-DG140-0025 |
1-O-Hexadecyl-2-O-arachidonoyl-sn-glycerol |
25mg |
¡ï65,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-DG6080-0100 |
Desmin(human)[37EH], mouse mAb, purified |
100ul |
¡ï24,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 37EH | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | WB(55kDa)¡¢ ICC |
|
|
¡¡ |
BML |
BML-DM100-0001 |
25-Hydroxyvitamin D3 |
1mg |
¡ï12,000 |
|
19356-17-3 |
|
|
|
¡¡ |
BML |
BML-DM100-0005 |
25-Hydroxyvitamin D3 |
5mg |
¡ï46,000 |
|
19356-17-3 |
|
|
|
¡¡ |
BML |
BML-DM101-0001 |
25-Hydroxyvitamin D2 ¡ÚErcalcidiol¡Û¡Ú25-Hydroxyergocalciferol¡Û¡Ú25-Hydroxycalciferol¡Û |
1mg |
¡ï25,000 |
-20¡î |
21343-40-8 |
|
TOXIC. Protect from light and oxygen
|
|
¡¡ |
BML |
BML-DM200-0050 |
1a,25-Dihydroxyvitamin D3 ¡ÚCalcitriol¡Û¡Ú1a,25-Dihydroxycholecalciferol¡Û |
50ug |
¡ï25,000 |
|
32222-06-3 |
|
|
|
¡¡ |
BML |
BML-DM200-1000 |
1a,25-Dihydroxyvitamin D3 ¡ÚCalcitriol¡Û¡Ú1a,25-Dihydroxycholecalciferol¡Û |
1mg |
¡ï234,000 |
|
32222-06-3 |
|
|
|
¡¡ |
BML |
BML-DM300-0050 |
24(R),25-Dihydroxyvitamin D3 |
50ug |
¡ï35,000 |
|
55721-11-4 |
|
|
|
¡¡ |
BML |
BML-DP9417-0100 |
Dishevelled-1 Peptide, Blocking peptide for Dishevelled-1(human)pAb(Prod. No. BML-DA4170) |
100ug |
¡ï6,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-DP9427-0100 |
Dishevelled-2 Peptide, Blocking peptide for Dishevelled-2 pAb(Prod. No. BML-DA4270) |
100ug |
¡ï6,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-DP9437-0100 |
Dishevelled-3 Peptide, Blocking peptide for Dishevelled-3 pAb(Prod. No. BML-DA4370) |
100ug |
¡ï6,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-DP9447-0100 |
Dishevelled-2 Peptide, Blocking peptide for Dishevelled-2(human)pAb(Prod. No. BML-DA4470) |
100ug |
¡ï6,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-DS056-0050 |
5(S),6(R)-Dihydroxyeicosa-7E,9E,11Z,14Z-tetraenoic Acid(DiHETE)¡Ú5(S),6(R)-DiHETE¡Û |
50ug |
¡ï25,000 |
|
82948-88-7 |
|
|
|
¡¡ |
BML |
BML-DS056-1000 |
5(S),6(R)-Dihydroxyeicosa-7E,9E,11Z,14Z-tetraenoic Acid(DiHETE)¡Ú5(S),6(R)-DiHETE¡Û |
1mg |
¡ï313,000 |
|
82948-88-7 |
|
|
|
¡¡ |
BML |
BML-DTR512-0050 |
5(S),12(R)-Dihydroxyeicosa-6E,8E,10E,14Z-tetraenoic Acid ¡Ú5(S),12(R)-DiHETE¡Û¡Ú6-trans-LTB4¡Û |
50ug |
¡ï25,000 |
|
71652-82-9 |
|
|
|
¡¡ |
BML |
BML-DTR512-1000 |
5(S),12(R)-Dihydroxyeicosa-6E,8E,10E,14Z-tetraenoic Acid ¡Ú5(S),12(R)-DiHETE¡Û¡Ú6-trans-LTB4¡Û |
1mg |
¡ï313,000 |
|
71652-82-9 |
|
|
|
¡¡ |
BML |
BML-DTR815-0050 |
8(R),15(S)-Dihydroxyeicosa-5Z,9E,11E,13E-tetraenoic Acid ¡Ú8(R),15(S)-DiHETE¡Û |
50ug |
¡ï25,000 |
|
80234-67-9 |
|
|
|
¡¡ |
BML |
BML-DTS512-0050 |
5(S),12(S)-Dihydroxyeicosa-6E,8E,10E,14Z-tetraenoic Acid ¡Ú5(S),12(S)-DiHETE¡Û¡Ú6-trans-12-epi-LTB4¡Û |
50ug |
¡ï25,000 |
|
73151-67-4 |
|
|
|
¡¡ |
BML |
BML-DTS815-0050 |
8(S),15(S)-Dihydroxyeicosa-5Z,9E,11E,13E-tetraenoic Acid ¡Ú8(S),15(S)-DiHETE(Z, E, E, E)¡Û |
50ug |
¡ï25,000 |
|
80234-66-8 |
|
|
|
¡¡ |
BML |
BML-DW8720-0005 |
pJY2 Plasmid |
5ug |
¡ï26,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-DZ1020-0050 |
Dopamine-B-hydroxylase ¡ÚDBH¡Û(bovine), rabbit pAb(antiserum) |
50ul |
¡ï45,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse¡¢ rat¡¢ cat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-DZ1041-0025 |
Dopamine, rat pAb(antiserum) |
25ul |
¡ï43,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rat | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-EA101-0050 |
AP4 ¡ÚDL-2-Amino-4-phosphonobutanoic Acid¡Û |
50mg |
¡ï4,000 |
|
20263-07-4 |
|
|
|
¡¡ |
BML |
BML-EA101-0250 |
AP4 ¡ÚDL-2-Amino-4-phosphonobutanoic Acid¡Û |
250mg |
¡ï19,000 |
|
20263-07-4 |
|
|
|
¡¡ |
BML |
BML-EA104-0005 |
D-AP5 ¡ÚD(-)-2-Amino-5-phosphonovaleric Acid¡Û |
5mg |
¡ï11,000 |
|
79055-68-8 |
|
|
|
¡¡ |
BML |
BML-EA105-0005 |
L-AP5 ¡ÚL(+)-2-Amino-5-phosphonovaleric Acid¡Û |
5mg |
¡ï19,000 |
|
79055-67-7 |
|
|
|
¡¡ |
BML |
BML-EA109-0050 |
Bicuculline Methobromide |
50mg |
¡ï17,000 |
|
73604-30-5 |
|
|
|
¡¡ |
BML |
BML-EA110-0005 |
AMPA ¡Ú(¡Þ)-a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid¡Û |
5mg |
¡ï13,000 |
|
74341-63-2 |
|
|
|
¡¡ |
BML |
BML-EA113-0010 |
5,7-Dichlorokynurenic Acid |
10mg |
¡ï12,000 |
|
131123-76-7 |
|
|
|
¡¡ |
BML |
BML-EA113-0050 |
5,7-Dichlorokynurenic Acid |
50mg |
¡ï53,000 |
|
131123-76-7 |
|
|
|
¡¡ |
BML |
BML-EA1149-0025 |
Leu Enkephalin ¡ÚLeucine Enkephalin¡Û¡Ú[Leu5]-enkephalin¡Û(synthetic leucine enkephalin), rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-EA1149-0100 |
Leu Enkephalin ¡ÚLeucine Enkephalin¡Û¡Ú[Leu5]-enkephalin¡Û(synthetic leucine enkephalin), rabbit pAb(antiserum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-EA1150-0025 |
Met Enkephalin ¡ÚMethionine enkephalin¡Û¡Ú[Met5]-enkephalin¡Û(synthetic methionine enkephalin), rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-EA115-0005 |
Dihydrokainic Acid |
5mg |
¡ï16,000 |
|
52497-36-6 |
|
|
|
¡¡ |
BML |
BML-EA1150-0100 |
Met Enkephalin ¡ÚMethionine enkephalin¡Û¡Ú[Met5]-enkephalin¡Û(synthetic methionine enkephalin), rabbit pAb(antiserum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-EA115-0025 |
Dihydrokainic Acid |
25mg |
¡ï64,000 |
|
52497-36-6 |
|
|
|
¡¡ |
BML |
BML-EA116-0010 |
6,7-Dinitroquinoxaline-2,3-dione ¡ÚDNQX¡Û |
10mg |
¡ï7,000 |
|
2379-57-9 |
|
|
|
¡¡ |
BML |
BML-EA117-0001 |
Domoic Acid ¡Ú[2S-[2a,3B,4B(1Z,3E,5R)]]-2-Carboxy-4-(5-carboxy-1-methyl-1,3-hexadienyl)-3-pyrrolidineacetic Acid¡Û(Isolated from Nitzschia pungens f. multiseries) |
1mg |
¡ï17,000 |
|
14277-97-5 |
|
|
|
¡¡ |
BML |
BML-EA120-0001 |
Ibotenic Acid ¡Úa-Amino-3-hydroxy-5-isoxazoleacetic Acid¡Û |
1mg |
¡ï12,000 |
|
2552-55-8 |
|
|
|
¡¡ |
BML |
BML-EA120-0005 |
Ibotenic Acid ¡Úa-Amino-3-hydroxy-5-isoxazoleacetic Acid¡Û |
5mg |
¡ï48,000 |
|
2552-55-8 |
|
|
|
¡¡ |
BML |
BML-EA121-0010 |
Isoguvacine |
10mg |
¡ï3,000 |
|
64603-90-3 |
|
|
|
¡¡ |
BML |
BML-EA121-0050 |
Isoguvacine |
50mg |
¡ï14,000 |
|
64603-90-3 |
|
|
|
¡¡ |
BML |
BML-EA123-0005 |
Kainic Acid |
5mg |
¡ï8,000 |
|
487-79-6 |
|
|
|
¡¡ |
BML |
BML-EA123-0025 |
Kainic Acid |
25mg |
¡ï33,000 |
|
487-79-6 |
|
|
|
¡¡ |
BML |
BML-EA124-0005 |
Homoquinolinic Acid |
5mg |
¡ï13,000 |
|
490-75-5 |
|
|
|
¡¡ |
BML |
BML-EA124-0025 |
Homoquinolinic Acid |
25mg |
¡ï53,000 |
|
490-75-5 |
|
|
|
¡¡ |
BML |
BML-EA127-0005 |
Phaclofen ¡Ú3-Amino-2-(4-chlorophenyl)propylphosphonic Acid¡Û |
5mg |
¡ï10,000 |
|
114012-12-3 |
|
|
|
¡¡ |
BML |
BML-EA127-0025 |
Phaclofen ¡Ú3-Amino-2-(4-chlorophenyl)propylphosphonic Acid¡Û |
25mg |
¡ï42,000 |
|
114012-12-3 |
|
|
|
¡¡ |
BML |
BML-EA128-0001 |
Baclofen |
1g |
¡ï11,000 |
|
1134-47-0 |
|
|
|
¡¡ |
BML |
BML-EA128-0005 |
Baclofen |
5g |
¡ï53,000 |
|
1134-47-0 |
|
|
|
¡¡ |
BML |
BML-EA133-0005 |
SK&F 97541 ¡Ú3-Aminopropyl(methyl)phosphinic Acid¡Û |
5mg |
¡ï13,000 |
|
127729-35-5 |
|
|
|
¡¡ |
BML |
BML-EA133-0025 |
SK&F 97541 ¡Ú3-Aminopropyl(methyl)phosphinic Acid¡Û |
25mg |
¡ï50,000 |
|
127729-35-5 |
|
|
|
¡¡ |
BML |
BML-EA134-0005 |
Z-3-(Amidinothio)propenoic Acid ¡ÚZAPA, H2SO4¡Û |
5mg |
¡ï9,000 |
|
92138-10-8 |
|
|
|
¡¡ |
BML |
BML-EA134-0025 |
Z-3-(Amidinothio)propenoic Acid ¡ÚZAPA, H2SO4¡Û |
25mg |
¡ï36,000 |
|
92138-10-8 |
|
|
|
¡¡ |
BML |
BML-EA135-0005 |
Gabaculine ¡Ú(¡Þ)3-Amino-2,3-dihydrobenzoic Acid, HCl¡Û |
5mg |
¡ï21,000 |
|
59556-17-1 |
|
|
|
¡¡ |
BML |
BML-EA136-0020 |
Arcaine Sulfate ¡ÚN,N'-1,4-Butanediyl-bis(guanidine), Sulfate¡Û |
20mg |
¡ï9,000 |
|
14923-17-2 |
|
|
|
¡¡ |
BML |
BML-EA137-0010 |
Synthalin ¡ÚN,N'-1,10-Decanediyl-bis(guanidine), Sulfate¡Û |
10mg |
¡ï15,000 |
|
111-23-9 |
|
|
|
¡¡ |
BML |
BML-EA138-0005 |
N-Acetylglycyl-D-glutamic Acid |
5mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EA138-0025 |
N-Acetylglycyl-D-glutamic Acid |
25mg |
¡ï33,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EA139-0005 |
L-trans-Pyrrolidine-2,4-dicarboxylic Acid |
5mg |
¡ï11,000 |
|
64769-66-0 |
|
|
|
¡¡ |
BML |
BML-EA139-0025 |
L-trans-Pyrrolidine-2,4-dicarboxylic Acid |
25mg |
¡ï55,000 |
|
64769-66-0 |
|
|
|
¡¡ |
BML |
BML-EA143-0010 |
L-701,252 ¡Ú7-Chloro-3-(cyclopropylcarbonyl)-4-hydroxy-2(1H)-quinoline¡Û |
10mg |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EA144-0005 |
U-54494A ¡Úcis(¡Þ)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzamide, HCl¡Û |
5mg |
¡ï12,000 |
|
92953-41-8 |
|
|
|
¡¡ |
BML |
BML-EA144-0025 |
U-54494A ¡Úcis(¡Þ)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzamide, HCl¡Û |
25mg |
¡ï52,000 |
|
92953-41-8 |
|
|
|
¡¡ |
BML |
BML-EA145-0010 |
CFM-2 ¡Ú1-(4'-Aminophenyl)-3,5-dihydro-7,8-Dimethoxy-4H-2,3-benzodiazepin-4-one¡Û |
10mg |
¡ï27,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EA146-0005 |
CPCCOEt ¡Ú7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylate Ethyl Ester¡Û |
5mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EA147-0005 |
CPPG ¡Ú(¡Þ)-a-Cyclopropyl-4-phosphonophenylglycine¡Û |
5mg |
¡ï14,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EA147-0025 |
CPPG ¡Ú(¡Þ)-a-Cyclopropyl-4-phosphonophenylglycine¡Û |
25mg |
¡ï57,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EA148-0010 |
AMN082 ¡ÚN,N¡Ç-Dibenzhydrylethane-1,2-diamine, 2HCl¡Û |
10mg |
¡ï11,000 |
|
83027-13-8 |
|
|
|
¡¡ |
BML |
BML-EA148-0050 |
AMN082 ¡ÚN,N¡Ç-Dibenzhydrylethane-1,2-diamine, 2HCl¡Û |
50mg |
¡ï48,000 |
|
83027-13-8 |
|
|
|
¡¡ |
BML |
BML-EA149-0050 |
(-)-Bicuculline Methiodide |
50mg |
¡ï16,000 |
|
40709-69-1 |
|
|
|
¡¡ |
BML |
BML-EA150-0005 |
FrPbAII ¡ÚL-2-Amino-5-ureidopentanamide¡Û |
5mg |
¡ï36,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EC23-0500 |
ec23 ¡Ú4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylethynyl)benzoic Acid¡Û |
5mg |
¡ï8,000 |
|
104561-41-3 |
|
|
|
¡¡ |
BML |
BML-EC23-2500 |
ec23 ¡Ú4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylethynyl)benzoic Acid¡Û |
25mg |
¡ï37,000 |
|
104561-41-3 |
|
|
|
¡¡ |
BML |
BML-EE11-0050 |
(¡Þ)11,12-Epoxyeicosa-5Z,8Z,14Z-trienoic Acid ¡Ú(¡Þ)11,12-EET¡Û¡Ú11(12)-EpETrE¡Û |
50ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EE11-1000 |
(¡Þ)11,12-Epoxyeicosa-5Z,8Z,14Z-trienoic Acid ¡Ú(¡Þ)11,12-EET¡Û¡Ú11(12)-EpETrE¡Û |
1mg |
¡ï105,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EE14-0050 |
(¡Þ)14,15-Epoxyeicosa-5Z,8Z,11Z-trienoic Acid ¡Ú(¡Þ)14,15-EET¡Û¡Ú14(15)-EpETrE¡Û |
50ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EE14-1000 |
(¡Þ)14,15-Epoxyeicosa-5Z,8Z,11Z-trienoic Acid ¡Ú(¡Þ)14,15-EET¡Û¡Ú14(15)-EpETrE¡Û |
1mg |
¡ï105,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EE56-0050 |
(¡Þ)5,6-Epoxyeicosa-8Z,11Z,14Z-trienoic Acid ¡Ú(¡Þ)5,6-EET¡Û¡Ú5(6)-EpETre¡Û |
50ug |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EE56-1000 |
(¡Þ)5,6-Epoxyeicosa-8Z,11Z,14Z-trienoic Acid ¡Ú(¡Þ)5,6-EET¡Û¡Ú5(6)-EpETre¡Û |
1mg |
¡ï108,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EE614-0050 |
(¡Þ)14,15-Epoxyeicosa-5Z,8Z,11Z-trienoic Acid-d8 ¡Ú(¡Þ)14,15-EET-d8¡Û |
50ug |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EE656-0050 |
(¡Þ)-5,6-EET-d8 Methyl Ester ¡Ú(¡Þ)5,6-Epoxyeicosa-8Z,11Z,14Z-trienoic Acid-d8 Methyl Ester¡Û |
50ug |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EE89-0050 |
(¡Þ)8,9-Epoxyeicosa-5Z,11Z,14Z-trienoic Acid ¡Ú(¡Þ)8,9-EET¡Û¡Ú8(9)-EpETrE¡Û |
50ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EE89-1000 |
(¡Þ)8,9-Epoxyeicosa-5Z,11Z,14Z-trienoic Acid ¡Ú(¡Þ)8,9-EET¡Û¡Ú8(9)-EpETrE¡Û |
1mg |
¡ï100,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EG6000-0100 |
PECAM-1 ¡ÚPlatelet Endothelial Cell Adhesion Molecule-1¡Û¡ÚCD31¡Û(human, umbilical vein endothelial cells)[CE6], mouse mAb, purified |
100ul |
¡ï24,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | CE6 | human | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-EI100-0001 |
Esculetin ¡Ú6,7-Dihydroxycoumarin¡Û |
1g |
¡ï4,000 |
|
305-01-1 |
|
|
|
¡¡ |
BML |
BML-EI101-0001 |
Nordihydroguairetic Acid ¡ÚNDGA¡Û¡Ú4,4'-(2,3-Dimethyl-1,4-butanediyl)bis[1,2-benzenediol]¡Û(synthetic) |
1g |
¡ï9,000 |
|
500-38-9 |
|
|
|
¡¡ |
BML |
BML-EI102-0050 |
Leukotriene B4-Dimethylamide |
50ug |
¡ï41,000 |
|
83024-92-4 |
|
|
|
¡¡ |
BML |
BML-EI103-0001 |
17-Octadecynoic Acid ¡Ú17-ODYA¡Û |
1mg |
¡ï5,000 |
|
34450-18-5 |
|
|
|
¡¡ |
BML |
BML-EI103-0010 |
17-Octadecynoic Acid ¡Ú17-ODYA¡Û |
10mg |
¡ï31,000 |
|
34450-18-5 |
|
|
|
¡¡ |
BML |
BML-EI104-0050 |
Leukotriene A3 Methyl Ester ¡ÚLTA3-ME¡Û |
50ug |
¡ï21,000 |
|
83851-38-1 |
|
|
|
¡¡ |
BML |
BML-EI105-0250 |
SKF-525A, HCl ¡ÚProadifen¡Û |
250mg |
¡ï10,000 |
|
62-68-0 |
|
|
|
¡¡ |
BML |
BML-EI105-1000 |
SKF-525A, HCl ¡ÚProadifen¡Û |
1g |
¡ï30,000 |
|
62-68-0 |
|
|
|
¡¡ |
BML |
BML-EI106-0010 |
Baicalein ¡Ú5,6,7-Trihydroxyflavone¡Û |
10mg |
¡ï8,000 |
|
491-67-8 |
|
|
|
¡¡ |
BML |
BML-EI106-0050 |
Baicalein ¡Ú5,6,7-Trihydroxyflavone¡Û |
50mg |
¡ï32,000 |
|
491-67-8 |
|
|
|
¡¡ |
BML |
BML-EI107-0050 |
Ketoconazole |
50mg |
¡ï6,000 |
|
65277-42-1 |
|
|
|
¡¡ |
BML |
BML-EI107-0500 |
Ketoconazole |
500mg |
¡ï32,000 |
|
65277-42-1 |
|
|
|
¡¡ |
BML |
BML-EI108-0020 |
4-Phenylchalcone Oxide ¡Ú4-PCO¡Û |
20mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI108-0100 |
4-Phenylchalcone Oxide ¡Ú4-PCO¡Û |
100mg |
¡ï40,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI110-0025 |
TMB-8, HCl ¡Ú8-(Diethylamino)octyl-3,4,5-trimethoxybenzoate, HCl¡Û |
25mg |
¡ï9,000 |
|
53464-72-5 |
|
|
|
¡¡ |
BML |
BML-EI112-0010 |
7,7-Dimethyleicosadienoic Acid ¡ÚDEDA¡Û |
10mg |
¡ï10,000 |
|
89560-01-0 |
|
|
|
¡¡ |
BML |
BML-EI112-0050 |
7,7-Dimethyleicosadienoic Acid ¡ÚDEDA¡Û |
50mg |
¡ï40,000 |
|
89560-01-0 |
|
|
|
¡¡ |
BML |
BML-EI113-0010 |
Acivicin ¡ÚU-42126¡Û¡ÚAT-125¡Û |
10mg |
¡ï16,000 |
-20¡î |
42228-92-2 |
|
Purity: ¡ä99%, Formula: C5H7ClN2O3, MW: 178.6 Solubility: soluble in water (max. 18mg/ml).
|
|
¡¡ |
BML |
BML-EI114-0010 |
Oxatomide |
10mg |
¡ï13,000 |
|
60607-34-3 |
|
|
|
¡¡ |
BML |
BML-EI114-0050 |
Oxatomide |
50mg |
¡ï50,000 |
|
60607-34-3 |
|
|
|
¡¡ |
BML |
BML-EI116-0001 |
8,11-Eicosadiynoic Acid ¡ÚEDYA¡Û |
1mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI117-0100 |
Ro 20-1724 ¡Ú4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone¡Û |
100mg |
¡ï13,000 |
|
29925-17-5 |
|
|
|
¡¡ |
BML |
BML-EI117-1000 |
Ro 20-1724 ¡Ú4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone¡Û |
1g |
¡ï43,000 |
|
29925-17-5 |
|
|
|
¡¡ |
BML |
BML-EI118-0010 |
Oleyloxyethyl Phosphorylcholine |
10mg |
¡ï8,000 |
|
96720-06-8 |
|
|
|
¡¡ |
BML |
BML-EI118-0050 |
Oleyloxyethyl Phosphorylcholine |
50mg |
¡ï34,000 |
|
96720-06-8 |
|
|
|
¡¡ |
BML |
BML-EI119-0010 |
Carboxyheptyl Imidazole |
10mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI119-0050 |
Carboxyheptyl Imidazole |
50mg |
¡ï32,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI120-0010 |
Carbethoxyhexyl Imidazole |
10mg |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI120-0050 |
Carbethoxyhexyl Imidazole |
50mg |
¡ï30,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI121-0001 |
Disodium Cromoglycate ¡ÚDSCG¡Û¡ÚCromolyn Sodium¡Û |
1g |
¡ï4,000 |
|
15826-37-6 |
|
|
|
¡¡ |
BML |
BML-EI121-0005 |
Disodium Cromoglycate ¡ÚDSCG¡Û¡ÚCromolyn Sodium¡Û |
5g |
¡ï10,000 |
|
15826-37-6 |
|
|
|
¡¡ |
BML |
BML-EI123-0100 |
CDP-Choline ¡ÚCytidine 5'-diphosphocholine, Na salt¡Û |
100mg |
¡ï6,000 |
|
33818-15-4 |
|
|
|
¡¡ |
BML |
BML-EI123-1000 |
CDP-Choline ¡ÚCytidine 5'-diphosphocholine, Na salt¡Û |
1g |
¡ï21,000 |
|
33818-15-4 |
|
|
|
¡¡ |
BML |
BML-EI125-0200 |
Capsaicin ¡Ú8-Methyl-N-vanillyl-6-nonenamide¡Û(Isolated from Capsicum fruit) |
200mg |
¡ï13,000 |
|
404-86-4 |
|
|
|
¡¡ |
BML |
BML-EI125-1000 |
Capsaicin ¡Ú8-Methyl-N-vanillyl-6-nonenamide¡Û(Isolated from Capsicum fruit) |
1g |
¡ï51,000 |
|
404-86-4 |
|
|
|
¡¡ |
BML |
BML-EI126-0001 |
Dexamethasone ¡Ú9a-Fluoro-16a-methylprednisolone¡Û |
1g |
¡ï8,000 |
|
50-02-2 |
|
|
|
¡¡ |
BML |
BML-EI126-0005 |
Dexamethasone ¡Ú9a-Fluoro-16a-methylprednisolone¡Û |
5g |
¡ï32,000 |
|
50-02-2 |
|
|
|
¡¡ |
BML |
BML-EI127-0001 |
Dipyridamole ¡Ú2,6-bis(Diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine¡Û |
1g |
¡ï3,000 |
|
58-32-2 |
|
|
|
¡¡ |
BML |
BML-EI127-0005 |
Dipyridamole ¡Ú2,6-bis(Diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine¡Û |
5g |
¡ï9,000 |
|
58-32-2 |
|
|
|
¡¡ |
BML |
BML-EI128-0001 |
Ethacrynic Acid ¡Ú2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxyacetic Acid¡Û |
1g |
¡ï4,000 |
|
58-54-8 |
|
|
|
¡¡ |
BML |
BML-EI130-0020 |
Gossypol ¡Ú2,2¡Ç-bis[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]¡Û(Isolated from Gossypium genus, Malvaceae) |
20mg |
¡ï4,000 |
|
303-45-7 |
|
|
|
¡¡ |
BML |
BML-EI130-0100 |
Gossypol ¡Ú2,2¡Ç-bis[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]¡Û(Isolated from Gossypium genus, Malvaceae) |
100mg |
¡ï13,000 |
|
303-45-7 |
|
|
|
¡¡ |
BML |
BML-EI132-0001 |
Methoxsalen ¡Ú8-Methoxypsoralen¡Û |
1g |
¡ï7,000 |
|
298-81-7 |
|
|
|
¡¡ |
BML |
BML-EI134-0005 |
Phenidone ¡Ú1-Phenyl-3-pyrazolidinone¡Û |
5g |
¡ï3,000 |
|
92-43-3 |
|
|
|
¡¡ |
BML |
BML-EI143-0010 |
SC-10 ¡Ú5-Chloro-N-heptylnaphthalene-1-sulfonamide¡Û¡ÚN-Heptyl-5-chloro-1-naphthalene-sulfonamide¡Û |
10mg |
¡ï7,000 |
|
102649-79-6 |
|
|
|
¡¡ |
BML |
BML-EI143-0050 |
SC-10 ¡ÚN-Heptyl-5-chloronaphthalene-1-sulfonamide¡Û |
50mg |
¡ï31,000 |
|
102649-79-6 |
|
|
|
¡¡ |
BML |
BML-EI145-0010 |
A-3 ¡ÚN-(2-Aminoethyl)-5-chloronaphthalene-1-sulfonamide, HCl¡Û |
10mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI146-0005 |
Erbstatin Analog ¡ÚMethyl 2,5-Dihydroxycinnamate¡Û |
5mg |
¡ï10,000 |
|
63177-57-1 |
|
|
|
¡¡ |
BML |
BML-EI146-0025 |
Erbstatin Analog ¡ÚMethyl 2,5-Dihydroxycinnamate¡Û |
25mg |
¡ï39,000 |
|
63177-57-1 |
|
|
|
¡¡ |
BML |
BML-EI148-0010 |
H-7 ¡Ú1-(5-Isoquinolinesulfonyl)-2-methylpiperazine, 2HCl¡Û |
10mg |
¡ï10,000 |
|
108930-17-2 |
|
|
|
¡¡ |
BML |
BML-EI148-0050 |
H-7 ¡Ú1-(5-Isoquinolinesulfonyl)-2-methylpiperazine, 2HCl¡Û |
50mg |
¡ï40,000 |
|
108930-17-2 |
|
|
|
¡¡ |
BML |
BML-EI150-0005 |
1-O-Hexadecyl-2-O-acetyl-sn-glycerol |
5mg |
¡ï12,000 |
|
77133-35-8 |
|
|
|
¡¡ |
BML |
BML-EI152-0100 |
K-252a |
100ug |
¡ï15,000 |
|
97161-97-2 |
|
|
|
¡¡ |
BML |
BML-EI152-1000 |
K-252a |
1mg |
¡ï61,000 |
|
97161-97-2 |
|
|
|
¡¡ |
BML |
BML-EI153-0010 |
ML-9 ¡Ú1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine, HCl¡Û |
10mg |
¡ï10,000 |
|
105637-50-1 |
|
|
|
¡¡ |
BML |
BML-EI153-0050 |
ML-9 ¡Ú1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine, HCl¡Û |
50mg |
¡ï40,000 |
|
105637-50-1 |
|
|
|
¡¡ |
BML |
BML-EI154-0200 |
Phloretin |
200mg |
¡ï7,000 |
|
60-82-2 |
|
|
|
¡¡ |
BML |
BML-EI154-1000 |
Phloretin |
1g |
¡ï31,000 |
|
60-82-2 |
|
|
|
¡¡ |
BML |
BML-EI155-0025 |
Sphingosine, D-erythro ¡ÚD-erythro-Sphingosine¡Û¡Ú D(+)-erythro-1,3-Dihydroxy-2-amino-4- trans-octadecene¡Û |
25mg |
¡ï13,000 |
|
123-78-4 |
|
|
|
¡¡ |
BML |
BML-EI155-0100 |
Sphingosine, D-erythro ¡ÚD-erythro-Sphingosine¡Û¡Ú D(+)-erythro-1,3-Dihydroxy-2-amino-4- trans-octadecene¡Û |
100mg |
¡ï38,000 |
|
123-78-4 |
|
|
|
¡¡ |
BML |
BML-EI156-0100 |
Staurosporine |
100ug |
¡ï10,000 |
|
62996-74-1 |
|
|
|
¡¡ |
BML |
BML-EI156-1000 |
Staurosporine |
1mg |
¡ï61,000 |
|
62996-74-1 |
|
|
|
¡¡ |
BML |
BML-EI158-0010 |
H-8, 2HCl ¡ÚN-[2-(Methylamino)ethyl]-5-isoquinolinesulfonamide, 2HCl¡Û |
10mg |
¡ï10,000 |
|
113276-94-1 |
|
|
|
¡¡ |
BML |
BML-EI158-0050 |
H-8, 2HCl ¡ÚN-[2-(Methylamino)ethyl]-5-isoquinolinesulfonamide, 2HCl¡Û |
50mg |
¡ï44,000 |
|
113276-94-1 |
|
|
|
¡¡ |
BML |
BML-EI161-0100 |
Muscone ¡Ú3-Methylcyclopentadecanone¡Û |
100mg |
¡ï7,000 |
|
541-91-3 |
|
|
|
¡¡ |
BML |
BML-EI161-0500 |
Muscone ¡Ú3-Methylcyclopentadecanone¡Û |
500mg |
¡ï32,000 |
|
541-91-3 |
|
|
|
¡¡ |
BML |
BML-EI162-0001 |
Benzylimidazole |
1g |
¡ï3,000 |
|
4238-71-5 |
|
|
|
¡¡ |
BML |
BML-EI162-0005 |
Benzylimidazole |
5g |
¡ï9,000 |
|
4238-71-5 |
|
|
|
¡¡ |
BML |
BML-EI163-0001 |
Meclofenamate Sodium ¡ÚSodium 2-[(2,6-Dichloro-3-methylphenyl)amino]benzoate¡Û |
1g |
¡ï3,000 |
|
6385-02-0 |
|
|
|
¡¡ |
BML |
BML-EI163-0005 |
Meclofenamate Sodium ¡ÚSodium 2-[(2,6-Dichloro-3-methylphenyl)amino]benzoate¡Û |
5g |
¡ï9,000 |
|
6385-02-0 |
|
|
|
¡¡ |
BML |
BML-EI164-0005 |
Ibuprofen ¡Úa-Methyl-4-(2-methylpropyl)benzeneacetic Acid¡Û¡Ú(¡Þ)-2-(4-Isobutylphenyl)propionic Acid¡Û |
5g |
¡ï10,000 |
|
15687-27-1 |
|
|
|
¡¡ |
BML |
BML-EI165-1000 |
Benserazide, HCl ¡ÚRo 4-4602¡Û |
1g |
¡ï6,000 |
|
322-35-0 |
|
|
|
¡¡ |
BML |
BML-EI166-0050 |
Debrisoquin Sulfate ¡ÚRo 5-3307¡Û |
50mg |
¡ï7,000 |
|
581-88-4 |
|
|
|
¡¡ |
BML |
BML-EI166-0500 |
Debrisoquin Sulfate ¡ÚRo 5-3307¡Û |
500mg |
¡ï46,000 |
|
581-88-4 |
|
|
|
¡¡ |
BML |
BML-EI168-0005 |
Bumetanide ¡ÚRo 10-6338¡Û |
5g |
¡ï23,000 |
|
28395-03-1 |
|
|
|
¡¡ |
BML |
BML-EI169-0010 |
(¡Þ)-4-Hydroxydebrisoquin |
10mg |
¡ï9,000 |
|
59333-79-8 |
|
|
|
¡¡ |
BML |
BML-EI169-0050 |
(¡Þ)-4-Hydroxydebrisoquin |
50mg |
¡ï37,000 |
|
59333-79-8 |
|
|
|
¡¡ |
BML |
BML-EI176-0050 |
Aristolochic Acid, Na salt |
50mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI176-0250 |
Aristolochic Acid, Na salt |
250mg |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI177-0001 |
Manoalide |
1mg |
¡ï21,000 |
|
75088-80-1 |
|
|
|
¡¡ |
BML |
BML-EI178-0050 |
N-(p-Amylcinnamoyl)anthranilic Acid ¡ÚACA¡Û |
50mg |
¡ï10,000 |
|
110683-10-8 |
|
|
|
¡¡ |
BML |
BML-EI178-0250 |
N-(p-Amylcinnamoyl)anthranilic Acid ¡ÚACA¡Û |
250mg |
¡ï38,000 |
|
110683-10-8 |
|
|
|
¡¡ |
BML |
BML-EI184-0010 |
HA-1004, HCl ¡ÚN-(2¡Ç-Guanidinoethyl)-5-isoquinolinesulfonamide, 2HCl¡Û |
10mg |
¡ï11,000 |
|
91742-10-8 |
|
|
|
¡¡ |
BML |
BML-EI184-0050 |
HA-1004, HCl ¡ÚN-(2¡Ç-Guanidinoethyl)-5-isoquinolinesulfonamide, 2HCl¡Û |
50mg |
¡ï43,000 |
|
91742-10-8 |
|
|
|
¡¡ |
BML |
BML-EI185-0001 |
Lavendustin A ¡Ú5-Amino-[(N-2,5-dihydroxybenzyl)-N'-2-hydroxybenzyl]salicylic acid¡Û¡ÚRG14355¡Û |
1mg |
¡ï13,000 |
|
125697-92-9 |
|
|
|
¡¡ |
BML |
BML-EI185-0005 |
Lavendustin A ¡Ú5-Amino-[(N-2,5-dihydroxybenzyl)-N'-2-hydroxybenzyl]salicylic acid¡Û¡ÚRG14355¡Û |
5mg |
¡ï58,000 |
|
125697-92-9 |
|
|
|
·àʪ |
BML |
BML-EI187-0005 |
Tyrphostin 25 ¡ÚRG-50875¡Û¡Ú3,4,5-Trihydroxybenzylidenemalononitrile¡Û |
5mg |
¡ï8,000 |
|
118409-58-8 |
|
|
|
·àʪ |
BML |
BML-EI187-0025 |
Tyrphostin 25 ¡ÚRG-50875¡Û¡Ú3,4,5-Trihydroxybenzylidenemalononitrile¡Û |
25mg |
¡ï36,000 |
|
118409-58-8 |
|
|
|
·àʪ |
BML |
BML-EI188-0005 |
Tyrphostin 47 ¡ÚRG-50864¡Û¡ÚAG-213¡Û¡Ú3,4-Dihydroxy-(a-cyano)thiocinnamamide¡Û |
5mg |
¡ï9,000 |
|
122520-86-9 |
|
|
|
·àʪ |
BML |
BML-EI188-0025 |
Tyrphostin 47 ¡ÚRG-50864¡Û¡ÚAG-213¡Û¡Ú3,4-Dihydroxy-(a-cyano)thiocinnamamide¡Û |
25mg |
¡ï39,000 |
|
122520-86-9 |
|
|
|
·àʪ |
BML |
BML-EI189-0005 |
Tyrphostin 51 |
5mg |
¡ï9,000 |
|
122520-90-5 |
|
|
|
·àʪ |
BML |
BML-EI189-0025 |
Tyrphostin 51 |
25mg |
¡ï39,000 |
|
122520-90-5 |
|
|
|
·àʪ |
BML |
BML-EI190-0020 |
Tyrphostin 1 ¡Úa-Cyano-(4-methoxy)cinnamonitrile¡Û |
20mg |
¡ï7,000 |
|
2826-26-8 |
|
|
|
·àʪ |
BML |
BML-EI190-0100 |
Tyrphostin 1 ¡Úa-Cyano-(4-methoxy)cinnamonitrile¡Û |
100mg |
¡ï31,000 |
|
2826-26-8 |
|
|
|
·àʪ |
BML |
BML-EI191-0010 |
Tyrphostin 23 ¡ÚRG-50810¡Û¡Úa-Cyano-(3,4-dihydroxy)cinnamonitrile¡Û |
10mg |
¡ï9,000 |
|
118409-57-7 |
|
|
|
·àʪ |
BML |
BML-EI191-0050 |
Tyrphostin 23 ¡ÚRG-50810¡Û¡Úa-Cyano-(3,4-dihydroxy)cinnamonitrile¡Û |
50mg |
¡ï36,000 |
|
118409-57-7 |
|
|
|
·àʪ |
BML |
BML-EI192-0025 |
Calyculin A |
25ug |
¡ï17,000 |
|
101932-71-2 |
|
|
|
·àʪ |
BML |
BML-EI192-0100 |
Calyculin A |
100ug |
¡ï48,000 |
|
101932-71-2 |
|
|
|
¡¡ |
BML |
BML-EI195-0010 |
H-9, HCl ¡ÚN-(2-Aminoethyl)-5-isoquinolinesulfonamide, HCl¡Û |
10mg |
¡ï10,000 |
|
116970-50-4 |
|
|
|
¡¡ |
BML |
BML-EI195-0050 |
H-9, HCl ¡ÚN-(2-Aminoethyl)-5-isoquinolinesulfonamide, HCl¡Û |
50mg |
¡ï41,000 |
|
116970-50-4 |
|
|
|
¡¡ |
BML |
BML-EI196-0005 |
H-89, 2HCl ¡ÚN-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide, 2HCl¡Û |
5mg |
¡ï11,000 |
|
127243-85-0 |
|
|
|
¡¡ |
BML |
BML-EI196-0025 |
H-89, 2HCl ¡ÚN-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide, 2HCl¡Û |
25mg |
¡ï48,000 |
|
127243-85-0 |
|
|
|
¡¡ |
BML |
BML-EI197-0010 |
ML-7, HCl ¡Ú1-(5-Iodonaphthalene-1-sulfonyl)-1H-hexahydro-l,4-diazepine, HCl¡Û |
10mg |
¡ï10,000 |
|
109376-83-2 |
|
|
|
¡¡ |
BML |
BML-EI197-0050 |
ML-7, HCl ¡Ú1-(5-Iodonaphthalene-1-sulfonyl)-1H-hexahydro-l,4-diazepine, HCl¡Û |
50mg |
¡ï42,000 |
|
109376-83-2 |
|
|
|
¡¡ |
BML |
BML-EI198-0100 |
Calphostin C ¡ÚUCN-1028C¡Û |
100ug |
¡ï13,000 |
|
121263-19-2 |
|
|
|
¡¡ |
BML |
BML-EI198-1000 |
Calphostin C ¡ÚUCN-1028C¡Û |
1mg |
¡ï92,000 |
|
121263-19-2 |
|
|
|
¡¡ |
BML |
BML-EI199-0100 |
KT5720 |
100ug |
¡ï17,000 |
|
108068-98-0 |
|
|
|
¡¡ |
BML |
BML-EI200-0100 |
KT5823 |
100ug |
¡ï17,000 |
|
126643-37-6 |
|
|
|
¡¡ |
BML |
BML-EI206-0100 |
Auranofin ¡ÚSKF 39162¡Û¡Ú1-Thio-b-D-glucopyranosatotriethylphosphine Gold-2,3,4,6-tetraacetate¡Û |
100mg |
¡ï9,000 |
|
34031-32-8 |
|
|
|
¡¡ |
BML |
BML-EI208-1000 |
NPC-14686 ¡ÚFmoc-L-Homophenylalanine¡Û |
1g |
¡ï25,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI209-0010 |
REV-5901 ¡Úa-Pentyl-3-(2-quinolinylmethoxy)benzenemethanol¡Û |
10mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI209-0050 |
REV-5901 ¡Úa-Pentyl-3-(2-quinolinylmethoxy)benzenemethanol¡Û |
50mg |
¡ï34,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI210-0010 |
L-655,238 ¡Úa-Pentyl-3-(2-quinolinylmethoxy)benzenemethanol REV-5901para-isomer¡Û |
10mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI210-0050 |
L-655,238 ¡Úa-Pentyl-3-(2-quinolinylmethoxy)benzenemethanol REV-5901para-isomer¡Û |
50mg |
¡ï43,000 |
|
none |
|
|
|
·àʪ |
BML |
BML-EI211-0010 |
CDC ¡ÚCinnamyl-3,4-dihydroxy-a-cyanocinnamate¡Û |
10mg |
¡ï9,000 |
|
132465-11-3 |
|
|
|
·àʪ |
BML |
BML-EI211-0050 |
CDC ¡ÚCinnamyl-3,4-dihydroxy-a-cyanocinnamate¡Û |
50mg |
¡ï39,000 |
|
132465-11-3 |
|
|
|
·àʪ |
BML |
BML-EI215-0050 |
Tyrphostin 9 ¡ÚRG-50872¡Û¡ÚMalonaben¡Û¡ÚSF 6847¡Û¡Ú3,5-Di-tert-butylhydroxybenzylidenemalononitrile¡Û |
50mg |
¡ï8,000 |
|
10537-47-0 |
|
|
|
·àʪ |
BML |
BML-EI215-0250 |
Tyrphostin 9 ¡ÚRG-50872¡Û¡ÚMalonaben¡Û¡ÚSF 6847¡Û¡Ú3,5-Di-tert-butylhydroxybenzylidenemalononitrile¡Û |
250mg |
¡ï35,000 |
|
10537-47-0 |
|
|
|
¡¡ |
BML |
BML-EI216-0020 |
AA-861 ¡Ú2-(12-Hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone¡Û |
20mg |
¡ï11,000 |
|
80809-81-0 |
|
|
|
¡¡ |
BML |
BML-EI216-0100 |
AA-861 ¡Ú2-(12-Hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone¡Û |
100mg |
¡ï43,000 |
|
80809-81-0 |
|
|
|
¡¡ |
BML |
BML-EI217-0001 |
Tranylcypromine ¡Útrans-2-Phenylcyclopropylamine, Hemisulfate¡Û |
1g |
¡ï13,000 |
|
13492-01-8 |
|
|
|
¡¡ |
BML |
BML-EI217-0005 |
Tranylcypromine ¡Útrans-2-Phenylcyclopropylamine, Hemisulfate¡Û |
5g |
¡ï53,000 |
|
13492-01-8 |
|
|
|
¡¡ |
BML |
BML-EI218-0100 |
Triacsin C ¡Ú2,4,7-Undecatrienal Nitrosohydrazone¡Û¡ÚWS1228A¡Û¡Ú2E, 4E, 7E-Undecatriene-1-triazene¡Û |
100ug |
¡ï14,000 |
|
76896-80-5 |
|
|
|
¡¡ |
BML |
BML-EI218-1000 |
Triacsin C ¡Ú2,4,7-Undecatrienal Nitrosohydrazone¡Û¡ÚWS1228A¡Û¡Ú2E, 4E, 7E-Undecatriene-1-triazene¡Û |
1mg |
¡ï58,000 |
|
76896-80-5 |
|
|
|
¡¡ |
BML |
BML-EI225-0005 |
Chelerythrine Chloride |
5mg |
¡ï10,000 |
|
3895-92-9 |
|
|
|
¡¡ |
BML |
BML-EI225-0025 |
Chelerythrine Chloride |
25mg |
¡ï43,000 |
|
3895-92-9 |
|
|
|
¡¡ |
BML |
BML-EI227-0100 |
Herbimycin A |
100ug |
¡ï19,000 |
|
70563-58-5 |
|
|
|
¡¡ |
BML |
BML-EI227-1000 |
Herbimycin A |
1mg |
¡ï106,000 |
|
70563-58-5 |
|
|
|
·àʪ |
BML |
BML-EI228-0010 |
AG-494 ¡ÚN-Phenyl-3,4-dihydroxybenzylidenecyanoacetamide¡Û |
10mg |
¡ï8,000 |
|
133550-35-3 |
|
|
|
·àʪ |
BML |
BML-EI228-0050 |
AG-494 ¡ÚN-Phenyl-3,4-dihydroxybenzylidenecyanoacetamide¡Û |
50mg |
¡ï33,000 |
|
133550-35-3 |
|
|
|
·àʪ |
BML |
BML-EI229-0002 |
AG-370 ¡ÚTyrphostin AG 370¡Û¡ÚTyrphostin B7¡Û¡Ú2-Amino-4-(1H-indol-5-yl)-1,1,3-tricyanobuta-1,3-diene¡Û |
2mg |
¡ï13,000 |
|
none |
|
|
|
·àʪ |
BML |
BML-EI229-0010 |
AG-370 ¡ÚTyrphostin AG 370¡Û¡ÚTyrphostin B7¡Û¡Ú2-Amino-4-(1H-indol-5-yl)-1,1,3-tricyanobuta-1,3-diene¡Û |
10mg |
¡ï50,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI230-0001 |
KN-62 ¡Ú4-[(2S)-2-[(5-Isoquinolinylsulfonyl)methylamino]-3-oxo-3-(4-phenyl-1-piperazinyl)propyl]phenyl isoquinolinesulfonic Acid Ester¡Û |
1mg |
¡ï17,000 |
|
127191-97-3 |
|
|
|
¡¡ |
BML |
BML-EI231-0010 |
5,6-Dichloro-1-B-D-ribofuranosylbenzimidazole ¡ÚDRB¡Û¡Ú5,6-Dichlorobenzimidazole Riboside¡Û |
10mg |
¡ï4,000 |
|
53-85-0 |
|
|
|
¡¡ |
BML |
BML-EI231-0050 |
5,6-Dichloro-1-B-D-ribofuranosylbenzimidazole ¡ÚDRB¡Û¡Ú5,6-Dichlorobenzimidazole Riboside¡Û |
50mg |
¡ï18,000 |
|
53-85-0 |
|
|
|
¡¡ |
BML |
BML-EI232-0002 |
2-Hydroxy-5-(2,5-dihydroxybenzylamino)benzoic Acid ¡ÚHDBA¡Û |
2mg |
¡ï5,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI232-0010 |
2-Hydroxy-5-(2,5-dihydroxybenzylamino)benzoic Acid ¡ÚHDBA¡Û |
10mg |
¡ï20,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI233-0010 |
HA-1077 ¡Ú1-(5-Isoquinolinesulfonyl)homopiperazine, 2HCl¡Û¡ÚFasudil¡Û |
10mg |
¡ï15,000 |
|
103745-39-7 |
|
|
|
¡¡ |
BML |
BML-EI233-0050 |
HA-1077 ¡Ú1-(5-Isoquinolinesulfonyl)homopiperazine, 2HCl¡Û¡ÚFasudil¡Û |
50mg |
¡ï61,000 |
|
103745-39-7 |
|
|
|
¡¡ |
BML |
BML-EI234-0100 |
K-252b |
100ug |
¡ï15,000 |
|
99570-78-2 |
|
|
|
¡¡ |
BML |
BML-EI234-1000 |
K-252b |
1mg |
¡ï63,000 |
|
99570-78-2 |
|
|
|
¡¡ |
BML |
BML-EI241-0200 |
Ro 16-6491 ¡ÚN-(2-Aminoethyl)-4-chlorobenzamide, HCl¡Û |
200mg |
¡ï7,000 |
|
94319-79-6 |
|
|
|
¡¡ |
BML |
BML-EI242-0020 |
U-5021 ¡Ú3',4'-Dihydroxy-2-methylpropiophenone¡Û |
20mg |
¡ï6,000 |
|
5466-89-7 |
|
|
|
¡¡ |
BML |
BML-EI242-0100 |
U-5021 ¡Ú3',4'-Dihydroxy-2-methylpropiophenone¡Û |
100mg |
¡ï27,000 |
|
5466-89-7 |
|
|
|
¡¡ |
BML |
BML-EI244-0100 |
Benzylphosphonic Acid |
100mg |
¡ï3,000 |
|
6881-57-8 |
|
|
|
¡¡ |
BML |
BML-EI244-0500 |
Benzylphosphonic Acid |
500mg |
¡ï6,000 |
|
6881-57-8 |
|
|
|
¡¡ |
BML |
BML-EI245-0010 |
Benzylphosphonic Acid-(AM)2 ¡ÚBenzylphosphonic Acid bis(Acetoxymethyl)Ester¡Û |
10mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI245-0050 |
Benzylphosphonic Acid-(AM)2 ¡ÚBenzylphosphonic Acid bis(Acetoxymethyl)Ester¡Û |
50mg |
¡ï36,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI246-0001 |
GF109203X ¡ÚBisindolylmaleimide I¡Û¡Ú2-[1-(3-Dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleimide¡Û |
1mg |
¡ï13,000 |
|
133052-90-1 |
|
|
|
¡¡ |
BML |
BML-EI247-0005 |
Hydroxy-2-naphthalenylmethylphosphonic Acid ¡ÚHNMPA¡Û |
5mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI247-0025 |
Hydroxy-2-naphthalenylmethylphosphonic Acid ¡ÚHNMPA¡Û |
25mg |
¡ï35,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI248-0005 |
HNMPA-(AM)3 ¡ÚHydroxy-2-naphthalenylmethylphosphonic Acid-tris(Acetoxymethyl)Ester¡Û |
5mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI248-0025 |
HNMPA-(AM)3 ¡ÚHydroxy-2-naphthalenylmethylphosphonic Acid-tris(Acetoxymethyl)Ester¡Û |
25mg |
¡ï56,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI249-0010 |
Troleandomycin |
10mg |
¡ï11,000 |
|
2751-09-9 |
|
|
|
¡¡ |
BML |
BML-EI249-0050 |
Troleandomycin |
50mg |
¡ï46,000 |
|
2751-09-9 |
|
|
|
·àʪ |
BML |
BML-EI252-0005 |
RG-13022 ¡Ú3,4-Dimethoxy-a-(3-pyridyl)-(Z)-cinnamonitrile¡Û |
5mg |
¡ï12,000 |
|
136831-48-6 |
|
|
|
·àʪ |
BML |
BML-EI252-0025 |
RG-13022 ¡Ú3,4-Dimethoxy-a-(3-pyridyl)-(Z)-cinnamonitrile¡Û |
25mg |
¡ï48,000 |
|
136831-48-6 |
|
|
|
·àʪ |
BML |
BML-EI253-0005 |
RG-14620 ¡Ú3,5-Dichloro-a-(3-pyridyl)-(Z)-cinnamonitrile¡Û |
5mg |
¡ï8,000 |
|
136831-49-7 |
|
|
|
¡¡ |
BML |
BML-EI254-0001 |
Lavendustin B ¡ÚN,N-bis(2'-Hydroxybenzyl)-3-aminosalicylic Acid¡Û |
1mg |
¡ï8,000 |
|
125697-91-8 |
|
|
|
¡¡ |
BML |
BML-EI254-0005 |
Lavendustin B ¡ÚN,N-bis(2'-Hydroxybenzyl)-3-aminosalicylic Acid¡Û |
5mg |
¡ï32,000 |
|
125697-91-8 |
|
|
|
¡¡ |
BML |
BML-EI256-0200 |
Metyrapone |
200mg |
¡ï4,000 |
|
54-36-4 |
|
|
|
·àʪ |
BML |
BML-EI257-0010 |
Tyrphostin 46 ¡Ú3,4-Dihydroxy-a-cyanocinnamide¡Û |
10mg |
¡ï7,000 |
|
122520-85-8 |
|
|
|
·àʪ |
BML |
BML-EI257-0050 |
Tyrphostin 46 ¡Ú3,4-Dihydroxy-a-cyanocinnamide¡Û |
50mg |
¡ï28,000 |
|
122520-85-8 |
|
|
|
·àʪ |
BML |
BML-EI258-0005 |
AG-879 ¡Ú3,5-Di-tert-butyl-4-hydroxybenzylidenecyanothioacetamide¡Û |
5mg |
¡ï10,000 |
|
148741-30-4 |
|
|
|
·àʪ |
BML |
BML-EI258-0025 |
AG-879 ¡Ú3,5-Di-tert-butyl-4-hydroxybenzylidenecyanothioacetamide¡Û |
25mg |
¡ï42,000 |
|
148741-30-4 |
|
|
|
¡¡ |
BML |
BML-EI259-0100 |
1-Aminobenzotriazole |
100mg |
¡ï15,000 |
|
1614-12-6 |
|
|
|
¡¡ |
BML |
BML-EI260-0010 |
6-Methoxy-2-naphthylacetic Acid |
10mg |
¡ï10,000 |
|
23981-47-7 |
|
|
|
¡¡ |
BML |
BML-EI260-0050 |
6-Methoxy-2-naphthylacetic Acid |
50mg |
¡ï42,000 |
|
23981-47-7 |
|
|
|
¡¡ |
BML |
BML-EI261-0005 |
NS-398 ¡ÚN-(2-Cyclohexyloxy-4-nitrophenyl)-Methanesulfonamide¡Û |
5mg |
¡ï10,000 |
|
123653-11-2 |
|
|
|
¡¡ |
BML |
BML-EI261-0025 |
NS-398 ¡ÚN-(2-Cyclohexyloxy-4-nitrophenyl)-Methanesulfonamide¡Û |
25mg |
¡ï42,000 |
|
123653-11-2 |
|
|
|
¡¡ |
BML |
BML-EI262-0010 |
7-Ethoxyresorufin ¡Ú7-ER¡Û |
10mg |
¡ï24,000 |
|
5725-91-7 |
|
|
|
·àʪ |
BML |
BML-EI263-0005 |
AG-126 ¡Ú3-Hydroxy-4-nitrobenzylidenemalononitrile¡Û |
5mg |
¡ï10,000 |
|
118409-62-4 |
|
|
|
·àʪ |
BML |
BML-EI263-0025 |
AG-126 ¡Ú3-Hydroxy-4-nitrobenzylidenemalononitrile¡Û |
25mg |
¡ï42,000 |
|
118409-62-4 |
|
|
|
¡¡ |
BML |
BML-EI265-0020 |
S(-)-Carbidopa ¡ÚS-a-Hydrazino-3,4-dihydroxy-a-methylbenzenepropanoic Acid¡Û |
20mg |
¡ï9,000 |
|
28860-95-9 |
|
|
|
¡¡ |
BML |
BML-EI265-0100 |
S(-)-Carbidopa ¡ÚS-a-Hydrazino-3,4-dihydroxy-a-methylbenzenepropanoic Acid¡Û |
100mg |
¡ï32,000 |
|
28860-95-9 |
|
|
|
¡¡ |
BML |
BML-EI266-0005 |
MK-886 ¡ÚL-663,536¡Û¡Ú3-[1-(p-Chlorobenzyl)-5-(isopropyl)-3-t-butylthioindol-2-yl]-2,2-dimethylpropanoic Acid, Na¡Û |
5mg |
¡ï10,000 |
|
118414-82-7 |
|
|
|
¡¡ |
BML |
BML-EI266-0025 |
MK-886 ¡ÚL-663,536¡Û¡Ú3-[1-(p-Chlorobenzyl)-5-(isopropyl)-3-t-butylthioindol-2-yl]-2,2-dimethylpropanoic Acid, Na¡Û |
25mg |
¡ï40,000 |
|
118414-82-7 |
|
|
|
·àʪ |
BML |
BML-EI267-0002 |
AG-825 ¡ÚTyrphostin AG 825¡Û¡ÚTyrphostin C15¡Û¡Ú5-[(Benzothiazol-2-yl)thiomethyl]-4-hydroxy-3-methoxybenzyl-idenecyanoacetamide¡Û |
2mg |
¡ï10,000 |
|
149092-50-2 |
|
|
|
·àʪ |
BML |
BML-EI267-0010 |
AG-825 ¡ÚTyrphostin AG 825¡Û¡ÚTyrphostin C15¡Û¡Ú5-[(Benzothiazol-2-yl)thiomethyl]-4-hydroxy-3-methoxybenzyl-idenecyanoacetamide¡Û |
10mg |
¡ï40,000 |
|
149092-50-2 |
|
|
|
¡¡ |
BML |
BML-EI268-0001 |
KN-93 ¡Ú2-[N-(2-Hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine¡Û |
1mg |
¡ï20,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI269-0500 |
G? 6976 ¡Ú12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole¡Û |
500ug |
¡ï27,000 |
|
136194-77-9 |
|
|
|
·àʪ |
BML |
BML-EI272-0010 |
AG-490 ¡ÚN-Benzyl-3,4-dihydroxybenzylidenecyanoacetamide¡Û |
10mg |
¡ï10,000 |
|
133550-30-8 |
|
|
|
·àʪ |
BML |
BML-EI272-0050 |
AG-490 ¡ÚN-Benzyl-3,4-dihydroxybenzylidenecyanoacetamide¡Û |
50mg |
¡ï40,000 |
|
133550-30-8¡¡ |
|
|
|
¡¡ |
BML |
BML-EI273-0001 |
HBDDE ¡Ú2,2',3,3',4,4'-Hexahydroxy-1,1'-biphenyl-6,6'-dimethanol Dimethyl Ether¡Û |
1mg |
¡ï16,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI273-0005 |
HBDDE ¡Ú2,2',3,3',4,4'-Hexahydroxy-1,1'-biphenyl-6,6'-dimethanol Dimethyl Ether¡Û |
5mg |
¡ï62,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI274-0001 |
Damnacanthal ¡Ú3-Hydroxy-1-methoxyanthraquinone-2-aldehyde¡Û |
1mg |
¡ï30,000 |
|
477-84-9 |
|
|
|
¡¡ |
BML |
BML-EI275-0001 |
PP1 ¡Ú1-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine¡Û |
1mg |
¡ï10,000 |
|
172889-26-8 |
|
|
|
¡¡ |
BML |
BML-EI275-0005 |
PP1 ¡Ú1-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine¡Û |
5mg |
¡ï42,000 |
|
172889-26-8 |
|
|
|
¡¡ |
BML |
BML-EI276-0001 |
(S)-Ibuprofen ¡Ú(S)-(+)-2-(4-Isobutylphenyl)propionic Acid¡Û |
1g |
¡ï10,000 |
|
51146-56-6 |
|
|
|
·àʪ |
BML |
BML-EI278-0010 |
BAY 11-7082 ¡Ú(E)-3-(4-Methylphenylsulfonyl)-2-propenenenitrile¡Û |
10mg |
¡ï10,000 |
|
195462-67-7 |
|
|
|
·àʪ |
BML |
BML-EI278-0050 |
BAY 11-7082 ¡Ú(E)-3-(4-Methylphenylsulfonyl)-2-propenenenitrile¡Û |
50mg |
¡ï42,000 |
|
195462-67-7 |
|
|
|
·àʪ |
BML |
BML-EI279-0010 |
BAY 11-7085 ¡Ú(E)-3-[(4-tert-Butylphenylsulfonyl]-2-propenenitrile¡Û |
10mg |
¡ï10,000 |
|
196309-76-9 |
|
|
|
·àʪ |
BML |
BML-EI279-0050 |
BAY 11-7085 ¡Ú(E)-3-[(4-tert-Butylphenylsulfonyl]-2-propenenitrile¡Û |
50mg |
¡ï42,000 |
|
196309-76-9 |
|
|
|
¡¡ |
BML |
BML-EI280-0001 |
Geldanamycin |
1mg |
¡ï11,000 |
|
30562-34-6 |
|
|
|
¡¡ |
BML |
BML-EI280-0005 |
Geldanamycin |
5mg |
¡ï48,000 |
|
30562-34-6 |
|
|
|
·àʪ |
BML |
BML-EI282-0001 |
U-0126 ¡ÚBis[amino[(2-aminophenyl)thio]methylene]butanedinitrile¡Û |
1mg |
¡ï8,000 |
|
109522-58-2 |
|
|
|
·àʪ |
BML |
BML-EI282-0005 |
U-0126 ¡ÚBis[amino[(2-aminophenyl)thio]methylene]butanedinitrile¡Û |
5mg |
¡ï30,000 |
|
109522-58-2 |
|
|
|
¡¡ |
BML |
BML-EI283-0001 |
Ro 31-8220 ¡ÚBisindolylmaleimide IX, Methanesulfonate¡Û |
1mg |
¡ï10,000 |
|
138489-18-6 |
|
|
|
¡¡ |
BML |
BML-EI284-0001 |
Ro 32-0432 ¡ÚBisindolylmaleimide XI, HCl¡Û |
1mg |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI285-0001 |
Radicicol ¡ÚMonorden¡Û¡Ú1aS-(1aR*,2Z,4E,14*,15aR*)]-8-Chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-6H-oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione¡Û(Isolated from Humicola fuscoatra.) |
1mg |
¡ï16,000 |
|
12772-57-5 |
|
|
|
¡¡ |
BML |
BML-EI286-0001 |
SB-203580 ¡Ú4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole¡Û |
1mg |
¡ï10,000 |
|
152121-47-6 |
|
|
|
¡¡ |
BML |
BML-EI286-0005 |
SB-203580 ¡Ú4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole¡Û |
5mg |
¡ï42,000 |
|
152121-47-6 |
|
|
|
¡¡ |
BML |
BML-EI288-0001 |
(S)-Ketoprofen ¡Ú(S)-(+)-3-Benzoyl-a-methylbenzeneacetic Acid¡Û |
1g |
¡ï20,000 |
|
22161-88-5 |
|
|
|
¡¡ |
BML |
BML-EI290-0200 |
(R)-Ibuprofen ¡Ú(R)-(-)-2-(4-Isobutylphenyl)propionic Acid¡Û |
200mg |
¡ï14,000 |
|
51146-57-7 |
|
|
|
¡¡ |
BML |
BML-EI292-0020 |
Meloxicam ¡Ú4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-2-carboxamide-1,1-dioxide¡Û |
20mg |
¡ï7,000 |
|
71125-38-7 |
|
|
|
¡¡ |
BML |
BML-EI292-0100 |
Meloxicam ¡Ú4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-2-carboxamide-1,1-dioxide¡Û |
100mg |
¡ï16,000 |
|
71125-38-7 |
|
|
|
¡¡ |
BML |
BML-EI293-0001 |
5-Iodotubercidin ¡Ú4-Amino-5-iodo-7-(b-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine¡Û |
1mg |
¡ï11,000 |
|
24386-93-4 |
|
|
|
¡¡ |
BML |
BML-EI293-0005 |
5-Iodotubercidin ¡Ú4-Amino-5-iodo-7-(b-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine¡Û |
5mg |
¡ï48,000 |
|
24386-93-4 |
|
|
|
¡¡ |
BML |
BML-EI294-0001 |
SB-202190 ¡ÚFHPI¡Û¡Ú4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole¡Û |
1mg |
¡ï12,000 |
|
152121-30-7 |
|
|
|
·àʪ |
BML |
BML-EI295-0005 |
LFM-A13 ¡Úa-Cyano-B-hydroxy-B-methyl-N-(2,5-dibromophenyl)propenamide¡Û |
5mg |
¡ï9,000 |
|
none |
|
|
|
·àʪ |
BML |
BML-EI295-0025 |
LFM-A13 ¡Úa-Cyano-B-hydroxy-B-methyl-N-(2,5-dibromophenyl)propenamide¡Û |
25mg |
¡ï40,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI296-0500 |
G?-6983 |
0.5mg |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI297-0001 |
PP2 ¡Ú4-Amino-5-(4-chlorophenyl)-7-(tert-butyl)pyrazolo[3,4-d]pyrimidine¡Û |
1mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI297-0005 |
PP2 ¡Ú4-Amino-5-(4-chlorophenyl)-7-(tert-butyl)pyrazolo[3,4-d]pyrimidine¡Û |
5mg |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI298-0005 |
ZM 336372 ¡ÚN-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide¡Û |
5mg |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI298-0025 |
ZM 336372 ¡ÚN-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide¡Û |
25mg |
¡ï71,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI300-0001 |
GM-6001 ¡ÚGalardin¡Û¡ÚIlomastat¡Û¡ÚN-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide¡Û |
1mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI300-0005 |
GM-6001 ¡ÚGalardin¡Û¡ÚIlomastat¡Û¡ÚN-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide¡Û |
5mg |
¡ï32,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI302-0005 |
CL-82198 ¡ÚN-[4-(4-Morpholinyl)butyl]-2-benzofurancarboxamide, HCl¡Û |
5mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI302-0025 |
CL-82198 ¡ÚN-[4-(4-Morpholinyl)butyl]-2-benzofurancarboxamide, HCl¡Û |
25mg |
¡ï33,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI303-0005 |
AG-1296 ¡ÚTyrphostin AG 1296¡Û¡Ú6,7-Dimethoxy-3-phenylquinoxaline¡Û |
5mg |
¡ï14,000 |
|
146535-11-7 |
|
|
|
¡¡ |
BML |
BML-EI303-0025 |
AG-1296 ¡ÚTyrphostin AG 1296¡Û¡Ú6,7-Dimethoxy-3-phenylquinoxaline¡Û |
25mg |
¡ï60,000 |
|
146535-11-7 |
|
|
|
¡¡ |
BML |
BML-EI304-0005 |
BW B70C ¡ÚN-[3-[3-(Fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea¡Û |
5mg |
¡ï14,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI304-0025 |
BW B70C ¡ÚN-[3-[3-(Fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea¡Û |
25mg |
¡ï56,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI305-0010 |
SP600125 ¡ÚAnthra[1,9-cd]pyrazol-6(2H)-one¡Û¡Ú1,9-Pyrazoloanthrone¡Û |
10mg |
¡ï8,000 |
|
129-56-6 |
|
|
|
¡¡ |
BML |
BML-EI305-0050 |
SP600125 ¡ÚAnthra[1,9-cd]pyrazol-6(2H)-one¡Û¡Ú1,9-Pyrazoloanthrone¡Û |
50mg |
¡ï34,000 |
|
129-56-6 |
|
|
|
¡¡ |
BML |
BML-EI306-0005 |
SU4312 ¡Ú3-(4-Dimethylaminobenzylidene)-1,3-dihydroindol-2-one¡Û |
5mg |
¡ï10,000 |
|
5812-07-7 |
|
|
|
¡¡ |
BML |
BML-EI306-0025 |
SU4312 ¡Ú3-(4-Dimethylaminobenzylidene)-1,3-dihydroindol-2-one¡Û |
25mg |
¡ï40,000 |
|
5812-07-7 |
|
|
|
¡¡ |
BML |
BML-EI307-0005 |
GW-5074 ¡Ú3-(3,5-Dibromo-4-hydroxybenzylidene)-5-iodo-1,3-dihydroindol-2-one¡Û |
5mg |
¡ï13,000 |
|
220904-83-6 |
|
|
|
¡¡ |
BML |
BML-EI307-0025 |
GW-5074 ¡Ú3-(3,5-Dibromo-4-hydroxybenzylidene)-5-iodo-1,3-dihydroindol-2-one¡Û |
25mg |
¡ï53,000 |
|
220904-83-6 |
|
|
|
¡¡ |
BML |
BML-EI308-0001 |
17-AAG ¡Ú17-(Allylamino)-17-demethoxygeldanamycin¡Û(semisynthetic derivative from geldanamycin) |
1mg |
¡ï25,000 |
|
75747-14-7 |
|
|
|
¡¡ |
BML |
BML-EI309-0005 |
NSC-95397 ¡Ú2,3-bis[(2-Hydroxyethyl)thiol]-1,4-naphthoquinone¡Û |
5mg |
¡ï16,000 |
|
93718-83-30 |
|
|
|
¡¡ |
BML |
BML-EI309-0025 |
NSC-95397 ¡Ú2,3-bis[(2-Hydroxyethyl)thiol]-1,4-naphthoquinone¡Û |
25mg |
¡ï67,000 |
|
93718-83-30 |
|
|
|
¡¡ |
BML |
BML-EI310-0005 |
Kenpaullone ¡Ú8-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one¡Û |
5mg |
¡ï26,000 |
|
142273-20-9 |
|
|
|
¡¡ |
BML |
BML-EI311-0001 |
SB-415286 ¡Ú3-[(3-Chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione¡Û |
1mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI311-0005 |
SB-415286 ¡Ú3-[(3-Chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione¡Û |
5mg |
¡ï24,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI312-0001 |
SB-216763 ¡Ú3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3yl)-1H-pyrrole-2,5-dione¡Û |
1mg |
¡ï8,000 |
|
280744-09-4 |
|
|
|
¡¡ |
BML |
BML-EI312-0005 |
SB-216763 ¡Ú3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3yl)-1H-pyrrole-2,5-dione¡Û |
5mg |
¡ï24,000 |
|
280744-09-4 |
|
|
|
¡¡ |
BML |
BML-EI313-0500 |
Ikarugamycin |
500ug |
¡ï25,000 |
|
36531-78-9 |
|
|
|
¡¡ |
BML |
BML-EI315-0005 |
Blebbistatin(+/-)¡Ú(¡Þ)-1-Phenyl-1,2,3,4-tetrahydro-4-hydroxypyrrolo[2,3-b]-7-methylquinolin-4-one¡Û |
5mg |
¡ï14,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI315-0025 |
Blebbistatin(+/-)¡Ú(¡Þ)-1-Phenyl-1,2,3,4-tetrahydro-4-hydroxypyrrolo[2,3-b]-7-methylquinolin-4-one¡Û |
25mg |
¡ï61,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI316-0001 |
Wedelolactone ¡Ú7-Methoxy-5,11,12-trihydroxycoumestan¡Û |
1mg |
¡ï13,000 |
|
524-12-9 |
|
|
|
¡¡ |
BML |
BML-EI317-0020 |
TMP-153 ¡ÚN-(4-(2-Chlorophenyl)-6,7-dimethyl-3-quinolyl)-N'-(2,4-difluorophenyl)urea¡Û |
20mg |
¡ï8,000 |
|
128831-46-9 |
|
|
|
¡¡ |
BML |
BML-EI317-0100 |
TMP-153 ¡ÚN-(4-(2-Chlorophenyl)-6,7-dimethyl-3-quinolyl)-N'-(2,4-difluorophenyl)urea¡Û |
100mg |
¡ï33,000 |
|
128831-46-9 |
|
|
|
¡¡ |
BML |
BML-EI318-0100 |
Terbinafine, HCl ¡ÚN-[(2E)-6,6-Dimethyl-2-hepten-4-ynyl]-N-methyl-1-naphthalenemethanamine, HCl¡Û |
100mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI319-0100 |
Depudecin ¡Ú(2R,3S,4S,5E,7S,8S,9R)-2,9-Dihydroxy-3,4;7,8-diepoxyundeca-5,10-diene¡Û |
100ug |
¡ï10,000 |
|
139508-73-9 |
|
|
|
¡¡ |
BML |
BML-EI320-0001 |
Phenylbutyrate Sodium ¡ÚSodium 4-Phenylbutyrate¡Û¡Ú4-Phenylbutyric Acid, Na salt¡Û¡ÚSBP¡Û¡Ú4PBA¡Û¡ÚPBNa¡Û |
1g |
¡ï8,000 |
|
1716-12-7 |
|
|
|
¡¡ |
BML |
BML-EI321-0010 |
TOFA ¡Ú5-(Tetradecyloxy)-2-furoic Acid¡Û¡ÚRMI-14514¡Û |
10mg |
¡ï8,000 |
|
54857-86-2 |
|
|
|
¡¡ |
BML |
BML-EI321-0050 |
TOFA ¡Ú5-(Tetradecyloxy)-2-furoic Acid¡Û¡ÚRMI-14514¡Û |
50mg |
¡ï36,000 |
|
54857-86-2 |
|
|
|
¡¡ |
BML |
BML-EI322-0010 |
Exo1 ¡Ú2-[(4-Fluorobenzoyl)amino]benzoic Acid Methyl Ester¡Û |
10mg |
¡ï8,000 |
|
461681-88-9 |
|
|
|
¡¡ |
BML |
BML-EI322-0050 |
Exo1 ¡Ú2-[(4-Fluorobenzoyl)amino]benzoic Acid Methyl Ester¡Û |
50mg |
¡ï36,000 |
|
461681-88-9 |
|
|
|
¡¡ |
BML |
BML-EI323-0001 |
MU-Phe-hPhe-FMK ¡ÚN-Morpholineureaphenylalanylhomophenylalanylfluoromethyl Ketone¡Û |
1mg |
¡ï23,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI325-0001 |
SB-3CT ¡Ú3-(4-Phenoxyphenylsulfonyl)propylthiirane¡Û |
1mg |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI325-0005 |
SB-3CT ¡Ú3-(4-Phenoxyphenylsulfonyl)propylthiirane¡Û |
5mg |
¡ï30,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI327-0005 |
URB-597 ¡ÚCyclohexylcarbamic Acid 3'-Carbamoylbiphenyl-3-yl Ester¡Û |
5mg |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI327-0025 |
URB-597 ¡ÚCyclohexylcarbamic Acid 3'-Carbamoylbiphenyl-3-yl Ester¡Û |
25mg |
¡ï20,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI328-0001 |
Terreic Acid ¡Ú(1R,6S)-3-Hydroxy-4-methyl-7-oxabicyclo[4.1.0]hept-3-ene-2,5-dione¡Û |
1mg |
¡ï7,000 |
|
121-40-4 |
|
|
|
¡¡ |
BML |
BML-EI328-0005 |
Terreic Acid ¡Ú(1R,6S)-3-Hydroxy-4-methyl-7-oxabicyclo[4.1.0]hept-3-ene-2,5-dione¡Û |
5mg |
¡ï30,000 |
|
121-40-4 |
|
|
|
¡¡ |
BML |
BML-EI330-0050 |
AICAR ¡Ú5-Aminoimidazole-4-carboxamide 1-B-D-Ribofuranoside¡Û |
50mg |
¡ï10,000 |
|
2627-69-2 |
|
|
|
¡¡ |
BML |
BML-EI330-0250 |
AICAR ¡Ú5-Aminoimidazole-4-carboxamide 1-B-D-Ribofuranoside¡Û |
250mg |
¡ï40,000 |
|
2627-69-2 |
|
|
|
¡¡ |
BML |
BML-EI331-0010 |
LM-4108 ¡ÚN-(2-Phenylethyl)Indomethacin Amide¡Û |
10mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI331-0050 |
LM-4108 ¡ÚN-(2-Phenylethyl)Indomethacin Amide¡Û |
50mg |
¡ï32,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI332-0001 |
Triciribine ¡ÚTricyclic Nucleoside(TCN)¡Û¡ÚNSC-154020¡Û¡ÚAPI-2¡Û |
1mg |
¡ï19,000 |
|
35943-35-2 |
|
|
|
¡¡ |
BML |
BML-EI332-0005 |
Triciribine ¡ÚTricyclic Nucleoside(TCN)¡Û¡ÚNSC-154020¡Û¡ÚAPI-2¡Û |
5mg |
¡ï80,000 |
|
35943-35-2 |
|
|
|
¡¡ |
BML |
BML-EI334-0001 |
Fusicoccin |
1mg |
¡ï22,000 |
|
20108-30-9 |
|
|
|
·àʪ |
BML |
BML-EI335-0010 |
AG-1288 ¡Úa-Cyano-(3,4-dihydroxy-5-nitro)cinnamonitrile¡Û |
10mg |
¡ï10,000 |
|
116313-73-6 |
|
|
|
·àʪ |
BML |
BML-EI335-0050 |
AG-1288 ¡Úa-Cyano-(3,4-dihydroxy-5-nitro)cinnamonitrile¡Û |
50mg |
¡ï39,000 |
|
116313-73-6 |
|
|
|
¡¡ |
BML |
BML-EI336-0010 |
BML-257 ¡Ú2,3-Diphenylquinoxaline-6-carboxylic Acid¡Û |
10mg |
¡ï9,000 |
|
32387-96-5 |
|
|
|
¡¡ |
BML |
BML-EI336-0050 |
BML-257 ¡Ú2,3-Diphenylquinoxaline-6-carboxylic Acid¡Û |
50mg |
¡ï37,000 |
|
32387-96-5 |
|
|
|
¡¡ |
BML |
BML-EI337-0001 |
17-DMAG ¡ÚNSC 707545¡Û¡Ú17-[2-(Dimethylamino)ethyl]amino-17-desmethoxygeldanamycin¡Û |
1mg |
¡ï25,000 |
|
150270-08-9 |
|
|
|
¡¡ |
BML |
BML-EI338-0001 |
17-GMB-APA-GA ¡Ú17-[3-(4-Maleimidobutyrcarboxamido)propylamino]demethoxygeldanamycin¡Û |
1mg |
¡ï27,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI339-0010 |
APHS ¡Ú2-Acetoxyphenylhept-2-ynylsulfide¡Û |
10mg |
¡ï10,000 |
|
209125-28-0 |
|
|
|
¡¡ |
BML |
BML-EI339-0050 |
APHS ¡Ú2-Acetoxyphenylhept-2-ynylsulfide¡Û |
50mg |
¡ï40,000 |
|
209125-28-0 |
|
|
|
¡¡ |
BML |
BML-EI340-0010 |
BIBB-515 ¡Ú1-(4-Chlorobenzoyl)-4-(4-(2-oxazolin-2-yl)benzylidene)piperidine¡Û |
10mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI340-0050 |
BIBB-515 ¡Ú1-(4-Chlorobenzoyl)-4-(4-(2-oxazolin-2-yl)benzylidene)piperidine¡Û |
50mg |
¡ï46,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI341-0001 |
Geldanamycin-Biotin ¡ÚGDA-Et-dPEG2-dPEG4-Biotin¡Û |
1mg |
¡ï24,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI342-0010 |
Ro 48-8071 ¡Ú4¡Ç-[6-(Allylmethylamino)hexyloxy]-4-bromo-2¡Ç-fluorobenzophenone Fumarate¡Û |
10mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI342-0050 |
Ro 48-8071 ¡Ú4¡Ç-[6-(Allylmethylamino)hexyloxy]-4-bromo-2¡Ç-fluorobenzophenone Fumarate¡Û |
50mg |
¡ï37,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI343-0010 |
SC-514 ¡Ú5-(Thien-3-yl)-3-aminothiophene-2-carboxamide¡Û |
10mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI343-0050 |
SC-514 ¡Ú5-(Thien-3-yl)-3-aminothiophene-2-carboxamide¡Û |
50mg |
¡ï40,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI344-0005 |
BML-259 ¡ÚN-(5-Isopropylthiazol-2-yl)phenylacetamide¡Û |
5mg |
¡ï9,000 |
|
267654-00-2 |
|
|
|
¡¡ |
BML |
BML-EI344-0025 |
BML-259 ¡ÚN-(5-Isopropylthiazol-2-yl)phenylacetamide¡Û |
25mg |
¡ï35,000 |
|
267654-00-2 |
|
|
|
¡¡ |
BML |
BML-EI345-0020 |
Apigenin ¡Ú4¡Ç,5,7-Trihydroxyflavone¡Û |
20mg |
¡ï10,000 |
|
520-36-5 |
|
|
|
¡¡ |
BML |
BML-EI345-0100 |
Apigenin ¡Ú4¡Ç,5,7-Trihydroxyflavone¡Û |
100mg |
¡ï40,000 |
|
520-36-5 |
|
|
|
¡¡ |
BML |
BML-EI347-0010 |
Dimethyloxaloylglycine ¡ÚDMOG¡Û¡ÚN-(Methoxyoxoacetyl)glycine Methyl Ester¡Û |
10mg |
¡ï9,000 |
|
89464-63-1 |
|
|
|
¡¡ |
BML |
BML-EI347-0050 |
Dimethyloxaloylglycine ¡ÚDMOG¡Û¡ÚN-(Methoxyoxoacetyl)glycine Methyl Ester¡Û |
50mg |
¡ï37,000 |
|
89464-63-1 |
|
|
|
¡¡ |
BML |
BML-EI348-0010 |
URB-602 ¡ÚBiphenyl-3-ylcarbamic Acid Cyclohexyl Ester¡Û |
10mg |
¡ï8,000 |
|
565460-15-3 |
|
|
|
¡¡ |
BML |
BML-EI348-0050 |
URB-602 ¡ÚBiphenyl-3-ylcarbamic Acid Cyclohexyl Ester¡Û |
50mg |
¡ï34,000 |
|
565460-15-3 |
|
|
|
¡¡ |
BML |
BML-EI349-0010 |
URB-754 ¡Ú6-Methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazine-4-one¡Û |
10mg |
¡ï8,000 |
|
86672-58-4 |
|
|
|
¡¡ |
BML |
BML-EI349-0050 |
URB-754 ¡Ú6-Methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazine-4-one¡Û |
50mg |
¡ï34,000 |
|
86672-58-4 |
|
|
|
¡¡ |
BML |
BML-EI350-0005 |
HET-0016 ¡ÚN-Hydroxy-N'-(4-butyl-2-methylphenyl)formamidine¡Û |
5mg |
¡ï10,000 |
|
339068-25-6 |
|
|
|
¡¡ |
BML |
BML-EI350-0025 |
HET-0016 ¡ÚN-Hydroxy-N'-(4-butyl-2-methylphenyl)formamidine¡Û |
25mg |
¡ï42,000 |
|
339068-25-6 |
|
|
|
¡¡ |
BML |
BML-EI351-0001 |
STA-21 ¡Ú(S)-Ochromycinone¡Û¡ÚDeoxytetrangomycin¡Û |
1mg |
¡ï24,000 |
|
28882-53-3 |
|
|
|
¡¡ |
BML |
BML-EI352-0001 |
QNZ ¡Ú6-Amino-4-(4-phenoxyphenylethylamino)quinazoline¡Û |
1mg |
¡ï14,000 |
|
545380-34-5 |
|
|
|
¡¡ |
BML |
BML-EI353-0001 |
ZM-306416 ¡Ú4-[(4'-Chloro-2'-fluoro)phenylamino]-6,7-dimethoxyquinazoline¡Û |
1mg |
¡ï9,000 |
|
690206-97-4 |
|
|
|
¡¡ |
BML |
BML-EI353-0010 |
ZM-306416 ¡Ú4-[(4'-Chloro-2'-fluoro)phenylamino]-6,7-dimethoxyquinazoline¡Û |
10mg |
¡ï19,000 |
|
690206-97-4 |
|
|
|
¡¡ |
BML |
BML-EI354-0001 |
L-JNKi1 ¡ÚJNK Inhibitor 1(L-stereoisomer)¡Û¡Úc-Jun N-terminal Kinase Peptide Inhibitor 1, L-stereoisomer¡Û |
1mg* |
¡ï38,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI356-0010 |
PD 146176 ¡Ú6,11-Dihydro[1]benzothiopyrano[4,3-b]indole¡Û |
10mg |
¡ï11,000 |
|
4079-26-9 |
|
|
|
¡¡ |
BML |
BML-EI356-0050 |
PD 146176 ¡Ú6,11-Dihydro[1]benzothiopyrano[4,3-b]indole¡Û |
50mg |
¡ï46,000 |
|
4079-26-9 |
|
|
|
¡¡ |
BML |
BML-EI358-0005 |
DuP-697 ¡Ú5-Bromo-2[4-fluorophenyl]-3-[4-methylsulfonylphenyl]thiophene¡Û |
5mg |
¡ï15,000 |
|
88149-94-4 |
|
|
|
¡¡ |
BML |
BML-EI358-0025 |
DuP-697 ¡Ú5-Bromo-2[4-fluorophenyl]-3-[4-methylsulfonylphenyl]thiophene¡Û |
25mg |
¡ï60,000 |
|
88149-94-4 |
|
|
|
¡¡ |
BML |
BML-EI360-0005 |
PD 98059 ¡ÚMEK Inhibitor¡Û¡Ú2'-Amino-3'-methoxyflavone¡Û |
5mg |
¡ï10,000 |
|
167869-21-8 |
|
|
|
¡¡ |
BML |
BML-EI361-0001 |
Geldanamycin-FITC |
1mg |
¡ï29,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI363-0100 |
GERI-BP002-A ¡Ú2,2'-Methylenebis(6-tert-butyl-4-methylphenol)¡Û |
100mg |
¡ï5,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI363-1000 |
GERI-BP002-A ¡Ú2,2'-Methylenebis(6-tert-butyl-4-methylphenol)¡Û |
1g |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI364-0010 |
GW-441756 ¡Ú1,3-Dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]-2H-pyrrolo[3,2-b]pyridin-2-one¡Û |
10mg |
¡ï18,000 |
|
504433-23-3 |
|
|
|
¡¡ |
BML |
BML-EI364-0050 |
GW-441756 ¡Ú1,3-Dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]-2H-pyrrolo[3,2-b]pyridin-2-one¡Û |
50mg |
¡ï74,000 |
|
504433-23-3 |
|
|
|
·àʪ |
BML |
BML-EI365-0001 |
SL-327 ¡Úa-[Amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile¡Û |
1mg |
¡ï7,000 |
|
305350-87-2 |
|
|
|
·àʪ |
BML |
BML-EI365-0010 |
SL-327 ¡Úa-[Amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile¡Û |
10mg |
¡ï23,000 |
|
305350-87-2 |
|
|
|
¡¡ |
BML |
BML-EI366-0001 |
JX-401 ¡Ú1-[2-Methoxy-4-(methylthio)benzoyl]-4-(phenylmethyl)piperidine¡Û |
1mg |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI366-0010 |
JX-401 ¡Ú1-[2-Methoxy-4-(methylthio)benzoyl]-4-(phenylmethyl)piperidine¡Û |
10mg |
¡ï18,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI367-0005 |
AAL-993 ¡Ú2-[(4-Pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide¡Û |
5mg |
¡ï18,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI367-0025 |
AAL-993 ¡Ú2-[(4-Pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide¡Û |
25mg |
¡ï72,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI368-0010 |
Stattic ¡Ú6-Nitro[b]thiophene-1,1-dioxide¡Û |
10mg |
¡ï6,000 |
|
19983-44-9 |
|
|
|
¡¡ |
BML |
BML-EI368-0050 |
Stattic ¡Ú6-Nitro[b]thiophene-1,1-dioxide¡Û |
50mg |
¡ï26,000 |
|
19983-44-9 |
|
|
|
¡¡ |
BML |
BML-EI369-0005 |
BML-275 ¡ÚDorsomorphin¡Û¡ÚCompound C¡Û¡Ú6-(4-(2-(Piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrrazolo[1,5-a]pyrimidine¡Û |
5mg |
¡ï10,000 |
|
866405-64-3 |
|
|
|
¡¡ |
BML |
BML-EI369-0025 |
BML-275 ¡ÚDorsomorphin¡Û¡ÚCompound C¡Û¡Ú6-(4-(2-(Piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrrazolo[1,5-a]pyrimidine¡Û |
25mg |
¡ï43,000 |
|
866405-64-3 |
|
|
|
¡¡ |
BML |
BML-EI370-0001 |
PKC-412 ¡Ú4'-N-Benzoylstaurosporine¡Û¡ÚMidostaurin¡Û¡ÚCGP 41251¡Û |
1mg |
¡ï14,000 |
|
120685-11-2 |
|
|
|
¡¡ |
BML |
BML-EI370-0005 |
PKC-412 ¡Ú4'-N-Benzoylstaurosporine¡Û¡ÚMidostaurin¡Û¡ÚCGP 41251¡Û |
5mg |
¡ï58,000 |
|
120685-11-2 |
|
|
|
¡¡ |
BML |
BML-EI371-0010 |
SD-169 ¡Ú1H-Indole-5-carboxamide¡Û |
10mg |
¡ï7,000 |
|
1670-87-7 |
|
|
|
¡¡ |
BML |
BML-EI371-0050 |
SD-169 ¡Ú1H-Indole-5-carboxamide¡Û |
50mg |
¡ï21,000 |
|
1670-87-7 |
|
|
|
¡¡ |
BML |
BML-EI372-0001 |
Picropodophyllin |
1mg |
¡ï20,000 |
|
447-47-4 |
|
|
|
¡¡ |
BML |
BML-EI373-0001 |
ZM-447439 ¡Ú4-(4-Benzoylaminophenylamino)-7-(3-morpholin-4-ylpropoxy)-6-methoxyquinazoline¡Û |
1mg |
¡ï8,000 |
|
331771-20-1 |
|
|
|
¡¡ |
BML |
BML-EI373-0010 |
ZM-447439 ¡Ú4-(4-Benzoylaminophenylamino)-7-(3-morpholin-4-ylpropoxy)-6-methoxyquinazoline¡Û |
10mg |
¡ï37,000 |
|
331771-20-1 |
|
|
|
¡¡ |
BML |
BML-EI377-0010 |
1,4-DPCA ¡Ú4-Oxo-1,4-dihydro-[1,10]phenanthroline-3-carboxylic Acid¡Û |
10mg |
¡ï4,000 |
|
331830-20-7 |
|
|
|
¡¡ |
BML |
BML-EI377-0050 |
1,4-DPCA ¡Ú4-Oxo-1,4-dihydro-[1,10]phenanthroline-3-carboxylic Acid¡Û |
50mg |
¡ï18,000 |
|
331830-20-7 |
|
|
|
¡¡ |
BML |
BML-EI378-0010 |
Ozagrel ¡Ú(E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic Acid¡Û |
10mg |
¡ï7,000 |
|
82571-53-7 |
|
|
|
¡¡ |
BML |
BML-EI378-0050 |
Ozagrel ¡Ú(E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic Acid¡Û |
50mg |
¡ï30,000 |
|
82571-53-7 |
|
|
|
¡¡ |
BML |
BML-EI379-0005 |
N-Arachidonyl Maleimide ¡ÚNAM¡Û |
5mg |
¡ï5,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI379-0025 |
N-Arachidonyl Maleimide ¡ÚNAM¡Û |
25mg |
¡ï23,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI384-0001 |
(D-Pro1,2)-retro-(D-HIV-TAT(48-57)) |
1mg |
¡ï23,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI385-0001 |
ZM-323881 ¡Ú5-[(7-Benzyloxyquinazolin-4-yl)amino]-4-fluoro-2-methylphenol¡Û |
1mg |
¡ï9,000 |
|
324077-30-7 |
|
|
|
¡¡ |
BML |
BML-EI385-0005 |
ZM-323881 ¡Ú5-[(7-Benzyloxyquinazolin-4-yl)amino]-4-fluoro-2-methylphenol¡Û |
5mg |
¡ï36,000 |
|
324077-30-7 |
|
|
|
¡¡ |
BML |
BML-EI386-0005 |
DAPH ¡Ú4,5-Dianilinophthalimide¡Û¡ÚCGP-52411¡Û |
5mg |
¡ï20,000 |
|
145915-58-8 |
|
|
|
¡¡ |
BML |
BML-EI387-0001 |
DAPH-7 ¡ÚCGP 53353¡Û¡Ú4,5-bis[(4-Fluorophenyl)amino]phthalimide¡Û |
1mg |
¡ï4,000 |
|
145915-60-2 |
|
|
|
¡¡ |
BML |
BML-EI388-0010 |
BML-277 ¡ÚChk2 Inhibitor II¡Û¡Ú2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide¡Û |
10mg |
¡ï13,000 |
|
516480-79-8 |
|
|
|
¡¡ |
BML |
BML-EI388-0050 |
BML-277 ¡ÚChk2 Inhibitor II¡Û¡Ú2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide¡Û |
50mg |
¡ï52,000 |
|
516480-79-8 |
|
|
|
¡¡ |
BML |
BML-EI389-0005 |
STO-609 ¡Ú7-Oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic Acid, Acetate salt¡Û |
5mg |
¡ï10,000 |
|
52029-86-4 |
|
|
|
¡¡ |
BML |
BML-EI389-0025 |
STO-609 ¡Ú7-Oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid, acetate salt¡Û |
25mg |
¡ï40,000 |
|
52029-86-4 |
|
|
|
¡¡ |
BML |
BML-EI390-0010 |
AS-041164 ¡ÚNSC31098¡Û¡Ú5-Benzo[1,3]dioxol-5-ylmethylenethiazolidine-2,4-dione¡Û |
10mg |
¡ï9,000 |
|
6318-41-8 |
|
|
|
¡¡ |
BML |
BML-EI390-0050 |
AS-041164 ¡ÚNSC31098¡Û¡Ú5-Benzo[1,3]dioxol-5-ylmethylenethiazolidine-2,4-dione¡Û |
50mg |
¡ï39,000 |
|
6318-41-8 |
|
|
|
¡¡ |
BML |
BML-EI391-0010 |
JZL-184 ¡Ú4-Nitrophenyl-4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate¡Û |
10mg |
¡ï8,000 |
|
1101854-58-3 |
|
|
|
¡¡ |
BML |
BML-EI391-0050 |
JZL-184 ¡Ú4-Nitrophenyl-4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate¡Û |
50mg |
¡ï35,000 |
|
1101854-58-3 |
|
|
|
¡¡ |
BML |
BML-EI392-0010 |
AUDA ¡Ú12-(3-Adamantan-1-ylureido)dodecanoic Acid¡Û |
10mg |
¡ï7,000 |
|
479413-70-2 |
|
|
|
¡¡ |
BML |
BML-EI392-0050 |
AUDA ¡Ú12-(3-Adamantan-1-ylureido)dodecanoic Acid¡Û |
50mg |
¡ï32,000 |
|
479413-70-2 |
|
|
|
¡¡ |
BML |
BML-EI394-0010 |
CCG-1423 ¡ÚN-(2-(4-Chloroanilino)-1-methyl-2-oxoethoxy)-3,5-bis(trifluoromethyl)benzamide¡Û |
10mg |
¡ï8,000 |
|
285986-88-1 |
|
|
|
¡¡ |
BML |
BML-EI394-0050 |
CCG-1423 ¡ÚN-(2-(4-Chloroanilino)-1-methyl-2-oxoethoxy)-3,5-bis(trifluoromethyl)benzamide¡Û |
50mg |
¡ï33,000 |
|
285986-88-1 |
|
|
|
¡¡ |
BML |
BML-EI395-0010 |
VAS-2870 ¡Ú3-Benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine¡Û |
10mg |
¡ï13,000 |
|
722456-31-7 |
|
|
|
¡¡ |
BML |
BML-EI395-0050 |
VAS-2870 ¡Ú3-Benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine¡Û |
50mg |
¡ï52,000 |
|
722456-31-7 |
|
|
|
¡¡ |
BML |
BML-EI396-0005 |
Ko143 ¡Ú(3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino-[1¡Ç,2¡Ç:1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl Ester¡Û |
5mg |
¡ï16,000 |
|
461054-93-3 |
|
|
|
¡¡ |
BML |
BML-EI396-0025 |
Ko143 ¡Ú(3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino-[1¡Ç,2¡Ç:1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl Ester¡Û |
25mg |
¡ï63,000 |
|
461054-93-3 |
|
|
|
¡¡ |
BML |
BML-EI397-0005 |
SMER28 ¡Ú6-Bromo-4-allylaminoquinazoline¡Û |
5mg |
¡ï10,000 |
|
307538-42-7 |
|
|
|
¡¡ |
BML |
BML-EI397-0025 |
SMER28 ¡Ú6-Bromo-4-allylaminoquinazoline¡Û |
25mg |
¡ï40,000 |
|
307538-42-7 |
|
|
|
¡¡ |
BML |
BML-EI398-0005 |
Src I1 ¡Ú6,7-Dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine¡Û |
5mg |
¡ï9,000 |
|
179248-59-0 |
|
|
|
¡¡ |
BML |
BML-EI398-0025 |
Src I1 ¡Ú6,7-Dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine¡Û |
25mg |
¡ï37,000 |
|
179248-59-0 |
|
|
|
¡¡ |
BML |
BML-EI399-0010 |
TCID ¡Ú4,5,6,7-Tetrachloroindan-1,3-dione¡Û |
10mg |
¡ï12,000 |
|
30675-13-9 |
|
|
|
¡¡ |
BML |
BML-EI399-0050 |
TCID ¡Ú4,5,6,7-Tetrachloroindan-1,3-dione¡Û |
50mg |
¡ï51,000 |
|
30675-13-9 |
|
|
|
¡¡ |
BML |
BML-EI400-0005 |
BML-282 ¡ÚN-(3,4-Dichlorobenzyl)-5-bromoisatin O-Acetyloxime¡Û |
5mg |
¡ï14,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI400-0025 |
BML-282 ¡ÚN-(3,4-Dichlorobenzyl)-5-bromoisatin O-Acetyloxime¡Û |
25mg |
¡ï56,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI401-0010 |
Tesmilifene ¡ÚDPPE¡Û¡ÚN,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine, HCl¡Û |
10mg |
¡ï9,000 |
|
92981-78-7 |
|
|
|
¡¡ |
BML |
BML-EI401-0050 |
Tesmilifene ¡ÚDPPE¡Û¡ÚN,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine, HCl¡Û |
50mg |
¡ï39,000 |
|
92981-78-7 |
|
|
|
¡¡ |
BML |
BML-EI402-0005 |
PF-622 ¡ÚN-Phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide¡Û |
5mg |
¡ï13,000 |
|
898235-65-9 |
|
|
|
¡¡ |
BML |
BML-EI402-0025 |
PF-622 ¡ÚN-Phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide¡Û |
25mg |
¡ï53,000 |
|
898235-65-9 |
|
|
|
¡¡ |
BML |
BML-EI404-0005 |
BML-283 ¡ÚNCGC00030335¡Û¡Ú1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-ylsulfonyl)-4-(4-methoxyphenylsulfonyl)piperazine¡Û |
5mg |
¡ï3,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI404-0025 |
BML-283 ¡ÚNCGC00030335¡Û¡Ú1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-ylsulfonyl)-4-(4-methoxyphenylsulfonyl)piperazine¡Û |
25mg |
¡ï18,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI405-0100 |
PAP-AMC, Tyrosinase Substrate ¡Ú1-(4-Methyl-coumarin-7-yl)-3-(4-hydroxyphenyl)urea¡Û |
0.1mg |
¡ï28,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EI406-0010 |
SKI-II ¡Ú4-{[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]amino}phenol¡Û |
10mg |
¡ï8,000 |
|
312636-16-1 |
|
|
|
¡¡ |
BML |
BML-EI406-0050 |
SKI-II ¡Ú4-{[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]amino}phenol¡Û |
50mg |
¡ï36,000 |
|
312636-16-1 |
|
|
|
¡¡ |
BML |
BML-EI407-0001 |
BI-D1870 ¡Ú2-[(3,5-Difluoro-4-hydroxyphenyl)amino]-7,8-dihydro-5,7-dimethyl-8-(3-methylbutyl)-6(5H)-pteridone¡Û |
1mg |
¡ï6,000 |
|
501437-28-1 |
|
|
|
¡¡ |
BML |
BML-EI407-0005 |
BI-D1870 ¡Ú2-[(3,5-Difluoro-4-hydroxyphenyl)amino]-7,8-dihydro-5,7-dimethyl-8-(3-methylbutyl)-6(5H)-pteridone¡Û |
5mg |
¡ï24,000 |
|
501437-28-1 |
|
|
|
¡¡ |
BML |
BML-EI408-0001 |
SU11652 ¡Ú5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid(2-Diethylaminoethyl)amide¡Û |
1mg |
¡ï22,000 |
|
326914-10-7 |
|
|
|
¡¡ |
BML |
BML-EI409-0010 |
Adaphostin ¡ÚAG 957 Adamantyl Ester¡Û¡ÚNSC 680410¡Û |
10mg |
¡ï18,000 |
|
241127-58-2 |
|
|
|
¡¡ |
BML |
BML-EI409-0050 |
Adaphostin ¡ÚAG 957 Adamantyl Ester¡Û¡ÚNSC 680410¡Û |
50mg |
¡ï78,000 |
|
241127-58-2 |
|
|
|
¡¡ |
BML |
BML-EI410-0100 |
Ibuproxam ¡Ú2-(4-Isobutylphenyl)propiohydroxamic Acid¡Û |
100mg |
¡ï3,000 |
|
53648-05-8 |
|
|
|
¡¡ |
BML |
BML-EI411-0005 |
SK1-I ¡Ú(2R,3S,4E)-N-methyl-5-(4'-pentylphenyl)-2-aminopent-4-ene-1,3-diol, HCl¡Û |
5mg |
¡ï17,000 |
-20¡î |
1072443-89-0 |
|
HARMFUL, Protect from light and air.
|
|
¡¡ |
BML |
BML-EI411-0025 |
SK1-I ¡Ú(2R,3S,4E)-N-methyl-5-(4'-pentylphenyl)-2-aminopent-4-ene-1,3-diol, HCl¡Û |
25mg |
¡ï54,000 |
-20¡î |
1072443-89-0 |
|
HARMFUL, Protect from light and air.
|
|
¡¡ |
BML |
BML-EM56-0050 |
(¡Þ)-5,6-EET Methyl Ester ¡Ú(¡Þ)5,6-Epoxyeicosa-8Z,11Z,14Z-trienoic Acid Methyl Ester¡Û¡Ú5(6)-EpETrE¡Û |
50ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EM56-1000 |
(¡Þ)-5,6-EET Methyl Ester ¡Ú(¡Þ)5,6-Epoxyeicosa-8Z,11Z,14Z-trienoic Acid Methyl Ester¡Û¡Ú5(6)-EpETrE¡Û |
1mg |
¡ï100,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-ET003-0001 |
5,8,11-Eicosatriynoic Acid ¡ÚETI ¡Û |
1mg |
¡ï10,000 |
|
13488-22-7 |
|
|
|
¡¡ |
BML |
BML-ET003-0010 |
5,8,11-Eicosatriynoic Acid ¡ÚETI ¡Û |
10mg |
¡ï78,000 |
|
13488-22-7 |
|
|
|
¡¡ |
BML |
BML-ET004-0020 |
5,8,11,14-Eicosatetraynoic Acid ¡ÚETYA¡Û |
20mg |
¡ï8,000 |
|
1191-85-1 |
|
|
|
¡¡ |
BML |
BML-ET004-0100 |
5,8,11,14-Eicosatetraynoic Acid ¡ÚETYA¡Û |
100mg |
¡ï37,000 |
|
1191-85-1 |
|
|
|
¡¡ |
BML |
BML-EW9805-0100 |
Mg2+/ATP Activating Solution ¡ÚATP Activating Solution, Mg2+¡Û |
100ul |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-EW9810-0100 |
ATP(Energy)Regeneration Solution |
100ul |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA001-0100 |
Eicosapentaenoic Acid ¡ÚEicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic Acid(20:5, n-3)¡Û |
100mg |
¡ï10,000 |
|
10417-94-4 |
|
|
|
¡¡ |
BML |
BML-FA001-1000 |
Eicosapentaenoic Acid ¡ÚEicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic Acid(20:5, n-3)¡Û |
1g |
¡ï44,000 |
|
10417-94-4 |
|
|
|
¡¡ |
BML |
BML-FA002-0100 |
Docosa-4Z,7Z,10Z,13Z,16Z,19Z-hexaenoic Acid |
100mg |
¡ï7,000 |
|
6217-54-5 |
|
|
|
¡¡ |
BML |
BML-FA002-1000 |
Docosa-4Z,7Z,10Z,13Z,16Z,19Z-hexaenoic Acid |
1g |
¡ï25,000 |
|
6217-54-5 |
|
|
|
¡¡ |
BML |
BML-FA003-0100 |
Arachidonic Acid(20:4, n-6)¡Ú5Z,8Z,11Z,14Z-Eicosatetraenoic Acid¡Û |
100mg |
¡ï11,000 |
|
506-32-1 |
|
|
|
¡¡ |
BML |
BML-FA003-1000 |
Arachidonic Acid(20:4, n-6)¡Ú5Z,8Z,11Z,14Z-Eicosatetraenoic Acid¡Û |
1g |
¡ï29,000 |
|
506-32-1 |
|
|
|
¡¡ |
BML |
BML-FA004-0001 |
Mead Acid ¡ÚEicosa-5Z,8Z,11Z-trienoic Acid¡Û |
1mg |
¡ï10,000 |
|
20590-32-3 |
|
|
|
¡¡ |
BML |
BML-FA004-0010 |
Mead Acid ¡ÚEicosa-5Z,8Z,11Z-trienoic Acid¡Û |
10mg |
¡ï62,000 |
|
20590-32-3 |
|
|
|
¡¡ |
BML |
BML-FA005-1000 |
Linolenic Acid(18:3, n-3)¡ÚOctadeca-9Z,12Z,15Z-trienoic Acid¡Û |
1g |
¡ï12,000 |
|
463-40-1 |
|
|
|
¡¡ |
BML |
BML-FA006-0100 |
¦Ã-Linolenic Acid ¡ÚOctadeca-6Z,9Z,12Z-trienoic Acid¡Û |
100mg |
¡ï3,000 |
|
506-26-3 |
|
|
|
¡¡ |
BML |
BML-FA006-1000 |
¦Ã-Linolenic Acid ¡ÚOctadeca-6Z,9Z,12Z-trienoic Acid¡Û |
1g |
¡ï20,000 |
|
506-26-3 |
|
|
|
¡¡ |
BML |
BML-FA007-0100 |
Eicosa-11Z,14Z-dienoic Acid |
100mg |
¡ï3,000 |
|
2091-39-6 |
|
|
|
¡¡ |
BML |
BML-FA007-1000 |
Eicosa-11Z,14Z-dienoic Acid |
1g |
¡ï20,000 |
|
2091-39-6 |
|
|
|
¡¡ |
BML |
BML-FA008-0100 |
Eicosa-11Z,14Z,17Z-trienoic Acid |
100mg |
¡ï3,000 |
|
2091-27-2 |
|
|
|
¡¡ |
BML |
BML-FA008-1000 |
Eicosa-11Z,14Z,17Z-trienoic Acid |
1g |
¡ï20,000 |
|
2091-27-2 |
|
|
|
¡¡ |
BML |
BML-FA009-0100 |
Dihomo-¦Ã-linolenic Acid(20:3, n-6)¡ÚEicosa-8Z,11Z,14Z-trienoic Acid¡Û |
100mg |
¡ï12,000 |
|
1783-84-2 |
|
|
|
¡¡ |
BML |
BML-FA009-1000 |
Dihomo-¦Ã-linolenic Acid(20:3, n-6)¡ÚEicosa-8Z,11Z,14Z-trienoic Acid¡Û |
1g |
¡ï77,000 |
|
1783-84-2 |
|
|
|
¡¡ |
BML |
BML-FA010-0020 |
Docosa-13Z,16Z,19Z-trienoic Acid |
20mg |
¡ï5,000 |
|
28845-86-5 |
|
|
|
¡¡ |
BML |
BML-FA011-0020 |
Adrenic Acid(22:4, n-6)¡ÚDocosa-7Z,10Z,13Z,16Z-tetraenoic Acid¡Û |
20mg |
¡ï5,000 |
|
28874-58-0 |
|
|
|
¡¡ |
BML |
BML-FA011-0100 |
Adrenic Acid(22:4, n-6)¡ÚDocosa-7Z,10Z,13Z,16Z-tetraenoic Acid¡Û |
100mg |
¡ï21,000 |
|
28874-58-0 |
|
|
|
¡¡ |
BML |
BML-FA012-0010 |
Docosa-7Z,10Z,13Z,16Z,19Z-pentaenoic Acid |
10mg |
¡ï7,000 |
|
24880-45-3 |
|
|
|
¡¡ |
BML |
BML-FA014-0100 |
Linoleic Acid ¡ÚOctadeca-9Z,12Z-dienoic Acid¡Û |
100mg |
¡ï3,000 |
|
60-33-3 |
|
|
|
¡¡ |
BML |
BML-FA014-1000 |
Linoleic Acid ¡ÚOctadeca-9Z,12Z-dienoic Acid¡Û |
1g |
¡ï6,000 |
|
60-33-3 |
|
|
|
¡¡ |
BML |
BML-FA017-0005 |
Anandamide ¡ÚAEA¡Û¡ÚN-Arachidonoylethanolamine¡Û¡Ú(all-Z)-N-(2-Hydroxyethyl)-5,8,11,14-eicosatetraenamide¡Û |
5mg |
¡ï7,000 |
|
94421-68-8 |
|
|
|
¡¡ |
BML |
BML-FA017-0025 |
Anandamide ¡ÚAEA¡Û¡ÚN-Arachidonoylethanolamine¡Û¡Ú(all-Z)-N-(2-Hydroxyethyl)-5,8,11,14-eicosatetraenamide¡Û |
25mg |
¡ï21,000 |
|
94421-68-8 |
|
|
|
¡¡ |
BML |
BML-FA018-0010 |
Palmitylethanolamide ¡ÚPEA¡Û |
10mg |
¡ï5,000 |
|
544-31-0 |
|
|
|
¡¡ |
BML |
BML-FA018-0050 |
Palmitylethanolamide ¡ÚPEA¡Û |
50mg |
¡ï19,000 |
|
544-31-0 |
|
|
|
¡¡ |
BML |
BML-FA019-0005 |
Anandamide(20:3, n-6)¡ÚDihomo-¦Ã-linolenylethanolamide¡Û |
5mg |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA020-0005 |
Anandamide(22:4, n-6)¡ÚDocosatetraenylethanolamide¡Û |
5mg |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA020-0025 |
Anandamide(22:4, n-6)¡ÚDocosatetraenylethanolamide¡Û |
25mg |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA021-0005 |
Methanandamide ¡ÚAM 356¡Û¡Ú(R)-(+)-Arachidonyl-1'-hydroxy-2'-propylamide¡Û¡ÚN-(2-Hydroxy-1R-methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide¡Û |
5mg |
¡ï7,000 |
|
157182-49-5 |
|
|
|
¡¡ |
BML |
BML-FA021-0025 |
Methanandamide ¡ÚAM 356¡Û¡Ú(R)-(+)-Arachidonyl-1'-hydroxy-2'-propylamide¡Û¡ÚN-(2-Hydroxy-1R-methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide¡Û |
25mg |
¡ï22,000 |
|
157182-49-5 |
|
|
|
¡¡ |
BML |
BML-FA022-0010 |
Arachidonamide |
10mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA022-0050 |
Arachidonamide |
50mg |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA023-0010 |
Linoleamide |
10mg |
¡ï6,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA023-0050 |
Linoleamide |
50mg |
¡ï27,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA024-0001 |
Eicosa-5Z,8Z-dienoic Acid |
1mg |
¡ï16,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA024-0005 |
Eicosa-5Z,8Z-dienoic Acid |
5mg |
¡ï65,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA025-0050 |
9,10-Octadecenoamide |
50mg |
¡ï25,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA026-0005 |
Anandamide(18:2, n-6)¡ÚLinoleylethanolamide¡Û |
5mg |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA026-0025 |
Anandamide(18:2, n-6)¡ÚLinoleylethanolamide¡Û |
25mg |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA027-0001 |
Mead Acid Ethanolamide ¡Ú(Z,Z,Z)-5,8,11-Eicosatrienoic Acid, N-(2-hydroxyethyl)-¡Û¡ÚEicosa-5Z,8Z,11Z-trienylethanolamide¡Û |
1mg |
¡ï11,000 |
|
169232-04-6 |
|
|
|
¡¡ |
BML |
BML-FA027-0010 |
Mead Acid Ethanolamide ¡Ú(Z,Z,Z)-5,8,11-Eicosatrienoic Acid, N-(2-hydroxyethyl)-¡Û¡ÚEicosa-5Z,8Z,11Z-trienylethanolamide¡Û |
10mg |
¡ï72,000 |
|
169232-04-6 |
|
|
|
¡¡ |
BML |
BML-FA028-0005 |
2-Arachidonoylglycerol ¡Ú2-AG¡Û |
5mg |
¡ï14,000 |
|
53847-30-6 |
|
|
|
¡¡ |
BML |
BML-FA029-0005 |
N-Arachidonylglycine ¡ÚNAGly¡Û |
5mg |
¡ï10,000 |
|
179113-91-8 |
|
|
|
¡¡ |
BML |
BML-FA029-0025 |
N-Arachidonylglycine ¡ÚNAGly¡Û |
25mg |
¡ï39,000 |
|
179113-91-8 |
|
|
|
¡¡ |
BML |
BML-FA030-0005 |
N-Linoleoylglycine |
5mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA030-0025 |
N-Linoleoylglycine |
25mg |
¡ï37,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA031-0010 |
Arachidonylcyclopropylamide ¡ÚACPA¡Û |
10mg |
¡ï8,000 |
|
229021-64-1 |
|
|
|
¡¡ |
BML |
BML-FA031-0050 |
Arachidonylcyclopropylamide ¡ÚACPA¡Û |
50mg |
¡ï31,000 |
|
229021-64-1 |
|
|
|
¡¡ |
BML |
BML-FA032-0010 |
Arachidonyl-2-chloroethylamide ¡ÚACEA¡Û¡ÚN-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide¡Û |
10mg |
¡ï8,000 |
|
220556-69-4 |
|
|
|
¡¡ |
BML |
BML-FA032-0050 |
Arachidonyl-2-chloroethylamide ¡ÚACEA¡Û¡ÚN-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide¡Û |
50mg |
¡ï32,000 |
|
220556-69-4 |
|
|
|
¡¡ |
BML |
BML-FA033-0001 |
Noladin Ether ¡Ú2-Arachidonyl Glycerol Ether¡Û¡Ú2-AG Ether¡Û¡Ú5Z,8Z,11Z,14Z-Eicosatetraen-2-glyceryl Ether¡Û |
1mg |
¡ï4,000 |
|
222723-55-9 |
|
|
|
¡¡ |
BML |
BML-FA033-0005 |
Noladin Ether ¡Ú2-Arachidonyl Glycerol Ether¡Û¡Ú2-AG Ether¡Û¡Ú5Z,8Z,11Z,14Z-Eicosatetraen-2-glyceryl Ether¡Û |
5mg |
¡ï18,000 |
|
222723-55-9 |
|
|
|
¡¡ |
BML |
BML-FA034-0005 |
N-Arachidonyl-L-alanine ¡ÚNA-Ala¡Û |
5mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA034-0025 |
N-Arachidonyl-L-alanine ¡ÚNA-Ala¡Û |
25mg |
¡ï37,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA035-0005 |
N-Arachidonyl-GABA ¡ÚNA-GABA¡Û¡Ú4-(1-oxo-5Z,8Z,11Z,14Z-Eicosatetraenyl)aminobutanoic Acid¡Û¡ÚN-Arachidonoyl-¦Ã-aminobutyric Acid¡Û |
5mg |
¡ï10,000 |
|
128201-89-8 |
|
|
|
¡¡ |
BML |
BML-FA035-0025 |
N-Arachidonyl-GABA ¡ÚNA-GABA¡Û¡Ú4-(1-oxo-5Z,8Z,11Z,14Z-Eicosatetraenyl)aminobutanoic Acid¡Û¡ÚN-Arachidonoyl-¦Ã-aminobutyric Acid¡Û |
25mg |
¡ï37,000 |
|
128201-89-8 |
|
|
|
¡¡ |
BML |
BML-FA036-0005 |
Virodhamine ¡ÚO-AEA¡Û¡ÚO-Arachidonoylethanolamine¡Û¡ÚArachidonic Acid(2-Aminoethyl)Ester¡Û |
5mg |
¡ï16,000 |
|
443129-35-9 |
|
|
|
¡¡ |
BML |
BML-FA036-0025 |
Virodhamine ¡ÚO-AEA¡Û¡ÚO-Arachidonoylethanolamine¡Û¡ÚArachidonic Acid(2-Aminoethyl)Ester¡Û |
25mg |
¡ï68,000 |
|
443129-35-9 |
|
|
|
¡¡ |
BML |
BML-FA037-0010 |
N-Arachidonoyl-L-serine |
10mg |
¡ï9,000 |
|
187224-29-9 |
|
|
|
¡¡ |
BML |
BML-FA037-0050 |
N-Arachidonoyl-L-serine |
50mg |
¡ï34,000 |
|
187224-29-9 |
|
|
|
¡¡ |
BML |
BML-FA039-0005 |
N-Arachidonoyl-L-tyrosine |
5mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA039-0025 |
N-Arachidonoyl-L-tyrosine |
25mg |
¡ï37,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA040-0005 |
N-Arachidonoyl-L-phenylalanine |
5mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA040-0025 |
N-Arachidonoyl-L-phenylalanine |
25mg |
¡ï35,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA041-0005 |
N-Arachidonoyl-L-methionine |
5mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA041-0025 |
N-Arachidonoyl-L-methionine |
25mg |
¡ï37,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA045-0010 |
Oleic Acid ¡Úcis-9-Octadecenoic Acid 18:1¡Û |
10g |
¡ï9,000 |
|
112-80-1 |
|
|
|
¡¡ |
BML |
BML-FA046-0005 |
N-Oleoyl-L-serine |
5mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA046-0025 |
N-Oleoyl-L-serine |
25mg |
¡ï36,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FA047-0005 |
Eicosapentaenoyl Ethanolamide ¡ÚEPEA¡Û |
5mg |
¡ï5,000 |
|
109001-03-8 |
|
|
|
¡¡ |
BML |
BML-FA047-0025 |
Eicosapentaenoyl Ethanolamide ¡ÚEPEA¡Û |
25mg |
¡ï21,000 |
|
109001-03-8 |
|
|
|
¡¡ |
BML |
BML-FA1155-0025 |
FMRFamide(Phe-Met-Arg-Phe.amide), rabbit pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-FA1155-0100 |
FMRFamide(Phe-Met-Arg-Phe.amide), rabbit pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-FG6010-0100 |
Fibronectin(cellular)¡ÚcFn¡Û(A8387 fibrosarcoma cells)[DH1], mouse mAb, Affinity-purified(specificity: human) |
100ul |
¡ï24,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | DH1 | human | WB(250kDa)¡¢ ICC |
|
|
¡¡ |
BML |
BML-FG6020-0100 |
Fibronectin(plasma)¡ÚpFn¡Û(A8387 fibrosarcoma cells)[BF12], mouse mAb, Affinity-purified(specificity: human) |
100ul |
¡ï23,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | BF12 | human | WB(225-250 kDa)¡¢ ICC |
|
|
¡¡ |
BML |
BML-FG6090-0100 |
a-Fodrin ¡ÚaII-spectrin¡Û(chicken blood cell membranes)[AA6], mouse mAb, purified |
100ul |
¡ï26,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | AA6 | mammalian¡¢ chicken | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-FG6090-0500 |
a-Fodrin ¡ÚaII-spectrin¡Û(chicken blood cell membranes)[AA6], mouse mAb, purified |
500ul |
¡ï90,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | AA6 | mammalian¡¢ chicken | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-FM004-0001 |
Mead Acid Methyl Ester ¡ÚMethyl 5,8,11-Eicosatrienoate¡Û |
1mg |
¡ï9,000 |
|
14602-39-2 |
|
|
|
¡¡ |
BML |
BML-FM004-0010 |
Mead Acid Methyl Ester ¡ÚMethyl 5,8,11-Eicosatrienoate¡Û |
10mg |
¡ï61,000 |
|
14602-39-2 |
|
|
|
¡¡ |
BML |
BML-FR100-0100 |
U-74389G ¡Ú21-(4-(2,6-di-1-Pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)pregna-1,4,9(11)-triene-3,20-dione(Z)-2-Butenedioate¡Û |
100mg |
¡ï14,000 |
|
153190-29-5 |
|
|
|
¡¡ |
BML |
BML-FR101-0100 |
U-83836E ¡Ú(-)2-{[4-(2,6-di-1-Pyrrolidinyl-4-pyrimidinyl]-1-piperazinyl)methyl}-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-ol, 2HCl¡Û |
100mg |
¡ï14,000 |
|
122003-11-6 |
|
|
|
¡¡ |
BML |
BML-FR103-0050 |
MCI-186 ¡Ú3-Methyl-1-phenyl-2-pyrazolin-5-one¡Û |
50mg |
¡ï6,000 |
|
89-25-8 |
|
|
|
¡¡ |
BML |
BML-FR103-0250 |
MCI-186 ¡Ú3-Methyl-1-phenyl-2-pyrazolin-5-one¡Û |
250mg |
¡ï19,000 |
|
89-25-8 |
|
|
|
¡¡ |
BML |
BML-FR104-0100 |
Resveratrol ¡Útrans-3,4¡Ç,5-Trihydroxystilbene¡Û |
100mg |
¡ï6,000 |
|
501-36-0 |
|
|
|
¡¡ |
BML |
BML-FR104-0500 |
Resveratrol ¡Útrans-3,4¡Ç,5-Trihydroxystilbene¡Û |
500mg |
¡ï28,000 |
|
501-36-0 |
|
|
|
¡¡ |
BML |
BML-FR106-0001 |
Procysteine ¡ÚL-2-Oxothiazolidine-4-carboxylic Acid¡Û |
1g |
¡ï3,000 |
|
19771-63-2 |
|
|
|
¡¡ |
BML |
BML-FR110-0050 |
Hinokitiol ¡Ú2-Hydroxy-4-isopropyl-2,4,6-cycloheptatriene¡Û |
50mg |
¡ï8,000 |
|
499-44-5 |
|
|
|
¡¡ |
BML |
BML-FR110-0250 |
Hinokitiol ¡Ú2-Hydroxy-4-isopropyl-2,4,6-cycloheptatriene¡Û |
250mg |
¡ï24,000 |
|
499-44-5 |
|
|
|
¡¡ |
BML |
BML-FR111-0010 |
L-Ergothioneine ¡Ú(S)-a-Carboxy-2,3-dihydro-N,N,N-trimethyl-2-thioxo-1H-imidazole-4-ethanaminium inner salt¡Û |
10mg |
¡ï13,000 |
|
497-30-3 |
|
|
|
¡¡ |
BML |
BML-FR111-0050 |
L-Ergothioneine ¡Ú(S)-a-Carboxy-2,3-dihydro-N,N,N-trimethyl-2-thioxo-1H-imidazole-4-ethanaminium inner salt¡Û |
50mg |
¡ï55,000 |
|
497-30-3 |
|
|
|
¡¡ |
BML |
BML-FR112-0001 |
Ambroxol ¡Útrans-4-(2-Amino-3,5-dibromobenzylamino)cyclohexane, HCl¡Û |
1g |
¡ï6,000 |
|
18683-91-5 |
|
|
|
¡¡ |
BML |
BML-FR113-0050 |
HBED ¡ÚN,N'-Di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic Acid, HCl¡Û |
50mg |
¡ï6,000 |
|
35369-53-0 |
|
|
|
¡¡ |
BML |
BML-FR113-0250 |
HBED ¡ÚN,N'-Di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic Acid, HCl¡Û |
250mg |
¡ï26,000 |
|
35369-53-0 |
|
|
|
¡¡ |
BML |
BML-FR114-0020 |
Idebenone ¡Ú6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone¡Û |
20mg |
¡ï10,000 |
|
58186-27-9 |
|
|
|
¡¡ |
BML |
BML-FR114-0100 |
Idebenone ¡Ú6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone¡Û |
100mg |
¡ï40,000 |
|
58186-27-9 |
|
|
|
¡¡ |
BML |
BML-FR115-0020 |
Tocopherylquinone, D-a- |
20mg |
¡ï8,000 |
|
7559-04-8 |
|
|
|
¡¡ |
BML |
BML-FR115-0100 |
Tocopherylquinone, D-a- |
100mg |
¡ï17,000 |
|
7559-04-8 |
|
|
|
¡¡ |
BML |
BML-FR116-0100 |
Ethyl Ferulate ¡ÚEthyl 4-Hydroxy-3-methoxycinnamate¡Û |
100mg |
¡ï7,000 |
|
4046-02-0 |
|
|
|
¡¡ |
BML |
BML-FR117-0500 |
Buthionine Sulfoximine ¡ÚBSO¡Û |
500mg |
¡ï19,000 |
|
83730-53-4 |
|
|
|
¡¡ |
BML |
BML-FR119-0010 |
Triacetylresveratrol |
10mg |
¡ï8,000 |
|
42206-94-0 |
|
|
|
¡¡ |
BML |
BML-FR119-0050 |
Triacetylresveratrol |
50mg |
¡ï31,000 |
|
42206-94-0 |
|
|
|
¡¡ |
BML |
BML-FW8820-0020 |
p53(human)(recombinant)with His-Tag |
20ug |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-FW9370-0050 |
p53(human)(recombinant)with GST-Tag |
50ug |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G100-0050 |
Pertussis Toxin(Bordetella pertussis)¡ÚPTX¡Û¡ÚIslet-Activating Protein¡Û¡ÚHolotoxin¡Û |
50ug |
¡ï45,000 |
|
82248-93-9 |
|
|
|
¡¡ |
BML |
BML-G101-0050 |
Bordetella pertussis toxin ¡ÚIslet-activating protein¡Û¡ÚPTX¡Û |
50ug |
¡ï35,000 |
+4¡î |
70323-44-3 |
|
TOXIC.
|
|
¡¡ |
BML |
BML-G105-0010 |
Pertussis Toxin A Protomer(Bordetella pertussis)¡ÚIslet-Activating Protein A Protomer¡Û¡ÚPTX A Protomer¡Û |
10ug |
¡ï38,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G110-0040 |
Pertussis Toxin B Oligomer(Bordetella pertussis)¡ÚIslet-Activating Protein B Oligomer¡Û¡ÚPTX B Oligomer¡Û |
40ug |
¡ï53,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G120-0250 |
Cholera Toxin A Subunit(Vibrio Cholerae) |
250ug |
¡ï38,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G125-0500 |
Cholera Toxin B Subunit(Vibrio Cholerae) |
500ug |
¡ï41,000 |
|
131096-89-4 |
|
|
|
¡¡ |
BML |
BML-G130-0010 |
C3 Exoenzyme(Clostridium botulinum) |
10ug |
¡ï18,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G130-0050 |
C3 Exoenzyme(Clostridium botulinum) |
50ug |
¡ï69,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G135-0500 |
Diphtheria Toxin(Corynebacterium diphtheriae) |
500ug |
¡ï46,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G140-0050 |
C. difficile toxin A ¡ÚClostridium difficile toxin A¡Û |
50ug |
¡ï39,000 |
+4¡î |
none |
|
TOXIC.
|
|
¡¡ |
BML |
BML-G145-0050 |
C. difficile toxoid A ¡ÚClostridium difficile toxoid A¡Û |
50ug |
¡ï43,000 |
+4¡î |
none |
|
Purity: ¡ä99%, Application: antibody capture, ELISA, LINE assay, cytotoxicity studies, immunogen
|
|
¡¡ |
BML |
BML-G150-0050 |
C. difficile toxin B ¡ÚClostridium difficile toxin B¡Û |
50ug |
¡ï74,000 |
+4¡î |
none |
|
TOXIC.
|
|
¡¡ |
BML |
BML-G155-0050 |
C. difficile toxoid B ¡ÚClostridium difficile toxoid B¡Û |
50ug |
¡ï76,000 |
+4¡î |
none |
|
Purity: ¡ä99%, Application: antibody capture, ELISA, LINE assay, cytotoxicity studies, immunogen
|
|
¡¡ |
BML |
BML-G200-0005 |
N-Acetyl-S-farnesyl-L-cysteine ¡ÚAFC¡Û |
5mg |
¡ï9,000 |
|
135304-07-3 |
|
|
|
¡¡ |
BML |
BML-G200-0025 |
N-Acetyl-S-farnesyl-L-cysteine ¡ÚAFC¡Û |
25mg |
¡ï38,000 |
|
135304-07-3 |
|
|
|
¡¡ |
BML |
BML-G201-0005 |
S-Farnesyl-L-cysteine Methyl Ester |
5mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G201-0025 |
S-Farnesyl-L-cysteine Methyl Ester |
25mg |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G210-0100 |
Perillic Acid ¡ÚS(-)-4-Isopropenyl-1-cyclohexene-1-carboxylic Acid¡Û¡ÚL(-)-4-Isopropenyl-1-cyclohexene-1-carboxylic Acid¡Û |
100mg |
¡ï5,000 |
|
7694-45-3 |
|
|
|
¡¡ |
BML |
BML-G210-0500 |
Perillic Acid ¡ÚS(-)-4-Isopropenyl-1-cyclohexene-1-carboxylic Acid¡Û¡ÚL(-)-4-Isopropenyl-1-cyclohexene-1-carboxylic Acid¡Û |
500mg |
¡ï25,000 |
|
7694-45-3 |
|
|
|
¡¡ |
BML |
BML-G220-0005 |
N-Acetyl-S-geranylgeranyl-L-cysteine ¡ÚAGGC¡Û |
5mg |
¡ï10,000 |
|
139332-94-8 |
|
|
|
¡¡ |
BML |
BML-G220-0025 |
N-Acetyl-S-geranylgeranyl-L-cysteine ¡ÚAGGC¡Û |
25mg |
¡ï42,000 |
|
139332-94-8 |
|
|
|
¡¡ |
BML |
BML-G221-0005 |
N-Acetyl-S-geranyl-L-cysteine ¡ÚAGC¡Û |
5mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G221-0025 |
N-Acetyl-S-geranyl-L-cysteine ¡ÚAGC¡Û |
25mg |
¡ï35,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G222-0005 |
Farnesylthioacetic Acid ¡ÚFTA¡Û |
5mg |
¡ï9,000 |
|
135784-48-4 |
|
|
|
¡¡ |
BML |
BML-G222-0025 |
Farnesylthioacetic Acid ¡ÚFTA¡Û |
25mg |
¡ï35,000 |
|
135784-48-4 |
|
|
|
¡¡ |
BML |
BML-G224-0200 |
Farnesylpyrophosphate ¡ÚFPP, 3NH4¡Û |
200ug |
¡ï8,000 |
|
13058-04-3 |
|
|
|
¡¡ |
BML |
BML-G224-5000 |
Farnesylpyrophosphate ¡ÚFPP, 3NH4¡Û |
5mg |
¡ï133,000 |
|
13058-04-3 |
|
|
|
¡¡ |
BML |
BML-G225-0200 |
Geranylgeranylpyrophosphate, 3NH3 |
200ug |
¡ï4,000 |
|
6699-20-3 |
|
|
|
¡¡ |
BML |
BML-G226-0010 |
Lovastatin ¡ÚMevinolin¡Û¡Ú6-a-Methylcompactin¡Û |
10mg |
¡ï6,000 |
|
75330-75-5 |
|
|
|
¡¡ |
BML |
BML-G226-0050 |
Lovastatin ¡ÚMevinolin¡Û¡Ú6-a-Methylcompactin¡Û |
50mg |
¡ï26,000 |
|
75330-75-5 |
|
|
|
¡¡ |
BML |
BML-G228-0001 |
a-Hydroxyfarnesylphosphonic Acid |
1mg |
¡ï17,000 |
|
140633-12-1 |
|
|
|
¡¡ |
BML |
BML-G229-0005 |
Chaetomellic Acid A |
5mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G229-0025 |
Chaetomellic Acid A |
25mg |
¡ï31,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G230-0050 |
2-Hydroxymyristic Acid ¡Ú2-Hydroxy-tetradecanoic Acid¡Û |
50mg |
¡ï6,000 |
|
2507-55-3 |
|
|
|
¡¡ |
BML |
BML-G230-0250 |
2-Hydroxymyristic Acid ¡Ú2-Hydroxy-tetradecanoic Acid¡Û |
250mg |
¡ï27,000 |
|
2507-55-3 |
|
|
|
¡¡ |
BML |
BML-G231-0005 |
2-Fluoropalmitic Acid |
5mg |
¡ï5,000 |
|
89270-22-4 |
|
|
|
¡¡ |
BML |
BML-G231-0025 |
2-Fluoropalmitic Acid |
25mg |
¡ï24,000 |
|
89270-22-4 |
|
|
|
¡¡ |
BML |
BML-G232-0010 |
4-Oxatetradecanoic Acid |
10mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G232-0050 |
4-Oxatetradecanoic Acid |
50mg |
¡ï44,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G233-0010 |
Mevastatin ¡ÚCompactin¡Û |
10mg |
¡ï9,000 |
|
73573-88-3 |
|
|
|
¡¡ |
BML |
BML-G233-0050 |
Mevastatin ¡ÚCompactin¡Û |
50mg |
¡ï21,000 |
|
73573-88-3 |
|
|
|
¡¡ |
BML |
BML-G234-0010 |
12-Methoxydodecanoic Acid |
10mg |
¡ï8,000 |
|
92169-28-3 |
|
|
|
¡¡ |
BML |
BML-G234-0050 |
12-Methoxydodecanoic Acid |
50mg |
¡ï31,000 |
|
92169-28-3 |
|
|
|
¡¡ |
BML |
BML-G235-0001 |
B581 ¡ÚN-(2(S)-(2(R)-Amino-3-mercaptopropylamino)-3-methylbutyl)-Phe-Met-OH¡Û |
1mg |
¡ï12,000 |
|
149759-96-6 |
|
|
|
¡¡ |
BML |
BML-G235-0005 |
B581 ¡ÚN-(2(S)-(2(R)-Amino-3-mercaptopropylamino)-3-methylbutyl)-Phe-Met-OH¡Û |
5mg |
¡ï68,000 |
|
149759-96-6 |
|
|
|
¡¡ |
BML |
BML-G237-0005 |
Cerulenin ¡Ú2,3-Epoxy-4-oxo-7,10-dodecadienamide¡Û |
5mg |
¡ï11,000 |
|
17397-89-6 |
|
|
|
¡¡ |
BML |
BML-G237-0025 |
Cerulenin ¡Ú2,3-Epoxy-4-oxo-7,10-dodecadienamide¡Û |
25mg |
¡ï47,000 |
|
17397-89-6 |
|
|
|
¡¡ |
BML |
BML-G238-0005 |
Mevastatin Sodium |
5mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G238-0025 |
Mevastatin Sodium |
25mg |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G242-0005 |
L-744,832 |
5mg |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G242-0025 |
L-744,832 |
25mg |
¡ï87,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G243-0020 |
Geranylgeraniol |
20mg |
¡ï10,000 |
|
24034-73-9 |
|
|
|
¡¡ |
BML |
BML-G243-0100 |
Geranylgeraniol |
100mg |
¡ï40,000 |
|
24034-73-9 |
|
|
|
¡¡ |
BML |
BML-G244-0050 |
Simvastatin ¡ÚZocor¡Û |
50mg |
¡ï15,000 |
|
79902-63-9 |
|
|
|
¡¡ |
BML |
BML-G244-0250 |
Simvastatin ¡ÚZocor¡Û |
250mg |
¡ï62,000 |
|
79902-63-9 |
|
|
|
¡¡ |
BML |
BML-G245-0005 |
Lovastatin, Na salt ¡ÚMevinolin, Na salt¡Û¡Ú6-a-Methylcompactin, Na salt¡Û |
5mg |
¡ï9,000 |
|
75225-50-2 |
|
|
|
¡¡ |
BML |
BML-G245-0025 |
Lovastatin, Na salt ¡ÚMevinolin, Na salt¡Û¡Ú6-a-Methylcompactin, Na salt¡Û |
25mg |
¡ï36,000 |
|
75225-50-2 |
|
|
|
¡¡ |
BML |
BML-G310-0005 |
Guanylylimidodiphosphate, 4Li salt ¡ÚGpp(NH)p¡Û |
5mg |
¡ï23,000 |
|
74812-64-9 |
|
|
|
¡¡ |
BML |
BML-G405-0005 |
Brefeldin A ¡ÚBFA¡Û¡ÚAscotoxin¡Û¡ÚDecumbin¡Û |
5mg |
¡ï11,000 |
|
20350-15-6 |
|
|
|
¡¡ |
BML |
BML-G405-0025 |
Brefeldin A ¡ÚBFA¡Û¡ÚAscotoxin¡Û¡ÚDecumbin¡Û |
25mg |
¡ï39,000 |
|
20350-15-6 |
|
|
|
¡¡ |
BML |
BML-G405-0100 |
Brefeldin A ¡ÚBFA¡Û¡ÚAscotoxin¡Û¡ÚDecumbin¡Û |
100mg |
¡ï112,000 |
|
20350-15-6 |
|
|
|
¡¡ |
BML |
BML-G410-0001 |
Mastoparan |
1mg |
¡ï13,000 |
|
72093-21-1 |
|
|
|
¡¡ |
BML |
BML-G415-0001 |
Mastoparan X |
1mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G420-0001 |
Mas 7 |
1mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G421-0001 |
Mas 17 |
1mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G425-0001 |
Mastoparan(Polistes) |
1mg |
¡ï12,000 |
|
74129-19-4 |
|
|
|
¡¡ |
BML |
BML-G435-0100 |
Ilimaquinone ¡Ú3-[(Decahydro-1B,2B,4aB-trimethyl-5-methylene-1-naphthyl)methyl]-2-hydroxy-5-methoxybenzoquinone¡Û |
100ug |
¡ï16,000 |
|
71678-03-0 |
|
|
|
¡¡ |
BML |
BML-G440-0010 |
M-Iodobenzylguanidine |
10mg |
¡ï25,000 |
|
80663-95-2 |
|
|
|
¡¡ |
BML |
BML-G445-0001 |
ARF Inhibitory Peptide(P-13)¡ÚADP-ribosylation Factor¡Û |
1mg |
¡ï16,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G510-0001 |
GP Antagonist-2 ¡ÚG Protein Antagonist-2¡Û |
1mg |
¡ï22,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G515-0001 |
GP Antagonist-2A ¡ÚG Protein Antagonist-2A¡Û |
1mg |
¡ï14,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-G520-0001 |
Isotetrandrine ¡ÚBerbamine Methyl Ether¡Û¡Ú6,6¡Ç,7,12-Tetramethoxy-2,2¡Ç-dimethylberbaman¡Û |
1mg |
¡ï8,000 |
|
477-57-6 |
|
|
|
¡¡ |
BML |
BML-G520-0005 |
Isotetrandrine ¡ÚBerbamine Methyl Ether¡Û¡Ú6,6¡Ç,7,12-Tetramethoxy-2,2¡Ç-dimethylberbaman¡Û |
5mg |
¡ï32,000 |
|
477-57-6 |
|
|
|
¡¡ |
BML |
BML-G521-0010 |
SCH-202676 ¡ÚN-(2,3-Diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene)methanamine, HBr¡Û |
10mg |
¡ï14,000 |
|
70375-43-8 |
|
|
|
¡¡ |
BML |
BML-G521-0050 |
SCH-202676 ¡ÚN-(2,3-Diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene)methanamine, HBr¡Û |
50mg |
¡ï55,000 |
|
70375-43-8 |
|
|
|
¡¡ |
BML |
BML-GA1159-0025 |
¦Ã-Aminobutyric Acid ¡ÚGABA¡Û, rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC¡¢ ELISA |
|
|
¡¡ |
BML |
BML-GA1159-0100 |
¦Ã-Aminobutyric Acid ¡ÚGABA¡Û, rabbit pAb(antiserum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC¡¢ ELISA |
|
|
¡¡ |
BML |
BML-GA1160-0025 |
¦Ã-Aminobutyric Acid ¡ÚGABA¡Û [5A9], mouse mAb, purified |
25ul |
¡ï13,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 5A9 | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-GA1160-0100 |
¦Ã-Aminobutyric Acid ¡ÚGABA¡Û [5A9], mouse mAb, purified |
100ul |
¡ï42,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 5A9 | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-GA1161-0025 |
Galanin(pig), rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ mammalian | IHC |
|
|
¡¡ |
BML |
BML-GA1161-0100 |
Galanin(pig), rabbit pAb(antiserum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ mammalian | IHC |
|
|
¡¡ |
BML |
BML-GA1164-0025 |
Peptide Serine Asparagine ¡ÚPSN¡Û¡ÚC-POG¡Û¡ÚC-terminal flanking peptide of pro-gastrin¡Û(Synthetic peptide(H-Ser-Ala-Glu-Asp-Glu-Asn-OH)of gastrin)(CT), rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC |
|
|
¡¡ |
BML |
BML-GA1164-0100 |
Peptide Serine Asparagine ¡ÚPSN¡Û¡ÚC-POG¡Û¡ÚC-terminal flanking peptide of pro-gastrin¡Û(Synthetic peptide(H-Ser-Ala-Glu-Asp-Glu-Asn-OH)of gastrin)(CT), rabbit pAb(antiserum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC |
|
|
¡¡ |
BML |
BML-GA1166-0025 |
Gastrin Releasing Peptide ¡ÚGRP¡Û, rabbit pAb(neat serum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC(FS) |
|
|
¡¡ |
BML |
BML-GA1166-0100 |
Gastrin Releasing Peptide ¡ÚGRP¡Û, rabbit pAb(neat serum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC(FS) |
|
|
¡¡ |
BML |
BML-GA1167-0025 |
Gastrin(peptide, aa 18-34), rabbit pAb(neat serum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ pig | IHC |
|
|
¡¡ |
BML |
BML-GA1170-0100 |
Glial Fibrillary Acidic Protein ¡ÚGFAP¡Û(human)[EB4], mouse mAb, purified |
100ul |
¡ï17,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG2b | BE4 | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-GA1173-0025 |
Glucose-dependent Insulinotropic Peptide ¡ÚGIP¡Û(pig, natural), rabbit pAb(neat serum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | mammalian | IHC |
|
|
¡¡ |
BML |
BML-GA1173-0100 |
Glucose-dependent Insulinotropic Peptide ¡ÚGIP¡Û(pig, natural), rabbit pAb(neat serum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | mammalian | IHC |
|
|
¡¡ |
BML |
BML-GA1176-0025 |
Glucagon Like Peptide 1 ¡ÚGLP 1¡Û(human, aa 1-19), rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | mammalian | IHC |
|
|
¡¡ |
BML |
BML-GA1176-0100 |
Glucagon Like Peptide 1 ¡ÚGLP 1¡Û(human, aa 1-19), rabbit pAb(antiserum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | mammalian | IHC |
|
|
¡¡ |
BML |
BML-GA1178-0250 |
Glucagon Like Peptide 1(7-36)Amide ¡ÚGLP 1(7-36)amide¡Û(human, aa 7-36), rabbit pAb |
250tb |
¡ï32,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ mammalian | RIA |
|
|
¡¡ |
BML |
BML-GA1179-0025 |
Glucagon Like Peptide 2 ¡ÚGLP 2¡Û(human, aa 1-33), rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | mammalian | IHC |
|
|
¡¡ |
BML |
BML-GA1181-0025 |
Glucagon(pig pancreatic, natural), rabbit pAb(neat serum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | mammalian | IHC |
|
|
¡¡ |
BML |
BML-GC3008-0025 |
Glutamic Acid Decarboxylase ¡ÚGAD¡Û(rat, aa 572-585), rabbit pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse¡¢ rat¡¢ cat | IHC¡¢ WB¡¢ ELISA |
|
|
¡¡ |
BML |
BML-GC3008-0100 |
Glutamic Acid Decarboxylase ¡ÚGAD¡Û(rat, aa 572-585), rabbit pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse¡¢ rat¡¢ cat | IHC¡¢ WB¡¢ ELISA |
|
|
¡¡ |
BML |
BML-GC3208-0025 |
Glutamic Acid Decarboxylase ¡ÚGAD¡Û(streptozotocin)[11], mouse mAb, purified |
25ul |
¡ï15,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 11 | human¡¢ mouse¡¢ rat¡¢ monkey | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-GC3208-0100 |
Glutamic Acid Decarboxylase ¡ÚGAD¡Û(streptozotocin)[11], mouse mAb, purified |
100ul |
¡ï44,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | 11 | human¡¢ mouse¡¢ rat¡¢ monkey | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-GP100-0005 |
AR231453 ¡Ú2-Fluoro-4-methanesulfonylphenyl)-{6-[4-(3-isopropyl[1,2,4]oxadiazol-5-yl)piperidin-1-yl]-5-nitropyrimidin-4-yl}amine¡Û |
5mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GP100-0025 |
AR231453 ¡Ú2-Fluoro-4-methanesulfonylphenyl)-{6-[4-(3-isopropyl[1,2,4]oxadiazol-5-yl)piperidin-1-yl]-5-nitropyrimidin-4-yl}amine¡Û |
25mg |
¡ï36,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GP102-0010 |
GW9508 ¡Ú4-{[(3-Phenoxyphenyl)methyl]amino}benzenepropanoic Acid¡Û |
10mg |
¡ï8,000 |
|
885101-89-3 |
|
|
|
¡¡ |
BML |
BML-GP102-0050 |
GW9508 ¡Ú4-{[(3-Phenoxyphenyl)methyl]amino}benzenepropanoic Acid¡Û |
50mg |
¡ï35,000 |
|
885101-89-3 |
|
|
|
¡¡ |
BML |
BML-GP1432-0100 |
Glucagon Peptide(human, aa 51-81), Blocking peptide for Glucagon pAb(Prod. No. BML-GA1181) |
100ug |
¡ï27,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GP1434-0100 |
Glucose Dependent Insulinotropic Peptide ¡ÚGIP¡Û, Blocking peptide for Glucose-dependent insulinotropic peptide pAb(Prod. No. BML-GA1173) |
100ug |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GP1436-0100 |
Glucagon Like Peptide 1(human, aa 1-19)¡ÚGLP 1(1-19)¡Û¡Úpro-Glucagon(92-110)¡Û, Blocking peptide for Glucagon like peptide 1 pAb(Prod. No. BML-GA1176) |
100ug |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GP1437-0100 |
Glucagon Like Peptide 1(human)(1-36)Amide ¡ÚGLP 1(1-36)amide¡Û, Blocking peptide for Glucagon like peptide 1 pAb(Prod. No. BML-GA1176) |
100ug |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GP1438-0100 |
Glucagon Like Peptide 1(human)(7-36)Amide ¡ÚGLP 1(7-36)amide¡Û, Blocking peptide for Glucagon like peptide 1(7-36)amide pAb(Prod. No. BML-GA1178) |
100ug |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GP1439-0100 |
Glucagon Like Peptide 2(human)¡ÚGLP2¡Û |
100ug |
¡ï17,000 |
|
99120-49-7 |
|
|
|
¡¡ |
BML |
BML-GP3009-0050 |
Glutamic Acid Decarboxylase ¡ÚGAD65/67 C-terminal¡Û Peptide, Blocking peptide for Glutamic acid decarboxylase pAb(Prod. No. BML-GC3008) |
50ug |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GP3209-0050 |
Glutamic Acid Decarboxylase ¡ÚGAD 65(4-17)¡Û Peptide(NT), Blocking peptide for Glutamic acid decarboxylase mAb(11)(Prod. No. BML-GC3208) |
50ug |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GP9106-0100 |
Vesicular Glutamate Transporter-2 Peptide ¡ÚVGLUT2(human, aa 533-542)¡Û, Blocking peptide for Vesicular glutamate transporter-2 pAbs(Prod. No. BML-GZ1060 & BML-GZ1065) |
100ug |
¡ï6,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR100-0500 |
Retinoic Acid, all trans |
500mg |
¡ï7,000 |
|
302-79-4 |
|
|
|
¡¡ |
BML |
BML-GR100-5000 |
Retinoic Acid, all trans |
5g |
¡ï40,000 |
|
302-79-4 |
|
|
|
¡¡ |
BML |
BML-GR101-0005 |
9-cis-Retinoic Acid |
5mg |
¡ï13,000 |
|
5300-03-8 |
|
|
|
¡¡ |
BML |
BML-GR101-0025 |
9-cis-Retinoic Acid |
25mg |
¡ï56,000 |
|
5300-03-8 |
|
|
|
¡¡ |
BML |
BML-GR102-0100 |
13-cis-Retinoic Acid |
100mg |
¡ï4,000 |
|
4759-48-2 |
|
|
|
¡¡ |
BML |
BML-GR102-0500 |
13-cis-Retinoic Acid |
500mg |
¡ï20,000 |
|
4759-48-2 |
|
|
|
¡¡ |
BML |
BML-GR103-0005 |
4-Hydroxyphenylretinamide |
5mg |
¡ï13,000 |
|
65646-68-6 |
|
|
|
¡¡ |
BML |
BML-GR103-0025 |
4-Hydroxyphenylretinamide |
25mg |
¡ï54,000 |
|
65646-68-6 |
|
|
|
¡¡ |
BML |
BML-GR104-0005 |
AM-580 ¡Ú4-[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic Acid¡Û |
5mg |
¡ï11,000 |
|
102121-60-8 |
|
|
|
¡¡ |
BML |
BML-GR104-0025 |
AM-580 ¡Ú4-[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic Acid¡Û |
25mg |
¡ï48,000 |
|
102121-60-8 |
|
|
|
¡¡ |
BML |
BML-GR105-0005 |
TTNPB ¡ÚRo 13-7410¡Û¡Ú4-[E-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetra-methyl-2-naphthalenyl)-1-propenyl]benzoic Acid¡Û |
5mg |
¡ï12,000 |
|
71441-28-6 |
|
|
|
¡¡ |
BML |
BML-GR105-0025 |
TTNPB ¡ÚRo 13-7410¡Û¡Ú4-[E-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetra-methyl-2-naphthalenyl)-1-propenyl]benzoic Acid¡Û |
25mg |
¡ï54,000 |
|
71441-28-6 |
|
|
|
¡¡ |
BML |
BML-GR106-0005 |
Methoprene Acid ¡Ú11-Methoxy-3,7,11-trimethyl-2E,4E-dodecadienoic Acid¡Û |
5mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR106-0025 |
Methoprene Acid ¡Ú11-Methoxy-3,7,11-trimethyl-2E,4E-dodecadienoic Acid¡Û |
25mg |
¡ï43,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR107-0010 |
Methoprene ¡Ú11-Methoxy-3,7,11-trimethyl-2E,4E-dodecadienoic Acid, Isopropyl Ester¡Û |
10mg |
¡ï8,000 |
|
40596-69-8 |
|
|
|
¡¡ |
BML |
BML-GR108-0010 |
Acitretin |
10mg |
¡ï14,000 |
|
55079-83-9 |
|
|
|
¡¡ |
BML |
BML-GR110-0005 |
Ro 41-5253 |
5mg |
¡ï10,000 |
|
144092-31-9 |
|
|
|
¡¡ |
BML |
BML-GR110-0025 |
Ro 41-5253 |
25mg |
¡ï41,000 |
|
144092-31-9 |
|
|
|
¡¡ |
BML |
BML-GR111-0020 |
Adapalene ¡Ú6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthoic Acid CD271¡Û |
20mg |
¡ï13,000 |
|
106685-40-9 |
|
|
|
¡¡ |
BML |
BML-GR111-0100 |
Adapalene ¡Ú6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthoic Acid CD271¡Û |
100mg |
¡ï54,000 |
|
106685-40-9 |
|
|
|
¡¡ |
BML |
BML-GR112-0010 |
AC-55469 ¡Ú4'-Octyl-4-biphenylcarboxylic Acid¡Û |
10mg |
¡ï8,000 |
|
59662-49-6 |
|
|
|
¡¡ |
BML |
BML-GR112-0050 |
AC-55469 ¡Ú4'-Octyl-4-biphenylcarboxylic Acid¡Û |
50mg |
¡ï34,000 |
|
59662-49-6 |
|
|
|
¡¡ |
BML |
BML-GR200-0050 |
WY-14643 ¡ÚPirinixic Acid¡Û¡Ú4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic Acid¡Û |
50mg |
¡ï11,000 |
|
50892-23-4 |
|
|
|
¡¡ |
BML |
BML-GR200-0250 |
WY-14643 ¡ÚPirinixic Acid¡Û¡Ú4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic Acid¡Û |
250mg |
¡ï44,000 |
|
50892-23-4 |
|
|
|
¡¡ |
BML |
BML-GR205-0005 |
Ciglitizone ¡ÚU-63287¡Û¡Ú(¡Þ)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione¡Û |
5mg |
¡ï13,000 |
|
74772-77-3 |
|
|
|
¡¡ |
BML |
BML-GR205-0025 |
Ciglitizone ¡ÚU-63287¡Û¡Ú(¡Þ)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione¡Û |
25mg |
¡ï54,000 |
|
74772-77-3 |
|
|
|
¡¡ |
BML |
BML-GR206-0100 |
6-Formylindolo[3,2-b]carbazole ¡ÚFICZ¡Û¡ÚIndolo[3,2-b]carbazole-6-carboxaldehyde-5,11-dihydro¡Û |
100ug |
¡ï11,000 |
|
172922-91-7 |
|
|
|
¡¡ |
BML |
BML-GR207-0050 |
Diindolylmethane |
50mg |
¡ï8,000 |
|
1968-05-4 |
|
|
|
¡¡ |
BML |
BML-GR207-0250 |
Diindolylmethane |
250mg |
¡ï33,000 |
|
1968-05-4 |
|
|
|
¡¡ |
BML |
BML-GR210-0005 |
Troglitazone ¡Ú(¡Þ)-5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]-benzyl]-2,4-thiazolidinedione¡Û |
5mg |
¡ï13,000 |
|
97322-87-7 |
|
|
|
¡¡ |
BML |
BML-GR210-0025 |
Troglitazone ¡Ú(¡Þ)-5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]-benzyl]-2,4-thiazolidinedione¡Û |
25mg |
¡ï54,000 |
|
97322-87-7 |
|
|
|
¡¡ |
BML |
BML-GR211-0001 |
Bezafibrate ¡Ú2-(4-{2-[(4-Chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic Acid¡Û |
1g |
¡ï6,000 |
|
41859-67-0 |
|
|
|
¡¡ |
BML |
BML-GR212-0010 |
T0070907 ¡Ú2-Chloro-5-nitro-N-4-pyridinylbenzamide¡Û |
10mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR212-0050 |
T0070907 ¡Ú2-Chloro-5-nitro-N-4-pyridinylbenzamide¡Û |
50mg |
¡ï43,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR230-0001 |
24(S)-Hydroxycholesterol |
1mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR230-0005 |
24(S)-Hydroxycholesterol |
5mg |
¡ï51,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR231-0001 |
24(S),25-Epoxycholesterol |
1mg |
¡ï24,000 |
|
77058-74-3 |
|
|
|
¡¡ |
BML |
BML-GR231-0005 |
24(S),25-Epoxycholesterol |
5mg |
¡ï110,000 |
|
77058-74-3 |
|
|
|
¡¡ |
BML |
BML-GR233-0005 |
CITCO ¡Ú6-(4-Chlorophenyl)imidazo[2,1-b] [1,3]thiazole-5-carbaldehyde O-3,4-Dichlorobenzyl)Oxime¡Û |
5mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR233-0025 |
CITCO ¡Ú6-(4-Chlorophenyl)imidazo[2,1-b] [1,3]thiazole-5-carbaldehyde O-3,4-Dichlorobenzyl)Oxime¡Û |
25mg |
¡ï32,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR234-0010 |
GW-9662 ¡Ú2-Chloro-5-nitrobenzanilide¡Û |
10mg |
¡ï10,000 |
|
22978-25-2 |
|
|
|
¡¡ |
BML |
BML-GR234-0050 |
GW-9662 ¡Ú2-Chloro-5-nitrobenzanilide¡Û |
50mg |
¡ï40,000 |
|
22978-25-2 |
|
|
|
¡¡ |
BML |
BML-GR235-0005 |
Z-Guggulsterone ¡Ú4,17(20)-Pregnadien-3,16-dione¡Û |
5mg |
¡ï10,000 |
|
39025-23-5 |
|
|
|
¡¡ |
BML |
BML-GR235-0025 |
Z-Guggulsterone ¡Ú4,17(20)-Pregnadien-3,16-dione¡Û |
25mg |
¡ï40,000 |
|
39025-23-5 |
|
|
|
¡¡ |
BML |
BML-GR236-0010 |
Tetradecylthioacetic Acid |
10mg |
¡ï8,000 |
|
2921-20-2 |
|
|
|
¡¡ |
BML |
BML-GR236-0050 |
Tetradecylthioacetic Acid |
50mg |
¡ï31,000 |
|
2921-20-2 |
|
|
|
¡¡ |
BML |
BML-GR239-0010 |
3-Methylcholanthrene |
10mg |
¡ï8,000 |
|
56-49-5 |
|
|
|
¡¡ |
BML |
BML-GR239-0050 |
3-Methylcholanthrene |
50mg |
¡ï32,000 |
|
56-49-5 |
|
|
|
¡¡ |
BML |
BML-GR242-0010 |
SR-12813 ¡ÚTetraethyl 2-(3,5-Di-tert-Butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate¡Û |
10mg |
¡ï10,000 |
|
126411-39-0 |
|
|
|
¡¡ |
BML |
BML-GR242-0050 |
SR-12813 ¡ÚTetraethyl 2-(3,5-Di-tert-Butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate¡Û |
50mg |
¡ï39,000 |
|
126411-39-0 |
|
|
|
¡¡ |
BML |
BML-GR243-0050 |
Raloxifene, HCI ¡Ú[6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperdinyl)ethoxy]phenyl]methanone, HCl¡Û |
50mg |
¡ï9,000 |
|
84449-90-1 |
|
|
|
¡¡ |
BML |
BML-GR243-0500 |
Raloxifene, HCI ¡Ú[6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperdinyl)ethoxy]phenyl]methanone, HCl¡Û |
500mg |
¡ï39,000 |
|
84449-90-1 |
|
|
|
¡¡ |
BML |
BML-GR245-0005 |
TCPOBOP ¡Ú3,3',5,5'-Tetrachloride-bispyridyloxybenzene¡Û |
5mg |
¡ï5,000 |
|
76150-91-9 |
|
|
|
¡¡ |
BML |
BML-GR245-0025 |
TCPOBOP ¡Ú3,3',5,5'-Tetrachloride-bispyridyloxybenzene¡Û |
25mg |
¡ï17,000 |
|
76150-91-9 |
|
|
|
¡¡ |
BML |
BML-GR246-0005 |
6-ECDCA ¡Ú6-Ethylchenodeoxycholic Acid¡Û¡Ú3a,7a-Dihydroxy-6a-ethyl-5B-cholan-24-oic Acid¡Û |
5mg |
¡ï11,000 |
|
459789-99-2 |
|
|
|
¡¡ |
BML |
BML-GR246-0025 |
6-ECDCA ¡Ú6-Ethylchenodeoxycholic Acid¡Û¡Ú3a,7a-Dihydroxy-6a-ethyl-5B-cholan-24-oic Acid¡Û |
25mg |
¡ï46,000 |
|
459789-99-2 |
|
|
|
¡¡ |
BML |
BML-GR247-0010 |
WAY-200070 ¡Ú7-Bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol¡Û |
10mg |
¡ï14,000 |
|
440122-66-7 |
|
|
|
¡¡ |
BML |
BML-GR247-0050 |
WAY-200070 ¡Ú7-Bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol¡Û |
50mg |
¡ï56,000 |
|
440122-66-7 |
|
|
|
·àʪ |
BML |
BML-GR248-0010 |
DPN ¡ÚDiarylpropionitrile¡Û¡Ú2,3-bis(4-Hydroxyphenyl)propionitrile¡Û |
10mg |
¡ï12,000 |
|
1428-67-7 |
|
|
|
·àʪ |
BML |
BML-GR248-0050 |
DPN ¡ÚDiarylpropionitrile¡Û¡Ú2,3-bis(4-Hydroxyphenyl)propionitrile¡Û |
50mg |
¡ï52,000 |
|
1428-67-7 |
|
|
|
¡¡ |
BML |
BML-GR300-0005 |
Actinomycin D(Isolated from Streptomyces parvulus) |
5mg |
¡ï8,000 |
|
50-76-0 |
|
|
|
¡¡ |
BML |
BML-GR302-0010 |
Chromomycin A3(Isolated from Streptomyces griseus) |
10mg |
¡ï27,000 |
|
7059-24-7 |
|
|
|
¡¡ |
BML |
BML-GR303-0100 |
HOE-33342, 3HCl ¡ÚBisbenzimide¡Û¡Ú2¡Ç-(4-Ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2¡Ç,5¡Ç-bi-1H-benzimidazole¡Û |
100mg |
¡ï24,000 |
|
23491-52-3 |
|
|
|
¡¡ |
BML |
BML-GR305-0001 |
Mithramycin A(Isolated from Streptomyces argillaceus) |
1mg |
¡ï6,000 |
|
18378-89-7 |
|
|
|
¡¡ |
BML |
BML-GR307-0100 |
Etoposide ¡Ú4-Desmethylepipodophyllotoxin 9-(4,6-O-Ethylidene)-B-D-glucopyranoside¡Û¡ÚVP-16-213¡Û |
100mg |
¡ï10,000 |
|
33419-42-0 |
|
|
|
¡¡ |
BML |
BML-GR307-0500 |
Etoposide ¡Ú4-Desmethylepipodophyllotoxin 9-(4,6-O-Ethylidene)-B-D-glucopyranoside¡Û¡ÚVP-16-213¡Û |
500mg |
¡ï42,000 |
|
33419-42-0 |
|
|
|
¡¡ |
BML |
BML-GR308-0005 |
B-Lapachone |
5mg |
¡ï9,000 |
|
4707-32-8 |
|
|
|
¡¡ |
BML |
BML-GR308-0025 |
B-Lapachone |
25mg |
¡ï38,000 |
|
4707-32-8 |
|
|
|
¡¡ |
BML |
BML-GR309-0001 |
Trichostatin A ¡Ú[R-(E,E)]-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide¡Û(Isolated from Streptomyces hygroscopicus) |
1mg |
¡ï17,000 |
|
58880-19-6 |
|
|
|
¡¡ |
BML |
BML-GR309-0005 |
Trichostatin A ¡Ú[R-(E,E)]-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide¡Û(Isolated from Streptomyces hygroscopicus) |
5mg |
¡ï59,000 |
|
58880-19-6 |
|
|
|
¡¡ |
BML |
BML-GR311-0002 |
Mitomycin C |
2mg |
¡ï8,000 |
|
50-07-7 |
|
|
|
¡¡ |
BML |
BML-GR311-0010 |
Mitomycin C |
10mg |
¡ï35,000 |
|
50-07-7 |
|
|
|
¡¡ |
BML |
BML-GR312-0050 |
Puromycin, 2HCl ¡Ú3'-[[2-Amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyl-adenosine, 2HCl¡Û¡Ú3'-(a-Amino-p-methoxy-hydrocinnamamido-3'-deoxy-N,N-dimethyl-adenosine, 2HCl¡Û |
50mg |
¡ï7,000 |
|
58-58-2 |
|
|
|
¡¡ |
BML |
BML-GR312-0250 |
Puromycin, 2HCl ¡Ú3'-[[2-Amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyl-adenosine, 2HCl¡Û¡Ú3'-(a-Amino-p-methoxy-hydrocinnamamido-3'-deoxy-N,N-dimethyl-adenosine, 2HCl¡Û |
250mg |
¡ï27,000 |
|
58-58-2 |
|
|
|
¡¡ |
BML |
BML-GR313-0010 |
Lycorine, HCl |
10mg |
¡ï9,000 |
|
476-28-8 |
|
|
|
¡¡ |
BML |
BML-GR313-0050 |
Lycorine, HCl |
50mg |
¡ï39,000 |
|
476-28-8 |
|
|
|
¡¡ |
BML |
BML-GR314-0050 |
Delavirdine ¡Ú1-{3-[(1-Methylethyl)amino]-2-pyridinyl}-4-{5-[(methylsulfonyl)amino-1Hindol-2-yl]carbonyl}piperazine, Mesylate¡Û |
50mg |
¡ï11,000 |
|
147221-93-0 |
|
|
|
¡¡ |
BML |
BML-GR314-0250 |
Delavirdine ¡Ú1-{3-[(1-Methylethyl)amino]-2-pyridinyl}-4-{5-[(methylsulfonyl)amino-1Hindol-2-yl]carbonyl}piperazine, Mesylate¡Û |
250mg |
¡ï43,000 |
|
147221-93-0 |
|
|
|
¡¡ |
BML |
BML-GR315-0010 |
Ellipticine ¡Ú5,11-Dimethyl-6H-pyrido[4,3-b]carbazole¡Û |
10mg |
¡ï12,000 |
|
519-23-3 |
|
|
|
¡¡ |
BML |
BML-GR315-0050 |
Ellipticine ¡Ú5,11-Dimethyl-6H-pyrido[4,3-b]carbazole¡Û |
50mg |
¡ï49,000 |
|
519-23-3 |
|
|
|
¡¡ |
BML |
BML-GR316-0020 |
10-Hydroxycamptothecin |
20mg |
¡ï9,000 |
|
64439-81-2 |
|
|
|
¡¡ |
BML |
BML-GR316-0100 |
10-Hydroxycamptothecin |
100mg |
¡ï39,000 |
|
64439-81-2 |
|
|
|
¡¡ |
BML |
BML-GR317-0005 |
Coumermycin A1 |
5mg |
¡ï17,000 |
|
4434-05-3 |
|
|
|
¡¡ |
BML |
BML-GR317-0025 |
Coumermycin A1 |
25mg |
¡ï68,000 |
|
4434-05-3 |
|
|
|
¡¡ |
BML |
BML-GR319-0005 |
Doxorubicin, HCl ¡ÚDXR, HCl¡Û¡Ú14-Hydroxydaunomycin, HCl¡Û¡ÚAdriamycin, HCl¡Û |
5mg |
¡ï10,000 |
|
25316-40-9 |
|
|
|
¡¡ |
BML |
BML-GR319-0025 |
Doxorubicin, HCl ¡ÚDXR, HCl¡Û¡Ú14-Hydroxydaunomycin, HCl¡Û¡ÚAdriamycin, HCl¡Û |
25mg |
¡ï40,000 |
|
25316-40-9 |
|
|
|
¡¡ |
BML |
BML-GR320-0001 |
HC Toxin ¡ÚCyclo-(D-Pro-L-Ala-D-Ala-L-2-amino-8-oxo-9,10-epoxydecanoic Acid)¡Û |
1mg |
¡ï25,000 |
|
83209-65-8 |
|
|
|
¡¡ |
BML |
BML-GR321-0005 |
BPPA ¡Ú2,6-bis(3-Piperidinopropionamido)anthraquinone Diacetate¡Û |
5mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR321-0025 |
BPPA ¡Ú2,6-bis(3-Piperidinopropionamido)anthraquinone Diacetate¡Û |
25mg |
¡ï31,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR322-0005 |
Monastrol ¡Ú4-(3-Hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-4H-pyrimidin-5-carboxylic Acid Ethyl Ester¡Û |
5mg |
¡ï16,000 |
|
329689-23-8 |
|
|
|
¡¡ |
BML |
BML-GR322-0025 |
Monastrol ¡Ú4-(3-Hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-4H-pyrimidin-5-carboxylic Acid Ethyl Ester¡Û |
25mg |
¡ï63,000 |
|
329689-23-8 |
|
|
|
¡¡ |
BML |
BML-GR323-0100 |
Suberoyl bis-Hydroxamic Acid |
100mg |
¡ï6,000 |
|
38937-66-5 |
|
|
|
¡¡ |
BML |
BML-GR323-0500 |
Suberoyl bis-Hydroxamic Acid |
500mg |
¡ï13,000 |
|
38937-66-5 |
|
|
|
¡¡ |
BML |
BML-GR324-0100 |
DIF-1 ¡Ú1-(3,5-Dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one¡Û |
100ug |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR324-0500 |
DIF-1 ¡Ú1-(3,5-Dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one¡Û |
500ug |
¡ï33,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR325-0005 |
Pifithrin-a ¡ÚPFT-a¡Û¡Ú1-(4-Methylphenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)-benzothiazoyl)ethanone, HBr¡Û |
5mg |
¡ï9,000 |
|
63208-82-2 |
|
|
|
¡¡ |
BML |
BML-GR325-0025 |
Pifithrin-a ¡ÚPFT-a¡Û¡Ú1-(4-Methylphenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)-benzothiazoyl)ethanone, HBr¡Û |
25mg |
¡ï37,000 |
|
63208-82-2 |
|
|
|
¡¡ |
BML |
BML-GR326-0001 |
Scriptaid ¡Ú6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide¡Û |
1mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR326-0005 |
Scriptaid ¡Ú6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide¡Û |
5mg |
¡ï32,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR327-0001 |
Nullscript ¡Ú4-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxybutanamide¡Û |
1mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR327-0005 |
Nullscript ¡Ú4-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxybutanamide¡Û |
5mg |
¡ï32,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR330-0001 |
BML-210 ¡ÚN-(2-Aminophenyl)-N'-phenyloctanediamide¡Û |
1mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR330-0005 |
BML-210 ¡ÚN-(2-Aminophenyl)-N'-phenyloctanediamide¡Û |
5mg |
¡ï34,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR331-0005 |
Splitomicin ¡Ú1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one¡Û |
5mg |
¡ï12,000 |
|
5690-03-9. |
|
|
|
¡¡ |
BML |
BML-GR331-0025 |
Splitomicin ¡Ú1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one¡Û |
25mg |
¡ï51,000 |
|
5690-03-9. |
|
|
|
¡¡ |
BML |
BML-GR332-0001 |
ICRF-193 ¡ÚMeso-4,4'-(2,3-butanediyl)-bis(2,6-piperazinedione)¡Û |
1mg |
¡ï15,000 |
|
21416-68-2 |
|
|
|
¡¡ |
BML |
BML-GR332-0005 |
ICRF-193 ¡ÚMeso-4,4'-(2,3-butanediyl)-bis(2,6-piperazinedione)¡Û |
5mg |
¡ï61,000 |
|
21416-68-2 |
|
|
|
¡¡ |
BML |
BML-GR333-0005 |
PRIMA-1 ¡Ú2,2-bis(Hydroxymethyl)-3-quinuclidinone¡Û¡Ú2,2-bis(Hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one¡Û |
5mg |
¡ï8,000 |
|
5608-24-2 |
|
|
|
¡¡ |
BML |
BML-GR333-0025 |
PRIMA-1 ¡Ú2,2-bis(Hydroxymethyl)-3-quinuclidinone¡Û¡Ú2,2-bis(Hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one¡Û |
25mg |
¡ï32,000 |
|
5608-24-2 |
|
|
|
¡¡ |
BML |
BML-GR334-0001 |
Cyclopamine |
1mg |
¡ï13,000 |
|
4449-51-8 |
|
|
|
¡¡ |
BML |
BML-GR334-0005 |
Cyclopamine |
5mg |
¡ï54,000 |
|
4449-51-8 |
|
|
|
¡¡ |
BML |
BML-GR335-0025 |
Tomatidine, HCl |
25mg |
¡ï6,000 |
|
6192-62-7 |
|
|
|
¡¡ |
BML |
BML-GR336-0005 |
Tanshinone IIA |
5mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR336-0025 |
Tanshinone IIA |
25mg |
¡ï43,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR339-0010 |
Dimethyl-Bisphenol A |
10mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR339-0050 |
Dimethyl-Bisphenol A |
50mg |
¡ï40,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR340-0001 |
Apicidin ¡ÚCyclo(N-O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-8-oxodecanoyl)¡Û¡Úcyclo-L-(2-Amino-8-oxodecanoyl)-L-(N-methoxytryptophan)-L-isoleucyl-D-pipecolinyl¡Û |
1mg |
¡ï8,000 |
|
183506-66-3 |
|
|
|
¡¡ |
BML |
BML-GR340-0005 |
Apicidin ¡ÚCyclo(N-O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-8-oxodecanoyl)¡Û¡Úcyclo-L-(2-Amino-8-oxodecanoyl)-L-(N-methoxytryptophan)-L-isoleucyl-D-pipecolinyl¡Û |
5mg |
¡ï33,000 |
|
183506-66-3 |
|
|
|
¡¡ |
BML |
BML-GR341-0010 |
Amifostine ¡ÚWR-2721¡Û¡ÚS-2[3-Aminopropylamino]ethylphosphothioic Acid¡Û |
10mg |
¡ï8,000 |
|
20537-88-6 |
|
|
|
¡¡ |
BML |
BML-GR341-0050 |
Amifostine ¡ÚWR-2721¡Û¡ÚS-2[3-Aminopropylamino]ethylphosphothioic Acid¡Û |
50mg |
¡ï37,000 |
|
20537-88-6 |
|
|
|
¡¡ |
BML |
BML-GR343-0010 |
Garcinol |
10mg |
¡ï11,000 |
|
78824-30-3 |
|
|
|
¡¡ |
BML |
BML-GR343-0050 |
Garcinol |
50mg |
¡ï44,000 |
|
78824-30-3 |
|
|
|
¡¡ |
BML |
BML-GR344-0010 |
Zebularine ¡Ú1-(B-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one¡Û¡Ú2-Pyrimidone-1-B-D-riboside¡Û |
10mg |
¡ï14,000 |
|
3690-10-6. |
|
|
|
¡¡ |
BML |
BML-GR346-0010 |
BML-266 ¡Ú1,4-Di[(4-hydroxyphenethyl)amino]-9,10-dihydroanthracene-9,10-dione¡Û |
10mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR346-0050 |
BML-266 ¡Ú1,4-Di[(4-hydroxyphenethyl)amino]-9,10-dihydroanthracene-9,10-dione¡Û |
50mg |
¡ï47,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR349-0200 |
Chaetocin |
200ug |
¡ï10,000 |
|
28097-03-2 |
|
|
|
¡¡ |
BML |
BML-GR350-0025 |
ITSA-1 ¡ÚN-(1H-Benzotriazol-1-yl)-2,4-dichlorobenzamide¡Û |
25mg |
¡ï10,000 |
|
200626-61-5 |
|
|
|
¡¡ |
BML |
BML-GR350-0100 |
ITSA-1 ¡ÚN-(1H-Benzotriazol-1-yl)-2,4-dichlorobenzamide¡Û |
100mg |
¡ï29,000 |
|
200626-61-5 |
|
|
|
¡¡ |
BML |
BML-GR357-0005 |
Mirin ¡Ú6-(4-Hydroxyphenyl)-2-thioxo-2,3-dihydro-4(1H)-pyrimidinone¡Û |
5mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR357-0025 |
Mirin ¡Ú6-(4-Hydroxyphenyl)-2-thioxo-2,3-dihydro-4(1H)-pyrimidinone¡Û |
25mg |
¡ï38,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR359-0005 |
BML-278 ¡ÚN-Benzyl-3,5-dicarbethoxy-4-phenyl-1,4-dihydropyridine¡Û |
5mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR359-0025 |
BML-278 ¡ÚN-Benzyl-3,5-dicarbethoxy-4-phenyl-1,4-dihydropyridine¡Û |
25mg |
¡ï37,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR360-0010 |
CP-31398 ¡ÚN¡Ç-{2-[2-(4-Methoxyphenyl)ethenyl]-4-quinazolinyl}-N,N-dimethyl-1,3-propanediamine, 2HCl¡Û |
10mg |
¡ï13,000 |
|
259199-65-0 |
|
|
|
¡¡ |
BML |
BML-GR360-0050 |
CP-31398 ¡ÚN¡Ç-{2-[2-(4-Methoxyphenyl)ethenyl]-4-quinazolinyl}-N,N-dimethyl-1,3-propanediamine, 2HCl¡Û |
50mg |
¡ï52,000 |
|
259199-65-0 |
|
|
|
¡¡ |
BML |
BML-GR361-0001 |
BML-281 ¡ÚN-Hydroxy-7-[5-(4-tertbutoxycarbonylaminophenyl)-3-isoxazolecarboxamido]heptanamide¡Û |
1mg |
¡ï10,000 |
|
1045792-66-2 |
|
|
|
¡¡ |
BML |
BML-GR361-0005 |
BML-281 ¡ÚN-Hydroxy-7-[5-(4-tertbutoxycarbonylaminophenyl)-3-isoxazolecarboxamido]heptanamide¡Û |
5mg |
¡ï42,000 |
|
1045792-66-2 |
|
|
|
¡¡ |
BML |
BML-GR362-0100 |
Tubacin ¡ÚN-(4-{(2R,4R,6S)-4-{[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanyl]methyl}-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl}phenyl)-N'-hydroxyoctanediamide¡Û |
100ug |
¡ï11,000 |
|
537049-40-4 |
|
|
|
¡¡ |
BML |
BML-GR362-0500 |
Tubacin ¡ÚN-(4-{(2R,4R,6S)-4-{[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanyl]methyl}-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl}phenyl)-N'-hydroxyoctanediamide¡Û |
500ug |
¡ï48,000 |
|
537049-40-4 |
|
|
|
¡¡ |
BML |
BML-GR363-0100 |
Niltubacin ¡Ú7-(4-((2R,4R,6S)-4-((4,5-dipenyloxazol-2-ylthio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenylcarbamoyl)heptanoic Acid¡Û |
100ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GR363-0500 |
Niltubacin ¡Ú7-(4-((2R,4R,6S)-4-((4,5-dipenyloxazol-2-ylthio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenylcarbamoyl)heptanoic Acid¡Û |
500ug |
¡ï36,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-GZ1031-0025 |
¦Ã-Aminobutyric Acid ¡ÚGABA¡Û(GABA glutaraldehyde-haemocyanin complex), rat pAb |
25ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rat | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-GZ1060-0025 |
Vesicular Glutamate Transporter-2 ¡ÚVGLUT2¡Û(human, aa 533-542), rabbit pAb, purified |
25ul |
¡ï36,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse¡¢ rat | IHC |
|
|
¡¡ |
BML |
BML-GZ1065-0025 |
Vesicular Glutamate Transporter-2 ¡ÚVGLUT2¡Û(human, aa 533-542), guinea pig pAb, purified |
25ul |
¡ï36,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
guinea pig | - | human¡¢ mouse¡¢ rat | IHC |
|
|
¡¡ |
BML |
BML-GZ1081-0025 |
¦Ã-Aminobutyric Acid ¡ÚGABA¡Û(GABA glutaraldehyde-haemocyanin complex), guinea pig pAb |
25ul |
¡ï36,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
guinea pig | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-GZ1092-0025 |
Gonadotropin Releasing Hormone ¡ÚGnRH¡Û [BML], mouse mAb, purified |
25ul |
¡ï43,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG | BML | human¡¢ rat¡¢ guinea pig¡¢ bovine | IHC |
|
|
¡¡ |
BML |
BML-GZ1110-0025 |
Gonadotropin Releasing Hormone ¡ÚGnRH¡Û, guinea pig pAb, purified |
25ul |
¡ï27,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
guinea pig | - | human¡¢ mouse¡¢ rat¡¢ bovine | IHC |
|
|
¡¡ |
BML |
BML-H005-0050 |
5(S)-Hydroxyeicosa-6E,8Z,11Z,14Z-tetraenoic Acid ¡Ú5(S)-HETE¡Û |
50ug |
¡ï28,000 |
|
70608-72-9 |
|
|
|
¡¡ |
BML |
BML-H008-0050 |
8(S)-Hydroxyeicosa-5Z,9E,11Z,14Z-tetraenoic Acid ¡Ú8(S)-HETE¡Û |
50ug |
¡ï29,000 |
|
98462-03-4 |
|
|
|
¡¡ |
BML |
BML-H009-0050 |
9(S)-Hydroxyeicosa-5Z,7E,11Z,14Z-tetraenoic Acid ¡Ú9(S)-HETE¡Û |
50ug |
¡ï33,000 |
|
79495-85-5 |
|
|
|
¡¡ |
BML |
BML-H015-0050 |
15(S)-Hydroxyeicosa-5Z,8Z,11Z,13E-tetraenoic Acid ¡Ú15(S)-HETE¡Û |
50ug |
¡ï9,000 |
|
54845-95-3 |
|
|
|
¡¡ |
BML |
BML-H015-1000 |
15(S)-Hydroxyeicosa-5Z,8Z,11Z,13E-tetraenoic Acid ¡Ú15(S)-HETE¡Û |
1mg |
¡ï108,000 |
|
54845-95-3 |
|
|
|
¡¡ |
BML |
BML-H112-0050 |
12(R)-Hydroxyeicosa-5Z,8Z,10E,14Z-tetraenoic Acid ¡Ú12-(R)-HETE¡Û |
50ug |
¡ï29,000 |
|
82337-46-0 |
|
|
|
¡¡ |
BML |
BML-H112-1000 |
12(R)-Hydroxyeicosa-5Z,8Z,10E,14Z-tetraenoic Acid ¡Ú12-(R)-HETE¡Û |
1mg |
¡ï357,000 |
|
82337-46-0 |
|
|
|
¡¡ |
BML |
BML-H215-0050 |
15(S)-Hydroxyeicosa-11Z,13E-dienoic Acid ¡Ú15(S)-HEDE¡Û |
50ug |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-H305-0050 |
(¡Þ)-5-Hydroxyeicosa-6E,8Z,11Z-trienoic Acid ¡Ú(¡Þ)5-HETrE¡Û |
50ug |
¡ï11,000 |
|
88053-46-7 |
|
|
|
¡¡ |
BML |
BML-H312-0050 |
Tetranor-12(R)-HETE ¡Ú8(R)-Hydroxy-4Z, 6E, 10Z-hexadecatrienoic Acid¡Û |
50ug |
¡ï29,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-H515-0050 |
15(S)-Hydroxyeicosa-5Z,8Z,11Z,13E,17Z-pentaenoic Acid ¡Ú15(S)-HEPE¡Û |
50ug |
¡ï10,000 |
|
86282-92-0 |
|
|
|
¡¡ |
BML |
BML-HA004-0001 |
(¡Þ)-4-Hydroxynon-2-enal |
1mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HA004-0010 |
(¡Þ)-4-Hydroxynon-2-enal |
10mg |
¡ï71,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HA005-0020 |
Decadienal ¡Ú2(E),4(E)-Decadienal¡Û |
20mg |
¡ï8,000 |
|
25152-84-5 |
|
|
|
¡¡ |
BML |
BML-HC3001-0025 |
Heme Oxygenase 1 ¡ÚHO 1¡Û(human, aa 12-25), rabbit pAb, purified |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-HC3001-0100 |
Heme Oxygenase 1 ¡ÚHO 1¡Û(human, aa 12-25), rabbit pAb, purified |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-HC3002-0025 |
Heme Oxygenase 2 ¡ÚHO 2¡Û(human, 246-264 ), rabbit pAb, purified |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-HC3002-0100 |
Heme Oxygenase 2 ¡ÚHO 2¡Û(human, 246-264 ), rabbit pAb, purified |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-HE008-0050 |
Hepoxilin A3 ¡Ú8,11(12)-HEpETrE¡Û |
50ug |
¡ï31,000 |
|
85589-24-8 |
|
|
|
¡¡ |
BML |
BML-HE008-1000 |
Hepoxilin A3 ¡Ú8,11(12)-HEpETrE¡Û |
1mg |
¡ï403,000 |
|
85589-24-8 |
|
|
|
¡¡ |
BML |
BML-HE010-0050 |
Hepoxilin B3 ¡Ú10,11(12)-HEpETrE¡Û |
50ug |
¡ï31,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HE010-1000 |
Hepoxilin B3 ¡Ú10,11(12)-HEpETrE¡Û |
1mg |
¡ï391,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HL005-0050 |
(¡Þ)-5-HETE Lactone |
50ug |
¡ï13,000 |
|
73279-37-5 |
|
|
|
¡¡ |
BML |
BML-HL005-1000 |
(¡Þ)-5-HETE Lactone |
1mg |
¡ï149,000 |
|
73279-37-5 |
|
|
|
¡¡ |
BML |
BML-HLB004-0050 |
20-Hydroxy-Leukotriene B4 ¡Ú20-Hydroxy-LTB4¡Û |
50ug |
¡ï44,000 |
|
79516-82-8 |
|
|
|
¡¡ |
BML |
BML-HLB004-1000 |
20-Hydroxy-Leukotriene B4 ¡Ú20-Hydroxy-LTB4¡Û |
1mg |
¡ï521,000 |
|
79516-82-8 |
|
|
|
¡¡ |
BML |
BML-HO013-0050 |
13(S)-Hydroxyoctadeca-9Z,11E-dienoic Acid ¡Ú13(S)-HODE¡Û |
50ug |
¡ï9,000 |
|
29623-28-7 |
|
|
|
¡¡ |
BML |
BML-HO013-1000 |
13(S)-Hydroxyoctadeca-9Z,11E-dienoic Acid ¡Ú13(S)-HODE¡Û |
1mg |
¡ï105,000 |
|
29623-28-7 |
|
|
|
¡¡ |
BML |
BML-HO309-0050 |
(¡Þ)9-Hydroxyoctadeca-10E,12Z-dienoic Acid ¡Ú(¡Þ)9-HODE¡Û |
50ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HO309-1000 |
(¡Þ)9-Hydroxyoctadeca-10E,12Z-dienoic Acid ¡Ú(¡Þ)9-HODE¡Û |
1mg |
¡ï108,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HO313-0050 |
13(S)-Hydroxyoctadeca-6Z,9Z,11E-trienoic Acid ¡Ú13(S)-HOTE¡Û |
50ug |
¡ï11,000 |
|
74784-20-6 |
|
|
|
¡¡ |
BML |
BML-HO313-1000 |
13(S)-Hydroxyoctadeca-6Z,9Z,11E-trienoic Acid ¡Ú13(S)-HOTE¡Û |
1mg |
¡ï126,000 |
|
74784-20-6 |
|
|
|
¡¡ |
BML |
BML-HO409-0050 |
9(S)-Hydroxyoctadeca-10E,12Z-dienoic Acid ¡Ú9(S)-HODE¡Û |
50ug |
¡ï9,000 |
|
73543-67-6 |
|
|
|
¡¡ |
BML |
BML-HO409-1000 |
9(S)-Hydroxyoctadeca-10E,12Z-dienoic Acid ¡Ú9(S)-HODE¡Û |
1mg |
¡ï100,000 |
|
73543-67-6 |
|
|
|
¡¡ |
BML |
BML-HP005-0050 |
5(S)-Hydroperoxyeicosa-6E,8Z,11Z,14Z-tetraenoic Acid(HPETE)¡Ú5(S)-HPETE¡Û |
50ug |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HP005-1000 |
5(S)-Hydroperoxyeicosa-6E,8Z,11Z,14Z-tetraenoic Acid(HPETE)¡Ú5(S)-HPETE¡Û |
1mg |
¡ï253,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HP012-0050 |
12(S)-Hydroperoxyeicosa-5Z,8Z,10E,14Z-tetraenoic Acid(HPETE)¡Ú12(S)-HPETE¡Û |
50ug |
¡ï33,000 |
|
71774-10-2 |
|
|
|
¡¡ |
BML |
BML-HP013-0050 |
13(S)-Hydroperoxyoctadeca-9Z,11E-dienoic Acid ¡Ú13(S)-HPODE¡Û |
50ug |
¡ï9,000 |
|
33964-75-9 |
|
|
|
¡¡ |
BML |
BML-HP013-1000 |
13(S)-Hydroperoxyoctadeca-9Z,11E-dienoic Acid ¡Ú13(S)-HPODE¡Û |
1mg |
¡ï105,000 |
|
33964-75-9 |
|
|
|
¡¡ |
BML |
BML-HP015-0050 |
15(S)-Hydroperoxyeicosa-5Z,8Z,11Z,13E-tetraenoic Acid(HPETE)¡Ú15(S)-HPETE¡Û |
50ug |
¡ï9,000 |
|
70981-96-3 |
|
|
|
¡¡ |
BML |
BML-HP015-1000 |
15(S)-Hydroperoxyeicosa-5Z,8Z,11Z,13E-tetraenoic Acid(HPETE)¡Ú15(S)-HPETE¡Û |
1mg |
¡ï105,000 |
|
70981-96-3 |
|
|
|
¡¡ |
BML |
BML-HP019-0050 |
9(S)-Hydroperoxyoctadeca-10E,12Z-dienoic Acid ¡Ú9(S)-HPODE¡Û |
50ug |
¡ï11,000 |
|
29774-12-7 |
|
|
|
¡¡ |
BML |
BML-HP125-0050 |
15(S)-Hydroperoxyeicosa-11Z,13E-dienoic Acid ¡Ú15(S)-HPEDE¡Û |
50ug |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HP125-1000 |
15(S)-Hydroperoxyeicosa-11Z,13E-dienoic Acid ¡Ú15(S)-HPEDE¡Û |
1mg |
¡ï133,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HP515-0050 |
15(S)-Hydroperoxyeicosa-5Z,8Z,11Z,13E,17Z-pentaenoic Acid ¡Ú15(S)-HPEPE¡Û |
50ug |
¡ï9,000 |
|
125992-60-1 |
|
|
|
¡¡ |
BML |
BML-HP9301-0100 |
Heme Oxygenase 1 Peptide, Blocking Peptide for Heme Oxygenase 1 pAb(Prod. No. BML-HC3001) |
100ug |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HP9302-0100 |
Heme Oxygenase 2 Peptide, Blocking Peptide for Heme Oxygenase 2 pAb(Prod. No. BML-HC3002) |
100ug |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HR005-0050 |
(¡Þ)5-Hydroxyeicosa-6E,8Z,11Z,14Z-tetraenoic Acid ¡Ú(¡Þ)-5-HETE¡Û |
50ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HR005-1000 |
(¡Þ)5-Hydroxyeicosa-6E,8Z,11Z,14Z-tetraenoic Acid ¡Ú(¡Þ)-5-HETE¡Û |
1mg |
¡ï105,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HR012-0050 |
(¡Þ)12-Hydroxyeicosa-5Z,8Z,10E,14Z-tetraenoic Acid(HETE)¡Ú(¡Þ)-12-HETE¡Û |
50ug |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HR013-0050 |
(¡Þ)13-Hydroxyoctadeca-9Z,11E-dienoic Acid ¡Ú(¡Þ)13-HODE¡Û |
50ug |
¡ï9,000 |
|
73804-64-5 |
|
|
|
¡¡ |
BML |
BML-HR013-1000 |
(¡Þ)13-Hydroxyoctadeca-9Z,11E-dienoic Acid ¡Ú(¡Þ)13-HODE¡Û |
1mg |
¡ï100,000 |
|
73804-64-5 |
|
|
|
¡¡ |
BML |
BML-HR505-0050 |
(¡Þ)5-Hydroxyeicosa-6E,8Z,11Z,14Z,17Z-pentaenoic Acid ¡Ú(¡Þ)13-HODE¡Û |
50ug |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HRT012-0050 |
12(S)-Hydroxyheptadeca-5Z,8E,10E-trienoic Acid ¡Ú12(S)-HHT¡Û |
50ug |
¡ï30,000 |
|
54397-84-1 |
|
|
|
¡¡ |
BML |
BML-HRT012-1000 |
12(S)-Hydroxyheptadeca-5Z,8E,10E-trienoic Acid ¡Ú12(S)-HHT¡Û |
1mg |
¡ï368,000 |
|
54397-84-1 |
|
|
|
¡¡ |
BML |
BML-HW8600-0001 |
Fraction I(HeLa)¡ÚFrI¡Û(Isolated from HeLa S3 cell lysate) |
1mg |
¡ï14,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-HW8605-0001 |
Fraction II(HeLa)¡ÚFrII¡Û(Isolated from HeLa S3 cell lysate) |
1mg |
¡ï14,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-IG6060-0100 |
B1-Integrin ¡ÚCD29¡Û(human fibroblasts)[DF5], mouse mAb, purified(specificity: human) |
100ul |
¡ï23,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | DF5 | human | WB¡¢ ICC |
|
|
¡¡ |
BML |
BML-IG6061-0100 |
B1-Integrin ¡ÚCD29¡Û(human fibroblasts)[DF7], mouse mAb, purified(specificity: human) |
100ul |
¡ï23,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | DF7 | human | WB¡¢ ICC |
|
|
¡¡ |
BML |
BML-IG6065-0100 |
aIIb Integrin ¡ÚCD41b¡Û(human platelets)[DB10], mouse mAb(CA3), purified(specificity: human) |
100ul |
¡ï23,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | DB10 | human | WB¡¢ ICC |
|
|
¡¡ |
BML |
BML-IM100-0010 |
Cycloheximide-N-ethylethanoate |
10mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-IM100-0050 |
Cycloheximide-N-ethylethanoate |
50mg |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-IM101-0020 |
Mycophenolate Mofetil(Isolated from Penicillium brevicompactum) |
20mg |
¡ï8,000 |
|
128794-94-5 |
|
|
|
¡¡ |
BML |
BML-IM101-0100 |
Mycophenolate Mofetil(Isolated from Penicillium brevicompactum) |
100mg |
¡ï24,000 |
|
128794-94-5 |
|
|
|
¡¡ |
BML |
BML-J100-0001 |
Norfentanyl ¡ÚN-Phenyl-N-(4-piperidinyl)propanamide¡Û |
1mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-J100-0010 |
Norfentanyl ¡ÚN-Phenyl-N-(4-piperidinyl)propanamide¡Û |
10mg |
¡ï69,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-J110-0001 |
Despropionylfentanyl ¡Ú1-Phenethyl-N-phenylpiperidin-4-amine¡Û |
1mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-J110-0010 |
Despropionylfentanyl ¡Ú1-Phenethyl-N-phenylpiperidin-4-amine¡Û |
10mg |
¡ï69,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-J115-0001 |
Despropionyl-3-methylfentanyl |
1mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-J115-0010 |
Despropionyl-3-methylfentanyl |
10mg |
¡ï102,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-J116-0005 |
Imipramine N-Oxide |
5mg |
¡ï11,000 |
|
6829-98-7 |
|
|
|
¡¡ |
BML |
BML-J116-0025 |
Imipramine N-Oxide |
25mg |
¡ï44,000 |
|
6829-98-7 |
|
|
|
¡¡ |
BML |
BML-J120-0005 |
(S)-Mephenytoin ¡Ú(S)-5-Ethyl-3-methyl-5-phenylhydantoin¡Û |
5mg |
¡ï9,000 |
|
70989-04-7 |
|
|
|
¡¡ |
BML |
BML-J120-0025 |
(S)-Mephenytoin ¡Ú(S)-5-Ethyl-3-methyl-5-phenylhydantoin¡Û |
25mg |
¡ï38,000 |
|
70989-04-7 |
|
|
|
¡¡ |
BML |
BML-J125-0005 |
a-Hydroxy-Alprazolam ¡Ú4H-s-Triazolo[4,3-a][1,4]benzodiazepine-1-methanol¡Û |
5mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-J126-0005 |
4-Hydroxy-Alprazolam ¡Ú8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepin-4-ol¡Û |
5mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-J130-0001 |
a-Hydroxy-Triazolam ¡Ú8-Chloro-6-(o-chlorophenyl)-4H-s-Triazolo[4,3-a][1,4]-benzodiazepine-1-methanol¡Û |
1mg |
¡ï16,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-J131-0005 |
4-Hydroxy-Triazolam ¡Ú8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepin-4-ol¡Û |
5mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-J135-0010 |
PNU-88822 ¡Ú2-[4-(5-Hydroxy-1H-indol-2-ylcarbonyl)-1-piperazinyl]-N-(1-methylethyl)-3-pyridineamine¡Û |
10mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-J135-0050 |
PNU-88822 ¡Ú2-[4-(5-Hydroxy-1H-indol-2-ylcarbonyl)-1-piperazinyl]-N-(1-methylethyl)-3-pyridineamine¡Û |
50mg |
¡ï23,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-JW8695-0010 |
c-Jun(human)(recombinant) with His-Tag |
10ug |
¡ï45,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-K005-0050 |
5-Ketoeicosa-6E,8Z,11Z,14E-tetraenoic Acid ¡Ú5-KETE¡Û |
50ug |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-K015-0050 |
15-Ketoeicosa-6E,8Z,11Z,13E-tetraenoic Acid ¡Ú15-KETE¡Û¡Ú15-oxo-ETE¡Û |
50ug |
¡ï20,000 |
|
81416-72-0 |
|
|
|
¡¡ |
BML |
BML-K015-1000 |
15-Ketoeicosa-6E,8Z,11Z,13E-tetraenoic Acid ¡Ú15-KETE¡Û¡Ú15-oxo-ETE¡Û |
1mg |
¡ï238,000 |
|
81416-72-0 |
|
|
|
¡¡ |
BML |
BML-KC120-0001 |
Glyburide ¡ÚGlibenclamide¡Û |
1g |
¡ï4,000 |
|
10238-21-8 |
|
|
|
¡¡ |
BML |
BML-KC120-0005 |
Glyburide ¡ÚGlibenclamide¡Û |
5g |
¡ï6,000 |
|
10238-21-8 |
|
|
|
¡¡ |
BML |
BML-KC125-0100 |
Minoxidil ¡ÚU-10858¡Û |
100mg |
¡ï8,000 |
|
38304-91-5 |
|
|
|
¡¡ |
BML |
BML-KC125-0500 |
Minoxidil ¡ÚU-10858¡Û |
500mg |
¡ï36,000 |
|
38304-91-5 |
|
|
|
¡¡ |
BML |
BML-KC127-0005 |
NS-1619 ¡Ú1,3-Dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-trifluoromethyl-2Hbenzimidazol-2-one¡Û |
5mg |
¡ï15,000 |
|
153587-01-0 |
|
|
|
¡¡ |
BML |
BML-KC130-0005 |
Minoxidil Sulfate ¡ÚU-58838¡Û |
5mg |
¡ï10,000 |
|
83701-22-8 |
|
|
|
¡¡ |
BML |
BML-KC130-0025 |
Minoxidil Sulfate ¡ÚU-58838¡Û |
25mg |
¡ï40,000 |
|
83701-22-8 |
|
|
|
·àʪ |
BML |
BML-KC131-0020 |
PCO 400 ¡Ú(-)-(3S,4R)-3,4-Dihydro-3-hydroxy-2,2-dimethyl-4-(3-oxocyclopent-1-enyl-1-oxy)-2H-1-benzpyran-6-carbonitrile¡Û |
20mg |
¡ï6,000 |
|
121055-10-5 |
|
|
|
·àʪ |
BML |
BML-KC131-0100 |
PCO 400 ¡Ú(-)-(3S,4R)-3,4-Dihydro-3-hydroxy-2,2-dimethyl-4-(3-oxocyclopent-1-enyl-1-oxy)-2H-1-benzpyran-6-carbonitrile¡Û |
100mg |
¡ï27,000 |
|
121055-10-5 |
|
|
|
¡¡ |
BML |
BML-KC140-0025 |
Valinomycin(Isolated from Streptomyces fulvissimus) |
25mg |
¡ï9,000 |
|
2001-95-8 |
|
|
|
¡¡ |
BML |
BML-KC141-0100 |
5-Hydroxydecanoate, Na salt |
100mg |
¡ï9,000 |
|
624-00-0 |
|
|
|
¡¡ |
BML |
BML-KC141-0500 |
5-Hydroxydecanoate, Na salt |
500mg |
¡ï36,000 |
|
624-00-0 |
|
|
|
¡¡ |
BML |
BML-KC152-0050 |
Nicorandil ¡ÚN-[2-(Nitrooxy)ethyl]-3-pyridinecarboxamide¡Û |
50mg |
¡ï6,000 |
|
65141-46-0 |
|
|
|
¡¡ |
BML |
BML-KC155-0005 |
Paxilline |
5mg |
¡ï11,000 |
|
57186-25-1 |
|
|
|
¡¡ |
BML |
BML-KC155-0025 |
Paxilline |
25mg |
¡ï53,000 |
|
57186-25-1 |
|
|
|
¡¡ |
BML |
BML-KC156-0002 |
Paxillinol |
2mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KC157-0001 |
Penitrem A ¡ÚTremortin A¡Û¡ÚNSC 354845¡Û |
1mg |
¡ï6,000 |
|
12627-35-9 |
|
|
|
¡¡ |
BML |
BML-KC157-0005 |
Penitrem A ¡ÚTremortin A¡Û¡ÚNSC 354845¡Û |
5mg |
¡ï19,000 |
|
12627-35-9 |
|
|
|
¡¡ |
BML |
BML-KC158-0005 |
E-4031, 2HCl , 2H2O ¡Ú4¡Ç-[[1-[2-(6-Methyl-2-pyridyl)ethyl]-4-piperidinyl]carbonyl]methanesulfonanilide, 2HCl, 2H2O¡Û |
5mg |
¡ï20,000 |
|
113558-89-7 |
|
|
|
¡¡ |
BML |
BML-KC158-0025 |
E-4031, 2HCl, 2H2O ¡Ú4¡Ç-[[1-[2-(6-Methyl-2-pyridyl)ethyl]-4-piperidinyl]carbonyl]methanesulfonanilide, 2HCl, 2H2O¡Û |
25mg |
¡ï81,000 |
|
113558-89-7 |
|
|
|
¡¡ |
BML |
BML-KC159-0005 |
U-37883A ¡ÚN-(1-Adamantyl)-N'-cyclohexyl-4-morpholinecarboxamidine, HCl¡Û |
5mg |
¡ï9,000 |
|
57568-80-6 |
|
|
|
¡¡ |
BML |
BML-KC159-0025 |
U-37883A ¡ÚN-(1-Adamantyl)-N'-cyclohexyl-4-morpholinecarboxamidine, HCl¡Û |
25mg |
¡ï39,000 |
|
57568-80-6 |
|
|
|
¡¡ |
BML |
BML-KC160-0050 |
Gabapentin-Lactam ¡Ú3-Azaspiro[4,5]decan-2-one¡Û |
50mg |
¡ï8,000 |
|
64744-50-9 |
|
|
|
¡¡ |
BML |
BML-KC160-0250 |
Gabapentin-Lactam ¡Ú3-Azaspiro[4,5]decan-2-one¡Û |
250mg |
¡ï25,000 |
|
64744-50-9 |
|
|
|
¡¡ |
BML |
BML-KC161-0005 |
TRAM-34 ¡Ú1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole¡Û |
5mg |
¡ï11,000 |
|
289905-88-0 |
|
|
|
¡¡ |
BML |
BML-KC161-0025 |
TRAM-34 ¡Ú1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole¡Û |
25mg |
¡ï47,000 |
|
289905-88-0 |
|
|
|
¡¡ |
BML |
BML-KC163-0140 |
Dendrotoxin-I(Dendroaspis p. polylepis), purified |
140ug |
¡ï58,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KC164 |
Dendrotoxin-K(Dendroaspis p. polylepis), purified |
70ug |
¡ï58,000 |
|
119128-61-9 |
|
|
|
¡¡ |
BML |
BML-KC166-0010 |
Margatoxin ¡ÚMgTx¡Û(recombinant) |
10ug |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KC167-0140 |
a-Dendrotoxin |
140ug |
¡ï58,000 |
|
74504-53-3 |
|
|
|
¡¡ |
BML |
BML-KC168-0100 |
Charybdotoxin(recombinant) |
100ug |
¡ï44,000 |
|
95751-30-7 |
|
|
|
¡¡ |
BML |
BML-KC169-0010 |
NS-1643 ¡ÚN,N¡Ç-Bis[2-hydroxy-5-(trifluoromethyl)phenyl] Urea¡Û |
10mg |
¡ï11,000 |
|
448895-37-2 |
|
|
|
¡¡ |
BML |
BML-KC169-0050 |
NS-1643 ¡ÚN,N¡Ç-Bis[2-hydroxy-5-(trifluoromethyl)phenyl] Urea¡Û |
50mg |
¡ï46,000 |
|
448895-37-2 |
|
|
|
¡¡ |
BML |
BML-KC170-0010 |
ZM-226600 ¡ÚN-(4-Phenylsulfonylphenyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide¡Û |
10mg |
¡ï11,000 |
|
147695-92-9 |
|
|
|
¡¡ |
BML |
BML-KC170-0050 |
ZM-226600 ¡ÚN-(4-Phenylsulfonylphenyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide¡Û |
50mg |
¡ï45,000 |
|
147695-92-9 |
|
|
|
¡¡ |
BML |
BML-KC171-0010 |
Iberiotoxin(synthetic) |
10ug |
¡ï21,000 |
|
|
|
|
|
¡¡ |
BML |
BML-KI100-0001 |
Desalting Column and Resin |
Set |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI101-0001 |
96 Well Plates |
Pack |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI102-0001 |
1mL Phosphate Standard(800uM)for BIOMOL GREEN ¡ÚPhosphate Standard¡Û |
1mL |
¡ï5,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI103-0001 |
Protease Inhibitor Cocktail |
Set |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI104-0050 |
Fluor-de-Lys Deacetylase Substrate ¡ÚDeacetylase Substrate¡Û |
50ul |
¡ï19,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI105 |
Fluor-de-Lys Developer I Concentrate ¡ÚDeveloper I Concentrate¡Û |
300ul |
¡ï18,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI106-0001 |
p-Nitroaniline ¡ÚpNA¡Û Standard |
1mL |
¡ï4,000 |
|
100-01-6 |
|
|
|
¡¡ |
BML |
BML-KI107-0001 |
AMC ¡Ú7-Amino-4-methylcoumarin¡Û Standard |
1mL |
¡ï4,000 |
|
26093-31-2 |
|
|
|
¡¡ |
BML |
BML-KI108-0001 |
AFC ¡Ú7-Amino-4-trifluoromethylcoumarin¡Û Standard |
1mg |
¡ï4,000 |
|
53518-15-3 |
|
|
|
¡¡ |
BML |
BML-KI110-0001 |
1/2 Volume White Microplates ¡ÚMicroplates(1/2 Volume White)¡Û(5 plates) |
1set |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI111-0020 |
Caspase Assay Buffer |
20ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI115-0020 |
MMP-3 Colorimetric Assay Buffer ¡ÚMatrix Metalloproteinase-3 Colorimetric Assay Buffer¡Û¡ÚStromelysin-1 Colorimetric Assay Buffer¡Û¡ÚTransin Colorimetric Assay Buffer¡Û |
20ml |
¡ï3,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI117-0030 |
Caspase Cell Lysis Buffer |
30ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI120-0020 |
Proteasome 20S Assay Buffer |
20ml |
¡ï3,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI127-0020 |
MMP-3 Fluorescent Assay Buffer ¡ÚMatrix Metalloproteinase-3 Fluorescent Assay Buffer¡Û¡ÚStromelysin-1 Fluorescent Assay Buffer¡Û¡ÚTransin Fluorescent Assay Buffer¡Û |
20ml |
¡ï3,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI128-0020 |
Calcineurin Assay Buffer(2x) |
20ml |
¡ï3,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI131-0020 |
PTP1B 2x Assay Buffer ¡ÚProtein Tyrosine Phosphatase 2x Assay Buffer¡Û |
20ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI134-0020 |
Caspase-14 Assay Buffer |
20ml |
¡ï3,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI136-0001 |
EGTA(2x)Buffer |
1mL |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI137-0500 |
Nuclear Extract for Colorimetric HDAC Assays |
500ul |
¡ï19,000 |
|
|
|
|
|
¡¡ |
BML |
BML-KI138-0050 |
Color-de-Lys Deacetylase Substrate ¡ÚDeacetylase Substrate¡Û |
50ul |
¡ï16,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI139 |
Color-de-Lys Developer |
300ul |
¡ï16,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI140-0100 |
Nuclear Extract from HeLa cells |
100ul |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI141-0030 |
Color-de-Lys Deacetylated Standard ¡ÚDeacetylated Standard¡Û |
30ul |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI142-0030 |
Fluor-de-Lys Deacetylated Standard ¡ÚDeacetylated Standard¡Û |
30ul |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI143-0020 |
HDAC Assay Buffer ¡ÚHistone Deacetylase Assay Buffer¡Û |
20ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI144-0001 |
AMC ¡Ú7-Amino-4-methylcoumarin¡Û Calibration Standard |
1mg |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI145-0001 |
pNA ¡Úp-Nitroaniline¡Û Calibration Standard |
1mg |
¡ï3,000 |
|
7300-59-6 |
|
|
|
¡¡ |
BML |
BML-KI164-0001 |
SR-VAD-fluoromethylketone |
1vial |
¡ï22,000 |
|
|
|
|
|
¡¡ |
BML |
BML-KI170-0012 |
5X Wash Buffer(from the AK120 Kit) |
12ml |
¡ï3,000 |
|
|
|
|
|
¡¡ |
BML |
BML-KI171-0001 |
Sterile 96-well Microplate ¡Ú96 Well Microplate, Sterile-¡Û |
96wells |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI173-0020 |
MMP-1 Colorimetric Assay Buffer ¡ÚMatrix Metalloproteinase-1 Colorimetric Assay Buffer¡Û |
20ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI174-0005 |
Fluor-de-Lys -H4-AcK16 Deacetylase Substrate ¡ÚH4-AcK16 Deacetylase Substrate¡Û |
0.5umol |
¡ï22,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI175-0020 |
MMP-1 Assay Buffer ¡ÚMatrix Metalloproteinase-1Assay Buffer¡Û |
20ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI176-1250 |
Fluor-de-Lys Developer II Concentrate ¡ÚDeveloper II Concentrate¡Û |
1.25mL |
¡ï24,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI177-0005 |
Fluor-de-Lys -SIRT1 Deacetylase Substrate ¡ÚSIRT1 Deacetylase Substrate¡Û |
0.5umol |
¡ï23,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI178-0005 |
Fluor-de-Lys -HDAC8 Deacetylase Substrate ¡ÚHDAC8 Deacetylase Substrate¡Û |
0.5umol |
¡ï22,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI179-0005 |
Fluor-de-Lys-SIRT2 Deacetylase Substrate ¡ÚSIRT2 Deacetylase Substrate¡Û |
0.5umol |
¡ï22,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI180-0002 |
3',5'-cAMP Substrate |
2ml |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI181-0040 |
PDE Assay Buffer |
2x20ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI182-0001 |
5'-GMP Standard |
1mL |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI184-0001 |
5'-AMP Standard |
1mL |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI190-0002 |
3',5'-cGMP Substrate |
2ml |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI282-0500 |
NAD+(SIRT Substrate)¡ÚB-Nicotinamide Adenine Dinucleotide, Oxidized form¡Û |
500ul |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI283-0500 |
Nicotinamide |
500ul |
¡ï4,000 |
|
98-92-0 |
|
|
|
¡¡ |
BML |
BML-KI285-0010 |
Suramin Sodium |
10mg |
¡ï3,000 |
|
|
|
|
|
¡¡ |
BML |
BML-KI286-0020 |
SIRT Assay Buffer |
20ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI307-5000 |
5'-Nucleotidase(from Crotalus atrox venom) |
5000kU |
¡ï19,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI311-0020 |
HDAC8 Assay Buffer ¡ÚHistone Deacetylase 8 Assay Buffer¡Û |
20ml |
¡ï3,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI340-0020 |
Proteasome Assay Buffer |
20ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI341-0012 |
Sodium Dodecyl Sulfate ¡ÚSDS¡Û |
12mg |
¡ï4,000 |
|
151-21-3 |
|
|
|
¡¡ |
BML |
BML-KI346-0020 |
HDAC Cell Lysis Buffer ¡ÚHistone Deacetylase Cell Lysis Buffer¡Û |
20ml |
¡ï3,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI347-0001 |
Sterile 1/2 Volume Microplate with Lid ¡ÚMicroplate(Sterile 1/2 Volume)with Lid¡Û(1 set of 5 plates¡Ë |
1set |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI422-0020 |
HDAC Assay Buffer II ¡ÚHistone Deacetylase Assay Buffer II¡Û |
20ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI431-0020 |
Cathepsin S Assay Buffer |
20ml |
¡ï5,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI432-0020 |
Cathepsin K assay buffer |
20ml |
¡ï3,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI456-0020 |
PDE Enzyme(from bovine brain) |
20U |
¡ï19,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI468-0005 |
BIOMOL RED Reagent |
5ml |
¡ï3,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI572-0050 |
Fluor-de-Lys-Green substrate ¡ÚGreen substrate¡Û |
50ul |
¡ï22,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI576-0020 |
Assay buffer |
20ml |
¡ï3,000 |
|
|
|
|
|
¡¡ |
BML |
BML-KI579-0050 |
Fluor-de-Lys-Propionyl Substrate ¡ÚPropionyl Substrate¡Û |
50ul |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI580-0050 |
Fluor-de-Lys-Butyryl Substrate ¡ÚButyryl Substrate¡Û |
50ul |
¡ï21,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI581-0020 |
Neutrophil Elastase Assay Buffer |
20ml |
¡ï3,000 |
|
|
|
|
|
¡¡ |
BML |
BML-KI584-0001 |
1/2 Volume White Microplates(non-binding surface)(for 96 wells) |
1set |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KI590-0050 |
Fluor-de-Lys-Succinyl, Desuccinylase Substrate ¡ÚDesuccinylase Substrate, Fluor-de-Lys-Succinyl-¡Û |
50ul |
¡ï21,000 |
-80¡î |
none |
|
Purity: ¡ä95% Application: Study of desuccinylase kinetics, regulation, and inhibitor sensitivity. Ideal for drug discovery and HTS applications
|
|
¡¡ |
BML |
BML-KI597-0400 |
DMSO |
400ul |
¡ï3,000 |
|
|
|
|
|
¡¡ |
BML |
BML-KI604-0001 |
1/2 Volume Black Microplate, Non-binding surface |
5plates |
¡ï7,000 |
|
|
|
|
|
¡¡ |
BML |
BML-KI605-0030 |
Fluor de Lys Green Standard |
30ul |
¡ï8,000 |
|
|
|
|
|
¡¡ |
BML |
BML-KO013-0050 |
13-Keto-octadeca-9Z,11E-dienoic Acid |
50ug |
¡ï20,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KO013-1000 |
13-Keto-octadeca-9Z,11E-dienoic Acid |
1mg |
¡ï238,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KW9885-0005 |
10x Ubiquitinylation Buffer(packaged as 5 x 1 ml)
|
5ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-KW9890-0005 |
10x SUMOylation Buffer(packaged as 5 x 1 ml)
|
5ml |
¡ï4,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L100-0005 |
1-O-Hexadecyl-2-O-acetyl-sn-glycero-3-phosphorylcholine ¡ÚPAF C-16¡Û |
5mg |
¡ï7,000 |
|
74389-68-7 |
|
|
|
¡¡ |
BML |
BML-L100-0025 |
1-O-Hexadecyl-2-O-acetyl-sn-glycero-3-phosphorylcholine ¡ÚPAF C-16¡Û |
25mg |
¡ï29,000 |
|
74389-68-7 |
|
|
|
¡¡ |
BML |
BML-L102-0005 |
1-O-Hexadecyl-2-O-arachidonoyl-sn-glycero-3-phosphorylcholine ¡Ú2-AA-PAF¡Û |
5mg |
¡ï24,000 |
|
86288-11-1 |
|
|
|
¡¡ |
BML |
BML-L102-0025 |
1-O-Hexadecyl-2-O-arachidonoyl-sn-glycero-3-phosphorylcholine ¡Ú2-AA-PAF¡Û |
25mg |
¡ï94,000 |
|
86288-11-1 |
|
|
|
¡¡ |
BML |
BML-L103-0005 |
CV-3988 ¡Úrac-3-(N-Octadecylcarbamoyl)-2-Methoxy)propyl-(2-thiazolioethyl)Phosphate¡Û |
5mg |
¡ï19,000 |
|
85703-73-7] |
|
|
|
¡¡ |
BML |
BML-L103-0025 |
CV-3988 ¡Úrac-3-(N-Octadecylcarbamoyl)-2-Methoxy)propyl-(2-thiazolioethyl)Phosphate¡Û |
25mg |
¡ï78,000 |
|
85703-73-7] |
|
|
|
¡¡ |
BML |
BML-L106-0005 |
(¡Þ)-1-O-Hexadecyl-2-O-methylglycero-3-phosphorylcholine ¡Ú2-O-Methyl PAF¡Û |
5mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L106-0025 |
(¡Þ)-1-O-Hexadecyl-2-O-methylglycero-3-phosphorylcholine ¡Ú2-O-Methyl PAF¡Û |
25mg |
¡ï35,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L107-0005 |
1-Oleoyl-2-acetyl-sn-glycero-3-phosphorylcholine ¡ÚPAF C-18:1¡Û |
5mg |
¡ï8,000 |
|
85966-90-1 |
|
|
|
¡¡ |
BML |
BML-L107-0025 |
1-Oleoyl-2-acetyl-sn-glycero-3-phosphorylcholine ¡ÚPAF C-18:1¡Û |
25mg |
¡ï36,000 |
|
85966-90-1 |
|
|
|
¡¡ |
BML |
BML-L108-0005 |
1-O-Octadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine ¡Ú2-O-Methyl-PAF-C-18¡Û¡Úsn-ET-18-OCH3¡Û¡ÚEdelfosine¡Û |
5mg |
¡ï9,000 |
|
77286-66-9 |
|
|
|
¡¡ |
BML |
BML-L108-0025 |
1-O-Octadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine ¡Ú2-O-Methyl-PAF-C-18¡Û¡Úsn-ET-18-OCH3¡Û¡ÚEdelfosine¡Û |
25mg |
¡ï38,000 |
|
77286-66-9 |
|
|
|
¡¡ |
BML |
BML-L115-0005 |
1-O-Hexadecyl-2-O-eicosapentaenoyl-sn-glycero-3-phosphorylcholine |
5mg |
¡ï24,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L115-0025 |
1-O-Hexadecyl-2-O-eicosapentaenoyl-sn-glycero-3-phosphorylcholine |
25mg |
¡ï94,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L116-0005 |
1-O-Hexadecyl-2-O-dihomo-¦Ã-linolenoyl-sn-glycero-3-phosphorylcholine |
5mg |
¡ï24,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L116-0025 |
1-O-Hexadecyl-2-O-dihomo-¦Ã-linolenoyl-sn-glycero-3-phosphorylcholine |
25mg |
¡ï94,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L117-0005 |
1-O-Hexadecyl-2-O-docosahexaenoyl-sn-glycero-3-phosphorylcholine |
5mg |
¡ï24,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L117-0025 |
1-O-Hexadecyl-2-O-docosahexaenoyl-sn-glycero-3-phosphorylcholine |
25mg |
¡ï94,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L119-0005 |
2-O-Ethyl-PAF ¡ÚE-PAF¡Û¡Ú1-O-Hexadecyl-2-O-ethyl-sn-glycero-3-phosphorylcholine¡Û |
5mg |
¡ï19,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L120-0005 |
Carbamyl-PAF ¡ÚC-PAF¡Û¡Ú1-O-Hexadecyl-2-N-methylcarbamyl-sn-glycero-3-phosphorylcholine¡Û |
5mg |
¡ï19,000 |
|
91575-58-5 |
|
|
|
¡¡ |
BML |
BML-L120-0025 |
Carbamyl-PAF ¡ÚC-PAF¡Û¡Ú1-O-Hexadecyl-2-N-methylcarbamyl-sn-glycero-3-phosphorylcholine¡Û |
25mg |
¡ï78,000 |
|
91575-58-5 |
|
|
|
¡¡ |
BML |
BML-L122-0001 |
bis(Methylthio)gliotoxin ¡ÚFR-49175¡Û |
1mg |
¡ï11,000 |
|
74149-38-5 |
|
|
|
¡¡ |
BML |
BML-L122-0005 |
bis(Methylthio)gliotoxin ¡ÚFR-49175¡Û |
5mg |
¡ï44,000 |
|
74149-38-5 |
|
|
|
¡¡ |
BML |
BML-L123-0001 |
(¡Þ)-trans-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane |
1mg |
¡ï10,000 |
|
116673-45-1 |
|
|
|
¡¡ |
BML |
BML-L123-0005 |
(¡Þ)-trans-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane |
5mg |
¡ï40,000 |
|
116673-45-1 |
|
|
|
¡¡ |
BML |
BML-L124-0001 |
(¡Þ)-cis-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane |
1mg |
¡ï6,000 |
|
116673-47-3 |
|
|
|
¡¡ |
BML |
BML-L124-0005 |
(¡Þ)-cis-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane |
5mg |
¡ï27,000 |
|
116673-47-3 |
|
|
|
¡¡ |
BML |
BML-L131-0005 |
Octylonium Bromide |
5mg |
¡ï10,000 |
|
26095-59-0 |
|
|
|
¡¡ |
BML |
BML-L131-0025 |
Octylonium Bromide |
25mg |
¡ï39,000 |
|
26095-59-0 |
|
|
|
¡¡ |
BML |
BML-L133-0010 |
PCA-4248 ¡ÚMethyl 2-(Phenylthio)ethyl-1,4-dihydro-2,4,6-trimethylpyridine-3,5-dicarboxylate¡Û |
10mg |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L133-0050 |
PCA-4248 ¡ÚMethyl 2-(Phenylthio)ethyl-1,4-dihydro-2,4,6-trimethylpyridine-3,5-dicarboxylate¡Û |
50mg |
¡ï76,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L134-0001 |
1-O-Palmitoyl-2-O-acetyl-sn-glycero-3-phosphorylcholine ¡Ú1-Acyl-PAF¡Û |
1mg |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L134-0005 |
1-O-Palmitoyl-2-O-acetyl-sn-glycero-3-phosphorylcholine ¡Ú1-Acyl-PAF¡Û |
5mg |
¡ï29,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-L135-0010 |
Ginkgolide B ¡ÚBN 52021¡Û |
10mg |
¡ï7,000 |
|
15291-77-7 |
|
|
|
¡¡ |
BML |
BML-L135-0050 |
Ginkgolide B ¡ÚBN 52021¡Û |
50mg |
¡ï29,000 |
|
15291-77-7] |
|
|
|
¡¡ |
BML |
BML-L137-0001 |
WEB-2086 ¡Ú4-(2-Chlorophenyl)-9-methyl-2-(3-morpholino-3-oxo-propyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine¡Û |
1mg |
¡ï10,000 |
|
105219-56-5 |
|
|
|
¡¡ |
BML |
BML-L137-0005 |
WEB-2086 ¡Ú4-(2-Chlorophenyl)-9-methyl-2-(3-morpholino-3-oxo-propyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine¡Û |
5mg |
¡ï42,000 |
|
105219-56-5 |
|
|
|
¡¡ |
BML |
BML-LA004-0050 |
Leukotriene A4 Methyl Ester ¡ÚLTA4-ME¡Û |
50ug |
¡ï23,000 |
|
73466-12-3 |
|
|
|
¡¡ |
BML |
BML-LA004-1000 |
Leukotriene A4 Methyl Ester ¡ÚLTA4-ME¡Û |
1mg |
¡ï306,000 |
|
73466-12-3 |
|
|
|
¡¡ |
BML |
BML-LB003-0050 |
Leukotriene B3 ¡ÚLTB3¡Û |
50ug |
¡ï38,000 |
|
88099-35-8 |
|
|
|
¡¡ |
BML |
BML-LB004-0050 |
Leukotriene B4 ¡ÚLTB4¡Û¡Ú5,12-Dihydroxy-[S-[R*,S*-(E,Z,Z,E)]]-6,8,10,14-eicosatetraenoic Acid¡Û |
50ug |
¡ï33,000 |
|
71160-24-2 |
|
|
|
¡¡ |
BML |
BML-LB004-1000 |
Leukotriene B4 ¡ÚLTB4¡Û¡Ú5,12-Dihydroxy-[S-[R*,S*-(E,Z,Z,E)]]-6,8,10,14-eicosatetraenoic Acid¡Û |
1mg |
¡ï430,000 |
|
71160-24-2 |
|
|
|
¡¡ |
BML |
BML-LB005-0050 |
Leukotriene B5 ¡ÚLTB5¡Û |
50ug |
¡ï42,000 |
|
88763-92-9 |
|
|
|
¡¡ |
BML |
BML-LB014-0050 |
14,15-Dehydro-Leukotriene B4 ¡Ú14,15-Dehydro-LTB4¡Û |
50ug |
¡ï30,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LB504-0050 |
Leukotriene B4-6,7,14,15-d4 ¡ÚLTB4-d4¡Û |
50ug |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LB704-0050 |
Leukotriene B4-3-Aminopropylamide ¡ÚLTB4-APA¡Û |
50ug |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LC004-0050 |
Leukotriene C4 ¡ÚLTC4¡Û¡Ú5S-Hydroxy-6R-(S-glutathionyl)-7E,9E,11Z,14Z-eicosatetraenoic Acid¡Û |
50ug |
¡ï31,000 |
|
72025-60-6 |
|
|
|
¡¡ |
BML |
BML-LD004-0050 |
Leukotriene D4 ¡ÚLTD4¡Û |
50ug |
¡ï30,000 |
|
73836-78-9 |
|
|
|
¡¡ |
BML |
BML-LD004-1000 |
Leukotriene D4 ¡ÚLTD4¡Û |
1mg |
¡ï372,000 |
|
73836-78-9 |
|
|
|
¡¡ |
BML |
BML-LE004-0050 |
Leukotriene E4 ¡ÚLTE4¡Û |
50ug |
¡ï26,000 |
|
75715-89-8 |
|
|
|
¡¡ |
BML |
BML-LE004-1000 |
Leukotriene E4 ¡ÚLTE4¡Û |
1mg |
¡ï340,000 |
|
75715-89-8 |
|
|
|
¡¡ |
BML |
BML-LE009-0050 |
Leukotoxin A ¡Ú9,10-EODE¡Û¡Ú9(10)-EpOME¡Û¡Ú(¡Þ)9,10-Epoxyoctadec-12Z-enoic Acid¡Û |
50ug |
¡ï9,000 |
|
6814-52-4 |
|
|
|
¡¡ |
BML |
BML-LE009-1000 |
Leukotoxin A ¡Ú9,10-EODE¡Û¡Ú9(10)-EpOME¡Û¡Ú(¡Þ)9,10-Epoxyoctadec-12Z-enoic Acid¡Û |
1mg |
¡ï105,000 |
|
6814-52-4 |
|
|
|
¡¡ |
BML |
BML-LE012-0050 |
Leukotoxin B ¡Ú12,13-EODE¡Û¡Ú12(13)-EpOME¡Û¡Ú(¡Þ)12,13-Epoxyoctadec-9Z-enoic Acid¡Û |
50ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LE504-0050 |
Leukotriene E4-20,20,20-d3 ¡ÚLTE4-d3¡Û |
50ug |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LEA004-0050 |
N-Acetyl-Leukotriene E4 ¡ÚN-Ac-LTE4¡Û |
50ug |
¡ï31,000 |
|
80115-95-3 |
|
|
|
¡¡ |
BML |
BML-LG6030-0100 |
Laminin B chain(human placenta)[DG10], mouse mAb, purified(specificity: human) |
100ul |
¡ï23,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | DG10 | human | WB¡¢ ICC |
|
|
¡¡ |
BML |
BML-LP100-0005 |
Lysophosphatidic Acid ¡Ú1-Oleoyl-2-hydroxy-sn-glycerol-3-phosphate, Na salt¡Û |
5mg |
¡ï8,000 |
|
22556-62-3 |
|
|
|
¡¡ |
BML |
BML-LP100-0025 |
Lysophosphatidic Acid ¡Ú1-Oleoyl-2-hydroxy-sn-glycerol-3-phosphate, Na salt¡Û |
25mg |
¡ï30,000 |
|
22556-62-3 |
|
|
|
¡¡ |
BML |
BML-LP101-0001 |
L-NASPA ¡ÚN-Palmitoyl-L-serine Phosphoric Acid¡Û |
1mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LP101-0005 |
L-NASPA ¡ÚN-Palmitoyl-L-serine Phosphoric Acid¡Û |
5mg |
¡ï44,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LP102-0010 |
(¡Þ)-Lisofylline ¡Ú(¡Þ)-1-(5-Hydroxyhexyl)-3,7-dimethylxanthine¡Û |
10mg |
¡ï10,000 |
|
6493-06-7 |
|
|
|
¡¡ |
BML |
BML-LP102-0050 |
(¡Þ)-Lisofylline ¡Ú(¡Þ)-1-(5-Hydroxyhexyl)-3,7-dimethylxanthine¡Û |
50mg |
¡ï40,000 |
|
6493-06-7 |
|
|
|
¡¡ |
BML |
BML-LP103-0100 |
Phosphatidic Acid, Dipalmitoyl ¡ÚDipalmitoylphosphatidic Acid¡Û¡Ú1,2-Dipalmitoyl-sn-glycero-3-phosphate, Na salt¡Û¡ÚDPPA¡Û |
100mg |
¡ï12,000 |
|
71065-87-7 |
|
|
|
¡¡ |
BML |
BML-LP103-0500 |
Phosphatidic Acid, Dipalmitoyl ¡ÚDipalmitoylphosphatidic Acid¡Û¡Ú1,2-Dipalmitoyl-sn-glycero-3-phosphate, Na salt¡Û¡ÚDPPA¡Û |
500mg |
¡ï51,000 |
|
71065-87-7 |
|
|
|
¡¡ |
BML |
BML-LP104-0010 |
Phosphatidic Acid, Dioleoyl ¡ÚDioleoylphosphatidic Acid¡Û¡Ú1,2-Dioleyoyl-sn-glycero-3-phosphate, Na salt¡Û |
10mg |
¡ï11,000 |
|
108392-02-5 |
|
|
|
¡¡ |
BML |
BML-LP105-0005 |
Dodecylphosphate |
5mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LP105-0025 |
Dodecylphosphate |
25mg |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LP106-0010 |
SEW-2871 ¡Ú5-[4-Phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole¡Û |
10mg |
¡ï6,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LP106-0050 |
SEW-2871 ¡Ú5-[4-Phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole¡Û |
50mg |
¡ï27,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LP107-0001 |
N-Arachidonoyl Phosphatidylethanolamine ¡ÚDipalmitoyl-N-arachidonoyl Phosphatidylethanolamine¡Û¡ÚNAPE¡Û¡ÚNARPE¡Û |
1mg |
¡ï15,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LP107-0005 |
N-Arachidonoyl Phosphatidylethanolamine ¡ÚDipalmitoyl-N-arachidonoyl Phosphatidylethanolamine¡Û¡ÚNAPE¡Û¡ÚNARPE¡Û |
5mg |
¡ï60,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LP108-0001 |
N-Palmitoyl Phosphatidylethanolamine ¡ÚC16:0 NAPE¡Û¡ÚNPPE¡Û |
1mg |
¡ï15,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LP108-0005 |
N-Palmitoyl Phosphatidylethanolamine ¡ÚC16:0 NAPE¡Û¡ÚNPPE¡Û |
5mg |
¡ï59,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LPA004-0050 |
14,15-Leukotriene A4 Methyl Ester ¡Ú14,15-LTA4 ME¡Û |
50ug |
¡ï23,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LPA004-1000 |
14,15-Leukotriene A4 Methyl Ester ¡Ú14,15-LTA4 ME¡Û |
1mg |
¡ï297,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LPC004-0050 |
14,15-Leukotriene C4 ¡Ú14,15-LTC4¡Û |
50ug |
¡ï30,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LPD004-0050 |
14,15-Leukotriene D4 ¡Ú14,15-LTD4¡Û |
50ug |
¡ï30,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-LPE004-0050 |
14,15-Leukotriene E4 ¡Ú14,15-LTE4¡Û |
50ug |
¡ï30,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-MA1198-0025 |
Motilin(pig, natural), rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-MA1366-0025 |
ERK1/ERK2(phosphorylated)¡ÚMAP Kinases¡Û¡ÚExtracellular Signal-Regulated Kinases¡Û(peptide, motif pThr-Glu-pTyr)[AMK1], mouse mAb, purified |
25ug |
¡ï23,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG1 | AMK1 | activated mammalian | WB |
|
|
¡¡ |
BML |
BML-MZ1111-0050 |
a-Melanocyte Stimulating Hormone ¡Úa-MSH¡Û(synthetic peptide), rabbit pAb, purified |
50ul |
¡ï23,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ mouse¡¢ rat¡¢ other mammalian | IHC(PS) |
|
|
¡¡ |
BML |
BML-N110-0005 |
ENMD-1068 |
5mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-N110-0025 |
ENMD-1068 |
25mg |
¡ï46,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-N140-0010 |
Bilobalide |
10mg |
¡ï8,000 |
|
33570-04-6 |
|
|
|
¡¡ |
BML |
BML-N140-0050 |
Bilobalide |
50mg |
¡ï35,000 |
|
33570-04-6 |
|
|
|
¡¡ |
BML |
BML-N155-0001 |
MMTC ¡Ú1-Methyl-6-methoxy-1,2,3,4-tetrahydro-B-carboline¡Û |
1mg |
¡ï8,000 |
|
1210-56-6 |
|
|
|
¡¡ |
BML |
BML-N156-0005 |
Bourgeonal ¡Ú4-tert-Butylbenzenepropionaldehyde¡Û |
5mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-N156-0025 |
Bourgeonal ¡Ú4-tert-Butylbenzenepropionaldehyde¡Û |
25mg |
¡ï40,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-N157-0001 |
Fipexide, HCI ¡Ú1-(1,3-Benzodioxol-5-yl-methyl)-4-[(4-chlorophenoxy)acetyl]piperazine, HCl¡Û |
1g |
¡ï3,000 |
|
34161-23-4 |
|
|
|
¡¡ |
BML |
BML-N158-0001 |
Clioquinol ¡Ú5-Chloro-7-iodo-8-quinolinol¡Û |
1g |
¡ï5,000 |
|
130-26-7 |
|
|
|
¡¡ |
BML |
BML-N158-0005 |
Clioquinol ¡Ú5-Chloro-7-iodo-8-quinolinol¡Û |
5g |
¡ï14,000 |
|
130-26-7 |
|
|
|
¡¡ |
BML |
BML-N159-0001 |
Gambogic Amide |
1mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-N159-0005 |
Gambogic Amide |
5mg |
¡ï42,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-N160-0005 |
P7C3 ¡Ú1-(3,6-Dibromocarbazol-9-yl)-3-phenylaminopropan-2-ol Dihydrate¡Û |
5mg |
¡ï9,000 |
|
301353-96-8 |
|
|
|
¡¡ |
BML |
BML-N701-0050 |
U-50488 ¡Útrans-(¡Þ)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide, HCl¡Û |
50mg |
¡ï25,000 |
|
67198-13-4 |
|
|
|
¡¡ |
BML |
BML-N705-0005 |
U-69593 ¡ÚN-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-, [5a,7a,8b]-(+)-benzeneacetamide¡Û |
5mg |
¡ï11,000 |
|
96744-75-1 |
|
|
|
¡¡ |
BML |
BML-N705-0025 |
U-69593 ¡ÚN-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-, [5a,7a,8b]-(+)-benzeneacetamide¡Û |
25mg |
¡ï47,000 |
|
96744-75-1 |
|
|
|
¡¡ |
BML |
BML-NA103-0050 |
Benzamyl, HCl ¡ÚBenzylamiloride, HCl¡Û¡ÚN-(Benzylamidino)-3,5-diamino-6-chloropyrazinecarboxamide, HCl¡Û |
50mg |
¡ï19,000 |
|
2898-76-2 |
|
|
|
¡¡ |
BML |
BML-NA106-0050 |
ATX II(recombinant) |
50ug |
¡ï39,000 |
|
none |
|
|
|
·àʪ |
BML |
BML-NA116-0020 |
SDZ-201 106(+/-)¡Ú4-(3-(4-Diphenylmethylpiperazine-1-yl)-2-hydroxypropoxy)-1H-indol-2-carbonitrile¡Û¡ÚDPI-201106¡Û |
20mg |
¡ï5,000 |
|
97730-95-5 |
|
|
|
·àʪ |
BML |
BML-NA116-0100 |
SDZ-201 106(+/-)¡Ú4-(3-(4-Diphenylmethylpiperazine-1-yl)-2-hydroxypropoxy)-1H-indol-2-carbonitrile¡Û¡ÚDPI-201106¡Û |
100mg |
¡ï25,000 |
|
97730-95-5 |
|
|
|
·àʪ |
BML |
BML-NA117-0005 |
SDZ-201 106(+)¡Ú(R)-4-(3-(4-Diphenylmethylpiperazine-1-yl)-2-hydroxypropoxy)-1H-indol-2-carbonitrile¡Û |
5mg |
¡ï11,000 |
|
none |
|
|
|
·àʪ |
BML |
BML-NA118-0005 |
SDZ-201 106(-)¡Ú(S)-4-(3-(4-Diphenylmethylpiperazine-1-yl)-2-hydroxypropoxy)-1H-indol-2-carbonitrile¡Û |
5mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NA120-0001 |
Tetrodotoxin ¡ÚTTX¡Û¡ÚFugu poison¡Û |
1mg |
¡ï26,000 |
|
4368-28-9 |
|
|
|
¡¡ |
BML |
BML-NA1215-0050 |
Neurofilament H ¡ÚNF H¡Û(human)[BE8], mouse mAb, purified |
50ul |
¡ï19,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG | BE8 | human¡¢ rat¡¢ monkey¡¢ pig | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA1216-0050 |
Neurofilament M ¡ÚNF M¡Û(primate, 150kDa), rabbit pAb(neat serum) |
50ul |
¡ï18,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA1216-0100 |
Neurofilament M ¡ÚNF M¡Û(primate, 150kDa), rabbit pAb(neat serum) |
100ul |
¡ï31,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA1223-0100 |
Neurofilament Triplet Proteins ¡Úpan-Neurofilaments¡Û(human spinal cord) [13AA], mouse mAb, purified |
100ul |
¡ï24,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG | 13AA | human¡¢ mouse¡¢ rat¡¢ other mammalian | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA1225-0100 |
Neurofilament L&H ¡ÚNF L & NF-H¡Û(human spinal cord) [14BA], mouse mAb, purified |
100ul |
¡ï24,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG | 14BA | human¡¢ mouse¡¢ rat¡¢ other mammalian | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA1230-0025 |
Neurotensin(peptide), rabbit pAb(neat serum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | mammalian | IHC |
|
|
¡¡ |
BML |
BML-NA1230-0100 |
Neurotensin(peptide), rabbit pAb(neat serum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | mammalian | IHC |
|
|
¡¡ |
BML |
BML-NA1233-0025 |
Neuropeptide Tyrosine ¡ÚNeuropeptide Y¡Û¡ÚNPY¡Û(pig, peptide), rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA1233-0100 |
Neuropeptide Tyrosine ¡ÚNeuropeptide Y¡Û¡ÚNPY¡Û(pig, peptide), rabbit pAb(antiserum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA1235-0025 |
Neuropeptide Tyrosine Precursor ¡ÚNeuropeptide Y Precursor¡Û¡ÚNPY Precursor¡Û(peptide)(CT), rabbit pAb |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ baboon¡¢ cat | IHC |
|
|
¡¡ |
BML |
BML-NA1235-0100 |
Neuropeptide Tyrosine Precursor ¡ÚNeuropeptide Y Precursor¡Û¡ÚNPY Precursor¡Û(peptide)(CT), rabbit pAb |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ baboon¡¢ cat | IHC |
|
|
¡¡ |
BML |
BML-NA1247-0025 |
Neuron Specific Enolase ¡Ú¦Ã,¦Ã'-enolase¡Û¡ÚNSE¡Û(human, aa 269-286), rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA1247-0100 |
Neuron Specific Enolase ¡Ú¦Ã,¦Ã'-enolase¡Û¡ÚNSE¡Û(human, aa 269-286), rabbit pAb(antiserum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA125-0010 |
Veratridine |
10mg |
¡ï16,000 |
|
71-62-5 |
|
|
|
¡¡ |
BML |
BML-NA1300-0025 |
Neurogranin ¡ÚBICKS¡Û¡ÚRC3¡Û¡Úp17¡Û¡ÚNg¡Û(rat, aa 9-25), rabbit pAb(neat serum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ goat¡¢ bovine | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA1300-0100 |
Neurogranin ¡ÚBICKS¡Û¡ÚRC3¡Û¡Úp17¡Û¡ÚNg¡Û(rat, aa 9-25), rabbit pAb(neat serum) |
100ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢ rat¡¢ goat¡¢ bovine | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA134-0100 |
QX-314 ¡ÚN-(2,6-Dimethylphenyl)acetamide-2-triethylammonium Bromide¡Û |
100mg |
¡ï8,000 |
|
21306-56-9 |
|
|
|
¡¡ |
BML |
BML-NA135-0001 |
Grayanotoxin III ¡ÚAndromedol¡Û |
1mg |
¡ï9,000 |
|
4678-45-9 |
|
|
|
¡¡ |
BML |
BML-NA136-0050 |
Kavain(+/-)¡Ú(¡Þ)-4-Methoxy-6-styryl-5,6-dihydro-a-pyrone¡Û |
50mg |
¡ï8,000 |
|
500-64-1 |
|
|
|
¡¡ |
BML |
BML-NA136-0250 |
Kavain(+/-)¡Ú(¡Þ)-4-Methoxy-6-styryl-5,6-dihydro-a-pyrone¡Û |
250mg |
¡ï32,000 |
|
500-64-1 |
|
|
|
¡¡ |
BML |
BML-NA138-0020 |
Riluzole ¡Ú2-Amino-6-(trifluoromethoxy)benzothiazole¡Û¡Ú6-(Trifluoromethoxy)-2-benzothiazolamine¡Û |
20mg |
¡ï7,000 |
|
1744-22-5 |
|
|
|
¡¡ |
BML |
BML-NA138-0100 |
Riluzole ¡Ú2-Amino-6-(trifluoromethoxy)benzothiazole¡Û¡Ú6-(Trifluoromethoxy)-2-benzothiazolamine¡Û |
100mg |
¡ï30,000 |
|
1744-22-5 |
|
|
|
¡¡ |
BML |
BML-NA139-0001 |
Bupivacaine ¡Ú1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide, HCl¡Û |
1g |
¡ï7,000 |
|
14252-80-3 |
|
|
|
¡¡ |
BML |
BML-NA140-0005 |
PD 85639 ¡Úa-Phenyl-N-(3-(2,6-dimethyl-1-piperizinyl)alphapropyl)benzeneacetamide¡Û |
5mg |
¡ï13,000 |
|
150034-24-5 |
|
|
|
¡¡ |
BML |
BML-NA140-0025 |
PD 85639 ¡Úa-Phenyl-N-(3-(2,6-dimethyl-1-piperizinyl)alphapropyl)benzeneacetamide¡Û |
25mg |
¡ï45,000 |
|
150034-24-5 |
|
|
|
¡¡ |
BML |
BML-NA141-0010 |
Batrachotoxin ¡ÚBTX¡Û |
10ug |
¡ï30,000 |
|
23509-16-2 |
|
|
|
¡¡ |
BML |
BML-NA142-0010 |
A-803467 ¡Ú5-(4-Chlorophenyl)-N-(3,5-dimethoxyphenyl)furan-2-carboxamide¡Û |
10mg |
¡ï10,000 |
|
944261-79-4 |
|
|
|
¡¡ |
BML |
BML-NA142-0050 |
A-803467 ¡Ú5-(4-Chlorophenyl)-N-(3,5-dimethoxyphenyl)furan-2-carboxamide¡Û |
50mg |
¡ï43,000 |
|
944261-79-4 |
|
|
|
¡¡ |
BML |
BML-NA143-0010 |
Lorcainide, HCl ¡ÚN-(4-Chlorophenyl)-N-[1-(1-isopropyl)-4-piperidinyl]phenylacetamide, HCl¡Û |
10mg |
¡ï10,000 |
|
58934-46-6 |
|
|
|
¡¡ |
BML |
BML-NA143-0050 |
Lorcainide, HCl ¡ÚN-(4-Chlorophenyl)-N-[1-(1-isopropyl)-4-piperidinyl]phenylacetamide, HCl¡Û |
50mg |
¡ï39,000 |
|
58934-46-6 |
|
|
|
¡¡ |
BML |
BML-NA144-0005 |
Tetracaine, HCl ¡Ú4-(Butylamino)benzoic Acid 2-(Dimethylamino)ethyl Ester, HCl ¡Û |
5g |
¡ï4,000 |
|
136-47-0 |
|
|
|
¡¡ |
BML |
BML-NA144-0025 |
Tetracaine, HCl ¡Ú4-(Butylamino)benzoic Acid 2-(Dimethylamino)ethyl Ester, HCl ¡Û |
25g |
¡ï7,000 |
|
136-47-0 |
|
|
|
¡¡ |
BML |
BML-NA1501-0100 |
Neuron Specific Enolase ¡ÚNSE¡Û¡Ú¦Ã,¦Ã¡Ç-enolase¡Û [NSE47], mouse mAb, purified |
100ul |
¡ï13,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG2b | NSE47 | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC¡¢ WB(~76kDa)¡¢ ELISA |
|
|
¡¡ |
BML |
BML-NA1501-0500 |
Neuron Specific Enolase ¡ÚNSE¡Û¡Ú¦Ã,¦Ã¡Ç-enolase¡Û [NSE47], mouse mAb, purified |
500ul |
¡ï40,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG2b | NSE47 | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC¡¢ WB(~76kDa)¡¢ ELISA |
|
|
¡¡ |
BML |
BML-NA4300-0025 |
Neurokinin-1 Receptor ¡ÚNK1R¡Û¡ÚSubstance P Receptor¡Û(rat, aa 393-407)(CT), rabbit pAb(antiserum)(specificity: rat) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat | IHC |
|
|
¡¡ |
BML |
BML-NA4400-0025 |
Neurokinin-1 Receptor ¡ÚNK1r¡Û¡ÚSubstance P Receptor¡Û(human, aa 393-407), rabbit pAb(specificity: human) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NA4400-0100 |
Neurokinin-1 Receptor ¡ÚNK1r¡Û¡ÚSubstance P Receptor¡Û(human, aa 393-407), rabbit pAb(specificity: human) |
100ul |
¡ï40,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human | IHC¡¢ WB |
|
|
¡¡ |
BML |
BML-NG1931-0100 |
N-Ethylmaleimide-Sensitive Fusion Protein ¡ÚNSF¡Û(human)(recombinant)[NSF1], mouse mAb, Affinity-purified |
100ug |
¡ï35,000 |
|
none |
|
¥µ¥Ö¥¯¥é¥¹ |
¥¯¥í¡¼¥ó̾ |
ÆÃ°ÛÀ |
ŬÍÑ |
mouse IgG | NSF1 | human¡¢ mouse¡¢ rat¡¢ bovine | WB¡¢ IP |
|
|
¡¡ |
BML |
BML-NH100-0005 |
Amthamine ¡Ú2-Amino-4-methylthiazole-5-ethanamine, 2HBr¡Û |
5mg |
¡ï11,000 |
|
142437-67-0 |
|
|
|
¡¡ |
BML |
BML-NH101-0010 |
Astemizole ¡Ú1-[(4-Fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine¡Û |
10mg |
¡ï9,000 |
|
68844-77-9 |
|
|
|
¡¡ |
BML |
BML-NH101-0050 |
Astemizole ¡Ú1-[(4-Fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine¡Û |
50mg |
¡ï36,000 |
|
68844-77-9 |
|
|
|
¡¡ |
BML |
BML-NH102-0100 |
Dimaprit ¡ÚS-(3-Dimethylaminopropyl)isothiourea, 2HCl¡Û |
100mg |
¡ï22,000 |
|
23256-33-9 |
|
|
|
¡¡ |
BML |
BML-NH103-0010 |
HTMT ¡Ú6-[2-(4-Imidazolyl)ethylamino]-N-(4-trifluoromethylphenyl)heptanecarboxamide, Dimaleate¡Û |
10mg |
¡ï23,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NH104-0010 |
R(-)-a-Methylhistamine, 2HBr ¡ÚHistamine,(R)-(-)-a-Methyl-, 2HBr¡Û |
10mg |
¡ï21,000 |
|
75614-87-8 |
|
|
|
¡¡ |
BML |
BML-NH105-0010 |
Thioperamide, Maleate ¡ÚN-Cyclohexyl-4-(imidazol-4-yl)-1-piperidinecarbothioamide, Maleate¡Û |
10mg |
¡ï12,000 |
|
106243-16-7 |
|
|
|
¡¡ |
BML |
BML-NH105-0050 |
Thioperamide, Maleate ¡ÚN-Cyclohexyl-4-(imidazol-4-yl)-1-piperidinecarbothioamide, Maleate¡Û |
50mg |
¡ï50,000 |
|
106243-16-7 |
|
|
|
¡¡ |
BML |
BML-NH106-0001 |
Ketotifen, Fumarate ¡Ú4-(1-Methyl-4-piperidylidene)-4H-benzo[4,5]cyclohepta[1,2-b]thiophene-10(9H)-one Fumarate¡Û |
1g |
¡ï8,000 |
|
34580-14-8 |
|
|
|
·àʪ |
BML |
BML-NH107-0010 |
Levocabastine, HCI |
10mg |
¡ï24,000 |
|
79547-78-7 |
|
|
|
¡¡ |
BML |
BML-NH108-0100 |
Azelastine, HCl ¡Ú4-(p-Chlorobenzyl)-2-(N-methylperhydroazepin-4-yl)-1(2H)-phthalazinone¡Û |
100mg |
¡ï9,000 |
|
79307-93-0 |
|
|
|
¡¡ |
BML |
BML-NH112-0010 |
Dimebon, 2HCl ¡Ú2,3,4,5-Tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-1H-pyrido(4,3-b)indole, 2HCl¡Û |
10mg |
¡ï22,000 |
|
97657-92-6 |
|
|
|
¡¡ |
BML |
BML-NH112-0050 |
Dimebon, 2HCl ¡Ú2,3,4,5-Tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-1H-pyrido(4,3-b)indole, 2HCl¡Û |
50mg |
¡ï87,000 |
|
97657-92-6 |
|
|
|
¡¡ |
BML |
BML-NK100-0001 |
Resiniferatoxin ¡ÚRTX¡Û(Isolated from Euphorbia poisonii) |
1mg |
¡ï15,000 |
|
57444-62-9 |
|
|
|
¡¡ |
BML |
BML-NK100-0005 |
Resiniferatoxin ¡ÚRTX¡Û(Isolated from Euphorbia poisonii) |
5mg |
¡ï58,000 |
|
57444-62-9 |
|
|
|
¡¡ |
BML |
BML-NK103-0010 |
L-732,138 ¡ÚN-Acetyl-L-tryptophan-3,5-bis(trifluoromethyl)Benzyl Ester¡Û |
10mg |
¡ï14,000 |
|
148451-96-1 |
|
|
|
¡¡ |
BML |
BML-NK103-0050 |
L-732,138 ¡ÚN-Acetyl-L-tryptophan-3,5-bis(trifluoromethyl)Benzyl Ester¡Û |
50mg |
¡ï54,000 |
|
148451-96-1 |
|
|
|
¡¡ |
BML |
BML-NK104-0001 |
HOE-140 ¡ÚIcatibant¡Û |
1mg |
¡ï29,000 |
|
130308-48-4 |
|
|
|
¡¡ |
BML |
BML-NL3720-0025 |
N-Ethylmaleimide-Sensitive Fusion Protein ¡ÚNSF¡Û(recombinant), rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat¡¢ bovine | IHC¡¢ WB¡¢ IP |
|
|
¡¡ |
BML |
BML-NL3720-0100 |
N-Ethylmaleimide-Sensitive Fusion Protein ¡ÚNSF¡Û(recombinant), rabbit pAb(antiserum) |
100ul |
¡ï40,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat¡¢ bovine | IHC¡¢ WB¡¢ IP |
|
|
¡¡ |
BML |
BML-NL3750-0025 |
Neuronal Ca2+ Sensor-1 ¡ÚNCS-1¡Û¡ÚFrequenin¡Û(rat)(recombinant), rabbit pAb(neat serum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat | IHC¡¢ WB¡¢ IP |
|
|
¡¡ |
BML |
BML-NL3750-0100 |
Neuronal Ca2+ Sensor-1 ¡ÚNCS-1¡Û¡ÚFrequenin¡Û(rat)(recombinant), rabbit pAb(neat serum) |
100ul |
¡ï40,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat | IHC¡¢ WB¡¢ IP |
|
|
¡¡ |
BML |
BML-NL3770-0025 |
Neurocalcin ¦Ä ¡ÚNCALD¡Û¡ÚVILIP-3¡Û(rat)(recombinant), rabbit pAb(antiserum) |
25ul |
¡ï13,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat | IHC¡¢ WB¡¢ IP |
|
|
¡¡ |
BML |
BML-NL3770-0100 |
Neurocalcin ¦Ä ¡ÚNCALD¡Û¡ÚVILIP-3¡Û(rat)(recombinant), rabbit pAb(antiserum) |
100ul |
¡ï40,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | rat | IHC¡¢ WB¡¢ IP |
|
|
¡¡ |
BML |
BML-NO102-0010 |
Naloxonazine, 2HCl ¡Úbis-[5-a-4,5-Epoxy-3-14-dihydroxy-17-(2-propenyl)morphan-6-ylidene]hydrazine, 2HCl¡Û |
10mg |
¡ï12,000 |
|
82824-01-9 |
|
|
|
¡¡ |
BML |
BML-NO103-0100 |
Carbetapentane, Citrate ¡ÚPentoxyverine¡Û |
100mg |
¡ï5,000 |
|
77-23-6 |
|
|
|
¡¡ |
BML |
BML-NO103-0500 |
Carbetapentane, Citrate ¡ÚPentoxyverine¡Û |
500mg |
¡ï23,000 |
|
77-23-6 |
|
|
|
¡¡ |
BML |
BML-NO104-0010 |
4-Phenyl-1-(4-phenylbutyl)piperidine, Maleate |
10mg |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NO105-0010 |
BD 1008 ¡ÚN-[2-(3,4-Dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine, 2HBr¡Û |
10mg |
¡ï20,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NO107-0010 |
PRE-084 ¡Ú2-(4-Morpholinethyl)-1-phenylcyclohexanecarboxylate, HCl¡Û |
10mg |
¡ï20,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NO110-0100 |
Nalmefene, HCl ¡Ú(5a)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol¡Û |
100mg |
¡ï11,000 |
|
58895-64-0 |
|
|
|
¡¡ |
BML |
BML-NO110-0500 |
Nalmefene, HCl ¡Ú(5a)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol¡Û |
500mg |
¡ï45,000 |
|
58895-64-0 |
|
|
|
¡¡ |
BML |
BML-NO490-0010 |
1-(4-Iodophenyl)-3-(1-adamantyl)guanidine |
10mg |
¡ï20,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NP1413-0100 |
Neurogranin Peptide, Blocking Peptide for Neurogranin pAb(Prod. No. BML-NA1300) |
100ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NP1442-0100 |
Neurokinin-1 Receptor(rat, aa 393-407)C-terminal Pentadecapeptide, Blocking Peptide for Neurokinin-1 receptor pAb(Prod. No. BML-NA4200) |
100ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NP1444-0100 |
Neurokinin-1 Receptor Peptide ¡ÚNK1r¡Û(human, aa 393-407), Blocking Peptide for Neurokinin-1 receptor(human)pAb(Prod. No. BML-NA4400) |
100ug |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NP1450-0050 |
Neuron Specific Enolase ¡ÚNSE¡Û¡Ú¦Ã,¦Ã'-Enolase¡Û(human), purified |
50ug |
¡ï24,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NS085-0010 |
CGS 12066B, Dimaleate ¡Ú7-Trifluoromethyl-4-(4-methyl-1-piperazinyl)pyrrolo-(1,2-a)quinoxaline, Maleate¡Û |
10mg |
¡ï14,000 |
|
109028-10-6 |
|
|
|
¡¡ |
BML |
BML-NS100-0005 |
Anpirtoline ¡ÚD-16949¡Û¡Ú6-Chloro-2-[piperidinyl-4-thio]pyridine, HCl¡Û |
5mg |
¡ï15,000 |
|
98330-05-3 |
|
|
|
¡¡ |
BML |
BML-NS100-0025 |
Anpirtoline ¡ÚD-16949¡Û¡Ú6-Chloro-2-[piperidinyl-4-thio]pyridine, HCl¡Û |
25mg |
¡ï59,000 |
|
98330-05-3 |
|
|
|
·àʪ |
BML |
BML-NS101-0005 |
3-(4-Allylpiperazin-1-yl)-2-quinoxalinecarbonitrile |
5mg |
¡ï12,000 |
|
none |
|
|
|
·àʪ |
BML |
BML-NS101-0025 |
3-(4-Allylpiperazin-1-yl)-2-quinoxalinecarbonitrile |
25mg |
¡ï50,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NS102-0010 |
Cinanserin ¡ÚN-[2-[[3-(Dimethylamino)propyl]thio]phenyl]-3-phenyl-2-propenamide¡Û |
10mg |
¡ï17,000 |
|
1166-34-3 |
|
|
|
¡¡ |
BML |
BML-NS104-0010 |
AMI-193 ¡Ú8-[3-(4-Fluorophenoxy)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one¡Û |
10mg |
¡ï22,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NS105-0005 |
Clozapine N-Oxide |
5mg |
¡ï11,000 |
|
34233-69-7 |
|
|
|
¡¡ |
BML |
BML-NS105-0025 |
Clozapine N-Oxide |
25mg |
¡ï44,000 |
|
34233-69-7 |
|
|
|
¡¡ |
BML |
BML-NS106-0005 |
N-Desmethyl Clozapine |
5mg |
¡ï10,000 |
|
6104-71-8 |
|
|
|
¡¡ |
BML |
BML-NS106-0025 |
N-Desmethyl Clozapine |
25mg |
¡ï42,000 |
|
6104-71-8 |
|
|
|
¡¡ |
BML |
BML-NS107-0100 |
Dibenzepine, HCl |
100mg |
¡ï7,000 |
|
315-80-0 |
|
|
|
¡¡ |
BML |
BML-NS107-0500 |
Dibenzepine, HCl |
500mg |
¡ï30,000 |
|
315-80-0 |
|
|
|
¡¡ |
BML |
BML-NS108-0200 |
Dihydroergocristine, Mesylate |
200mg |
¡ï6,000 |
|
24730-10-7 |
|
|
|
¡¡ |
BML |
BML-NS108-1000 |
Dihydroergocristine, Mesylate |
1g |
¡ï27,000 |
|
24730-10-7 |
|
|
|
¡¡ |
BML |
BML-NS109-0020 |
Fluperlapine ¡Ú3-Fluoro-6-(4-methyl-1-piperazinyl)-11H-dibenz[b,e]azepine¡Û |
20mg |
¡ï14,000 |
|
67121-76-0 |
|
|
|
¡¡ |
BML |
BML-NS109-0100 |
Fluperlapine ¡Ú3-Fluoro-6-(4-methyl-1-piperazinyl)-11H-dibenz[b,e]azepine¡Û |
100mg |
¡ï32,000 |
|
67121-76-0 |
|
|
|
¡¡ |
BML |
BML-NS111-0050 |
Bupropion, HCl ¡Ú(¡Þ)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone, HCl¡Û |
50mg |
¡ï8,000 |
|
31677-93-7 |
|
|
|
¡¡ |
BML |
BML-NS111-0250 |
Bupropion, HCl ¡Ú(¡Þ)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone, HCl¡Û |
250mg |
¡ï36,000 |
|
31677-93-7 |
|
|
|
¡¡ |
BML |
BML-NS112-0010 |
Citalopram, HBr ¡Ú1-[3-Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, HBr¡Û |
10mg |
¡ï10,000 |
|
59729-32-7 |
|
|
|
¡¡ |
BML |
BML-NS112-0050 |
Citalopram, HBr ¡Ú1-[3-Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, HBr¡Û |
50mg |
¡ï40,000 |
|
59729-32-7 |
|
|
|
¡¡ |
BML |
BML-NS114-0010 |
Venlafaxine, HCl ¡ÚWY-45030¡Û¡Ú(¡Þ)-1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol, HCl¡Û |
10mg |
¡ï8,000 |
|
99300-78-4 |
|
|
|
¡¡ |
BML |
BML-NS114-0050 |
Venlafaxine, HCl ¡ÚWY-45030¡Û¡Ú(¡Þ)-1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol, HCl¡Û |
50mg |
¡ï35,000 |
|
99300-78-4 |
|
|
|
¡¡ |
BML |
BML-NS115-0010 |
Sertraline, HCl ¡ÚCP-51974¡Û¡Ú(1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine, HCl¡Û |
10mg |
¡ï8,000 |
|
79559-97-0 |
|
|
|
¡¡ |
BML |
BML-NS115-0050 |
Sertraline, HCl ¡ÚCP-51974¡Û¡Ú(1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine, HCl¡Û |
50mg |
¡ï33,000 |
|
79559-97-0 |
|
|
|
¡¡ |
BML |
BML-NS140-0050 |
Fluoxetine, HCl ¡Ú(¡Þ)-N-Methyl-¦Ã-[4-(trifluoromethyl)phenoxy]benzenepropanamine, HCl¡Û |
50mg |
¡ï8,000 |
|
56296-78-7 |
|
|
|
¡¡ |
BML |
BML-NS140-0250 |
Fluoxetine, HCl ¡Ú(¡Þ)-N-Methyl-¦Ã-[4-(trifluoromethyl)phenoxy]benzenepropanamine, HCl¡Û |
250mg |
¡ï25,000 |
|
56296-78-7 |
|
|
|
¡¡ |
BML |
BML-NS145-0010 |
Ondansteron ¡Ú1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1Himidazol-1-ylmethyl]-4H-carbazol-4-one¡Û |
10mg |
¡ï10,000 |
|
99614-02-5 |
|
|
|
¡¡ |
BML |
BML-NS145-0050 |
Ondansteron ¡Ú1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-ylmethyl]-4H-carbazol-4-one¡Û |
50mg |
¡ï41,000 |
|
99614-02-5 |
|
|
|
¡¡ |
BML |
BML-NS515-0050 |
Ketanserin, Tartrate |
50mg |
¡ï13,000 |
|
74050-98-9 |
|
|
|
¡¡ |
BML |
BML-NS520-0001 |
Melatonin ¡ÚN-Acetyl-5-methoxytryptamine¡Û |
1g |
¡ï6,000 |
|
73-31-4 |
|
|
|
¡¡ |
BML |
BML-NS530-0050 |
MDL-72222 ¡Ú3-Tropanyl-3,5-dichlorobenzoate¡Û |
50mg |
¡ï22,000 |
|
40796-97-2 |
|
|
|
¡¡ |
BML |
BML-NS531-1000 |
Mesoridazine, Besylate ¡Ú10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine Benzenesulfonate¡Û |
1g |
¡ï3,000 |
|
32672-69-8 |
|
|
|
¡¡ |
BML |
BML-NS550-0020 |
N-Methylquipazine, Dimaleate ¡Ú2-[1-(4-Methyl)piperazinyl]quinoline, Dimaleates¡Û |
20mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NS560-0010 |
(¡Þ)-a-Methylserotonin, Maleate |
10mg |
¡ï14,000 |
|
304-52-9 |
|
|
|
¡¡ |
BML |
BML-NS560-0050 |
(¡Þ)-a-Methylserotonin, Maleate |
50mg |
¡ï55,000 |
|
304-52-9 |
|
|
|
¡¡ |
BML |
BML-NS570-0010 |
2-Methylserotonin, HCl |
10mg |
¡ï13,000 |
|
78263-90-8 |
|
|
|
¡¡ |
BML |
BML-NS570-0050 |
2-Methylserotonin, HCl |
50mg |
¡ï66,000 |
|
78263-90-8 |
|
|
|
¡¡ |
BML |
BML-NS640-0050 |
NAN-190 ¡Ú1-(2-Methoxyphenyl)-4-(4-phthalimidobutyl)piperazine, HBr¡Û |
50mg |
¡ï15,000 |
|
115338-32-4 |
|
|
|
¡¡ |
BML |
BML-NS660-0020 |
1-(1-Naphthyl)piperazine, HCl |
20mg |
¡ï6,000 |
|
57536-86-4 |
|
|
|
¡¡ |
BML |
BML-NS660-0100 |
1-(1-Naphthyl)piperazine, HCl |
100mg |
¡ï27,000 |
|
57536-86-4 |
|
|
|
¡¡ |
BML |
BML-NS705-0010 |
ORG-12962 ¡Ú1-[6-Chloro-5-trifluoromethyl)-2-pyridinyl]piperazine¡Û |
10mg |
¡ï11,000 |
|
210821-63-9 |
|
|
|
¡¡ |
BML |
BML-NS705-0050 |
ORG-12962 ¡Ú1-[6-Chloro-5-trifluoromethyl)-2-pyridinyl]piperazine¡Û |
50mg |
¡ï45,000 |
|
210821-63-9 |
|
|
|
¡¡ |
BML |
BML-NS710-0020 |
Paroxetine, HCl |
20mg |
¡ï9,000 |
|
110429-49-8 |
|
|
|
¡¡ |
BML |
BML-NS710-0100 |
Paroxetine, HCl |
100mg |
¡ï39,000 |
|
110429-49-8 |
|
|
|
¡¡ |
BML |
BML-NS740-0100 |
Pizotifen, Maleate |
100mg |
¡ï7,000 |
|
5189-11-7 |
|
|
|
¡¡ |
BML |
BML-NS740-0500 |
Pizotifen, Maleate |
500mg |
¡ï28,000 |
|
5189-11-7 |
|
|
|
¡¡ |
BML |
BML-NS830-0010 |
Spiroxatrine ¡ÚR 5188¡Û¡Ú(¡Þ)-8-[(2,3-Dihydro-1,4-benzodioxin-2-yl)methyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one¡Û |
10mg |
¡ï21,000 |
|
1054-88-2 |
|
|
|
¡¡ |
BML |
BML-NS835-0005 |
Thioridazine, HCl ¡Ú10-[2-(1-Methyl-2-piperidyl)ethyl]-2-(methylthio)phenothiazine, HCl¡Û |
5g |
¡ï3,000 |
|
130-61-0 |
|
|
|
¡¡ |
BML |
BML-NS901-0005 |
Y-25130 ¡ÚN-(1-Azabicyclo[2.2.2]oct-3-yl)-6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide, HCl¡Û |
5mg |
¡ï12,000 |
|
123040-16-4 |
|
|
|
¡¡ |
BML |
BML-NW8780-0500 |
NIP-(Leu)3-vinyl Sulfone ¡Ú4-Hydroxy-5-iodo-3-nitrophenylacetyl-L-leucyl-L-leucyl-L-leucinyl Vinyl Sulphone¡Û¡ÚNLVS¡Û |
500ug |
¡ï34,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-NZ1112-0025 |
Neurotensin(peptide), rat pAb |
25ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rat | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-NZ1113-0025 |
Neurotensin(peptide), rabbit pAb |
25ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rabbit | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-NZ1115-0025 |
Neuropeptide Tyrosine ¡ÚNPY¡Û¡ÚNeuropeptide Y¡Û(pig, peptide 36aa), rat pAb, purified |
25ul |
¡ï42,000 |
|
none |
|
ÌÈ±ÖÆ°Êª |
·Á¾õ |
ÆÃ°ÛÀ |
ŬÍÑ |
rat | - | human¡¢mouse¡¢rat¡¢ goat¡¢sheep¡¢dog¡¢pig¡¢monkey | IHC |
|
|
¡¡ |
BML |
BML-P100-0001 |
CaM Kinase IV Substrate ¡ÚCa2+/Calmodulin-dependent Protein Kinase II¦Ã(345-358)¡Û¡ÚPeptide ¦Ã¡Û¡ÚCa2+/Calmodulin-dependent Protein Kinase IV Substrate¡Û¡ÚCAMKIV Substrate¡Û |
1mg |
¡ï14,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P101-0001 |
Autocamtide-2 [CaMK Substrates] |
1mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P102-0001 |
Syntide-2 [CaMK Substrates] |
1mg |
¡ï19,000 |
|
108334-68-5 |
|
|
|
¡¡ |
BML |
BML-P103-0001 |
Casein Kinase II B(198-215)¡ÚCdk Substrate¡Û¡ÚCell-cycle Dependent Kinase Substrate¡Û |
1mg |
¡ï19,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P104-0500 |
CSH103 Substrate ¡Úp34cdc2(CDK1)Protein Kinase Substrate¡Û |
500ug |
¡ï11,000 |
|
135546-44-0 |
|
|
|
¡¡ |
BML |
BML-P106-0001 |
H1-7 ¡ÚHistone H1 Phosphorylation site¡Û¡ÚPKA Substrate¡Û¡ÚArg-Arg-Lys-Ala-Ser-Gly-Pro¡Û¡ÚRRKASGP¡Û |
1mg |
¡ï7,000 |
|
65189-70-0 |
|
|
|
¡¡ |
BML |
BML-P107-0001 |
Kemptide [Protein Kinase Substrate] |
1mg |
¡ï5,000 |
|
65189-71-1 |
|
|
|
¡¡ |
BML |
BML-P108-0001 |
Malantide [Protein Kinase Substrate] |
1mg |
¡ï13,000 |
|
86555-35-3 |
|
|
|
¡¡ |
BML |
BML-P109-0001 |
EGF Receptor Fragment(651-658)¡ÚEpidermal Growth Factor Receptor¡Û¡ÚEGFR¡Û [Protein Kinase Substrate] |
1mg |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P110-0001 |
MBP(4-14)(N-Acetylated)¡ÚMyelin Basic Protein(4-14)(N-Acetylated)¡Û |
1mg |
¡ï10,000 |
|
126768-94-3 |
|
|
|
¡¡ |
BML |
BML-P111-0001 |
[Ser25]-Protein Kinase C(19-31)¡ÚProtein Kinase C, [Ser25]-¡Û¡Ú[Ser25]-PKC(19-31)¡Û |
1mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P112-0001 |
BPDEtide ¡ÚcGMP-dependent Protein Kinase Substrate¡Û¡ÚcGMP-dependent PK Substrate¡Û |
1mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P113-0001 |
Casein Kinase II Substrate ¡ÚArg-Arg-Arg-Glu-Glu-Glu-Thr-Glu-Glu-Glu¡Û¡ÚCKII Substrate¡Û |
1mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P114-0001 |
MLCK Substrate(Skeletal and smooth muscle)¡ÚMyosin Light Chain Kinase Substrate¡Û¡ÚLys-Lys-Arg-Ala-Ala-Arg-Ala-Thr-Ser-Asn-Val-Phe-Ala-NH2¡Û |
1mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P115-0001 |
MLCK Substrate(skeletal muscle)¡ÚMyosin Light Chain Kinase Substrate¡Û¡ÚAla-Lys-Arg-Pro-Gln-Arg-Ala-Thr-Ser-Asn-Val-Phe-Ser-NH2¡Û |
1mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P118-0500 |
[Ala97]-RII(81-99)¡ÚRII(81-99), Ala97]-¡Û¡ÚDLDVPIPGRFDRRVSVAAE¡Û |
0.5mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P120-0005 |
Ac-Leu-Leu-Nle-al ¡ÚAc-Leu-Leu-Nle-CHO¡Û¡ÚCalpain Inhibitor I¡Û¡ÚALLN¡Û¡ÚAc-LL-norleucinal¡Û |
5mg |
¡ï10,000 |
|
110044-82-1 |
|
|
|
¡¡ |
BML |
BML-P120-0025 |
Ac-Leu-Leu-Nle-al ¡ÚAc-Leu-Leu-Nle-CHO¡Û¡ÚCalpain Inhibitor I¡Û¡ÚALLN¡Û¡ÚAc-LL-norleucinal¡Û |
25mg |
¡ï41,000 |
|
110044-82-1 |
|
|
|
¡¡ |
BML |
BML-P121-0001 |
Epidermal Growth Factor Receptor(661-681)¡ÚEGF Receptor(661-681)¡Û [MAP Kinase Substrate] |
1mg |
¡ï14,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P122-0001 |
MBP(95-98)S5 Peptide ¡ÚMyelin Basic Protein(95-98)S5 Peptide¡Û¡ÚMBP(95-98)¡Û¡ÚAla-Pro-Arg-Thr-Pro-Gly-Gly-Arg-Arg¡Û [MAP Kinase Substrate] |
1mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P123-0001 |
Tyrosine Hydroxylase(rat)(24-33)Peptide ¡ÚTH(24-33)¡Û¡ÚLys-Gln-Ala-Glu-Ala-Val-Thr-Ser-Pro-Arg¡Û [MAP Kinase Substrate] |
1mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P124-0001 |
ERK1/ERK2 Peptide(172-190)[MAP Kinase Kinase Substrate] |
1mg |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P125-0005 |
MMP Substrate(chromogenic)¡ÚMatrix Metalloproteinase Substrate¡Û¡ÚAc-Pro-Leu-Gly-[2-mercapto-4-methylpentanoyl]-Leu-Gly-OC2H5¡Û |
5mg |
¡ï23,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P126-0001 |
OmniMMP Fluorogenic Substrate ¡ÚMca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 . AcOH¡Û¡ÚMatrix Metalloproteinase Substrate¡Û |
1mg |
¡ï23,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P127-0001 |
OmniMMP Fluorogenic Control Peptide ¡ÚMca-Pro-Leu-OH¡Û¡ÚMatrix Metalloproteinase Fluorogenic Control¡Û |
1mg* |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P128-0001 |
MMP Substrate(Fluorogenic)¡ÚMatrix Metalloproteinase Substrate¡Û¡ÚDnp-Pro-B-cyclohexyl-Ala-Gly-Cys(Me)-His-Ala-Lys(Nma)-NH2¡Û |
1mg |
¡ï22,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P129-0001 |
Akt Substrate ¡ÚProtein Kinase B substrate¡Û¡ÚPKB Substrate¡Û¡ÚArg-Pro-Arg-Ala-Ala-Thr-Phe¡Û |
1mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P131-0001 |
Matrix Metalloproteinase Substrate a(Fluorescent)¡ÚMMP Substrate a(Fluorogenic)¡Û |
1mg |
¡ï13,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P132-0500 |
ADAM17(TACE)Substrate(Fluorescent)¡ÚTACE Substrate(Fluorogenic)¡Û¡ÚADAM17 Substrate¡Û |
0.5mg |
¡ï16,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P133-0005 |
Ac-IEPD-pNA ¡ÚCaspase-8 Substrate(Chromogenic)¡Û¡ÚGranzyme B Substrate(Chromogenic)¡Û |
5mg |
¡ï16,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P134-0005 |
Ac-IEPD-AMC ¡ÚCaspase-8 Substrate(Fluorogenic)¡Û¡ÚGranzyme B Substrate(Fluorogenic)¡Û |
5mg |
¡ï19,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P135-0025 |
H-Arg-AMC, 2HCl |
25mg |
¡ï15,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P136-0025 |
H-Arg-Pna, 2HCl |
25mg |
¡ï3,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P137-0010 |
Z-RR-AMC ¡ÚZ-Arg-Arg-AMC¡Û |
10mg |
¡ï10,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P137-0050 |
Z-RR-AMC ¡ÚZ-Arg-Arg-AMC¡Û |
50mg |
¡ï49,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P138-0025 |
Z-RR-pNA ¡ÚZ-Arg-Arg-pNA¡Û |
25mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P139-0010 |
OmniCathepsin Fluorogenic Substrate ¡ÚZ-FR-AMC¡Û¡ÚZ-Phe-Arg-AMC¡Û |
10mg |
¡ï7,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P139-0050 |
OmniCathepsin Fluorogenic Substrate ¡ÚZ-FR-AMC¡Û¡ÚZ-Phe-Arg-AMC¡Û |
50mg |
¡ï26,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P141-0025 |
Suc-AAPF-pNA ¡ÚSuc-Ala-Ala-Pro-Phe-pNA¡Û |
25mg |
¡ï9,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P142-0005 |
Z-GPR-AMC ¡ÚZ-Gly-Pro-Arg-AMC¡Û |
5mg |
¡ï11,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P142-0020 |
Z-GPR-AMC ¡ÚZ-Gly-Pro-Arg-AMC¡Û |
20mg |
¡ï33,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P144-0001 |
S6 Ribosomal Protein/Peptide ¡ÚRibosomal Protein S6(rat)(229-239)¡Û [Protein Kinase Substrate] |
1mg |
¡ï8,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P145-0001 |
Cathepsin D&E Fluorogenic Substrate |
1mg |
¡ï18,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P146-0001 |
Casein Kinase I Peptide Substrate ¡ÚCKI Peptide Substrate¡Û |
1mg |
¡ï18,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P147-0001 |
Casein Kinase II Peptide Substrate ¡ÚCKII Peptide Substrate¡Û |
1mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P148-0001 |
IkB Kinase Substrate, Biotinylated |
1mg |
¡ï18,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P149-0001 |
Crosstide ¡ÚH-Gly-Arg-Pro-Arg-Thr-Ser-Ser-Phe-Ala-Glu-Gly-OH¡Û |
1mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P150-0500 |
Protein Kinase C(19-36)Pseudosubstrate ¡ÚPKC¡Û |
0.5mg |
¡ï15,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P151-0001 |
GSK3 Peptide Substrate ¡ÚGlycogen Synthase Kinase 3 Substrate¡Û |
1mg |
¡ï12,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P152-0001 |
Protein Phosphatase 2 Peptide Substrate ¡ÚPP2 Substrate¡Û¡ÚProtein Serine/Threonine Phosphatase Peptide Substrate¡Û |
1mg |
¡ï17,000 |
|
none |
|
|
|
¡¡ |
BML |
BML-P153-0001 |
Protein Tyrosine Phosphatase Peptide Substrate ¡ÚPTP Substrate¡Û |
1mg |
¡ï13,000 |
|
none |
|
< | |